bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
Torsionskontrolle is an umlsterm, Unterschenkelfrakturen is an umlsterm, Torsionsabweichungen is an umlsterm, Analyse is an umlsterm, Beingeometrie is an umlsterm, Korrekturosteotomie is an umlsterm, -technik is an umlsterm, Torsionskorrekturen is an umlsterm, Marknagel is an umlsterm, Torsionsabweichungen is an umlsterm, Korrekturosteotomien is an umlsterm, Oberschenkel is an umlsterm, Korrekturosteotomien is an umlsterm, Torsionsabweichungen is an umlsterm, Oberschenkel is an umlsterm, Torsionstoleranz is an umlsterm, Patienten is an umlsterm, Mark - nagel is an umlsterm	DerUnfallchirurg.71000029.ger.abstr_task1	Sentence: Die mangelhafte intraoperative Torsionskontrolle gilt als typisches Problem von Marknagel-osteosynthesen von Ober- und Unterschenkelfrakturen . Posttraumatische Torsionsabweichungen fuehren zu klinischen Beschwerden , wenn der rotatorische 0-Durchgang , entsprechend der Neutral-0-Methode nicht erreicht oder durchschritten werden kann . Nur auf der Grundlage einer gewissenhaften klinischen , uebersichtsradiographischen und computertomographischen Analyse der Beingeometrie koennen Indikationsstellung und Planung einer Korrekturosteotomie erfolgen . Operationstaktik und -technik von Torsionskorrekturen ueber dem liegenden Marknagel werden beschrieben . Die intraindividuellen Torsionsabweichungen vor den 15 Korrekturosteotomien am Oberschenkel betrugen 33 Grad ( -37/+50 ) und vor den 7 Korrekturosteotomien am Unterschenkel 23 Grad ( -21/ +29 ) . Negative Vorzeichen beschreiben hierbei Innentorsionsabweichungen , positive Vorzeichen Aussentorsionsabweichungen . Postoperativ lagen die intraindividuellen Torsionsabweichungen am Oberschenkel bei 6 Grad ( -3/+14 ) und am Unterschenkel bei 7 Grad ( +3/+12 ) und somit im Bereich der physiologischen Torsionstoleranz von 15 Grad . Bei 4 Patienten mit Femurverkuerzung wurde zusaetzlich eine Laengenkorrektur ueber dem liegenden Mark-nagel durchgefuehrt , davon 3 mal einzeitig durch Interposition von allogener Spongiosa und einmal durch kontinuierliche Kallusdistraktion mittels Fixateur externe . Instructions: please typing these entity words according to sentence: Torsionskontrolle, Unterschenkelfrakturen, Torsionsabweichungen, Analyse, Beingeometrie, Korrekturosteotomie, -technik, Torsionskorrekturen, Marknagel, Torsionsabweichungen, Korrekturosteotomien, Oberschenkel, Korrekturosteotomien, Torsionsabweichungen, Oberschenkel, Torsionstoleranz, Patienten, Mark - nagel Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die mangelhafte intraoperative Torsionskontrolle gilt als typisches Problem von Marknagel-osteosynthesen von Ober- und Unterschenkelfrakturen . Posttraumatische Torsionsabweichungen fuehren zu klinischen Beschwerden , wenn der rotatorische 0-Durchgang , entsprechend der Neutral-0-Methode nicht erreicht oder durchschritten werden kann . Nur auf der Grundlage einer gewissenhaften klinischen , uebersichtsradiographischen und computertomographischen Analyse der Beingeometrie koennen Indikationsstellung und Planung einer Korrekturosteotomie erfolgen . Operationstaktik und -technik von Torsionskorrekturen ueber dem liegenden Marknagel werden beschrieben . Die intraindividuellen Torsionsabweichungen vor den 15 Korrekturosteotomien am Oberschenkel betrugen 33 Grad ( -37/+50 ) und vor den 7 Korrekturosteotomien am Unterschenkel 23 Grad ( -21/ +29 ) . Negative Vorzeichen beschreiben hierbei Innentorsionsabweichungen , positive Vorzeichen Aussentorsionsabweichungen . Postoperativ lagen die intraindividuellen Torsionsabweichungen am Oberschenkel bei 6 Grad ( -3/+14 ) und am Unterschenkel bei 7 Grad ( +3/+12 ) und somit im Bereich der physiologischen Torsionstoleranz von 15 Grad . Bei 4 Patienten mit Femurverkuerzung wurde zusaetzlich eine Laengenkorrektur ueber dem liegenden Mark-nagel durchgefuehrt , davon 3 mal einzeitig durch Interposition von allogener Spongiosa und einmal durch kontinuierliche Kallusdistraktion mittels Fixateur externe .	[ "Die", "mangelhafte", "intraoperative", "Torsionskontrolle", "gilt", "als", "typisches", "Problem", "von", "Marknagel", "-", "osteosynthesen", "von", "Ober-", "und", "Unterschenkelfrakturen", ".", "Posttraumatische", "Torsionsabweichungen", "fuehren", "zu", "klinischen", "Beschwerden", ",", "wenn", "der", "rotatorische", "0-Durchgang", ",", "entsprechend", "der", "Neutral-0-Methode", "nicht", "erreicht", "oder", "durchschritten", "werden", "kann", ".", "Nur", "auf", "der", "Grundlage", "einer", "gewissenhaften", "klinischen", ",", "uebersichtsradiographischen", "und", "computertomographischen", "Analyse", "der", "Beingeometrie", "koennen", "Indikationsstellung", "und", "Planung", "einer", "Korrekturosteotomie", "erfolgen", ".", "Operationstaktik", "und", "-technik", "von", "Torsionskorrekturen", "ueber", "dem", "liegenden", "Marknagel", "werden", "beschrieben", ".", "Die", "intraindividuellen", "Torsionsabweichungen", "vor", "den", "15", "Korrekturosteotomien", "am", "Oberschenkel", "betrugen", "33", "Grad", "(", "-37/+50", ")", "und", "vor", "den", "7", "Korrekturosteotomien", "am", "Unterschenkel", "23", "Grad", "(", "-21/", "+29", ")", ".", "Negative", "Vorzeichen", "beschreiben", "hierbei", "Innentorsionsabweichungen", ",", "positive", "Vorzeichen", "Aussentorsionsabweichungen", ".", "Postoperativ", "lagen", "die", "intraindividuellen", "Torsionsabweichungen", "am", "Oberschenkel", "bei", "6", "Grad", "(", "-3/+14", ")", "und", "am", "Unterschenkel", "bei", "7", "Grad", "(", "+3/+12", ")", "und", "somit", "im", "Bereich", "der", "physiologischen", "Torsionstoleranz", "von", "15", "Grad", ".", "Bei", "4", "Patienten", "mit", "Femurverkuerzung", "wurde", "zusaetzlich", "eine", "Laengenkorrektur", "ueber", "dem", "liegenden", "Mark", "-", "nagel", "durchgefuehrt", ",", "davon", "3", "mal", "einzeitig", "durch", "Interposition", "von", "allogener", "Spongiosa", "und", "einmal", "durch", "kontinuierliche", "Kallusdistraktion", "mittels", "Fixateur", "externe", "." ]	[ "umlsterm" ]
Torsionskontrolle, Unterschenkelfrakturen, Torsionsabweichungen, Analyse, Beingeometrie, Korrekturosteotomie, -technik, Torsionskorrekturen, Marknagel, Torsionsabweichungen, Korrekturosteotomien, Oberschenkel, Korrekturosteotomien, Torsionsabweichungen, Oberschenkel, Torsionstoleranz, Patienten, Mark - nagel	DerUnfallchirurg.71000029.ger.abstr_task2	Sentence: Die mangelhafte intraoperative Torsionskontrolle gilt als typisches Problem von Marknagel-osteosynthesen von Ober- und Unterschenkelfrakturen . Posttraumatische Torsionsabweichungen fuehren zu klinischen Beschwerden , wenn der rotatorische 0-Durchgang , entsprechend der Neutral-0-Methode nicht erreicht oder durchschritten werden kann . Nur auf der Grundlage einer gewissenhaften klinischen , uebersichtsradiographischen und computertomographischen Analyse der Beingeometrie koennen Indikationsstellung und Planung einer Korrekturosteotomie erfolgen . Operationstaktik und -technik von Torsionskorrekturen ueber dem liegenden Marknagel werden beschrieben . Die intraindividuellen Torsionsabweichungen vor den 15 Korrekturosteotomien am Oberschenkel betrugen 33 Grad ( -37/+50 ) und vor den 7 Korrekturosteotomien am Unterschenkel 23 Grad ( -21/ +29 ) . Negative Vorzeichen beschreiben hierbei Innentorsionsabweichungen , positive Vorzeichen Aussentorsionsabweichungen . Postoperativ lagen die intraindividuellen Torsionsabweichungen am Oberschenkel bei 6 Grad ( -3/+14 ) und am Unterschenkel bei 7 Grad ( +3/+12 ) und somit im Bereich der physiologischen Torsionstoleranz von 15 Grad . Bei 4 Patienten mit Femurverkuerzung wurde zusaetzlich eine Laengenkorrektur ueber dem liegenden Mark-nagel durchgefuehrt , davon 3 mal einzeitig durch Interposition von allogener Spongiosa und einmal durch kontinuierliche Kallusdistraktion mittels Fixateur externe . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die mangelhafte intraoperative Torsionskontrolle gilt als typisches Problem von Marknagel-osteosynthesen von Ober- und Unterschenkelfrakturen . Posttraumatische Torsionsabweichungen fuehren zu klinischen Beschwerden , wenn der rotatorische 0-Durchgang , entsprechend der Neutral-0-Methode nicht erreicht oder durchschritten werden kann . Nur auf der Grundlage einer gewissenhaften klinischen , uebersichtsradiographischen und computertomographischen Analyse der Beingeometrie koennen Indikationsstellung und Planung einer Korrekturosteotomie erfolgen . Operationstaktik und -technik von Torsionskorrekturen ueber dem liegenden Marknagel werden beschrieben . Die intraindividuellen Torsionsabweichungen vor den 15 Korrekturosteotomien am Oberschenkel betrugen 33 Grad ( -37/+50 ) und vor den 7 Korrekturosteotomien am Unterschenkel 23 Grad ( -21/ +29 ) . Negative Vorzeichen beschreiben hierbei Innentorsionsabweichungen , positive Vorzeichen Aussentorsionsabweichungen . Postoperativ lagen die intraindividuellen Torsionsabweichungen am Oberschenkel bei 6 Grad ( -3/+14 ) und am Unterschenkel bei 7 Grad ( +3/+12 ) und somit im Bereich der physiologischen Torsionstoleranz von 15 Grad . Bei 4 Patienten mit Femurverkuerzung wurde zusaetzlich eine Laengenkorrektur ueber dem liegenden Mark-nagel durchgefuehrt , davon 3 mal einzeitig durch Interposition von allogener Spongiosa und einmal durch kontinuierliche Kallusdistraktion mittels Fixateur externe .	[ "Die", "mangelhafte", "intraoperative", "Torsionskontrolle", "gilt", "als", "typisches", "Problem", "von", "Marknagel", "-", "osteosynthesen", "von", "Ober-", "und", "Unterschenkelfrakturen", ".", "Posttraumatische", "Torsionsabweichungen", "fuehren", "zu", "klinischen", "Beschwerden", ",", "wenn", "der", "rotatorische", "0-Durchgang", ",", "entsprechend", "der", "Neutral-0-Methode", "nicht", "erreicht", "oder", "durchschritten", "werden", "kann", ".", "Nur", "auf", "der", "Grundlage", "einer", "gewissenhaften", "klinischen", ",", "uebersichtsradiographischen", "und", "computertomographischen", "Analyse", "der", "Beingeometrie", "koennen", "Indikationsstellung", "und", "Planung", "einer", "Korrekturosteotomie", "erfolgen", ".", "Operationstaktik", "und", "-technik", "von", "Torsionskorrekturen", "ueber", "dem", "liegenden", "Marknagel", "werden", "beschrieben", ".", "Die", "intraindividuellen", "Torsionsabweichungen", "vor", "den", "15", "Korrekturosteotomien", "am", "Oberschenkel", "betrugen", "33", "Grad", "(", "-37/+50", ")", "und", "vor", "den", "7", "Korrekturosteotomien", "am", "Unterschenkel", "23", "Grad", "(", "-21/", "+29", ")", ".", "Negative", "Vorzeichen", "beschreiben", "hierbei", "Innentorsionsabweichungen", ",", "positive", "Vorzeichen", "Aussentorsionsabweichungen", ".", "Postoperativ", "lagen", "die", "intraindividuellen", "Torsionsabweichungen", "am", "Oberschenkel", "bei", "6", "Grad", "(", "-3/+14", ")", "und", "am", "Unterschenkel", "bei", "7", "Grad", "(", "+3/+12", ")", "und", "somit", "im", "Bereich", "der", "physiologischen", "Torsionstoleranz", "von", "15", "Grad", ".", "Bei", "4", "Patienten", "mit", "Femurverkuerzung", "wurde", "zusaetzlich", "eine", "Laengenkorrektur", "ueber", "dem", "liegenden", "Mark", "-", "nagel", "durchgefuehrt", ",", "davon", "3", "mal", "einzeitig", "durch", "Interposition", "von", "allogener", "Spongiosa", "und", "einmal", "durch", "kontinuierliche", "Kallusdistraktion", "mittels", "Fixateur", "externe", "." ]	[ "umlsterm" ]
Entscheidungsbaeume is an umlsterm, Radiologie is an umlsterm, Erwachsenenradiologie is an umlsterm, Computertomographie is an umlsterm, Nieren- is an umlsterm, Harnwegsuntersuchung is an umlsterm, Ultraschall is an umlsterm, Erwachsenenalter is an umlsterm, Szintigraphie is an umlsterm, Magnetresonanztomographie is an umlsterm, Standardsituationen is an umlsterm, Kinderradiologie is an umlsterm, Harnwegspathologie is an umlsterm, Harntransportstoerung is an umlsterm, Harnwegsinfektion is an umlsterm	DerRadiologe.90390415.ger.abstr_task0	Sentence: Die diagnostischen Entscheidungsbaeume in der Paediatrischen Radiologie unterscheiden sich oft erheblich von denen der Erwachsenenradiologie . Die Ursache hierfuer besteht im unterschiedlichen Erkrankungsspektrum , in den unterschiedlichen therapeutischen Konsequenzen , die aus einem erhobenen Befund gezogen werden und auch im unterschiedlichen Stellenwert der bildgebenden Verfahren . Abgesehen vom schweren Abdominaltrauma , das primaer mittels Computertomographie ( CT ) untersucht werden muss , beginnt jede Nieren- und Harnwegsuntersuchung mit einer Ultraschall ( US ) -untersuchung Die Entscheidung , ob ein normaler oder ein pathologischer Befund der Bildgebung vorliegt , ist fast immer mittels US zu treffen . Die Aussagekraft und damit der diagnostische Stellenwert des US unterscheiden sich infolge der Moeglichkeit , hoeherfrequente Schallsysteme mit exzellenter Aufloesung zu verwenden , erheblich von der Situation im Erwachsenenalter . Erst in Kenntnis des sonographischen Befundes wird der Ablauf der weiteren Bildgebung ( Szintigraphie Roentgen , Magnetresonanztomographie ( , MRT ) und sehr selten CT ) festgelegt . Nachfolgend sollen , ausgehend von den wichtigsten klinischen Symptomen , die diagnostischen Flussschemata fuer drei haeufige Standardsituationen in der Kinderradiologie dargestellt werden : Praenatal erkannte Harnwegspathologie Harntransportstoerung und Harnwegsinfektion . , Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Die diagnostischen Entscheidungsbaeume in der Paediatrischen Radiologie unterscheiden sich oft erheblich von denen der Erwachsenenradiologie . Die Ursache hierfuer besteht im unterschiedlichen Erkrankungsspektrum , in den unterschiedlichen therapeutischen Konsequenzen , die aus einem erhobenen Befund gezogen werden und auch im unterschiedlichen Stellenwert der bildgebenden Verfahren . Abgesehen vom schweren Abdominaltrauma , das primaer mittels Computertomographie ( CT ) untersucht werden muss , beginnt jede Nieren- und Harnwegsuntersuchung mit einer Ultraschall ( US ) -untersuchung Die Entscheidung , ob ein normaler oder ein pathologischer Befund der Bildgebung vorliegt , ist fast immer mittels US zu treffen . Die Aussagekraft und damit der diagnostische Stellenwert des US unterscheiden sich infolge der Moeglichkeit , hoeherfrequente Schallsysteme mit exzellenter Aufloesung zu verwenden , erheblich von der Situation im Erwachsenenalter . Erst in Kenntnis des sonographischen Befundes wird der Ablauf der weiteren Bildgebung ( Szintigraphie Roentgen , Magnetresonanztomographie ( , MRT ) und sehr selten CT ) festgelegt . Nachfolgend sollen , ausgehend von den wichtigsten klinischen Symptomen , die diagnostischen Flussschemata fuer drei haeufige Standardsituationen in der Kinderradiologie dargestellt werden : Praenatal erkannte Harnwegspathologie Harntransportstoerung und Harnwegsinfektion . ,	[ "Die", "diagnostischen", "Entscheidungsbaeume", "in", "der", "Paediatrischen", "Radiologie", "unterscheiden", "sich", "oft", "erheblich", "von", "denen", "der", "Erwachsenenradiologie", ".", "Die", "Ursache", "hierfuer", "besteht", "im", "unterschiedlichen", "Erkrankungsspektrum", ",", "in", "den", "unterschiedlichen", "therapeutischen", "Konsequenzen", ",", "die", "aus", "einem", "erhobenen", "Befund", "gezogen", "werden", "und", "auch", "im", "unterschiedlichen", "Stellenwert", "der", "bildgebenden", "Verfahren", ".", "Abgesehen", "vom", "schweren", "Abdominaltrauma", ",", "das", "primaer", "mittels", "Computertomographie", "(", "CT", ")", "untersucht", "werden", "muss", ",", "beginnt", "jede", "Nieren-", "und", "Harnwegsuntersuchung", "mit", "einer", "Ultraschall", "(", "US", ")", "-untersuchung", "Die", "Entscheidung", ",", "ob", "ein", "normaler", "oder", "ein", "pathologischer", "Befund", "der", "Bildgebung", "vorliegt", ",", "ist", "fast", "immer", "mittels", "US", "zu", "treffen", ".", "Die", "Aussagekraft", "und", "damit", "der", "diagnostische", "Stellenwert", "des", "US", "unterscheiden", "sich", "infolge", "der", "Moeglichkeit", ",", "hoeherfrequente", "Schallsysteme", "mit", "exzellenter", "Aufloesung", "zu", "verwenden", ",", "erheblich", "von", "der", "Situation", "im", "Erwachsenenalter", ".", "Erst", "in", "Kenntnis", "des", "sonographischen", "Befundes", "wird", "der", "Ablauf", "der", "weiteren", "Bildgebung", "(", "Szintigraphie", "Roentgen", ",", "Magnetresonanztomographie", "(", ",", "MRT", ")", "und", "sehr", "selten", "CT", ")", "festgelegt", ".", "Nachfolgend", "sollen", ",", "ausgehend", "von", "den", "wichtigsten", "klinischen", "Symptomen", ",", "die", "diagnostischen", "Flussschemata", "fuer", "drei", "haeufige", "Standardsituationen", "in", "der", "Kinderradiologie", "dargestellt", "werden", ":", "Praenatal", "erkannte", "Harnwegspathologie", "Harntransportstoerung", "und", "Harnwegsinfektion", ".", "," ]	[ "umlsterm" ]
Entscheidungsbaeume is an umlsterm, Radiologie is an umlsterm, Erwachsenenradiologie is an umlsterm, Computertomographie is an umlsterm, Nieren- is an umlsterm, Harnwegsuntersuchung is an umlsterm, Ultraschall is an umlsterm, Erwachsenenalter is an umlsterm, Szintigraphie is an umlsterm, Magnetresonanztomographie is an umlsterm, Standardsituationen is an umlsterm, Kinderradiologie is an umlsterm, Harnwegspathologie is an umlsterm, Harntransportstoerung is an umlsterm, Harnwegsinfektion is an umlsterm	DerRadiologe.90390415.ger.abstr_task1	Sentence: Die diagnostischen Entscheidungsbaeume in der Paediatrischen Radiologie unterscheiden sich oft erheblich von denen der Erwachsenenradiologie . Die Ursache hierfuer besteht im unterschiedlichen Erkrankungsspektrum , in den unterschiedlichen therapeutischen Konsequenzen , die aus einem erhobenen Befund gezogen werden und auch im unterschiedlichen Stellenwert der bildgebenden Verfahren . Abgesehen vom schweren Abdominaltrauma , das primaer mittels Computertomographie ( CT ) untersucht werden muss , beginnt jede Nieren- und Harnwegsuntersuchung mit einer Ultraschall ( US ) -untersuchung Die Entscheidung , ob ein normaler oder ein pathologischer Befund der Bildgebung vorliegt , ist fast immer mittels US zu treffen . Die Aussagekraft und damit der diagnostische Stellenwert des US unterscheiden sich infolge der Moeglichkeit , hoeherfrequente Schallsysteme mit exzellenter Aufloesung zu verwenden , erheblich von der Situation im Erwachsenenalter . Erst in Kenntnis des sonographischen Befundes wird der Ablauf der weiteren Bildgebung ( Szintigraphie Roentgen , Magnetresonanztomographie ( , MRT ) und sehr selten CT ) festgelegt . Nachfolgend sollen , ausgehend von den wichtigsten klinischen Symptomen , die diagnostischen Flussschemata fuer drei haeufige Standardsituationen in der Kinderradiologie dargestellt werden : Praenatal erkannte Harnwegspathologie Harntransportstoerung und Harnwegsinfektion . , Instructions: please typing these entity words according to sentence: Entscheidungsbaeume, Radiologie, Erwachsenenradiologie, Computertomographie, Nieren-, Harnwegsuntersuchung, Ultraschall, Erwachsenenalter, Szintigraphie, Magnetresonanztomographie, Standardsituationen, Kinderradiologie, Harnwegspathologie, Harntransportstoerung, Harnwegsinfektion Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Die diagnostischen Entscheidungsbaeume in der Paediatrischen Radiologie unterscheiden sich oft erheblich von denen der Erwachsenenradiologie . Die Ursache hierfuer besteht im unterschiedlichen Erkrankungsspektrum , in den unterschiedlichen therapeutischen Konsequenzen , die aus einem erhobenen Befund gezogen werden und auch im unterschiedlichen Stellenwert der bildgebenden Verfahren . Abgesehen vom schweren Abdominaltrauma , das primaer mittels Computertomographie ( CT ) untersucht werden muss , beginnt jede Nieren- und Harnwegsuntersuchung mit einer Ultraschall ( US ) -untersuchung Die Entscheidung , ob ein normaler oder ein pathologischer Befund der Bildgebung vorliegt , ist fast immer mittels US zu treffen . Die Aussagekraft und damit der diagnostische Stellenwert des US unterscheiden sich infolge der Moeglichkeit , hoeherfrequente Schallsysteme mit exzellenter Aufloesung zu verwenden , erheblich von der Situation im Erwachsenenalter . Erst in Kenntnis des sonographischen Befundes wird der Ablauf der weiteren Bildgebung ( Szintigraphie Roentgen , Magnetresonanztomographie ( , MRT ) und sehr selten CT ) festgelegt . Nachfolgend sollen , ausgehend von den wichtigsten klinischen Symptomen , die diagnostischen Flussschemata fuer drei haeufige Standardsituationen in der Kinderradiologie dargestellt werden : Praenatal erkannte Harnwegspathologie Harntransportstoerung und Harnwegsinfektion . ,	[ "Die", "diagnostischen", "Entscheidungsbaeume", "in", "der", "Paediatrischen", "Radiologie", "unterscheiden", "sich", "oft", "erheblich", "von", "denen", "der", "Erwachsenenradiologie", ".", "Die", "Ursache", "hierfuer", "besteht", "im", "unterschiedlichen", "Erkrankungsspektrum", ",", "in", "den", "unterschiedlichen", "therapeutischen", "Konsequenzen", ",", "die", "aus", "einem", "erhobenen", "Befund", "gezogen", "werden", "und", "auch", "im", "unterschiedlichen", "Stellenwert", "der", "bildgebenden", "Verfahren", ".", "Abgesehen", "vom", "schweren", "Abdominaltrauma", ",", "das", "primaer", "mittels", "Computertomographie", "(", "CT", ")", "untersucht", "werden", "muss", ",", "beginnt", "jede", "Nieren-", "und", "Harnwegsuntersuchung", "mit", "einer", "Ultraschall", "(", "US", ")", "-untersuchung", "Die", "Entscheidung", ",", "ob", "ein", "normaler", "oder", "ein", "pathologischer", "Befund", "der", "Bildgebung", "vorliegt", ",", "ist", "fast", "immer", "mittels", "US", "zu", "treffen", ".", "Die", "Aussagekraft", "und", "damit", "der", "diagnostische", "Stellenwert", "des", "US", "unterscheiden", "sich", "infolge", "der", "Moeglichkeit", ",", "hoeherfrequente", "Schallsysteme", "mit", "exzellenter", "Aufloesung", "zu", "verwenden", ",", "erheblich", "von", "der", "Situation", "im", "Erwachsenenalter", ".", "Erst", "in", "Kenntnis", "des", "sonographischen", "Befundes", "wird", "der", "Ablauf", "der", "weiteren", "Bildgebung", "(", "Szintigraphie", "Roentgen", ",", "Magnetresonanztomographie", "(", ",", "MRT", ")", "und", "sehr", "selten", "CT", ")", "festgelegt", ".", "Nachfolgend", "sollen", ",", "ausgehend", "von", "den", "wichtigsten", "klinischen", "Symptomen", ",", "die", "diagnostischen", "Flussschemata", "fuer", "drei", "haeufige", "Standardsituationen", "in", "der", "Kinderradiologie", "dargestellt", "werden", ":", "Praenatal", "erkannte", "Harnwegspathologie", "Harntransportstoerung", "und", "Harnwegsinfektion", ".", "," ]	[ "umlsterm" ]
Entscheidungsbaeume, Radiologie, Erwachsenenradiologie, Computertomographie, Nieren-, Harnwegsuntersuchung, Ultraschall, Erwachsenenalter, Szintigraphie, Magnetresonanztomographie, Standardsituationen, Kinderradiologie, Harnwegspathologie, Harntransportstoerung, Harnwegsinfektion	DerRadiologe.90390415.ger.abstr_task2	Sentence: Die diagnostischen Entscheidungsbaeume in der Paediatrischen Radiologie unterscheiden sich oft erheblich von denen der Erwachsenenradiologie . Die Ursache hierfuer besteht im unterschiedlichen Erkrankungsspektrum , in den unterschiedlichen therapeutischen Konsequenzen , die aus einem erhobenen Befund gezogen werden und auch im unterschiedlichen Stellenwert der bildgebenden Verfahren . Abgesehen vom schweren Abdominaltrauma , das primaer mittels Computertomographie ( CT ) untersucht werden muss , beginnt jede Nieren- und Harnwegsuntersuchung mit einer Ultraschall ( US ) -untersuchung Die Entscheidung , ob ein normaler oder ein pathologischer Befund der Bildgebung vorliegt , ist fast immer mittels US zu treffen . Die Aussagekraft und damit der diagnostische Stellenwert des US unterscheiden sich infolge der Moeglichkeit , hoeherfrequente Schallsysteme mit exzellenter Aufloesung zu verwenden , erheblich von der Situation im Erwachsenenalter . Erst in Kenntnis des sonographischen Befundes wird der Ablauf der weiteren Bildgebung ( Szintigraphie Roentgen , Magnetresonanztomographie ( , MRT ) und sehr selten CT ) festgelegt . Nachfolgend sollen , ausgehend von den wichtigsten klinischen Symptomen , die diagnostischen Flussschemata fuer drei haeufige Standardsituationen in der Kinderradiologie dargestellt werden : Praenatal erkannte Harnwegspathologie Harntransportstoerung und Harnwegsinfektion . , Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Die diagnostischen Entscheidungsbaeume in der Paediatrischen Radiologie unterscheiden sich oft erheblich von denen der Erwachsenenradiologie . Die Ursache hierfuer besteht im unterschiedlichen Erkrankungsspektrum , in den unterschiedlichen therapeutischen Konsequenzen , die aus einem erhobenen Befund gezogen werden und auch im unterschiedlichen Stellenwert der bildgebenden Verfahren . Abgesehen vom schweren Abdominaltrauma , das primaer mittels Computertomographie ( CT ) untersucht werden muss , beginnt jede Nieren- und Harnwegsuntersuchung mit einer Ultraschall ( US ) -untersuchung Die Entscheidung , ob ein normaler oder ein pathologischer Befund der Bildgebung vorliegt , ist fast immer mittels US zu treffen . Die Aussagekraft und damit der diagnostische Stellenwert des US unterscheiden sich infolge der Moeglichkeit , hoeherfrequente Schallsysteme mit exzellenter Aufloesung zu verwenden , erheblich von der Situation im Erwachsenenalter . Erst in Kenntnis des sonographischen Befundes wird der Ablauf der weiteren Bildgebung ( Szintigraphie Roentgen , Magnetresonanztomographie ( , MRT ) und sehr selten CT ) festgelegt . Nachfolgend sollen , ausgehend von den wichtigsten klinischen Symptomen , die diagnostischen Flussschemata fuer drei haeufige Standardsituationen in der Kinderradiologie dargestellt werden : Praenatal erkannte Harnwegspathologie Harntransportstoerung und Harnwegsinfektion . ,	[ "Die", "diagnostischen", "Entscheidungsbaeume", "in", "der", "Paediatrischen", "Radiologie", "unterscheiden", "sich", "oft", "erheblich", "von", "denen", "der", "Erwachsenenradiologie", ".", "Die", "Ursache", "hierfuer", "besteht", "im", "unterschiedlichen", "Erkrankungsspektrum", ",", "in", "den", "unterschiedlichen", "therapeutischen", "Konsequenzen", ",", "die", "aus", "einem", "erhobenen", "Befund", "gezogen", "werden", "und", "auch", "im", "unterschiedlichen", "Stellenwert", "der", "bildgebenden", "Verfahren", ".", "Abgesehen", "vom", "schweren", "Abdominaltrauma", ",", "das", "primaer", "mittels", "Computertomographie", "(", "CT", ")", "untersucht", "werden", "muss", ",", "beginnt", "jede", "Nieren-", "und", "Harnwegsuntersuchung", "mit", "einer", "Ultraschall", "(", "US", ")", "-untersuchung", "Die", "Entscheidung", ",", "ob", "ein", "normaler", "oder", "ein", "pathologischer", "Befund", "der", "Bildgebung", "vorliegt", ",", "ist", "fast", "immer", "mittels", "US", "zu", "treffen", ".", "Die", "Aussagekraft", "und", "damit", "der", "diagnostische", "Stellenwert", "des", "US", "unterscheiden", "sich", "infolge", "der", "Moeglichkeit", ",", "hoeherfrequente", "Schallsysteme", "mit", "exzellenter", "Aufloesung", "zu", "verwenden", ",", "erheblich", "von", "der", "Situation", "im", "Erwachsenenalter", ".", "Erst", "in", "Kenntnis", "des", "sonographischen", "Befundes", "wird", "der", "Ablauf", "der", "weiteren", "Bildgebung", "(", "Szintigraphie", "Roentgen", ",", "Magnetresonanztomographie", "(", ",", "MRT", ")", "und", "sehr", "selten", "CT", ")", "festgelegt", ".", "Nachfolgend", "sollen", ",", "ausgehend", "von", "den", "wichtigsten", "klinischen", "Symptomen", ",", "die", "diagnostischen", "Flussschemata", "fuer", "drei", "haeufige", "Standardsituationen", "in", "der", "Kinderradiologie", "dargestellt", "werden", ":", "Praenatal", "erkannte", "Harnwegspathologie", "Harntransportstoerung", "und", "Harnwegsinfektion", ".", "," ]	[ "umlsterm" ]
FEV1 is a Measurement, > = 80 % is a Value, FEV1 is a Measurement, < 20 % of predicted value is a Value, post - bronchodilator is a Qualifier, History is a Observation, lung transplant is a Procedure, lung surgery is a Procedure, within the past two years is a Temporal, thoracic surgery waiting list is a Observation, exacerbation is a Condition, less than 6 weeks prior to screening / re - screening visit is a Temporal, Clinically significant is a Qualifier, intercurrent illnesses is a Condition, except for is a Negation, respiratory or liver disease is a Scope, secondary to AAT deficiency is a Qualifier, cardiac , hepatic , renal , endocrine , neurological , hematological , neoplastic , immunological , skeletal or other is a Scope, Active smoking is a Condition, during the last 12 months from screening date is a Temporal, Pregnancy is a Condition, lactation is a Condition, Woman is a Person, child - bearing potential is a Condition, not is a Negation, adequate is a Qualifier, contraception is a Procedure, deemed reliable by the investigator is a Qualifier, psychiatric/ mental disorder or any other medical disorder is a Scope, impair the patient 's ability to give informed consent is a Observation, ongoing is a Temporal, viral infection is a Condition, HCV , HBV and / or HIV is a Scope, alcohol abuse is a Condition, history is a Observation, alcohol abuse or illegal and / or legally prescribed drugs is a Scope, IgA Deficiency is a Condition, History is a Observation, life threatening allergy , anaphylactic reaction , or systemic response to human plasma derived products is a Scope	NCT01217671_exc_task0	Sentence: FEV1 >= 80% or FEV1 < 20% of predicted value post-bronchodilator. FEV1/SVC>=70% History of lung transplant. Any lung surgery within the past two years. On any thoracic surgery waiting list. End of last exacerbation less than 6 weeks prior to screening/re-screening visit. Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor. Active smoking during the last 12 months from screening date. Pregnancy or lactation. Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. Evidence of ongoing viral infection with HCV, HBV and/or HIV. Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs. IgA Deficiency History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. Participation in another clinical trial within 30 days prior to baseline visit. Inability to attend scheduled clinic visits and/or comply with the study protocol. Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Observation, Procedure, Negation, Scope, Measurement	[ "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "O", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Condition", "O", "B-Condition", "O", "O", "B-Person", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "B-Negation", "O", "B-Qualifier", "B-Procedure", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	FEV1 >= 80% or FEV1 < 20% of predicted value post-bronchodilator. FEV1/SVC>=70% History of lung transplant. Any lung surgery within the past two years. On any thoracic surgery waiting list. End of last exacerbation less than 6 weeks prior to screening/re-screening visit. Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor. Active smoking during the last 12 months from screening date. Pregnancy or lactation. Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. Evidence of ongoing viral infection with HCV, HBV and/or HIV. Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs. IgA Deficiency History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. Participation in another clinical trial within 30 days prior to baseline visit. Inability to attend scheduled clinic visits and/or comply with the study protocol. Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol.	[ "FEV1", ">", "=", "80", "%", "or", "FEV1", "<", "20", "%", "of", "predicted", "value", "post", "-", "bronchodilator", ".", "\n", "FEV1", "/", "SVC>=70", "%", "\n", "History", "of", "lung", "transplant", ".", "\n", "Any", "lung", "surgery", "within", "the", "past", "two", "years", ".", "\n", "On", "any", "thoracic", "surgery", "waiting", "list", ".", "\n", "End", "of", "last", "exacerbation", "less", "than", "6", "weeks", "prior", "to", "screening", "/", "re", "-", "screening", "visit", ".", "\n", "Clinically", "significant", "intercurrent", "illnesses", "(", "except", "for", "respiratory", "or", "liver", "disease", "secondary", "to", "AAT", "deficiency", ")", ",", "including", ":", "cardiac", ",", "hepatic", ",", "renal", ",", "endocrine", ",", "neurological", ",", "hematological", ",", "neoplastic", ",", "immunological", ",", "skeletal", "or", "other", ")", "that", "in", "the", "opinion", "of", "the", "investigator", ",", "could", "interfere", "with", "the", "safety", ",", "compliance", "or", "other", "aspects", "of", "this", "study", ".", "Patients", "with", "well", "-", "controlled", ",", "chronic", "diseases", "could", "possibly", "be", "included", "after", "consultation", "with", "the", "treating", "physician", "and", "the", "sponsor", ".", "\n", "Active", "smoking", "during", "the", "last", "12", "months", "from", "screening", "date", ".", "\n", "Pregnancy", "or", "lactation", ".", "\n", "Woman", "of", "child", "-", "bearing", "potential", "not", "taking", "adequate", "contraception", "deemed", "reliable", "by", "the", "investigator", ".", "\n", "Presence", "of", "psychiatric/", "mental", "disorder", "or", "any", "other", "medical", "disorder", "which", "might", "impair", "the", "patient", "'s", "ability", "to", "give", "informed", "consent", "or", "to", "comply", "with", "the", "requirements", "of", "the", "study", "protocol", ".", "\n", "Evidence", "of", "ongoing", "viral", "infection", "with", "HCV", ",", "HBV", "and", "/", "or", "HIV", ".", "\n", "Evidence", "of", "alcohol", "abuse", "or", "history", "of", "alcohol", "abuse", "or", "illegal", "and", "/", "or", "legally", "prescribed", "drugs", ".", "\n", "IgA", "Deficiency", "\n", "History", "of", "life", "threatening", "allergy", ",", "anaphylactic", "reaction", ",", "or", "systemic", "response", "to", "human", "plasma", "derived", "products", ".", "\n", "Participation", "in", "another", "clinical", "trial", "within", "30", "days", "prior", "to", "baseline", "visit", ".", "\n", "Inability", "to", "attend", "scheduled", "clinic", "visits", "and", "/", "or", "comply", "with", "the", "study", "protocol", ".", "\n", "Any", "other", "factor", "that", ",", "in", "the", "opinion", "of", "the", "investigator", ",", "would", "prevent", "the", "patient", "from", "complying", "with", "the", "requirements", "of", "the", "protocol", ".", " \n \n" ]	[ "Scope", "Temporal", "Observation", "Condition", "Qualifier", "Reference_point", "Value", "Procedure", "Drug", "Negation", "Measurement", "Person" ]
FEV1 is a Measurement, > = 80 % is a Value, FEV1 is a Measurement, < 20 % of predicted value is a Value, post - bronchodilator is a Qualifier, History is a Observation, lung transplant is a Procedure, lung surgery is a Procedure, within the past two years is a Temporal, thoracic surgery waiting list is a Observation, exacerbation is a Condition, less than 6 weeks prior to screening / re - screening visit is a Temporal, Clinically significant is a Qualifier, intercurrent illnesses is a Condition, except for is a Negation, respiratory or liver disease is a Scope, secondary to AAT deficiency is a Qualifier, cardiac , hepatic , renal , endocrine , neurological , hematological , neoplastic , immunological , skeletal or other is a Scope, Active smoking is a Condition, during the last 12 months from screening date is a Temporal, Pregnancy is a Condition, lactation is a Condition, Woman is a Person, child - bearing potential is a Condition, not is a Negation, adequate is a Qualifier, contraception is a Procedure, deemed reliable by the investigator is a Qualifier, psychiatric/ mental disorder or any other medical disorder is a Scope, impair the patient 's ability to give informed consent is a Observation, ongoing is a Temporal, viral infection is a Condition, HCV , HBV and / or HIV is a Scope, alcohol abuse is a Condition, history is a Observation, alcohol abuse or illegal and / or legally prescribed drugs is a Scope, IgA Deficiency is a Condition, History is a Observation, life threatening allergy , anaphylactic reaction , or systemic response to human plasma derived products is a Scope	NCT01217671_exc_task1	Sentence: FEV1 >= 80% or FEV1 < 20% of predicted value post-bronchodilator. FEV1/SVC>=70% History of lung transplant. Any lung surgery within the past two years. On any thoracic surgery waiting list. End of last exacerbation less than 6 weeks prior to screening/re-screening visit. Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor. Active smoking during the last 12 months from screening date. Pregnancy or lactation. Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. Evidence of ongoing viral infection with HCV, HBV and/or HIV. Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs. IgA Deficiency History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. Participation in another clinical trial within 30 days prior to baseline visit. Inability to attend scheduled clinic visits and/or comply with the study protocol. Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol. Instructions: please typing these entity words according to sentence: FEV1, > = 80 %, FEV1, < 20 % of predicted value, post - bronchodilator, History, lung transplant, lung surgery, within the past two years, thoracic surgery waiting list, exacerbation, less than 6 weeks prior to screening / re - screening visit, Clinically significant, intercurrent illnesses, except for, respiratory or liver disease, secondary to AAT deficiency, cardiac , hepatic , renal , endocrine , neurological , hematological , neoplastic , immunological , skeletal or other, Active smoking, during the last 12 months from screening date, Pregnancy, lactation, Woman, child - bearing potential, not, adequate, contraception, deemed reliable by the investigator, psychiatric/ mental disorder or any other medical disorder, impair the patient 's ability to give informed consent, ongoing, viral infection, HCV , HBV and / or HIV, alcohol abuse, history, alcohol abuse or illegal and / or legally prescribed drugs, IgA Deficiency, History, life threatening allergy , anaphylactic reaction , or systemic response to human plasma derived products Options: Temporal, Condition, Qualifier, Value, Person, Observation, Procedure, Negation, Scope, Measurement	[ "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "O", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Condition", "O", "B-Condition", "O", "O", "B-Person", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "B-Negation", "O", "B-Qualifier", "B-Procedure", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	FEV1 >= 80% or FEV1 < 20% of predicted value post-bronchodilator. FEV1/SVC>=70% History of lung transplant. Any lung surgery within the past two years. On any thoracic surgery waiting list. End of last exacerbation less than 6 weeks prior to screening/re-screening visit. Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor. Active smoking during the last 12 months from screening date. Pregnancy or lactation. Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. Evidence of ongoing viral infection with HCV, HBV and/or HIV. Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs. IgA Deficiency History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. Participation in another clinical trial within 30 days prior to baseline visit. Inability to attend scheduled clinic visits and/or comply with the study protocol. Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol.	[ "FEV1", ">", "=", "80", "%", "or", "FEV1", "<", "20", "%", "of", "predicted", "value", "post", "-", "bronchodilator", ".", "\n", "FEV1", "/", "SVC>=70", "%", "\n", "History", "of", "lung", "transplant", ".", "\n", "Any", "lung", "surgery", "within", "the", "past", "two", "years", ".", "\n", "On", "any", "thoracic", "surgery", "waiting", "list", ".", "\n", "End", "of", "last", "exacerbation", "less", "than", "6", "weeks", "prior", "to", "screening", "/", "re", "-", "screening", "visit", ".", "\n", "Clinically", "significant", "intercurrent", "illnesses", "(", "except", "for", "respiratory", "or", "liver", "disease", "secondary", "to", "AAT", "deficiency", ")", ",", "including", ":", "cardiac", ",", "hepatic", ",", "renal", ",", "endocrine", ",", "neurological", ",", "hematological", ",", "neoplastic", ",", "immunological", ",", "skeletal", "or", "other", ")", "that", "in", "the", "opinion", "of", "the", "investigator", ",", "could", "interfere", "with", "the", "safety", ",", "compliance", "or", "other", "aspects", "of", "this", "study", ".", "Patients", "with", "well", "-", "controlled", ",", "chronic", "diseases", "could", "possibly", "be", "included", "after", "consultation", "with", "the", "treating", "physician", "and", "the", "sponsor", ".", "\n", "Active", "smoking", "during", "the", "last", "12", "months", "from", "screening", "date", ".", "\n", "Pregnancy", "or", "lactation", ".", "\n", "Woman", "of", "child", "-", "bearing", "potential", "not", "taking", "adequate", "contraception", "deemed", "reliable", "by", "the", "investigator", ".", "\n", "Presence", "of", "psychiatric/", "mental", "disorder", "or", "any", "other", "medical", "disorder", "which", "might", "impair", "the", "patient", "'s", "ability", "to", "give", "informed", "consent", "or", "to", "comply", "with", "the", "requirements", "of", "the", "study", "protocol", ".", "\n", "Evidence", "of", "ongoing", "viral", "infection", "with", "HCV", ",", "HBV", "and", "/", "or", "HIV", ".", "\n", "Evidence", "of", "alcohol", "abuse", "or", "history", "of", "alcohol", "abuse", "or", "illegal", "and", "/", "or", "legally", "prescribed", "drugs", ".", "\n", "IgA", "Deficiency", "\n", "History", "of", "life", "threatening", "allergy", ",", "anaphylactic", "reaction", ",", "or", "systemic", "response", "to", "human", "plasma", "derived", "products", ".", "\n", "Participation", "in", "another", "clinical", "trial", "within", "30", "days", "prior", "to", "baseline", "visit", ".", "\n", "Inability", "to", "attend", "scheduled", "clinic", "visits", "and", "/", "or", "comply", "with", "the", "study", "protocol", ".", "\n", "Any", "other", "factor", "that", ",", "in", "the", "opinion", "of", "the", "investigator", ",", "would", "prevent", "the", "patient", "from", "complying", "with", "the", "requirements", "of", "the", "protocol", ".", " \n \n" ]	[ "Scope", "Temporal", "Observation", "Condition", "Qualifier", "Reference_point", "Value", "Procedure", "Drug", "Negation", "Measurement", "Person" ]
FEV1, > = 80 %, FEV1, < 20 % of predicted value, post - bronchodilator, History, lung transplant, lung surgery, within the past two years, thoracic surgery waiting list, exacerbation, less than 6 weeks prior to screening / re - screening visit, Clinically significant, intercurrent illnesses, except for, respiratory or liver disease, secondary to AAT deficiency, cardiac , hepatic , renal , endocrine , neurological , hematological , neoplastic , immunological , skeletal or other, Active smoking, during the last 12 months from screening date, Pregnancy, lactation, Woman, child - bearing potential, not, adequate, contraception, deemed reliable by the investigator, psychiatric/ mental disorder or any other medical disorder, impair the patient 's ability to give informed consent, ongoing, viral infection, HCV , HBV and / or HIV, alcohol abuse, history, alcohol abuse or illegal and / or legally prescribed drugs, IgA Deficiency, History, life threatening allergy , anaphylactic reaction , or systemic response to human plasma derived products	NCT01217671_exc_task2	Sentence: FEV1 >= 80% or FEV1 < 20% of predicted value post-bronchodilator. FEV1/SVC>=70% History of lung transplant. Any lung surgery within the past two years. On any thoracic surgery waiting list. End of last exacerbation less than 6 weeks prior to screening/re-screening visit. Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor. Active smoking during the last 12 months from screening date. Pregnancy or lactation. Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. Evidence of ongoing viral infection with HCV, HBV and/or HIV. Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs. IgA Deficiency History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. Participation in another clinical trial within 30 days prior to baseline visit. Inability to attend scheduled clinic visits and/or comply with the study protocol. Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol. Instructions: please extract entity words from the input sentence	[ "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "O", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Condition", "O", "B-Condition", "O", "O", "B-Person", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "B-Negation", "O", "B-Qualifier", "B-Procedure", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	FEV1 >= 80% or FEV1 < 20% of predicted value post-bronchodilator. FEV1/SVC>=70% History of lung transplant. Any lung surgery within the past two years. On any thoracic surgery waiting list. End of last exacerbation less than 6 weeks prior to screening/re-screening visit. Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor. Active smoking during the last 12 months from screening date. Pregnancy or lactation. Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. Evidence of ongoing viral infection with HCV, HBV and/or HIV. Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs. IgA Deficiency History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. Participation in another clinical trial within 30 days prior to baseline visit. Inability to attend scheduled clinic visits and/or comply with the study protocol. Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol.	[ "FEV1", ">", "=", "80", "%", "or", "FEV1", "<", "20", "%", "of", "predicted", "value", "post", "-", "bronchodilator", ".", "\n", "FEV1", "/", "SVC>=70", "%", "\n", "History", "of", "lung", "transplant", ".", "\n", "Any", "lung", "surgery", "within", "the", "past", "two", "years", ".", "\n", "On", "any", "thoracic", "surgery", "waiting", "list", ".", "\n", "End", "of", "last", "exacerbation", "less", "than", "6", "weeks", "prior", "to", "screening", "/", "re", "-", "screening", "visit", ".", "\n", "Clinically", "significant", "intercurrent", "illnesses", "(", "except", "for", "respiratory", "or", "liver", "disease", "secondary", "to", "AAT", "deficiency", ")", ",", "including", ":", "cardiac", ",", "hepatic", ",", "renal", ",", "endocrine", ",", "neurological", ",", "hematological", ",", "neoplastic", ",", "immunological", ",", "skeletal", "or", "other", ")", "that", "in", "the", "opinion", "of", "the", "investigator", ",", "could", "interfere", "with", "the", "safety", ",", "compliance", "or", "other", "aspects", "of", "this", "study", ".", "Patients", "with", "well", "-", "controlled", ",", "chronic", "diseases", "could", "possibly", "be", "included", "after", "consultation", "with", "the", "treating", "physician", "and", "the", "sponsor", ".", "\n", "Active", "smoking", "during", "the", "last", "12", "months", "from", "screening", "date", ".", "\n", "Pregnancy", "or", "lactation", ".", "\n", "Woman", "of", "child", "-", "bearing", "potential", "not", "taking", "adequate", "contraception", "deemed", "reliable", "by", "the", "investigator", ".", "\n", "Presence", "of", "psychiatric/", "mental", "disorder", "or", "any", "other", "medical", "disorder", "which", "might", "impair", "the", "patient", "'s", "ability", "to", "give", "informed", "consent", "or", "to", "comply", "with", "the", "requirements", "of", "the", "study", "protocol", ".", "\n", "Evidence", "of", "ongoing", "viral", "infection", "with", "HCV", ",", "HBV", "and", "/", "or", "HIV", ".", "\n", "Evidence", "of", "alcohol", "abuse", "or", "history", "of", "alcohol", "abuse", "or", "illegal", "and", "/", "or", "legally", "prescribed", "drugs", ".", "\n", "IgA", "Deficiency", "\n", "History", "of", "life", "threatening", "allergy", ",", "anaphylactic", "reaction", ",", "or", "systemic", "response", "to", "human", "plasma", "derived", "products", ".", "\n", "Participation", "in", "another", "clinical", "trial", "within", "30", "days", "prior", "to", "baseline", "visit", ".", "\n", "Inability", "to", "attend", "scheduled", "clinic", "visits", "and", "/", "or", "comply", "with", "the", "study", "protocol", ".", "\n", "Any", "other", "factor", "that", ",", "in", "the", "opinion", "of", "the", "investigator", ",", "would", "prevent", "the", "patient", "from", "complying", "with", "the", "requirements", "of", "the", "protocol", ".", " \n \n" ]	[ "Scope", "Temporal", "Observation", "Condition", "Qualifier", "Reference_point", "Value", "Procedure", "Drug", "Negation", "Measurement", "Person" ]
ARE - containing genes is a DNA_family_or_group, AU - motif - directed display is an other_name	71773_task0	Sentence: Cloning of ARE-containing genes by AU-motif-directed display. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_family_or_group, other_name	[ "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]	Cloning of ARE-containing genes by AU-motif-directed display.	[ "Cloning", "of", "ARE", "-", "containing", "genes", "by", "AU", "-", "motif", "-", "directed", "display", "." ]	[ "DNA_domain_or_region", "protein_family_or_group", "cell_type", "other_name", "DNA_family_or_group", "RNA_family_or_group", "tissue", "cell_line", "RNA_substructure" ]
ARE - containing genes is a DNA_family_or_group, AU - motif - directed display is an other_name	71773_task1	Sentence: Cloning of ARE-containing genes by AU-motif-directed display. Instructions: please typing these entity words according to sentence: ARE - containing genes, AU - motif - directed display Options: DNA_family_or_group, other_name	[ "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]	Cloning of ARE-containing genes by AU-motif-directed display.	[ "Cloning", "of", "ARE", "-", "containing", "genes", "by", "AU", "-", "motif", "-", "directed", "display", "." ]	[ "DNA_domain_or_region", "protein_family_or_group", "cell_type", "other_name", "DNA_family_or_group", "RNA_family_or_group", "tissue", "cell_line", "RNA_substructure" ]
ARE - containing genes, AU - motif - directed display	71773_task2	Sentence: Cloning of ARE-containing genes by AU-motif-directed display. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]	Cloning of ARE-containing genes by AU-motif-directed display.	[ "Cloning", "of", "ARE", "-", "containing", "genes", "by", "AU", "-", "motif", "-", "directed", "display", "." ]	[ "DNA_domain_or_region", "protein_family_or_group", "cell_type", "other_name", "DNA_family_or_group", "RNA_family_or_group", "tissue", "cell_line", "RNA_substructure" ]
Consensus is an umlsterm, -adrenoceptor is an umlsterm, antagonists is an umlsterm, therapy is an umlsterm, benign prostatic hyperplasia is an umlsterm, BPH is an umlsterm, review is an umlsterm, double - blind studies is an umlsterm, patients is an umlsterm, clinical studies is an umlsterm, patients is an umlsterm, treatment is an umlsterm, -adrenoceptor is an umlsterm, antagonists is an umlsterm, BPH is an umlsterm, therapeutic is an umlsterm, -adrenoceptor is an umlsterm, antagonists is an umlsterm, symptom is an umlsterm, quality of life is an umlsterm, antagonists is an umlsterm, side effects is an umlsterm, side effects is an umlsterm, development is an umlsterm, antagonists is an umlsterm, treatment is an umlsterm, BPH is an umlsterm, side effects is an umlsterm, vasodilatation is an umlsterm, therapy is an umlsterm, antagonists is an umlsterm, phytotherapy is an umlsterm, treatment is an umlsterm, inhibitors is an umlsterm, combination therapy is an umlsterm, antagonists is an umlsterm, BPH is an umlsterm, patients is an umlsterm, prostatectomy is an umlsterm, patients is an umlsterm, surgical treatment is an umlsterm, therapy is an umlsterm, antagonists is an umlsterm, choice is an umlsterm, clinical trials is an umlsterm, choice is an umlsterm, antagonists is an umlsterm, safety is an umlsterm, costs is an umlsterm	DerUrologeA.70360018.eng.abstr_task0	Sentence: The International Consensus Committee recommends -adrenoceptor antagonists for medical therapy of benign prostatic hyperplasia ( BPH ) . This review evaluates 52 randomized , placebo-controlled , double-blind studies , including 10 399 patients and , moreover , 40 clinical studies including 33 600 patients undergoing treatment with -adrenoceptor antagonists because of BPH . The therapeutic efficacy of all -adrenoceptor antagonists is more or less the same . There is an average improvement of symptom scores of about 35 % and a mean increase in maximum flow rate of between 1.8 and 2.5 ml/s . Studies investigating long-term efficacy and quality of life tend to show a long-term benefit . The introduction of selective 1-adrenoceptor antagonists led to a significant reduction of side effects . These side effects are primarily caused by the vasodilatatory qualities of -blockers . The development of so-called uroselective 1A-adrenoceptor antagonists in the treatment of BPH possibly leads to further reduction of side effects related to vasodilatation . Medical therapy by 1-adrenoceptor antagonists seems to be superior to phytotherapy or treatment with 5-reductase inhibitors , as shown in a few studies . So far , it is not clear whether there is any advantage of combination therapy . The application of 1-adrenoceptor antagonists is indicated in all cases of symptomatic BPH , excluding patients who need TUR-P ( e . g . , middle lobe ) or prostatectomy . If patients are either willing or eligible to have surgical treatment , therapy by 1-adrenoceptor antagonists is a rational choice . Comparative clinical trials have to be conducted to provide additional information and to clarify which -blocker may be recommended as the first choice . Until then , those 1-adrenoceptor antagonists should be used for which safety and efficacy are well documented and which can be prescribed at reasonable costs . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	The International Consensus Committee recommends -adrenoceptor antagonists for medical therapy of benign prostatic hyperplasia ( BPH ) . This review evaluates 52 randomized , placebo-controlled , double-blind studies , including 10 399 patients and , moreover , 40 clinical studies including 33 600 patients undergoing treatment with -adrenoceptor antagonists because of BPH . The therapeutic efficacy of all -adrenoceptor antagonists is more or less the same . There is an average improvement of symptom scores of about 35 % and a mean increase in maximum flow rate of between 1.8 and 2.5 ml/s . Studies investigating long-term efficacy and quality of life tend to show a long-term benefit . The introduction of selective 1-adrenoceptor antagonists led to a significant reduction of side effects . These side effects are primarily caused by the vasodilatatory qualities of -blockers . The development of so-called uroselective 1A-adrenoceptor antagonists in the treatment of BPH possibly leads to further reduction of side effects related to vasodilatation . Medical therapy by 1-adrenoceptor antagonists seems to be superior to phytotherapy or treatment with 5-reductase inhibitors , as shown in a few studies . So far , it is not clear whether there is any advantage of combination therapy . The application of 1-adrenoceptor antagonists is indicated in all cases of symptomatic BPH , excluding patients who need TUR-P ( e . g . , middle lobe ) or prostatectomy . If patients are either willing or eligible to have surgical treatment , therapy by 1-adrenoceptor antagonists is a rational choice . Comparative clinical trials have to be conducted to provide additional information and to clarify which -blocker may be recommended as the first choice . Until then , those 1-adrenoceptor antagonists should be used for which safety and efficacy are well documented and which can be prescribed at reasonable costs .	[ "The", "International", "Consensus", "Committee", "recommends", "-adrenoceptor", "antagonists", "for", "medical", "therapy", "of", "benign", "prostatic", "hyperplasia", "(", "BPH", ")", ".", "This", "review", "evaluates", "52", "randomized", ",", "placebo", "-", "controlled", ",", "double", "-", "blind", "studies", ",", "including", "10", "399", "patients", "and", ",", "moreover", ",", "40", "clinical", "studies", "including", "33", "600", "patients", "undergoing", "treatment", "with", "-adrenoceptor", "antagonists", "because", "of", "BPH", ".", "The", "therapeutic", "efficacy", "of", "all", "-adrenoceptor", "antagonists", "is", "more", "or", "less", "the", "same", ".", "There", "is", "an", "average", "improvement", "of", "symptom", "scores", "of", "about", "35", "%", "and", "a", "mean", "increase", "in", "maximum", "flow", "rate", "of", "between", "1.8", "and", "2.5", "ml", "/", "s", ".", "Studies", "investigating", "long", "-", "term", "efficacy", "and", "quality", "of", "life", "tend", "to", "show", "a", "long", "-", "term", "benefit", ".", "The", "introduction", "of", "selective", "1-adrenoceptor", "antagonists", "led", "to", "a", "significant", "reduction", "of", "side", "effects", ".", "These", "side", "effects", "are", "primarily", "caused", "by", "the", "vasodilatatory", "qualities", "of", "-blockers", ".", "The", "development", "of", "so", "-", "called", "uroselective", "1A", "-", "adrenoceptor", "antagonists", "in", "the", "treatment", "of", "BPH", "possibly", "leads", "to", "further", "reduction", "of", "side", "effects", "related", "to", "vasodilatation", ".", "Medical", "therapy", "by", "1-adrenoceptor", "antagonists", "seems", "to", "be", "superior", "to", "phytotherapy", "or", "treatment", "with", "5-reductase", "inhibitors", ",", "as", "shown", "in", "a", "few", "studies", ".", "So", "far", ",", "it", "is", "not", "clear", "whether", "there", "is", "any", "advantage", "of", "combination", "therapy", ".", "The", "application", "of", "1-adrenoceptor", "antagonists", "is", "indicated", "in", "all", "cases", "of", "symptomatic", "BPH", ",", "excluding", "patients", "who", "need", "TUR", "-", "P", "(", "e", ".", "g", ".", ",", "middle", "lobe", ")", "or", "prostatectomy", ".", "If", "patients", "are", "either", "willing", "or", "eligible", "to", "have", "surgical", "treatment", ",", "therapy", "by", "1-adrenoceptor", "antagonists", "is", "a", "rational", "choice", ".", "Comparative", "clinical", "trials", "have", "to", "be", "conducted", "to", "provide", "additional", "information", "and", "to", "clarify", "which", "-blocker", "may", "be", "recommended", "as", "the", "first", "choice", ".", "Until", "then", ",", "those", "1-adrenoceptor", "antagonists", "should", "be", "used", "for", "which", "safety", "and", "efficacy", "are", "well", "documented", "and", "which", "can", "be", "prescribed", "at", "reasonable", "costs", "." ]	[ "umlsterm" ]
Consensus is an umlsterm, -adrenoceptor is an umlsterm, antagonists is an umlsterm, therapy is an umlsterm, benign prostatic hyperplasia is an umlsterm, BPH is an umlsterm, review is an umlsterm, double - blind studies is an umlsterm, patients is an umlsterm, clinical studies is an umlsterm, patients is an umlsterm, treatment is an umlsterm, -adrenoceptor is an umlsterm, antagonists is an umlsterm, BPH is an umlsterm, therapeutic is an umlsterm, -adrenoceptor is an umlsterm, antagonists is an umlsterm, symptom is an umlsterm, quality of life is an umlsterm, antagonists is an umlsterm, side effects is an umlsterm, side effects is an umlsterm, development is an umlsterm, antagonists is an umlsterm, treatment is an umlsterm, BPH is an umlsterm, side effects is an umlsterm, vasodilatation is an umlsterm, therapy is an umlsterm, antagonists is an umlsterm, phytotherapy is an umlsterm, treatment is an umlsterm, inhibitors is an umlsterm, combination therapy is an umlsterm, antagonists is an umlsterm, BPH is an umlsterm, patients is an umlsterm, prostatectomy is an umlsterm, patients is an umlsterm, surgical treatment is an umlsterm, therapy is an umlsterm, antagonists is an umlsterm, choice is an umlsterm, clinical trials is an umlsterm, choice is an umlsterm, antagonists is an umlsterm, safety is an umlsterm, costs is an umlsterm	DerUrologeA.70360018.eng.abstr_task1	Sentence: The International Consensus Committee recommends -adrenoceptor antagonists for medical therapy of benign prostatic hyperplasia ( BPH ) . This review evaluates 52 randomized , placebo-controlled , double-blind studies , including 10 399 patients and , moreover , 40 clinical studies including 33 600 patients undergoing treatment with -adrenoceptor antagonists because of BPH . The therapeutic efficacy of all -adrenoceptor antagonists is more or less the same . There is an average improvement of symptom scores of about 35 % and a mean increase in maximum flow rate of between 1.8 and 2.5 ml/s . Studies investigating long-term efficacy and quality of life tend to show a long-term benefit . The introduction of selective 1-adrenoceptor antagonists led to a significant reduction of side effects . These side effects are primarily caused by the vasodilatatory qualities of -blockers . The development of so-called uroselective 1A-adrenoceptor antagonists in the treatment of BPH possibly leads to further reduction of side effects related to vasodilatation . Medical therapy by 1-adrenoceptor antagonists seems to be superior to phytotherapy or treatment with 5-reductase inhibitors , as shown in a few studies . So far , it is not clear whether there is any advantage of combination therapy . The application of 1-adrenoceptor antagonists is indicated in all cases of symptomatic BPH , excluding patients who need TUR-P ( e . g . , middle lobe ) or prostatectomy . If patients are either willing or eligible to have surgical treatment , therapy by 1-adrenoceptor antagonists is a rational choice . Comparative clinical trials have to be conducted to provide additional information and to clarify which -blocker may be recommended as the first choice . Until then , those 1-adrenoceptor antagonists should be used for which safety and efficacy are well documented and which can be prescribed at reasonable costs . Instructions: please typing these entity words according to sentence: Consensus, -adrenoceptor, antagonists, therapy, benign prostatic hyperplasia, BPH, review, double - blind studies, patients, clinical studies, patients, treatment, -adrenoceptor, antagonists, BPH, therapeutic, -adrenoceptor, antagonists, symptom, quality of life, antagonists, side effects, side effects, development, antagonists, treatment, BPH, side effects, vasodilatation, therapy, antagonists, phytotherapy, treatment, inhibitors, combination therapy, antagonists, BPH, patients, prostatectomy, patients, surgical treatment, therapy, antagonists, choice, clinical trials, choice, antagonists, safety, costs Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	The International Consensus Committee recommends -adrenoceptor antagonists for medical therapy of benign prostatic hyperplasia ( BPH ) . This review evaluates 52 randomized , placebo-controlled , double-blind studies , including 10 399 patients and , moreover , 40 clinical studies including 33 600 patients undergoing treatment with -adrenoceptor antagonists because of BPH . The therapeutic efficacy of all -adrenoceptor antagonists is more or less the same . There is an average improvement of symptom scores of about 35 % and a mean increase in maximum flow rate of between 1.8 and 2.5 ml/s . Studies investigating long-term efficacy and quality of life tend to show a long-term benefit . The introduction of selective 1-adrenoceptor antagonists led to a significant reduction of side effects . These side effects are primarily caused by the vasodilatatory qualities of -blockers . The development of so-called uroselective 1A-adrenoceptor antagonists in the treatment of BPH possibly leads to further reduction of side effects related to vasodilatation . Medical therapy by 1-adrenoceptor antagonists seems to be superior to phytotherapy or treatment with 5-reductase inhibitors , as shown in a few studies . So far , it is not clear whether there is any advantage of combination therapy . The application of 1-adrenoceptor antagonists is indicated in all cases of symptomatic BPH , excluding patients who need TUR-P ( e . g . , middle lobe ) or prostatectomy . If patients are either willing or eligible to have surgical treatment , therapy by 1-adrenoceptor antagonists is a rational choice . Comparative clinical trials have to be conducted to provide additional information and to clarify which -blocker may be recommended as the first choice . Until then , those 1-adrenoceptor antagonists should be used for which safety and efficacy are well documented and which can be prescribed at reasonable costs .	[ "The", "International", "Consensus", "Committee", "recommends", "-adrenoceptor", "antagonists", "for", "medical", "therapy", "of", "benign", "prostatic", "hyperplasia", "(", "BPH", ")", ".", "This", "review", "evaluates", "52", "randomized", ",", "placebo", "-", "controlled", ",", "double", "-", "blind", "studies", ",", "including", "10", "399", "patients", "and", ",", "moreover", ",", "40", "clinical", "studies", "including", "33", "600", "patients", "undergoing", "treatment", "with", "-adrenoceptor", "antagonists", "because", "of", "BPH", ".", "The", "therapeutic", "efficacy", "of", "all", "-adrenoceptor", "antagonists", "is", "more", "or", "less", "the", "same", ".", "There", "is", "an", "average", "improvement", "of", "symptom", "scores", "of", "about", "35", "%", "and", "a", "mean", "increase", "in", "maximum", "flow", "rate", "of", "between", "1.8", "and", "2.5", "ml", "/", "s", ".", "Studies", "investigating", "long", "-", "term", "efficacy", "and", "quality", "of", "life", "tend", "to", "show", "a", "long", "-", "term", "benefit", ".", "The", "introduction", "of", "selective", "1-adrenoceptor", "antagonists", "led", "to", "a", "significant", "reduction", "of", "side", "effects", ".", "These", "side", "effects", "are", "primarily", "caused", "by", "the", "vasodilatatory", "qualities", "of", "-blockers", ".", "The", "development", "of", "so", "-", "called", "uroselective", "1A", "-", "adrenoceptor", "antagonists", "in", "the", "treatment", "of", "BPH", "possibly", "leads", "to", "further", "reduction", "of", "side", "effects", "related", "to", "vasodilatation", ".", "Medical", "therapy", "by", "1-adrenoceptor", "antagonists", "seems", "to", "be", "superior", "to", "phytotherapy", "or", "treatment", "with", "5-reductase", "inhibitors", ",", "as", "shown", "in", "a", "few", "studies", ".", "So", "far", ",", "it", "is", "not", "clear", "whether", "there", "is", "any", "advantage", "of", "combination", "therapy", ".", "The", "application", "of", "1-adrenoceptor", "antagonists", "is", "indicated", "in", "all", "cases", "of", "symptomatic", "BPH", ",", "excluding", "patients", "who", "need", "TUR", "-", "P", "(", "e", ".", "g", ".", ",", "middle", "lobe", ")", "or", "prostatectomy", ".", "If", "patients", "are", "either", "willing", "or", "eligible", "to", "have", "surgical", "treatment", ",", "therapy", "by", "1-adrenoceptor", "antagonists", "is", "a", "rational", "choice", ".", "Comparative", "clinical", "trials", "have", "to", "be", "conducted", "to", "provide", "additional", "information", "and", "to", "clarify", "which", "-blocker", "may", "be", "recommended", "as", "the", "first", "choice", ".", "Until", "then", ",", "those", "1-adrenoceptor", "antagonists", "should", "be", "used", "for", "which", "safety", "and", "efficacy", "are", "well", "documented", "and", "which", "can", "be", "prescribed", "at", "reasonable", "costs", "." ]	[ "umlsterm" ]
Consensus, -adrenoceptor, antagonists, therapy, benign prostatic hyperplasia, BPH, review, double - blind studies, patients, clinical studies, patients, treatment, -adrenoceptor, antagonists, BPH, therapeutic, -adrenoceptor, antagonists, symptom, quality of life, antagonists, side effects, side effects, development, antagonists, treatment, BPH, side effects, vasodilatation, therapy, antagonists, phytotherapy, treatment, inhibitors, combination therapy, antagonists, BPH, patients, prostatectomy, patients, surgical treatment, therapy, antagonists, choice, clinical trials, choice, antagonists, safety, costs	DerUrologeA.70360018.eng.abstr_task2	Sentence: The International Consensus Committee recommends -adrenoceptor antagonists for medical therapy of benign prostatic hyperplasia ( BPH ) . This review evaluates 52 randomized , placebo-controlled , double-blind studies , including 10 399 patients and , moreover , 40 clinical studies including 33 600 patients undergoing treatment with -adrenoceptor antagonists because of BPH . The therapeutic efficacy of all -adrenoceptor antagonists is more or less the same . There is an average improvement of symptom scores of about 35 % and a mean increase in maximum flow rate of between 1.8 and 2.5 ml/s . Studies investigating long-term efficacy and quality of life tend to show a long-term benefit . The introduction of selective 1-adrenoceptor antagonists led to a significant reduction of side effects . These side effects are primarily caused by the vasodilatatory qualities of -blockers . The development of so-called uroselective 1A-adrenoceptor antagonists in the treatment of BPH possibly leads to further reduction of side effects related to vasodilatation . Medical therapy by 1-adrenoceptor antagonists seems to be superior to phytotherapy or treatment with 5-reductase inhibitors , as shown in a few studies . So far , it is not clear whether there is any advantage of combination therapy . The application of 1-adrenoceptor antagonists is indicated in all cases of symptomatic BPH , excluding patients who need TUR-P ( e . g . , middle lobe ) or prostatectomy . If patients are either willing or eligible to have surgical treatment , therapy by 1-adrenoceptor antagonists is a rational choice . Comparative clinical trials have to be conducted to provide additional information and to clarify which -blocker may be recommended as the first choice . Until then , those 1-adrenoceptor antagonists should be used for which safety and efficacy are well documented and which can be prescribed at reasonable costs . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	The International Consensus Committee recommends -adrenoceptor antagonists for medical therapy of benign prostatic hyperplasia ( BPH ) . This review evaluates 52 randomized , placebo-controlled , double-blind studies , including 10 399 patients and , moreover , 40 clinical studies including 33 600 patients undergoing treatment with -adrenoceptor antagonists because of BPH . The therapeutic efficacy of all -adrenoceptor antagonists is more or less the same . There is an average improvement of symptom scores of about 35 % and a mean increase in maximum flow rate of between 1.8 and 2.5 ml/s . Studies investigating long-term efficacy and quality of life tend to show a long-term benefit . The introduction of selective 1-adrenoceptor antagonists led to a significant reduction of side effects . These side effects are primarily caused by the vasodilatatory qualities of -blockers . The development of so-called uroselective 1A-adrenoceptor antagonists in the treatment of BPH possibly leads to further reduction of side effects related to vasodilatation . Medical therapy by 1-adrenoceptor antagonists seems to be superior to phytotherapy or treatment with 5-reductase inhibitors , as shown in a few studies . So far , it is not clear whether there is any advantage of combination therapy . The application of 1-adrenoceptor antagonists is indicated in all cases of symptomatic BPH , excluding patients who need TUR-P ( e . g . , middle lobe ) or prostatectomy . If patients are either willing or eligible to have surgical treatment , therapy by 1-adrenoceptor antagonists is a rational choice . Comparative clinical trials have to be conducted to provide additional information and to clarify which -blocker may be recommended as the first choice . Until then , those 1-adrenoceptor antagonists should be used for which safety and efficacy are well documented and which can be prescribed at reasonable costs .	[ "The", "International", "Consensus", "Committee", "recommends", "-adrenoceptor", "antagonists", "for", "medical", "therapy", "of", "benign", "prostatic", "hyperplasia", "(", "BPH", ")", ".", "This", "review", "evaluates", "52", "randomized", ",", "placebo", "-", "controlled", ",", "double", "-", "blind", "studies", ",", "including", "10", "399", "patients", "and", ",", "moreover", ",", "40", "clinical", "studies", "including", "33", "600", "patients", "undergoing", "treatment", "with", "-adrenoceptor", "antagonists", "because", "of", "BPH", ".", "The", "therapeutic", "efficacy", "of", "all", "-adrenoceptor", "antagonists", "is", "more", "or", "less", "the", "same", ".", "There", "is", "an", "average", "improvement", "of", "symptom", "scores", "of", "about", "35", "%", "and", "a", "mean", "increase", "in", "maximum", "flow", "rate", "of", "between", "1.8", "and", "2.5", "ml", "/", "s", ".", "Studies", "investigating", "long", "-", "term", "efficacy", "and", "quality", "of", "life", "tend", "to", "show", "a", "long", "-", "term", "benefit", ".", "The", "introduction", "of", "selective", "1-adrenoceptor", "antagonists", "led", "to", "a", "significant", "reduction", "of", "side", "effects", ".", "These", "side", "effects", "are", "primarily", "caused", "by", "the", "vasodilatatory", "qualities", "of", "-blockers", ".", "The", "development", "of", "so", "-", "called", "uroselective", "1A", "-", "adrenoceptor", "antagonists", "in", "the", "treatment", "of", "BPH", "possibly", "leads", "to", "further", "reduction", "of", "side", "effects", "related", "to", "vasodilatation", ".", "Medical", "therapy", "by", "1-adrenoceptor", "antagonists", "seems", "to", "be", "superior", "to", "phytotherapy", "or", "treatment", "with", "5-reductase", "inhibitors", ",", "as", "shown", "in", "a", "few", "studies", ".", "So", "far", ",", "it", "is", "not", "clear", "whether", "there", "is", "any", "advantage", "of", "combination", "therapy", ".", "The", "application", "of", "1-adrenoceptor", "antagonists", "is", "indicated", "in", "all", "cases", "of", "symptomatic", "BPH", ",", "excluding", "patients", "who", "need", "TUR", "-", "P", "(", "e", ".", "g", ".", ",", "middle", "lobe", ")", "or", "prostatectomy", ".", "If", "patients", "are", "either", "willing", "or", "eligible", "to", "have", "surgical", "treatment", ",", "therapy", "by", "1-adrenoceptor", "antagonists", "is", "a", "rational", "choice", ".", "Comparative", "clinical", "trials", "have", "to", "be", "conducted", "to", "provide", "additional", "information", "and", "to", "clarify", "which", "-blocker", "may", "be", "recommended", "as", "the", "first", "choice", ".", "Until", "then", ",", "those", "1-adrenoceptor", "antagonists", "should", "be", "used", "for", "which", "safety", "and", "efficacy", "are", "well", "documented", "and", "which", "can", "be", "prescribed", "at", "reasonable", "costs", "." ]	[ "umlsterm" ]
relapses is an umlsterm, surgical is an umlsterm, maxilla is an umlsterm, osteotomy is an umlsterm, patients is an umlsterm, complications is an umlsterm, aim is an umlsterm, technique is an umlsterm, distraction osteogenesis is an umlsterm, patients is an umlsterm, maxillary is an umlsterm, Maxillary is an umlsterm, patients is an umlsterm, mask is an umlsterm, maxilla is an umlsterm, patients is an umlsterm, device designed is an umlsterm, patients is an umlsterm, maxilla is an umlsterm, distraction osteogenesis is an umlsterm, maxilla is an umlsterm, technique is an umlsterm, minor surgical procedure is an umlsterm	MundKieferGesichtschirurgie.0004s438.eng.abstr_task0	Sentence: Total or partial relapses after conventional surgical advancement of the maxilla following Le Fort I osteotomy in CLP patients are frequent and major complications . The aim of this investigation was to find out whether the technique of distraction osteogenesis in these patients shows more stability and whether maxillary distraction is able to replace conventional advancement . Maxillary distraction was performed in 12 patients . In two cases , a Delaire mask was used to bring the maxilla forward , ten patients were treated with the extraoral distraction device designed by Polley . In all patients , planned advancement of the maxilla could be achieved ; one partial relapse occurred . The results indicate that distraction osteogenesis offers the possibility of advancement of the maxilla with the required stability . The technique presents a major improvement which is achieved with a relatively minor surgical procedure . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]	Total or partial relapses after conventional surgical advancement of the maxilla following Le Fort I osteotomy in CLP patients are frequent and major complications . The aim of this investigation was to find out whether the technique of distraction osteogenesis in these patients shows more stability and whether maxillary distraction is able to replace conventional advancement . Maxillary distraction was performed in 12 patients . In two cases , a Delaire mask was used to bring the maxilla forward , ten patients were treated with the extraoral distraction device designed by Polley . In all patients , planned advancement of the maxilla could be achieved ; one partial relapse occurred . The results indicate that distraction osteogenesis offers the possibility of advancement of the maxilla with the required stability . The technique presents a major improvement which is achieved with a relatively minor surgical procedure .	[ "Total", "or", "partial", "relapses", "after", "conventional", "surgical", "advancement", "of", "the", "maxilla", "following", "Le", "Fort", "I", "osteotomy", "in", "CLP", "patients", "are", "frequent", "and", "major", "complications", ".", "The", "aim", "of", "this", "investigation", "was", "to", "find", "out", "whether", "the", "technique", "of", "distraction", "osteogenesis", "in", "these", "patients", "shows", "more", "stability", "and", "whether", "maxillary", "distraction", "is", "able", "to", "replace", "conventional", "advancement", ".", "Maxillary", "distraction", "was", "performed", "in", "12", "patients", ".", "In", "two", "cases", ",", "a", "Delaire", "mask", "was", "used", "to", "bring", "the", "maxilla", "forward", ",", "ten", "patients", "were", "treated", "with", "the", "extraoral", "distraction", "device", "designed", "by", "Polley", ".", "In", "all", "patients", ",", "planned", "advancement", "of", "the", "maxilla", "could", "be", "achieved", ";", "one", "partial", "relapse", "occurred", ".", "The", "results", "indicate", "that", "distraction", "osteogenesis", "offers", "the", "possibility", "of", "advancement", "of", "the", "maxilla", "with", "the", "required", "stability", ".", "The", "technique", "presents", "a", "major", "improvement", "which", "is", "achieved", "with", "a", "relatively", "minor", "surgical", "procedure", "." ]	[ "umlsterm" ]
relapses is an umlsterm, surgical is an umlsterm, maxilla is an umlsterm, osteotomy is an umlsterm, patients is an umlsterm, complications is an umlsterm, aim is an umlsterm, technique is an umlsterm, distraction osteogenesis is an umlsterm, patients is an umlsterm, maxillary is an umlsterm, Maxillary is an umlsterm, patients is an umlsterm, mask is an umlsterm, maxilla is an umlsterm, patients is an umlsterm, device designed is an umlsterm, patients is an umlsterm, maxilla is an umlsterm, distraction osteogenesis is an umlsterm, maxilla is an umlsterm, technique is an umlsterm, minor surgical procedure is an umlsterm	MundKieferGesichtschirurgie.0004s438.eng.abstr_task1	Sentence: Total or partial relapses after conventional surgical advancement of the maxilla following Le Fort I osteotomy in CLP patients are frequent and major complications . The aim of this investigation was to find out whether the technique of distraction osteogenesis in these patients shows more stability and whether maxillary distraction is able to replace conventional advancement . Maxillary distraction was performed in 12 patients . In two cases , a Delaire mask was used to bring the maxilla forward , ten patients were treated with the extraoral distraction device designed by Polley . In all patients , planned advancement of the maxilla could be achieved ; one partial relapse occurred . The results indicate that distraction osteogenesis offers the possibility of advancement of the maxilla with the required stability . The technique presents a major improvement which is achieved with a relatively minor surgical procedure . Instructions: please typing these entity words according to sentence: relapses, surgical, maxilla, osteotomy, patients, complications, aim, technique, distraction osteogenesis, patients, maxillary, Maxillary, patients, mask, maxilla, patients, device designed, patients, maxilla, distraction osteogenesis, maxilla, technique, minor surgical procedure Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]	Total or partial relapses after conventional surgical advancement of the maxilla following Le Fort I osteotomy in CLP patients are frequent and major complications . The aim of this investigation was to find out whether the technique of distraction osteogenesis in these patients shows more stability and whether maxillary distraction is able to replace conventional advancement . Maxillary distraction was performed in 12 patients . In two cases , a Delaire mask was used to bring the maxilla forward , ten patients were treated with the extraoral distraction device designed by Polley . In all patients , planned advancement of the maxilla could be achieved ; one partial relapse occurred . The results indicate that distraction osteogenesis offers the possibility of advancement of the maxilla with the required stability . The technique presents a major improvement which is achieved with a relatively minor surgical procedure .	[ "Total", "or", "partial", "relapses", "after", "conventional", "surgical", "advancement", "of", "the", "maxilla", "following", "Le", "Fort", "I", "osteotomy", "in", "CLP", "patients", "are", "frequent", "and", "major", "complications", ".", "The", "aim", "of", "this", "investigation", "was", "to", "find", "out", "whether", "the", "technique", "of", "distraction", "osteogenesis", "in", "these", "patients", "shows", "more", "stability", "and", "whether", "maxillary", "distraction", "is", "able", "to", "replace", "conventional", "advancement", ".", "Maxillary", "distraction", "was", "performed", "in", "12", "patients", ".", "In", "two", "cases", ",", "a", "Delaire", "mask", "was", "used", "to", "bring", "the", "maxilla", "forward", ",", "ten", "patients", "were", "treated", "with", "the", "extraoral", "distraction", "device", "designed", "by", "Polley", ".", "In", "all", "patients", ",", "planned", "advancement", "of", "the", "maxilla", "could", "be", "achieved", ";", "one", "partial", "relapse", "occurred", ".", "The", "results", "indicate", "that", "distraction", "osteogenesis", "offers", "the", "possibility", "of", "advancement", "of", "the", "maxilla", "with", "the", "required", "stability", ".", "The", "technique", "presents", "a", "major", "improvement", "which", "is", "achieved", "with", "a", "relatively", "minor", "surgical", "procedure", "." ]	[ "umlsterm" ]
relapses, surgical, maxilla, osteotomy, patients, complications, aim, technique, distraction osteogenesis, patients, maxillary, Maxillary, patients, mask, maxilla, patients, device designed, patients, maxilla, distraction osteogenesis, maxilla, technique, minor surgical procedure	MundKieferGesichtschirurgie.0004s438.eng.abstr_task2	Sentence: Total or partial relapses after conventional surgical advancement of the maxilla following Le Fort I osteotomy in CLP patients are frequent and major complications . The aim of this investigation was to find out whether the technique of distraction osteogenesis in these patients shows more stability and whether maxillary distraction is able to replace conventional advancement . Maxillary distraction was performed in 12 patients . In two cases , a Delaire mask was used to bring the maxilla forward , ten patients were treated with the extraoral distraction device designed by Polley . In all patients , planned advancement of the maxilla could be achieved ; one partial relapse occurred . The results indicate that distraction osteogenesis offers the possibility of advancement of the maxilla with the required stability . The technique presents a major improvement which is achieved with a relatively minor surgical procedure . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]	Total or partial relapses after conventional surgical advancement of the maxilla following Le Fort I osteotomy in CLP patients are frequent and major complications . The aim of this investigation was to find out whether the technique of distraction osteogenesis in these patients shows more stability and whether maxillary distraction is able to replace conventional advancement . Maxillary distraction was performed in 12 patients . In two cases , a Delaire mask was used to bring the maxilla forward , ten patients were treated with the extraoral distraction device designed by Polley . In all patients , planned advancement of the maxilla could be achieved ; one partial relapse occurred . The results indicate that distraction osteogenesis offers the possibility of advancement of the maxilla with the required stability . The technique presents a major improvement which is achieved with a relatively minor surgical procedure .	[ "Total", "or", "partial", "relapses", "after", "conventional", "surgical", "advancement", "of", "the", "maxilla", "following", "Le", "Fort", "I", "osteotomy", "in", "CLP", "patients", "are", "frequent", "and", "major", "complications", ".", "The", "aim", "of", "this", "investigation", "was", "to", "find", "out", "whether", "the", "technique", "of", "distraction", "osteogenesis", "in", "these", "patients", "shows", "more", "stability", "and", "whether", "maxillary", "distraction", "is", "able", "to", "replace", "conventional", "advancement", ".", "Maxillary", "distraction", "was", "performed", "in", "12", "patients", ".", "In", "two", "cases", ",", "a", "Delaire", "mask", "was", "used", "to", "bring", "the", "maxilla", "forward", ",", "ten", "patients", "were", "treated", "with", "the", "extraoral", "distraction", "device", "designed", "by", "Polley", ".", "In", "all", "patients", ",", "planned", "advancement", "of", "the", "maxilla", "could", "be", "achieved", ";", "one", "partial", "relapse", "occurred", ".", "The", "results", "indicate", "that", "distraction", "osteogenesis", "offers", "the", "possibility", "of", "advancement", "of", "the", "maxilla", "with", "the", "required", "stability", ".", "The", "technique", "presents", "a", "major", "improvement", "which", "is", "achieved", "with", "a", "relatively", "minor", "surgical", "procedure", "." ]	[ "umlsterm" ]
lymphotoxin promoter is a DNA_domain_or_region, HTLV - I tax activation is an other_name, NF - kappa B is a protein_molecule, human T - cell lines is a cell_line	83714_task0	Sentence: The lymphotoxin promoter is stimulated by HTLV-I tax activation of NF-kappa B in human T-cell lines. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, cell_line, protein_molecule, other_name	[ "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	The lymphotoxin promoter is stimulated by HTLV-I tax activation of NF-kappa B in human T-cell lines.	[ "The", "lymphotoxin", "promoter", "is", "stimulated", "by", "HTLV", "-", "I", "tax", "activation", "of", "NF", "-", "kappa", "B", "in", "human", "T", "-", "cell", "lines", "." ]	[ "other_name", "protein_molecule", "DNA_molecule", "cell_line", "DNA_domain_or_region", "protein_family_or_group", "virus", "DNA_family_or_group" ]
lymphotoxin promoter is a DNA_domain_or_region, HTLV - I tax activation is an other_name, NF - kappa B is a protein_molecule, human T - cell lines is a cell_line	83714_task1	Sentence: The lymphotoxin promoter is stimulated by HTLV-I tax activation of NF-kappa B in human T-cell lines. Instructions: please typing these entity words according to sentence: lymphotoxin promoter, HTLV - I tax activation, NF - kappa B, human T - cell lines Options: DNA_domain_or_region, cell_line, protein_molecule, other_name	[ "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	The lymphotoxin promoter is stimulated by HTLV-I tax activation of NF-kappa B in human T-cell lines.	[ "The", "lymphotoxin", "promoter", "is", "stimulated", "by", "HTLV", "-", "I", "tax", "activation", "of", "NF", "-", "kappa", "B", "in", "human", "T", "-", "cell", "lines", "." ]	[ "other_name", "protein_molecule", "DNA_molecule", "cell_line", "DNA_domain_or_region", "protein_family_or_group", "virus", "DNA_family_or_group" ]
lymphotoxin promoter, HTLV - I tax activation, NF - kappa B, human T - cell lines	83714_task2	Sentence: The lymphotoxin promoter is stimulated by HTLV-I tax activation of NF-kappa B in human T-cell lines. Instructions: please extract entity words from the input sentence	[ "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	The lymphotoxin promoter is stimulated by HTLV-I tax activation of NF-kappa B in human T-cell lines.	[ "The", "lymphotoxin", "promoter", "is", "stimulated", "by", "HTLV", "-", "I", "tax", "activation", "of", "NF", "-", "kappa", "B", "in", "human", "T", "-", "cell", "lines", "." ]	[ "other_name", "protein_molecule", "DNA_molecule", "cell_line", "DNA_domain_or_region", "protein_family_or_group", "virus", "DNA_family_or_group" ]
cardiac myosin heavy chain is a Gene/protein/RNA, actin is a Gene/protein/RNA	269_task0	Sentence: Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA	[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families.	[ "Exclusion", "of", "cardiac", "myosin", "heavy", "chain", "and", "actin", "gene", "involvement", "in", "hypertrophic", "cardiomyopathy", "of", "several", "French", "families", "." ]	[ "Gene/protein/RNA" ]
cardiac myosin heavy chain is a Gene/protein/RNA, actin is a Gene/protein/RNA	269_task1	Sentence: Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families. Instructions: please typing these entity words according to sentence: cardiac myosin heavy chain, actin Options: Gene/protein/RNA	[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families.	[ "Exclusion", "of", "cardiac", "myosin", "heavy", "chain", "and", "actin", "gene", "involvement", "in", "hypertrophic", "cardiomyopathy", "of", "several", "French", "families", "." ]	[ "Gene/protein/RNA" ]
cardiac myosin heavy chain, actin	269_task2	Sentence: Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families.	[ "Exclusion", "of", "cardiac", "myosin", "heavy", "chain", "and", "actin", "gene", "involvement", "in", "hypertrophic", "cardiomyopathy", "of", "several", "French", "families", "." ]	[ "Gene/protein/RNA" ]
Abstract is an umlsterm, software is an umlsterm, vascular surgery is an umlsterm, database is an umlsterm, vascular surgery is an umlsterm, life is an umlsterm, procedures is an umlsterm, Instruments is an umlsterm, organization is an umlsterm, functions is an umlsterm, program is an umlsterm, surgery is an umlsterm, Society is an umlsterm, Vascular Surgery is an umlsterm, program is an umlsterm, documentation is an umlsterm, computer systems is an umlsterm, budgets is an umlsterm, resources is an umlsterm, time is an umlsterm, controls is an umlsterm	Gefaesschirurgie.00050166.eng.abstr_task0	Sentence: Abstract There is little commercial medical software available for department management in the field of vascular surgery . The database VasoDat was created as an eventual study of vascular surgery 10 years ago . In the meantime it has been autonomously developed into an integral part of daily life in our department . With its relational structure it covers all routine procedures in the department with an intense working stability . Instruments have been developed for optimizing the department's organization and for supporting scientific works . Statistical functions have been added . Data exchange with other systems at the moment is restricted to the program " Quality management in carotid surgery " of the DGG ( German Society of Vascular Surgery ) , and linking to the practising program PatiO and the accompanying private liquidation . Adding tools for image storing , visual report documentation , and linking with other computer systems is possible . Extensions for supporting the management of budgets and resources , e.g. , in managing operative capacity , were developed in order to provide adequate time results and department controls . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Abstract There is little commercial medical software available for department management in the field of vascular surgery . The database VasoDat was created as an eventual study of vascular surgery 10 years ago . In the meantime it has been autonomously developed into an integral part of daily life in our department . With its relational structure it covers all routine procedures in the department with an intense working stability . Instruments have been developed for optimizing the department's organization and for supporting scientific works . Statistical functions have been added . Data exchange with other systems at the moment is restricted to the program " Quality management in carotid surgery " of the DGG ( German Society of Vascular Surgery ) , and linking to the practising program PatiO and the accompanying private liquidation . Adding tools for image storing , visual report documentation , and linking with other computer systems is possible . Extensions for supporting the management of budgets and resources , e.g. , in managing operative capacity , were developed in order to provide adequate time results and department controls .	[ "Abstract", "There", "is", "little", "commercial", "medical", "software", "available", "for", "department", "management", "in", "the", "field", "of", "vascular", "surgery", ".", "The", "database", "VasoDat", "was", "created", "as", "an", "eventual", "study", "of", "vascular", "surgery", "10", "years", "ago", ".", "In", "the", "meantime", "it", "has", "been", "autonomously", "developed", "into", "an", "integral", "part", "of", "daily", "life", "in", "our", "department", ".", "With", "its", "relational", "structure", "it", "covers", "all", "routine", "procedures", "in", "the", "department", "with", "an", "intense", "working", "stability", ".", "Instruments", "have", "been", "developed", "for", "optimizing", "the", "department", "'s", "organization", "and", "for", "supporting", "scientific", "works", ".", "Statistical", "functions", "have", "been", "added", ".", "Data", "exchange", "with", "other", "systems", "at", "the", "moment", "is", "restricted", "to", "the", "program", "\"", "Quality", "management", "in", "carotid", "surgery", "\"", "of", "the", "DGG", "(", "German", "Society", "of", "Vascular", "Surgery", ")", ",", "and", "linking", "to", "the", "practising", "program", "PatiO", "and", "the", "accompanying", "private", "liquidation", ".", "Adding", "tools", "for", "image", "storing", ",", "visual", "report", "documentation", ",", "and", "linking", "with", "other", "computer", "systems", "is", "possible", ".", "Extensions", "for", "supporting", "the", "management", "of", "budgets", "and", "resources", ",", "e.g", ".", ",", "in", "managing", "operative", "capacity", ",", "were", "developed", "in", "order", "to", "provide", "adequate", "time", "results", "and", "department", "controls", "." ]	[ "umlsterm" ]
Abstract is an umlsterm, software is an umlsterm, vascular surgery is an umlsterm, database is an umlsterm, vascular surgery is an umlsterm, life is an umlsterm, procedures is an umlsterm, Instruments is an umlsterm, organization is an umlsterm, functions is an umlsterm, program is an umlsterm, surgery is an umlsterm, Society is an umlsterm, Vascular Surgery is an umlsterm, program is an umlsterm, documentation is an umlsterm, computer systems is an umlsterm, budgets is an umlsterm, resources is an umlsterm, time is an umlsterm, controls is an umlsterm	Gefaesschirurgie.00050166.eng.abstr_task1	Sentence: Abstract There is little commercial medical software available for department management in the field of vascular surgery . The database VasoDat was created as an eventual study of vascular surgery 10 years ago . In the meantime it has been autonomously developed into an integral part of daily life in our department . With its relational structure it covers all routine procedures in the department with an intense working stability . Instruments have been developed for optimizing the department's organization and for supporting scientific works . Statistical functions have been added . Data exchange with other systems at the moment is restricted to the program " Quality management in carotid surgery " of the DGG ( German Society of Vascular Surgery ) , and linking to the practising program PatiO and the accompanying private liquidation . Adding tools for image storing , visual report documentation , and linking with other computer systems is possible . Extensions for supporting the management of budgets and resources , e.g. , in managing operative capacity , were developed in order to provide adequate time results and department controls . Instructions: please typing these entity words according to sentence: Abstract, software, vascular surgery, database, vascular surgery, life, procedures, Instruments, organization, functions, program, surgery, Society, Vascular Surgery, program, documentation, computer systems, budgets, resources, time, controls Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Abstract There is little commercial medical software available for department management in the field of vascular surgery . The database VasoDat was created as an eventual study of vascular surgery 10 years ago . In the meantime it has been autonomously developed into an integral part of daily life in our department . With its relational structure it covers all routine procedures in the department with an intense working stability . Instruments have been developed for optimizing the department's organization and for supporting scientific works . Statistical functions have been added . Data exchange with other systems at the moment is restricted to the program " Quality management in carotid surgery " of the DGG ( German Society of Vascular Surgery ) , and linking to the practising program PatiO and the accompanying private liquidation . Adding tools for image storing , visual report documentation , and linking with other computer systems is possible . Extensions for supporting the management of budgets and resources , e.g. , in managing operative capacity , were developed in order to provide adequate time results and department controls .	[ "Abstract", "There", "is", "little", "commercial", "medical", "software", "available", "for", "department", "management", "in", "the", "field", "of", "vascular", "surgery", ".", "The", "database", "VasoDat", "was", "created", "as", "an", "eventual", "study", "of", "vascular", "surgery", "10", "years", "ago", ".", "In", "the", "meantime", "it", "has", "been", "autonomously", "developed", "into", "an", "integral", "part", "of", "daily", "life", "in", "our", "department", ".", "With", "its", "relational", "structure", "it", "covers", "all", "routine", "procedures", "in", "the", "department", "with", "an", "intense", "working", "stability", ".", "Instruments", "have", "been", "developed", "for", "optimizing", "the", "department", "'s", "organization", "and", "for", "supporting", "scientific", "works", ".", "Statistical", "functions", "have", "been", "added", ".", "Data", "exchange", "with", "other", "systems", "at", "the", "moment", "is", "restricted", "to", "the", "program", "\"", "Quality", "management", "in", "carotid", "surgery", "\"", "of", "the", "DGG", "(", "German", "Society", "of", "Vascular", "Surgery", ")", ",", "and", "linking", "to", "the", "practising", "program", "PatiO", "and", "the", "accompanying", "private", "liquidation", ".", "Adding", "tools", "for", "image", "storing", ",", "visual", "report", "documentation", ",", "and", "linking", "with", "other", "computer", "systems", "is", "possible", ".", "Extensions", "for", "supporting", "the", "management", "of", "budgets", "and", "resources", ",", "e.g", ".", ",", "in", "managing", "operative", "capacity", ",", "were", "developed", "in", "order", "to", "provide", "adequate", "time", "results", "and", "department", "controls", "." ]	[ "umlsterm" ]
Abstract, software, vascular surgery, database, vascular surgery, life, procedures, Instruments, organization, functions, program, surgery, Society, Vascular Surgery, program, documentation, computer systems, budgets, resources, time, controls	Gefaesschirurgie.00050166.eng.abstr_task2	Sentence: Abstract There is little commercial medical software available for department management in the field of vascular surgery . The database VasoDat was created as an eventual study of vascular surgery 10 years ago . In the meantime it has been autonomously developed into an integral part of daily life in our department . With its relational structure it covers all routine procedures in the department with an intense working stability . Instruments have been developed for optimizing the department's organization and for supporting scientific works . Statistical functions have been added . Data exchange with other systems at the moment is restricted to the program " Quality management in carotid surgery " of the DGG ( German Society of Vascular Surgery ) , and linking to the practising program PatiO and the accompanying private liquidation . Adding tools for image storing , visual report documentation , and linking with other computer systems is possible . Extensions for supporting the management of budgets and resources , e.g. , in managing operative capacity , were developed in order to provide adequate time results and department controls . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Abstract There is little commercial medical software available for department management in the field of vascular surgery . The database VasoDat was created as an eventual study of vascular surgery 10 years ago . In the meantime it has been autonomously developed into an integral part of daily life in our department . With its relational structure it covers all routine procedures in the department with an intense working stability . Instruments have been developed for optimizing the department's organization and for supporting scientific works . Statistical functions have been added . Data exchange with other systems at the moment is restricted to the program " Quality management in carotid surgery " of the DGG ( German Society of Vascular Surgery ) , and linking to the practising program PatiO and the accompanying private liquidation . Adding tools for image storing , visual report documentation , and linking with other computer systems is possible . Extensions for supporting the management of budgets and resources , e.g. , in managing operative capacity , were developed in order to provide adequate time results and department controls .	[ "Abstract", "There", "is", "little", "commercial", "medical", "software", "available", "for", "department", "management", "in", "the", "field", "of", "vascular", "surgery", ".", "The", "database", "VasoDat", "was", "created", "as", "an", "eventual", "study", "of", "vascular", "surgery", "10", "years", "ago", ".", "In", "the", "meantime", "it", "has", "been", "autonomously", "developed", "into", "an", "integral", "part", "of", "daily", "life", "in", "our", "department", ".", "With", "its", "relational", "structure", "it", "covers", "all", "routine", "procedures", "in", "the", "department", "with", "an", "intense", "working", "stability", ".", "Instruments", "have", "been", "developed", "for", "optimizing", "the", "department", "'s", "organization", "and", "for", "supporting", "scientific", "works", ".", "Statistical", "functions", "have", "been", "added", ".", "Data", "exchange", "with", "other", "systems", "at", "the", "moment", "is", "restricted", "to", "the", "program", "\"", "Quality", "management", "in", "carotid", "surgery", "\"", "of", "the", "DGG", "(", "German", "Society", "of", "Vascular", "Surgery", ")", ",", "and", "linking", "to", "the", "practising", "program", "PatiO", "and", "the", "accompanying", "private", "liquidation", ".", "Adding", "tools", "for", "image", "storing", ",", "visual", "report", "documentation", ",", "and", "linking", "with", "other", "computer", "systems", "is", "possible", ".", "Extensions", "for", "supporting", "the", "management", "of", "budgets", "and", "resources", ",", "e.g", ".", ",", "in", "managing", "operative", "capacity", ",", "were", "developed", "in", "order", "to", "provide", "adequate", "time", "results", "and", "department", "controls", "." ]	[ "umlsterm" ]
Pankreastumoren is an umlsterm, Patienten is an umlsterm, Pankreaskarzinom is an umlsterm, Kontrastmittel is an umlsterm, Pankreasparenchymphase is an umlsterm, Pankreasloge is an umlsterm, Tumorausdehnung is an umlsterm, Tumoren is an umlsterm, Fettgewebe is an umlsterm, Duodenum is an umlsterm, Magen is an umlsterm, Lymphknoten is an umlsterm, Pankreaskarzinomen is an umlsterm	DerRadiologe.90390958.ger.abstr_task0	Sentence: Ziel unserer Untersuchungen war es , die Moeglichkeiten der Mehrzeilen-Detektor-Spiral-CT und ihre Bedeutung fuer das Staging von Pankreastumoren zu evaluieren . Bei insgesamt 50 Patienten , bei denen der Verdacht auf ein Pankreaskarzinom bestand , wurde im Rahmen der Tumorstagings ein biphasisches hochaufgeloestes Mehrzeilen-Spiral-CT mit einer Schichtkollimation von 4x1 mm , einem Pitch von 3,5-4, 120 ml Kontrastmittel , 50 ml 0,9%NaCl-Bolus, 3,0 ml/s Fluss und einem Startdelay von durchschnittlich 40 s ( Pankreasparenchymphase ) und 80 s ( portalvenoese Phase ) durchgefuehrt . Die Mehrzeilen-Spiral-CT ist in der Lage die gesamte Pankreasloge und auch die angrenzenden Organe mit hoher Ortsaufloesung in allen Raumebenen abzubilden . Die nahezu isotrope multiplanare Bildgebung erlaubt die vollstaendige Erfassung der Tumorausdehnung in allen Raumebenen und eine bessere Abgrenzung der Tumoren gegenueber dem angrenzenden Fettgewebe , den benachbarten Organen ( Gefaesse Duodenum , Magen ) , und einen sichereren Nachweis von peripankreatischen Lymphknoten . Die Mehrzeilen-Spiral-CT und der Einsatz von interaktiven multiplanaren Rekonstruktionen verbessern nachhaltig die Bestimmung der Ausdehnung von Pankreaskarzinomen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Ziel unserer Untersuchungen war es , die Moeglichkeiten der Mehrzeilen-Detektor-Spiral-CT und ihre Bedeutung fuer das Staging von Pankreastumoren zu evaluieren . Bei insgesamt 50 Patienten , bei denen der Verdacht auf ein Pankreaskarzinom bestand , wurde im Rahmen der Tumorstagings ein biphasisches hochaufgeloestes Mehrzeilen-Spiral-CT mit einer Schichtkollimation von 4x1 mm , einem Pitch von 3,5-4, 120 ml Kontrastmittel , 50 ml 0,9%NaCl-Bolus, 3,0 ml/s Fluss und einem Startdelay von durchschnittlich 40 s ( Pankreasparenchymphase ) und 80 s ( portalvenoese Phase ) durchgefuehrt . Die Mehrzeilen-Spiral-CT ist in der Lage die gesamte Pankreasloge und auch die angrenzenden Organe mit hoher Ortsaufloesung in allen Raumebenen abzubilden . Die nahezu isotrope multiplanare Bildgebung erlaubt die vollstaendige Erfassung der Tumorausdehnung in allen Raumebenen und eine bessere Abgrenzung der Tumoren gegenueber dem angrenzenden Fettgewebe , den benachbarten Organen ( Gefaesse Duodenum , Magen ) , und einen sichereren Nachweis von peripankreatischen Lymphknoten . Die Mehrzeilen-Spiral-CT und der Einsatz von interaktiven multiplanaren Rekonstruktionen verbessern nachhaltig die Bestimmung der Ausdehnung von Pankreaskarzinomen .	[ "Ziel", "unserer", "Untersuchungen", "war", "es", ",", "die", "Moeglichkeiten", "der", "Mehrzeilen", "-", "Detektor", "-", "Spiral", "-", "CT", "und", "ihre", "Bedeutung", "fuer", "das", "Staging", "von", "Pankreastumoren", "zu", "evaluieren", ".", "Bei", "insgesamt", "50", "Patienten", ",", "bei", "denen", "der", "Verdacht", "auf", "ein", "Pankreaskarzinom", "bestand", ",", "wurde", "im", "Rahmen", "der", "Tumorstagings", "ein", "biphasisches", "hochaufgeloestes", "Mehrzeilen", "-", "Spiral", "-", "CT", "mit", "einer", "Schichtkollimation", "von", "4x1", "mm", ",", "einem", "Pitch", "von", "3,5", "-", "4", ",", "120", "ml", "Kontrastmittel", ",", "50", "ml", "0,9%NaCl", "-", "Bolus", ",", "3,0", "ml", "/", "s", "Fluss", "und", "einem", "Startdelay", "von", "durchschnittlich", "40", "s", "(", "Pankreasparenchymphase", ")", "und", "80", "s", "(", "portalvenoese", "Phase", ")", "durchgefuehrt", ".", "Die", "Mehrzeilen", "-", "Spiral", "-", "CT", "ist", "in", "der", "Lage", "die", "gesamte", "Pankreasloge", "und", "auch", "die", "angrenzenden", "Organe", "mit", "hoher", "Ortsaufloesung", "in", "allen", "Raumebenen", "abzubilden", ".", "Die", "nahezu", "isotrope", "multiplanare", "Bildgebung", "erlaubt", "die", "vollstaendige", "Erfassung", "der", "Tumorausdehnung", "in", "allen", "Raumebenen", "und", "eine", "bessere", "Abgrenzung", "der", "Tumoren", "gegenueber", "dem", "angrenzenden", "Fettgewebe", ",", "den", "benachbarten", "Organen", "(", "Gefaesse", "Duodenum", ",", "Magen", ")", ",", "und", "einen", "sichereren", "Nachweis", "von", "peripankreatischen", "Lymphknoten", ".", "Die", "Mehrzeilen", "-", "Spiral", "-", "CT", "und", "der", "Einsatz", "von", "interaktiven", "multiplanaren", "Rekonstruktionen", "verbessern", "nachhaltig", "die", "Bestimmung", "der", "Ausdehnung", "von", "Pankreaskarzinomen", "." ]	[ "umlsterm" ]
Pankreastumoren is an umlsterm, Patienten is an umlsterm, Pankreaskarzinom is an umlsterm, Kontrastmittel is an umlsterm, Pankreasparenchymphase is an umlsterm, Pankreasloge is an umlsterm, Tumorausdehnung is an umlsterm, Tumoren is an umlsterm, Fettgewebe is an umlsterm, Duodenum is an umlsterm, Magen is an umlsterm, Lymphknoten is an umlsterm, Pankreaskarzinomen is an umlsterm	DerRadiologe.90390958.ger.abstr_task1	Sentence: Ziel unserer Untersuchungen war es , die Moeglichkeiten der Mehrzeilen-Detektor-Spiral-CT und ihre Bedeutung fuer das Staging von Pankreastumoren zu evaluieren . Bei insgesamt 50 Patienten , bei denen der Verdacht auf ein Pankreaskarzinom bestand , wurde im Rahmen der Tumorstagings ein biphasisches hochaufgeloestes Mehrzeilen-Spiral-CT mit einer Schichtkollimation von 4x1 mm , einem Pitch von 3,5-4, 120 ml Kontrastmittel , 50 ml 0,9%NaCl-Bolus, 3,0 ml/s Fluss und einem Startdelay von durchschnittlich 40 s ( Pankreasparenchymphase ) und 80 s ( portalvenoese Phase ) durchgefuehrt . Die Mehrzeilen-Spiral-CT ist in der Lage die gesamte Pankreasloge und auch die angrenzenden Organe mit hoher Ortsaufloesung in allen Raumebenen abzubilden . Die nahezu isotrope multiplanare Bildgebung erlaubt die vollstaendige Erfassung der Tumorausdehnung in allen Raumebenen und eine bessere Abgrenzung der Tumoren gegenueber dem angrenzenden Fettgewebe , den benachbarten Organen ( Gefaesse Duodenum , Magen ) , und einen sichereren Nachweis von peripankreatischen Lymphknoten . Die Mehrzeilen-Spiral-CT und der Einsatz von interaktiven multiplanaren Rekonstruktionen verbessern nachhaltig die Bestimmung der Ausdehnung von Pankreaskarzinomen . Instructions: please typing these entity words according to sentence: Pankreastumoren, Patienten, Pankreaskarzinom, Kontrastmittel, Pankreasparenchymphase, Pankreasloge, Tumorausdehnung, Tumoren, Fettgewebe, Duodenum, Magen, Lymphknoten, Pankreaskarzinomen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Ziel unserer Untersuchungen war es , die Moeglichkeiten der Mehrzeilen-Detektor-Spiral-CT und ihre Bedeutung fuer das Staging von Pankreastumoren zu evaluieren . Bei insgesamt 50 Patienten , bei denen der Verdacht auf ein Pankreaskarzinom bestand , wurde im Rahmen der Tumorstagings ein biphasisches hochaufgeloestes Mehrzeilen-Spiral-CT mit einer Schichtkollimation von 4x1 mm , einem Pitch von 3,5-4, 120 ml Kontrastmittel , 50 ml 0,9%NaCl-Bolus, 3,0 ml/s Fluss und einem Startdelay von durchschnittlich 40 s ( Pankreasparenchymphase ) und 80 s ( portalvenoese Phase ) durchgefuehrt . Die Mehrzeilen-Spiral-CT ist in der Lage die gesamte Pankreasloge und auch die angrenzenden Organe mit hoher Ortsaufloesung in allen Raumebenen abzubilden . Die nahezu isotrope multiplanare Bildgebung erlaubt die vollstaendige Erfassung der Tumorausdehnung in allen Raumebenen und eine bessere Abgrenzung der Tumoren gegenueber dem angrenzenden Fettgewebe , den benachbarten Organen ( Gefaesse Duodenum , Magen ) , und einen sichereren Nachweis von peripankreatischen Lymphknoten . Die Mehrzeilen-Spiral-CT und der Einsatz von interaktiven multiplanaren Rekonstruktionen verbessern nachhaltig die Bestimmung der Ausdehnung von Pankreaskarzinomen .	[ "Ziel", "unserer", "Untersuchungen", "war", "es", ",", "die", "Moeglichkeiten", "der", "Mehrzeilen", "-", "Detektor", "-", "Spiral", "-", "CT", "und", "ihre", "Bedeutung", "fuer", "das", "Staging", "von", "Pankreastumoren", "zu", "evaluieren", ".", "Bei", "insgesamt", "50", "Patienten", ",", "bei", "denen", "der", "Verdacht", "auf", "ein", "Pankreaskarzinom", "bestand", ",", "wurde", "im", "Rahmen", "der", "Tumorstagings", "ein", "biphasisches", "hochaufgeloestes", "Mehrzeilen", "-", "Spiral", "-", "CT", "mit", "einer", "Schichtkollimation", "von", "4x1", "mm", ",", "einem", "Pitch", "von", "3,5", "-", "4", ",", "120", "ml", "Kontrastmittel", ",", "50", "ml", "0,9%NaCl", "-", "Bolus", ",", "3,0", "ml", "/", "s", "Fluss", "und", "einem", "Startdelay", "von", "durchschnittlich", "40", "s", "(", "Pankreasparenchymphase", ")", "und", "80", "s", "(", "portalvenoese", "Phase", ")", "durchgefuehrt", ".", "Die", "Mehrzeilen", "-", "Spiral", "-", "CT", "ist", "in", "der", "Lage", "die", "gesamte", "Pankreasloge", "und", "auch", "die", "angrenzenden", "Organe", "mit", "hoher", "Ortsaufloesung", "in", "allen", "Raumebenen", "abzubilden", ".", "Die", "nahezu", "isotrope", "multiplanare", "Bildgebung", "erlaubt", "die", "vollstaendige", "Erfassung", "der", "Tumorausdehnung", "in", "allen", "Raumebenen", "und", "eine", "bessere", "Abgrenzung", "der", "Tumoren", "gegenueber", "dem", "angrenzenden", "Fettgewebe", ",", "den", "benachbarten", "Organen", "(", "Gefaesse", "Duodenum", ",", "Magen", ")", ",", "und", "einen", "sichereren", "Nachweis", "von", "peripankreatischen", "Lymphknoten", ".", "Die", "Mehrzeilen", "-", "Spiral", "-", "CT", "und", "der", "Einsatz", "von", "interaktiven", "multiplanaren", "Rekonstruktionen", "verbessern", "nachhaltig", "die", "Bestimmung", "der", "Ausdehnung", "von", "Pankreaskarzinomen", "." ]	[ "umlsterm" ]
Pankreastumoren, Patienten, Pankreaskarzinom, Kontrastmittel, Pankreasparenchymphase, Pankreasloge, Tumorausdehnung, Tumoren, Fettgewebe, Duodenum, Magen, Lymphknoten, Pankreaskarzinomen	DerRadiologe.90390958.ger.abstr_task2	Sentence: Ziel unserer Untersuchungen war es , die Moeglichkeiten der Mehrzeilen-Detektor-Spiral-CT und ihre Bedeutung fuer das Staging von Pankreastumoren zu evaluieren . Bei insgesamt 50 Patienten , bei denen der Verdacht auf ein Pankreaskarzinom bestand , wurde im Rahmen der Tumorstagings ein biphasisches hochaufgeloestes Mehrzeilen-Spiral-CT mit einer Schichtkollimation von 4x1 mm , einem Pitch von 3,5-4, 120 ml Kontrastmittel , 50 ml 0,9%NaCl-Bolus, 3,0 ml/s Fluss und einem Startdelay von durchschnittlich 40 s ( Pankreasparenchymphase ) und 80 s ( portalvenoese Phase ) durchgefuehrt . Die Mehrzeilen-Spiral-CT ist in der Lage die gesamte Pankreasloge und auch die angrenzenden Organe mit hoher Ortsaufloesung in allen Raumebenen abzubilden . Die nahezu isotrope multiplanare Bildgebung erlaubt die vollstaendige Erfassung der Tumorausdehnung in allen Raumebenen und eine bessere Abgrenzung der Tumoren gegenueber dem angrenzenden Fettgewebe , den benachbarten Organen ( Gefaesse Duodenum , Magen ) , und einen sichereren Nachweis von peripankreatischen Lymphknoten . Die Mehrzeilen-Spiral-CT und der Einsatz von interaktiven multiplanaren Rekonstruktionen verbessern nachhaltig die Bestimmung der Ausdehnung von Pankreaskarzinomen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Ziel unserer Untersuchungen war es , die Moeglichkeiten der Mehrzeilen-Detektor-Spiral-CT und ihre Bedeutung fuer das Staging von Pankreastumoren zu evaluieren . Bei insgesamt 50 Patienten , bei denen der Verdacht auf ein Pankreaskarzinom bestand , wurde im Rahmen der Tumorstagings ein biphasisches hochaufgeloestes Mehrzeilen-Spiral-CT mit einer Schichtkollimation von 4x1 mm , einem Pitch von 3,5-4, 120 ml Kontrastmittel , 50 ml 0,9%NaCl-Bolus, 3,0 ml/s Fluss und einem Startdelay von durchschnittlich 40 s ( Pankreasparenchymphase ) und 80 s ( portalvenoese Phase ) durchgefuehrt . Die Mehrzeilen-Spiral-CT ist in der Lage die gesamte Pankreasloge und auch die angrenzenden Organe mit hoher Ortsaufloesung in allen Raumebenen abzubilden . Die nahezu isotrope multiplanare Bildgebung erlaubt die vollstaendige Erfassung der Tumorausdehnung in allen Raumebenen und eine bessere Abgrenzung der Tumoren gegenueber dem angrenzenden Fettgewebe , den benachbarten Organen ( Gefaesse Duodenum , Magen ) , und einen sichereren Nachweis von peripankreatischen Lymphknoten . Die Mehrzeilen-Spiral-CT und der Einsatz von interaktiven multiplanaren Rekonstruktionen verbessern nachhaltig die Bestimmung der Ausdehnung von Pankreaskarzinomen .	[ "Ziel", "unserer", "Untersuchungen", "war", "es", ",", "die", "Moeglichkeiten", "der", "Mehrzeilen", "-", "Detektor", "-", "Spiral", "-", "CT", "und", "ihre", "Bedeutung", "fuer", "das", "Staging", "von", "Pankreastumoren", "zu", "evaluieren", ".", "Bei", "insgesamt", "50", "Patienten", ",", "bei", "denen", "der", "Verdacht", "auf", "ein", "Pankreaskarzinom", "bestand", ",", "wurde", "im", "Rahmen", "der", "Tumorstagings", "ein", "biphasisches", "hochaufgeloestes", "Mehrzeilen", "-", "Spiral", "-", "CT", "mit", "einer", "Schichtkollimation", "von", "4x1", "mm", ",", "einem", "Pitch", "von", "3,5", "-", "4", ",", "120", "ml", "Kontrastmittel", ",", "50", "ml", "0,9%NaCl", "-", "Bolus", ",", "3,0", "ml", "/", "s", "Fluss", "und", "einem", "Startdelay", "von", "durchschnittlich", "40", "s", "(", "Pankreasparenchymphase", ")", "und", "80", "s", "(", "portalvenoese", "Phase", ")", "durchgefuehrt", ".", "Die", "Mehrzeilen", "-", "Spiral", "-", "CT", "ist", "in", "der", "Lage", "die", "gesamte", "Pankreasloge", "und", "auch", "die", "angrenzenden", "Organe", "mit", "hoher", "Ortsaufloesung", "in", "allen", "Raumebenen", "abzubilden", ".", "Die", "nahezu", "isotrope", "multiplanare", "Bildgebung", "erlaubt", "die", "vollstaendige", "Erfassung", "der", "Tumorausdehnung", "in", "allen", "Raumebenen", "und", "eine", "bessere", "Abgrenzung", "der", "Tumoren", "gegenueber", "dem", "angrenzenden", "Fettgewebe", ",", "den", "benachbarten", "Organen", "(", "Gefaesse", "Duodenum", ",", "Magen", ")", ",", "und", "einen", "sichereren", "Nachweis", "von", "peripankreatischen", "Lymphknoten", ".", "Die", "Mehrzeilen", "-", "Spiral", "-", "CT", "und", "der", "Einsatz", "von", "interaktiven", "multiplanaren", "Rekonstruktionen", "verbessern", "nachhaltig", "die", "Bestimmung", "der", "Ausdehnung", "von", "Pankreaskarzinomen", "." ]	[ "umlsterm" ]
glucose is a compound, IGF - I is a protein, PRL is a protein	DS.d388_task0	Sentence: Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL and TSH, seen in both Snell and Ames dwarf mice. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL and TSH, seen in both Snell and Ames dwarf mice.	[ "Hence", ",", "resistance", "to", "cancer", "in", "old", "Snell", "dwarf", "mice", "may", "be", "mediated", "by", "neuroendocrine", "factors", "that", "reduce", "glucose", "utilization", "besides", "elevated", "adiponectin", ",", "reduced", "IGF", "-", "I", "and", "a", "lack", "of", "GH", ",", "PRL", "and", "TSH", ",", "seen", "in", "both", "Snell", "and", "Ames", "dwarf", "mice", "." ]	[ "compound", "protein" ]
glucose is a compound, IGF - I is a protein, PRL is a protein	DS.d388_task1	Sentence: Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL and TSH, seen in both Snell and Ames dwarf mice. Instructions: please typing these entity words according to sentence: glucose, IGF - I, PRL Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL and TSH, seen in both Snell and Ames dwarf mice.	[ "Hence", ",", "resistance", "to", "cancer", "in", "old", "Snell", "dwarf", "mice", "may", "be", "mediated", "by", "neuroendocrine", "factors", "that", "reduce", "glucose", "utilization", "besides", "elevated", "adiponectin", ",", "reduced", "IGF", "-", "I", "and", "a", "lack", "of", "GH", ",", "PRL", "and", "TSH", ",", "seen", "in", "both", "Snell", "and", "Ames", "dwarf", "mice", "." ]	[ "compound", "protein" ]
glucose, IGF - I, PRL	DS.d388_task2	Sentence: Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL and TSH, seen in both Snell and Ames dwarf mice. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL and TSH, seen in both Snell and Ames dwarf mice.	[ "Hence", ",", "resistance", "to", "cancer", "in", "old", "Snell", "dwarf", "mice", "may", "be", "mediated", "by", "neuroendocrine", "factors", "that", "reduce", "glucose", "utilization", "besides", "elevated", "adiponectin", ",", "reduced", "IGF", "-", "I", "and", "a", "lack", "of", "GH", ",", "PRL", "and", "TSH", ",", "seen", "in", "both", "Snell", "and", "Ames", "dwarf", "mice", "." ]	[ "compound", "protein" ]
severe comorbidities is a Scope, cardiovascular disease , chronic obstructive pulmonary disease , diabetes mellitus , and chronic renal dysfunction is a Scope, bad compliance is a Condition, contraindication to enrollment is a Condition, Pregnant woman is a Scope, lactating woman is a Scope, contraindication is a Condition, adjuvant chemotherapy is a Procedure	NCT02466113_exc_task0	Sentence: With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. With bad compliance or contraindication to enrollment. Pregnant woman or lactating woman. With contraindication to receive adjuvant chemotherapy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Condition, Procedure	[ "O", "B-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "O", "O", "O", "B-Condition", "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]	With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. With bad compliance or contraindication to enrollment. Pregnant woman or lactating woman. With contraindication to receive adjuvant chemotherapy.	[ "With", "severe", "comorbidities", ",", "such", "as", "cardiovascular", "disease", ",", "chronic", "obstructive", "pulmonary", "disease", ",", "diabetes", "mellitus", ",", "and", "chronic", "renal", "dysfunction", ".", "\n", "With", "bad", "compliance", "or", "contraindication", "to", "enrollment", ".", "\n", "Pregnant", "woman", "or", "lactating", "woman", ".", "\n", "With", "contraindication", "to", "receive", "adjuvant", "chemotherapy", ".", " \n \n" ]	[ "Scope", "Condition", "Procedure", "Qualifier", "Person" ]
severe comorbidities is a Scope, cardiovascular disease , chronic obstructive pulmonary disease , diabetes mellitus , and chronic renal dysfunction is a Scope, bad compliance is a Condition, contraindication to enrollment is a Condition, Pregnant woman is a Scope, lactating woman is a Scope, contraindication is a Condition, adjuvant chemotherapy is a Procedure	NCT02466113_exc_task1	Sentence: With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. With bad compliance or contraindication to enrollment. Pregnant woman or lactating woman. With contraindication to receive adjuvant chemotherapy. Instructions: please typing these entity words according to sentence: severe comorbidities, cardiovascular disease , chronic obstructive pulmonary disease , diabetes mellitus , and chronic renal dysfunction, bad compliance, contraindication to enrollment, Pregnant woman, lactating woman, contraindication, adjuvant chemotherapy Options: Scope, Condition, Procedure	[ "O", "B-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "O", "O", "O", "B-Condition", "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]	With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. With bad compliance or contraindication to enrollment. Pregnant woman or lactating woman. With contraindication to receive adjuvant chemotherapy.	[ "With", "severe", "comorbidities", ",", "such", "as", "cardiovascular", "disease", ",", "chronic", "obstructive", "pulmonary", "disease", ",", "diabetes", "mellitus", ",", "and", "chronic", "renal", "dysfunction", ".", "\n", "With", "bad", "compliance", "or", "contraindication", "to", "enrollment", ".", "\n", "Pregnant", "woman", "or", "lactating", "woman", ".", "\n", "With", "contraindication", "to", "receive", "adjuvant", "chemotherapy", ".", " \n \n" ]	[ "Scope", "Condition", "Procedure", "Qualifier", "Person" ]
severe comorbidities, cardiovascular disease , chronic obstructive pulmonary disease , diabetes mellitus , and chronic renal dysfunction, bad compliance, contraindication to enrollment, Pregnant woman, lactating woman, contraindication, adjuvant chemotherapy	NCT02466113_exc_task2	Sentence: With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. With bad compliance or contraindication to enrollment. Pregnant woman or lactating woman. With contraindication to receive adjuvant chemotherapy. Instructions: please extract entity words from the input sentence	[ "O", "B-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "O", "O", "O", "B-Condition", "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]	With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. With bad compliance or contraindication to enrollment. Pregnant woman or lactating woman. With contraindication to receive adjuvant chemotherapy.	[ "With", "severe", "comorbidities", ",", "such", "as", "cardiovascular", "disease", ",", "chronic", "obstructive", "pulmonary", "disease", ",", "diabetes", "mellitus", ",", "and", "chronic", "renal", "dysfunction", ".", "\n", "With", "bad", "compliance", "or", "contraindication", "to", "enrollment", ".", "\n", "Pregnant", "woman", "or", "lactating", "woman", ".", "\n", "With", "contraindication", "to", "receive", "adjuvant", "chemotherapy", ".", " \n \n" ]	[ "Scope", "Condition", "Procedure", "Qualifier", "Person" ]
profilin is a Individual_protein, actin is a Individual_protein	789_task0	Sentence: These regions also interact with the physiologically relevant ligands of profilin, actin and proline-rich peptides. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O" ]	These regions also interact with the physiologically relevant ligands of profilin, actin and proline-rich peptides.	[ "These", "regions", "also", "interact", "with", "the", "physiologically", "relevant", "ligands", "of", "profilin", ",", "actin", "and", "proline", "-", "rich", "peptides", "." ]	[ "Individual_protein" ]
profilin is a Individual_protein, actin is a Individual_protein	789_task1	Sentence: These regions also interact with the physiologically relevant ligands of profilin, actin and proline-rich peptides. Instructions: please typing these entity words according to sentence: profilin, actin Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O" ]	These regions also interact with the physiologically relevant ligands of profilin, actin and proline-rich peptides.	[ "These", "regions", "also", "interact", "with", "the", "physiologically", "relevant", "ligands", "of", "profilin", ",", "actin", "and", "proline", "-", "rich", "peptides", "." ]	[ "Individual_protein" ]
profilin, actin	789_task2	Sentence: These regions also interact with the physiologically relevant ligands of profilin, actin and proline-rich peptides. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O" ]	These regions also interact with the physiologically relevant ligands of profilin, actin and proline-rich peptides.	[ "These", "regions", "also", "interact", "with", "the", "physiologically", "relevant", "ligands", "of", "profilin", ",", "actin", "and", "proline", "-", "rich", "peptides", "." ]	[ "Individual_protein" ]
giant cell granuloma is an umlsterm, middle aged is an umlsterm, women is an umlsterm, skin is an umlsterm, sunlight is an umlsterm, female is an umlsterm, patient is an umlsterm, abdomen is an umlsterm, criteria is an umlsterm, giant cell granuloma is an umlsterm, findings is an umlsterm, light is an umlsterm, transient is an umlsterm, Differential diagnosis is an umlsterm, skin disorders is an umlsterm, discrimination is an umlsterm	DerHautarzt.50460490.eng.abstr_task0	Sentence: Annular elastolytic giant cell granuloma is mostly found in middle aged women in skin areas exposed to sunlight . Our 17-year-old female patient had a widespread reddish-brown lesion on the abdomen that met the histological criteria for annular elastolytic giant cell granuloma . However , the clinical findings and the localization were uncommon . UV light was excluded as a trigger . Other , still unknown , factors that might change antigenicity of elastic fibres must be considered . Spontaneous resolution suggests a transient influence of such factors . Differential diagnosis includes skin disorders with elastolysis ; discrimination especially from mid-dermal elastolysis is not well defined . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Annular elastolytic giant cell granuloma is mostly found in middle aged women in skin areas exposed to sunlight . Our 17-year-old female patient had a widespread reddish-brown lesion on the abdomen that met the histological criteria for annular elastolytic giant cell granuloma . However , the clinical findings and the localization were uncommon . UV light was excluded as a trigger . Other , still unknown , factors that might change antigenicity of elastic fibres must be considered . Spontaneous resolution suggests a transient influence of such factors . Differential diagnosis includes skin disorders with elastolysis ; discrimination especially from mid-dermal elastolysis is not well defined .	[ "Annular", "elastolytic", "giant", "cell", "granuloma", "is", "mostly", "found", "in", "middle", "aged", "women", "in", "skin", "areas", "exposed", "to", "sunlight", ".", "Our", "17-year", "-", "old", "female", "patient", "had", "a", "widespread", "reddish", "-", "brown", "lesion", "on", "the", "abdomen", "that", "met", "the", "histological", "criteria", "for", "annular", "elastolytic", "giant", "cell", "granuloma", ".", "However", ",", "the", "clinical", "findings", "and", "the", "localization", "were", "uncommon", ".", "UV", "light", "was", "excluded", "as", "a", "trigger", ".", "Other", ",", "still", "unknown", ",", "factors", "that", "might", "change", "antigenicity", "of", "elastic", "fibres", "must", "be", "considered", ".", "Spontaneous", "resolution", "suggests", "a", "transient", "influence", "of", "such", "factors", ".", "Differential", "diagnosis", "includes", "skin", "disorders", "with", "elastolysis", ";", "discrimination", "especially", "from", "mid", "-", "dermal", "elastolysis", "is", "not", "well", "defined", "." ]	[ "umlsterm" ]
giant cell granuloma is an umlsterm, middle aged is an umlsterm, women is an umlsterm, skin is an umlsterm, sunlight is an umlsterm, female is an umlsterm, patient is an umlsterm, abdomen is an umlsterm, criteria is an umlsterm, giant cell granuloma is an umlsterm, findings is an umlsterm, light is an umlsterm, transient is an umlsterm, Differential diagnosis is an umlsterm, skin disorders is an umlsterm, discrimination is an umlsterm	DerHautarzt.50460490.eng.abstr_task1	Sentence: Annular elastolytic giant cell granuloma is mostly found in middle aged women in skin areas exposed to sunlight . Our 17-year-old female patient had a widespread reddish-brown lesion on the abdomen that met the histological criteria for annular elastolytic giant cell granuloma . However , the clinical findings and the localization were uncommon . UV light was excluded as a trigger . Other , still unknown , factors that might change antigenicity of elastic fibres must be considered . Spontaneous resolution suggests a transient influence of such factors . Differential diagnosis includes skin disorders with elastolysis ; discrimination especially from mid-dermal elastolysis is not well defined . Instructions: please typing these entity words according to sentence: giant cell granuloma, middle aged, women, skin, sunlight, female, patient, abdomen, criteria, giant cell granuloma, findings, light, transient, Differential diagnosis, skin disorders, discrimination Options: umlsterm	[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Annular elastolytic giant cell granuloma is mostly found in middle aged women in skin areas exposed to sunlight . Our 17-year-old female patient had a widespread reddish-brown lesion on the abdomen that met the histological criteria for annular elastolytic giant cell granuloma . However , the clinical findings and the localization were uncommon . UV light was excluded as a trigger . Other , still unknown , factors that might change antigenicity of elastic fibres must be considered . Spontaneous resolution suggests a transient influence of such factors . Differential diagnosis includes skin disorders with elastolysis ; discrimination especially from mid-dermal elastolysis is not well defined .	[ "Annular", "elastolytic", "giant", "cell", "granuloma", "is", "mostly", "found", "in", "middle", "aged", "women", "in", "skin", "areas", "exposed", "to", "sunlight", ".", "Our", "17-year", "-", "old", "female", "patient", "had", "a", "widespread", "reddish", "-", "brown", "lesion", "on", "the", "abdomen", "that", "met", "the", "histological", "criteria", "for", "annular", "elastolytic", "giant", "cell", "granuloma", ".", "However", ",", "the", "clinical", "findings", "and", "the", "localization", "were", "uncommon", ".", "UV", "light", "was", "excluded", "as", "a", "trigger", ".", "Other", ",", "still", "unknown", ",", "factors", "that", "might", "change", "antigenicity", "of", "elastic", "fibres", "must", "be", "considered", ".", "Spontaneous", "resolution", "suggests", "a", "transient", "influence", "of", "such", "factors", ".", "Differential", "diagnosis", "includes", "skin", "disorders", "with", "elastolysis", ";", "discrimination", "especially", "from", "mid", "-", "dermal", "elastolysis", "is", "not", "well", "defined", "." ]	[ "umlsterm" ]
giant cell granuloma, middle aged, women, skin, sunlight, female, patient, abdomen, criteria, giant cell granuloma, findings, light, transient, Differential diagnosis, skin disorders, discrimination	DerHautarzt.50460490.eng.abstr_task2	Sentence: Annular elastolytic giant cell granuloma is mostly found in middle aged women in skin areas exposed to sunlight . Our 17-year-old female patient had a widespread reddish-brown lesion on the abdomen that met the histological criteria for annular elastolytic giant cell granuloma . However , the clinical findings and the localization were uncommon . UV light was excluded as a trigger . Other , still unknown , factors that might change antigenicity of elastic fibres must be considered . Spontaneous resolution suggests a transient influence of such factors . Differential diagnosis includes skin disorders with elastolysis ; discrimination especially from mid-dermal elastolysis is not well defined . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Annular elastolytic giant cell granuloma is mostly found in middle aged women in skin areas exposed to sunlight . Our 17-year-old female patient had a widespread reddish-brown lesion on the abdomen that met the histological criteria for annular elastolytic giant cell granuloma . However , the clinical findings and the localization were uncommon . UV light was excluded as a trigger . Other , still unknown , factors that might change antigenicity of elastic fibres must be considered . Spontaneous resolution suggests a transient influence of such factors . Differential diagnosis includes skin disorders with elastolysis ; discrimination especially from mid-dermal elastolysis is not well defined .	[ "Annular", "elastolytic", "giant", "cell", "granuloma", "is", "mostly", "found", "in", "middle", "aged", "women", "in", "skin", "areas", "exposed", "to", "sunlight", ".", "Our", "17-year", "-", "old", "female", "patient", "had", "a", "widespread", "reddish", "-", "brown", "lesion", "on", "the", "abdomen", "that", "met", "the", "histological", "criteria", "for", "annular", "elastolytic", "giant", "cell", "granuloma", ".", "However", ",", "the", "clinical", "findings", "and", "the", "localization", "were", "uncommon", ".", "UV", "light", "was", "excluded", "as", "a", "trigger", ".", "Other", ",", "still", "unknown", ",", "factors", "that", "might", "change", "antigenicity", "of", "elastic", "fibres", "must", "be", "considered", ".", "Spontaneous", "resolution", "suggests", "a", "transient", "influence", "of", "such", "factors", ".", "Differential", "diagnosis", "includes", "skin", "disorders", "with", "elastolysis", ";", "discrimination", "especially", "from", "mid", "-", "dermal", "elastolysis", "is", "not", "well", "defined", "." ]	[ "umlsterm" ]
depression after admission for a cardiac condition is a Participant_Condition, general - practitioner - based interventions is a Intervention_Educational, identifying depression and offering an evidence - based intervention is a Intervention_Educational, multidisciplinary telephone case conferencing is a Intervention_Educational, economic costs . is a Outcome_Other, 1455 is a Participant_Sample-size, Center for Epidemiological Studies Depression Scale is a Outcome_Mental, Hospital Anxiety and Depression Scale is a Outcome_Mental, Center for Epidemiological Studies Depression Scale scores > 27 is a Outcome_Mental, depressive symptoms is a Outcome_Mental	15547_task0	Sentence: Identification , course , and treatment of depression after admission for a cardiac condition : rationale and patient characteristics for the Identifying Depression As a Comorbid Condition ( IDACC ) project . BACKGROUND Given the prevalence of cardiovascular disease and the high rates of depression among cardiac patients , there is a need to develop practical ways to identify this population and provide pragmatic general-practitioner-based interventions for managing depression as a comorbid condition . METHOD The Identifying Depression As a Comorbid Condition ( IDACC ) study employed a hybrid design , incorporating a randomized controlled trial nested within a prospective cohort study . IDACC screened for depression in patients hospitalized in South Australia for a range of cardiac conditions , with outcome measures monitored for 12 months after discharge . The subgroup identified as depressed was entered into the nested IDACC trial , which tests the hypothesis that identifying depression and offering an evidence-based intervention to general practitioners , incorporating multidisciplinary telephone case conferencing , will reduce levels of depression , improve quality of life , and reduce associated economic costs . RESULTS At baseline , 46.3 % of 1455 participants screened were classified as depression cases on the basis of their score on the Center for Epidemiological Studies Depression Scale ( > or =16 ) or the Hospital Anxiety and Depression Scale ( > or =8 ) . Elevated scores were associated with being younger , female , divorced or separated , not employed , living alone , having a lower level of education , and having poorer health and quality of life . Nearly one fifth ( 19.4 % ) of participants had Center for Epidemiological Studies Depression Scale scores > 27 , which is indicative of major depression . CONCLUSIONS This project confirms , in an Australian setting , the high prevalence of depressive symptoms among hospitalized cardiac patients . Follow-up over 12 months will enhance understanding of the natural history of depression in cardiac patients , while the nested trial will inform on effectiveness of an intervention involving tailored advice and support to general practitioners . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Educational, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Identification , course , and treatment of depression after admission for a cardiac condition : rationale and patient characteristics for the Identifying Depression As a Comorbid Condition ( IDACC ) project . BACKGROUND Given the prevalence of cardiovascular disease and the high rates of depression among cardiac patients , there is a need to develop practical ways to identify this population and provide pragmatic general-practitioner-based interventions for managing depression as a comorbid condition . METHOD The Identifying Depression As a Comorbid Condition ( IDACC ) study employed a hybrid design , incorporating a randomized controlled trial nested within a prospective cohort study . IDACC screened for depression in patients hospitalized in South Australia for a range of cardiac conditions , with outcome measures monitored for 12 months after discharge . The subgroup identified as depressed was entered into the nested IDACC trial , which tests the hypothesis that identifying depression and offering an evidence-based intervention to general practitioners , incorporating multidisciplinary telephone case conferencing , will reduce levels of depression , improve quality of life , and reduce associated economic costs . RESULTS At baseline , 46.3 % of 1455 participants screened were classified as depression cases on the basis of their score on the Center for Epidemiological Studies Depression Scale ( > or =16 ) or the Hospital Anxiety and Depression Scale ( > or =8 ) . Elevated scores were associated with being younger , female , divorced or separated , not employed , living alone , having a lower level of education , and having poorer health and quality of life . Nearly one fifth ( 19.4 % ) of participants had Center for Epidemiological Studies Depression Scale scores > 27 , which is indicative of major depression . CONCLUSIONS This project confirms , in an Australian setting , the high prevalence of depressive symptoms among hospitalized cardiac patients . Follow-up over 12 months will enhance understanding of the natural history of depression in cardiac patients , while the nested trial will inform on effectiveness of an intervention involving tailored advice and support to general practitioners .	[ "Identification", ",", "course", ",", "and", "treatment", "of", "depression", "after", "admission", "for", "a", "cardiac", "condition", ":", "rationale", "and", "patient", "characteristics", "for", "the", "Identifying", "Depression", "As", "a", "Comorbid", "Condition", "(", "IDACC", ")", "project", ".", "BACKGROUND", "Given", "the", "prevalence", "of", "cardiovascular", "disease", "and", "the", "high", "rates", "of", "depression", "among", "cardiac", "patients", ",", "there", "is", "a", "need", "to", "develop", "practical", "ways", "to", "identify", "this", "population", "and", "provide", "pragmatic", "general", "-", "practitioner", "-", "based", "interventions", "for", "managing", "depression", "as", "a", "comorbid", "condition", ".", "METHOD", "The", "Identifying", "Depression", "As", "a", "Comorbid", "Condition", "(", "IDACC", ")", "study", "employed", "a", "hybrid", "design", ",", "incorporating", "a", "randomized", "controlled", "trial", "nested", "within", "a", "prospective", "cohort", "study", ".", "IDACC", "screened", "for", "depression", "in", "patients", "hospitalized", "in", "South", "Australia", "for", "a", "range", "of", "cardiac", "conditions", ",", "with", "outcome", "measures", "monitored", "for", "12", "months", "after", "discharge", ".", "The", "subgroup", "identified", "as", "depressed", "was", "entered", "into", "the", "nested", "IDACC", "trial", ",", "which", "tests", "the", "hypothesis", "that", "identifying", "depression", "and", "offering", "an", "evidence", "-", "based", "intervention", "to", "general", "practitioners", ",", "incorporating", "multidisciplinary", "telephone", "case", "conferencing", ",", "will", "reduce", "levels", "of", "depression", ",", "improve", "quality", "of", "life", ",", "and", "reduce", "associated", "economic", "costs", ".", "RESULTS", "At", "baseline", ",", "46.3", "%", "of", "1455", "participants", "screened", "were", "classified", "as", "depression", "cases", "on", "the", "basis", "of", "their", "score", "on", "the", "Center", "for", "Epidemiological", "Studies", "Depression", "Scale", "(", ">", "or", "=", "16", ")", "or", "the", "Hospital", "Anxiety", "and", "Depression", "Scale", "(", ">", "or", "=", "8", ")", ".", "Elevated", "scores", "were", "associated", "with", "being", "younger", ",", "female", ",", "divorced", "or", "separated", ",", "not", "employed", ",", "living", "alone", ",", "having", "a", "lower", "level", "of", "education", ",", "and", "having", "poorer", "health", "and", "quality", "of", "life", ".", "Nearly", "one", "fifth", "(", "19.4", "%", ")", "of", "participants", "had", "Center", "for", "Epidemiological", "Studies", "Depression", "Scale", "scores", ">", "27", ",", "which", "is", "indicative", "of", "major", "depression", ".", "CONCLUSIONS", "This", "project", "confirms", ",", "in", "an", "Australian", "setting", ",", "the", "high", "prevalence", "of", "depressive", "symptoms", "among", "hospitalized", "cardiac", "patients", ".", "Follow", "-", "up", "over", "12", "months", "will", "enhance", "understanding", "of", "the", "natural", "history", "of", "depression", "in", "cardiac", "patients", ",", "while", "the", "nested", "trial", "will", "inform", "on", "effectiveness", "of", "an", "intervention", "involving", "tailored", "advice", "and", "support", "to", "general", "practitioners", "." ]	[ "Intervention_Educational", "Outcome_Mental", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
depression after admission for a cardiac condition is a Participant_Condition, general - practitioner - based interventions is a Intervention_Educational, identifying depression and offering an evidence - based intervention is a Intervention_Educational, multidisciplinary telephone case conferencing is a Intervention_Educational, economic costs . is a Outcome_Other, 1455 is a Participant_Sample-size, Center for Epidemiological Studies Depression Scale is a Outcome_Mental, Hospital Anxiety and Depression Scale is a Outcome_Mental, Center for Epidemiological Studies Depression Scale scores > 27 is a Outcome_Mental, depressive symptoms is a Outcome_Mental	15547_task1	Sentence: Identification , course , and treatment of depression after admission for a cardiac condition : rationale and patient characteristics for the Identifying Depression As a Comorbid Condition ( IDACC ) project . BACKGROUND Given the prevalence of cardiovascular disease and the high rates of depression among cardiac patients , there is a need to develop practical ways to identify this population and provide pragmatic general-practitioner-based interventions for managing depression as a comorbid condition . METHOD The Identifying Depression As a Comorbid Condition ( IDACC ) study employed a hybrid design , incorporating a randomized controlled trial nested within a prospective cohort study . IDACC screened for depression in patients hospitalized in South Australia for a range of cardiac conditions , with outcome measures monitored for 12 months after discharge . The subgroup identified as depressed was entered into the nested IDACC trial , which tests the hypothesis that identifying depression and offering an evidence-based intervention to general practitioners , incorporating multidisciplinary telephone case conferencing , will reduce levels of depression , improve quality of life , and reduce associated economic costs . RESULTS At baseline , 46.3 % of 1455 participants screened were classified as depression cases on the basis of their score on the Center for Epidemiological Studies Depression Scale ( > or =16 ) or the Hospital Anxiety and Depression Scale ( > or =8 ) . Elevated scores were associated with being younger , female , divorced or separated , not employed , living alone , having a lower level of education , and having poorer health and quality of life . Nearly one fifth ( 19.4 % ) of participants had Center for Epidemiological Studies Depression Scale scores > 27 , which is indicative of major depression . CONCLUSIONS This project confirms , in an Australian setting , the high prevalence of depressive symptoms among hospitalized cardiac patients . Follow-up over 12 months will enhance understanding of the natural history of depression in cardiac patients , while the nested trial will inform on effectiveness of an intervention involving tailored advice and support to general practitioners . Instructions: please typing these entity words according to sentence: depression after admission for a cardiac condition, general - practitioner - based interventions, identifying depression and offering an evidence - based intervention, multidisciplinary telephone case conferencing, economic costs ., 1455, Center for Epidemiological Studies Depression Scale, Hospital Anxiety and Depression Scale, Center for Epidemiological Studies Depression Scale scores > 27, depressive symptoms Options: Participant_Condition, Intervention_Educational, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Identification , course , and treatment of depression after admission for a cardiac condition : rationale and patient characteristics for the Identifying Depression As a Comorbid Condition ( IDACC ) project . BACKGROUND Given the prevalence of cardiovascular disease and the high rates of depression among cardiac patients , there is a need to develop practical ways to identify this population and provide pragmatic general-practitioner-based interventions for managing depression as a comorbid condition . METHOD The Identifying Depression As a Comorbid Condition ( IDACC ) study employed a hybrid design , incorporating a randomized controlled trial nested within a prospective cohort study . IDACC screened for depression in patients hospitalized in South Australia for a range of cardiac conditions , with outcome measures monitored for 12 months after discharge . The subgroup identified as depressed was entered into the nested IDACC trial , which tests the hypothesis that identifying depression and offering an evidence-based intervention to general practitioners , incorporating multidisciplinary telephone case conferencing , will reduce levels of depression , improve quality of life , and reduce associated economic costs . RESULTS At baseline , 46.3 % of 1455 participants screened were classified as depression cases on the basis of their score on the Center for Epidemiological Studies Depression Scale ( > or =16 ) or the Hospital Anxiety and Depression Scale ( > or =8 ) . Elevated scores were associated with being younger , female , divorced or separated , not employed , living alone , having a lower level of education , and having poorer health and quality of life . Nearly one fifth ( 19.4 % ) of participants had Center for Epidemiological Studies Depression Scale scores > 27 , which is indicative of major depression . CONCLUSIONS This project confirms , in an Australian setting , the high prevalence of depressive symptoms among hospitalized cardiac patients . Follow-up over 12 months will enhance understanding of the natural history of depression in cardiac patients , while the nested trial will inform on effectiveness of an intervention involving tailored advice and support to general practitioners .	[ "Identification", ",", "course", ",", "and", "treatment", "of", "depression", "after", "admission", "for", "a", "cardiac", "condition", ":", "rationale", "and", "patient", "characteristics", "for", "the", "Identifying", "Depression", "As", "a", "Comorbid", "Condition", "(", "IDACC", ")", "project", ".", "BACKGROUND", "Given", "the", "prevalence", "of", "cardiovascular", "disease", "and", "the", "high", "rates", "of", "depression", "among", "cardiac", "patients", ",", "there", "is", "a", "need", "to", "develop", "practical", "ways", "to", "identify", "this", "population", "and", "provide", "pragmatic", "general", "-", "practitioner", "-", "based", "interventions", "for", "managing", "depression", "as", "a", "comorbid", "condition", ".", "METHOD", "The", "Identifying", "Depression", "As", "a", "Comorbid", "Condition", "(", "IDACC", ")", "study", "employed", "a", "hybrid", "design", ",", "incorporating", "a", "randomized", "controlled", "trial", "nested", "within", "a", "prospective", "cohort", "study", ".", "IDACC", "screened", "for", "depression", "in", "patients", "hospitalized", "in", "South", "Australia", "for", "a", "range", "of", "cardiac", "conditions", ",", "with", "outcome", "measures", "monitored", "for", "12", "months", "after", "discharge", ".", "The", "subgroup", "identified", "as", "depressed", "was", "entered", "into", "the", "nested", "IDACC", "trial", ",", "which", "tests", "the", "hypothesis", "that", "identifying", "depression", "and", "offering", "an", "evidence", "-", "based", "intervention", "to", "general", "practitioners", ",", "incorporating", "multidisciplinary", "telephone", "case", "conferencing", ",", "will", "reduce", "levels", "of", "depression", ",", "improve", "quality", "of", "life", ",", "and", "reduce", "associated", "economic", "costs", ".", "RESULTS", "At", "baseline", ",", "46.3", "%", "of", "1455", "participants", "screened", "were", "classified", "as", "depression", "cases", "on", "the", "basis", "of", "their", "score", "on", "the", "Center", "for", "Epidemiological", "Studies", "Depression", "Scale", "(", ">", "or", "=", "16", ")", "or", "the", "Hospital", "Anxiety", "and", "Depression", "Scale", "(", ">", "or", "=", "8", ")", ".", "Elevated", "scores", "were", "associated", "with", "being", "younger", ",", "female", ",", "divorced", "or", "separated", ",", "not", "employed", ",", "living", "alone", ",", "having", "a", "lower", "level", "of", "education", ",", "and", "having", "poorer", "health", "and", "quality", "of", "life", ".", "Nearly", "one", "fifth", "(", "19.4", "%", ")", "of", "participants", "had", "Center", "for", "Epidemiological", "Studies", "Depression", "Scale", "scores", ">", "27", ",", "which", "is", "indicative", "of", "major", "depression", ".", "CONCLUSIONS", "This", "project", "confirms", ",", "in", "an", "Australian", "setting", ",", "the", "high", "prevalence", "of", "depressive", "symptoms", "among", "hospitalized", "cardiac", "patients", ".", "Follow", "-", "up", "over", "12", "months", "will", "enhance", "understanding", "of", "the", "natural", "history", "of", "depression", "in", "cardiac", "patients", ",", "while", "the", "nested", "trial", "will", "inform", "on", "effectiveness", "of", "an", "intervention", "involving", "tailored", "advice", "and", "support", "to", "general", "practitioners", "." ]	[ "Intervention_Educational", "Outcome_Mental", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
depression after admission for a cardiac condition, general - practitioner - based interventions, identifying depression and offering an evidence - based intervention, multidisciplinary telephone case conferencing, economic costs ., 1455, Center for Epidemiological Studies Depression Scale, Hospital Anxiety and Depression Scale, Center for Epidemiological Studies Depression Scale scores > 27, depressive symptoms	15547_task2	Sentence: Identification , course , and treatment of depression after admission for a cardiac condition : rationale and patient characteristics for the Identifying Depression As a Comorbid Condition ( IDACC ) project . BACKGROUND Given the prevalence of cardiovascular disease and the high rates of depression among cardiac patients , there is a need to develop practical ways to identify this population and provide pragmatic general-practitioner-based interventions for managing depression as a comorbid condition . METHOD The Identifying Depression As a Comorbid Condition ( IDACC ) study employed a hybrid design , incorporating a randomized controlled trial nested within a prospective cohort study . IDACC screened for depression in patients hospitalized in South Australia for a range of cardiac conditions , with outcome measures monitored for 12 months after discharge . The subgroup identified as depressed was entered into the nested IDACC trial , which tests the hypothesis that identifying depression and offering an evidence-based intervention to general practitioners , incorporating multidisciplinary telephone case conferencing , will reduce levels of depression , improve quality of life , and reduce associated economic costs . RESULTS At baseline , 46.3 % of 1455 participants screened were classified as depression cases on the basis of their score on the Center for Epidemiological Studies Depression Scale ( > or =16 ) or the Hospital Anxiety and Depression Scale ( > or =8 ) . Elevated scores were associated with being younger , female , divorced or separated , not employed , living alone , having a lower level of education , and having poorer health and quality of life . Nearly one fifth ( 19.4 % ) of participants had Center for Epidemiological Studies Depression Scale scores > 27 , which is indicative of major depression . CONCLUSIONS This project confirms , in an Australian setting , the high prevalence of depressive symptoms among hospitalized cardiac patients . Follow-up over 12 months will enhance understanding of the natural history of depression in cardiac patients , while the nested trial will inform on effectiveness of an intervention involving tailored advice and support to general practitioners . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Identification , course , and treatment of depression after admission for a cardiac condition : rationale and patient characteristics for the Identifying Depression As a Comorbid Condition ( IDACC ) project . BACKGROUND Given the prevalence of cardiovascular disease and the high rates of depression among cardiac patients , there is a need to develop practical ways to identify this population and provide pragmatic general-practitioner-based interventions for managing depression as a comorbid condition . METHOD The Identifying Depression As a Comorbid Condition ( IDACC ) study employed a hybrid design , incorporating a randomized controlled trial nested within a prospective cohort study . IDACC screened for depression in patients hospitalized in South Australia for a range of cardiac conditions , with outcome measures monitored for 12 months after discharge . The subgroup identified as depressed was entered into the nested IDACC trial , which tests the hypothesis that identifying depression and offering an evidence-based intervention to general practitioners , incorporating multidisciplinary telephone case conferencing , will reduce levels of depression , improve quality of life , and reduce associated economic costs . RESULTS At baseline , 46.3 % of 1455 participants screened were classified as depression cases on the basis of their score on the Center for Epidemiological Studies Depression Scale ( > or =16 ) or the Hospital Anxiety and Depression Scale ( > or =8 ) . Elevated scores were associated with being younger , female , divorced or separated , not employed , living alone , having a lower level of education , and having poorer health and quality of life . Nearly one fifth ( 19.4 % ) of participants had Center for Epidemiological Studies Depression Scale scores > 27 , which is indicative of major depression . CONCLUSIONS This project confirms , in an Australian setting , the high prevalence of depressive symptoms among hospitalized cardiac patients . Follow-up over 12 months will enhance understanding of the natural history of depression in cardiac patients , while the nested trial will inform on effectiveness of an intervention involving tailored advice and support to general practitioners .	[ "Identification", ",", "course", ",", "and", "treatment", "of", "depression", "after", "admission", "for", "a", "cardiac", "condition", ":", "rationale", "and", "patient", "characteristics", "for", "the", "Identifying", "Depression", "As", "a", "Comorbid", "Condition", "(", "IDACC", ")", "project", ".", "BACKGROUND", "Given", "the", "prevalence", "of", "cardiovascular", "disease", "and", "the", "high", "rates", "of", "depression", "among", "cardiac", "patients", ",", "there", "is", "a", "need", "to", "develop", "practical", "ways", "to", "identify", "this", "population", "and", "provide", "pragmatic", "general", "-", "practitioner", "-", "based", "interventions", "for", "managing", "depression", "as", "a", "comorbid", "condition", ".", "METHOD", "The", "Identifying", "Depression", "As", "a", "Comorbid", "Condition", "(", "IDACC", ")", "study", "employed", "a", "hybrid", "design", ",", "incorporating", "a", "randomized", "controlled", "trial", "nested", "within", "a", "prospective", "cohort", "study", ".", "IDACC", "screened", "for", "depression", "in", "patients", "hospitalized", "in", "South", "Australia", "for", "a", "range", "of", "cardiac", "conditions", ",", "with", "outcome", "measures", "monitored", "for", "12", "months", "after", "discharge", ".", "The", "subgroup", "identified", "as", "depressed", "was", "entered", "into", "the", "nested", "IDACC", "trial", ",", "which", "tests", "the", "hypothesis", "that", "identifying", "depression", "and", "offering", "an", "evidence", "-", "based", "intervention", "to", "general", "practitioners", ",", "incorporating", "multidisciplinary", "telephone", "case", "conferencing", ",", "will", "reduce", "levels", "of", "depression", ",", "improve", "quality", "of", "life", ",", "and", "reduce", "associated", "economic", "costs", ".", "RESULTS", "At", "baseline", ",", "46.3", "%", "of", "1455", "participants", "screened", "were", "classified", "as", "depression", "cases", "on", "the", "basis", "of", "their", "score", "on", "the", "Center", "for", "Epidemiological", "Studies", "Depression", "Scale", "(", ">", "or", "=", "16", ")", "or", "the", "Hospital", "Anxiety", "and", "Depression", "Scale", "(", ">", "or", "=", "8", ")", ".", "Elevated", "scores", "were", "associated", "with", "being", "younger", ",", "female", ",", "divorced", "or", "separated", ",", "not", "employed", ",", "living", "alone", ",", "having", "a", "lower", "level", "of", "education", ",", "and", "having", "poorer", "health", "and", "quality", "of", "life", ".", "Nearly", "one", "fifth", "(", "19.4", "%", ")", "of", "participants", "had", "Center", "for", "Epidemiological", "Studies", "Depression", "Scale", "scores", ">", "27", ",", "which", "is", "indicative", "of", "major", "depression", ".", "CONCLUSIONS", "This", "project", "confirms", ",", "in", "an", "Australian", "setting", ",", "the", "high", "prevalence", "of", "depressive", "symptoms", "among", "hospitalized", "cardiac", "patients", ".", "Follow", "-", "up", "over", "12", "months", "will", "enhance", "understanding", "of", "the", "natural", "history", "of", "depression", "in", "cardiac", "patients", ",", "while", "the", "nested", "trial", "will", "inform", "on", "effectiveness", "of", "an", "intervention", "involving", "tailored", "advice", "and", "support", "to", "general", "practitioners", "." ]	[ "Intervention_Educational", "Outcome_Mental", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
Cyclooxygenase is a GENE-N, 5-lipoxygenase is a GENE-Y, cyclooxygenase is a GENE-N, COX is a GENE-N, 5-lipoxygenase is a GENE-Y, 5-LOX is a GENE-Y, COX is a GENE-N, prostaglandins is a CHEMICAL, 5-LOX is a GENE-Y, leukotrienes is a CHEMICAL, COX-1 is a GENE-Y, COX-2 is a GENE-Y, NS-398 is a CHEMICAL, COX-1 is a GENE-Y, COX-2 is a GENE-Y, ibuprofen is a CHEMICAL, nitric oxide is a CHEMICAL, NO is a CHEMICAL, indomethacin is a CHEMICAL, ibuprofen is a CHEMICAL, flurbiprofen is a CHEMICAL, 5-LOX is a GENE-Y, REV 5901 is a CHEMICAL, 5-LOX activating protein is a GENE-Y, FLAP is a GENE-Y, MK-886 is a CHEMICAL, FLAP is a GENE-Y, COX is a GENE-N, 5-LOX is a GENE-Y, COX is a GENE-N, 5-LOX is a GENE-Y	33469_task0	Sentence: Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neuroinflammation and oxidative stress are believed to be contributing factors to neurodegeneration in normal aging, as well as in age-related neurological disorders. Reactive microglia are found in increased numbers in aging brain and are prominently associated with lesions in such age-related degenerative conditions as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). In vitro, stimulated microglia or microglial-like cells secrete neurotoxic materials and are generators of free radicals through their respiratory burst system. Agents that suppress microglial activation are therefore candidates for neuroprotection. We have developed quantitative in vitro assays for measuring neurotoxicity of microglia or other mononuclear phagocytes. Neuronal like SH-SY5Y cells are cultured in supernatants from activated cells of the human monocytic THP-1 line and their survival is followed. Respiratory burst is directly measured on the activated cells. We tested inhibitors of the cyclooxygenase (COX) or the 5-lipoxygenase (5-LOX) pathways as possible neuroprotective agents. The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes. We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion. They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886. The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin. Combinations of COX and 5-LOX inhibitors were more effective than single inhibitors. The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL	[ "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neuroinflammation and oxidative stress are believed to be contributing factors to neurodegeneration in normal aging, as well as in age-related neurological disorders. Reactive microglia are found in increased numbers in aging brain and are prominently associated with lesions in such age-related degenerative conditions as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). In vitro, stimulated microglia or microglial-like cells secrete neurotoxic materials and are generators of free radicals through their respiratory burst system. Agents that suppress microglial activation are therefore candidates for neuroprotection. We have developed quantitative in vitro assays for measuring neurotoxicity of microglia or other mononuclear phagocytes. Neuronal like SH-SY5Y cells are cultured in supernatants from activated cells of the human monocytic THP-1 line and their survival is followed. Respiratory burst is directly measured on the activated cells. We tested inhibitors of the cyclooxygenase (COX) or the 5-lipoxygenase (5-LOX) pathways as possible neuroprotective agents. The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes. We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion. They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886. The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin. Combinations of COX and 5-LOX inhibitors were more effective than single inhibitors. The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class.	[ "Cyclooxygenase", "and", "5-lipoxygenase", "inhibitors", "protect", "against", "mononuclear", "phagocyte", "neurotoxicity", ".", "\n", "Neuroinflammation", "and", "oxidative", "stress", "are", "believed", "to", "be", "contributing", "factors", "to", "neurodegeneration", "in", "normal", "aging", ",", "as", "well", "as", "in", "age", "-", "related", "neurological", "disorders", ".", "Reactive", "microglia", "are", "found", "in", "increased", "numbers", "in", "aging", "brain", "and", "are", "prominently", "associated", "with", "lesions", "in", "such", "age", "-", "related", "degenerative", "conditions", "as", "Alzheimer", "'s", "disease", "(", "AD", ")", ",", "Parkinson", "'s", "disease", "(", "PD", ")", "and", "amyotrophic", "lateral", "sclerosis", "(", "ALS", ")", ".", "In", "vitro", ",", "stimulated", "microglia", "or", "microglial", "-", "like", "cells", "secrete", "neurotoxic", "materials", "and", "are", "generators", "of", "free", "radicals", "through", "their", "respiratory", "burst", "system", ".", "Agents", "that", "suppress", "microglial", "activation", "are", "therefore", "candidates", "for", "neuroprotection", ".", "We", "have", "developed", "quantitative", "in", "vitro", "assays", "for", "measuring", "neurotoxicity", "of", "microglia", "or", "other", "mononuclear", "phagocytes", ".", "Neuronal", "like", "SH", "-", "SY5Y", "cells", "are", "cultured", "in", "supernatants", "from", "activated", "cells", "of", "the", "human", "monocytic", "THP-1", "line", "and", "their", "survival", "is", "followed", ".", "Respiratory", "burst", "is", "directly", "measured", "on", "the", "activated", "cells", ".", "We", "tested", "inhibitors", "of", "the", "cyclooxygenase", "(", "COX", ")", "or", "the", "5-lipoxygenase", "(", "5-LOX", ")", "pathways", "as", "possible", "neuroprotective", "agents", ".", "The", "COX", "pathway", "generates", "inflammatory", "prostaglandins", ",", "while", "the", "5-LOX", "pathway", "generates", "inflammatory", "leukotrienes", ".", "We", "found", "that", "inhibitors", "of", "both", "these", "pathways", "suppressed", "neurotoxicity", "in", "a", "dose", "-", "dependent", "fashion", ".", "They", "included", "the", "COX-1", "inhibitor", "indomethacin", ";", "the", "COX-2", "inhibitor", "NS-398", ";", "the", "mixed", "COX-1", "/", "COX-2", "inhibitor", "ibuprofen", ";", "the", "nitric", "oxide", "(", "NO", ")", "derivatives", "of", "indomethacin", ",", "ibuprofen", "and", "flurbiprofen", ";", "the", "5-LOX", "inhibitor", "REV", "5901", ";", "and", "the", "5-LOX", "activating", "protein", "(", "FLAP", ")", "inhibitor", "MK-886", ".", "The", "FLAP", "inhibitor", "also", "reduced", "respiratory", "burst", "activity", "in", "a", "more", "potent", "manner", "than", "indomethacin", ".", "Combinations", "of", "COX", "and", "5-LOX", "inhibitors", "were", "more", "effective", "than", "single", "inhibitors", ".", "The", "data", "suggest", "that", "both", "COX", "inhibitors", "and", "5-LOX", "inhibitors", "may", "be", "neuroprotective", "in", "vivo", "by", "suppressing", "toxic", "actions", "of", "microglia", "/", "macrophages", ",", "and", "that", "combinations", "of", "the", "two", "might", "have", "greater", "therapeutic", "potential", "than", "single", "inhibitors", "of", "either", "class", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
Cyclooxygenase is a GENE-N, 5-lipoxygenase is a GENE-Y, cyclooxygenase is a GENE-N, COX is a GENE-N, 5-lipoxygenase is a GENE-Y, 5-LOX is a GENE-Y, COX is a GENE-N, prostaglandins is a CHEMICAL, 5-LOX is a GENE-Y, leukotrienes is a CHEMICAL, COX-1 is a GENE-Y, COX-2 is a GENE-Y, NS-398 is a CHEMICAL, COX-1 is a GENE-Y, COX-2 is a GENE-Y, ibuprofen is a CHEMICAL, nitric oxide is a CHEMICAL, NO is a CHEMICAL, indomethacin is a CHEMICAL, ibuprofen is a CHEMICAL, flurbiprofen is a CHEMICAL, 5-LOX is a GENE-Y, REV 5901 is a CHEMICAL, 5-LOX activating protein is a GENE-Y, FLAP is a GENE-Y, MK-886 is a CHEMICAL, FLAP is a GENE-Y, COX is a GENE-N, 5-LOX is a GENE-Y, COX is a GENE-N, 5-LOX is a GENE-Y	33469_task1	Sentence: Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neuroinflammation and oxidative stress are believed to be contributing factors to neurodegeneration in normal aging, as well as in age-related neurological disorders. Reactive microglia are found in increased numbers in aging brain and are prominently associated with lesions in such age-related degenerative conditions as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). In vitro, stimulated microglia or microglial-like cells secrete neurotoxic materials and are generators of free radicals through their respiratory burst system. Agents that suppress microglial activation are therefore candidates for neuroprotection. We have developed quantitative in vitro assays for measuring neurotoxicity of microglia or other mononuclear phagocytes. Neuronal like SH-SY5Y cells are cultured in supernatants from activated cells of the human monocytic THP-1 line and their survival is followed. Respiratory burst is directly measured on the activated cells. We tested inhibitors of the cyclooxygenase (COX) or the 5-lipoxygenase (5-LOX) pathways as possible neuroprotective agents. The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes. We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion. They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886. The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin. Combinations of COX and 5-LOX inhibitors were more effective than single inhibitors. The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class. Instructions: please typing these entity words according to sentence: Cyclooxygenase, 5-lipoxygenase, cyclooxygenase, COX, 5-lipoxygenase, 5-LOX, COX, prostaglandins, 5-LOX, leukotrienes, COX-1, COX-2, NS-398, COX-1, COX-2, ibuprofen, nitric oxide, NO, indomethacin, ibuprofen, flurbiprofen, 5-LOX, REV 5901, 5-LOX activating protein, FLAP, MK-886, FLAP, COX, 5-LOX, COX, 5-LOX Options: GENE-Y, GENE-N, CHEMICAL	[ "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neuroinflammation and oxidative stress are believed to be contributing factors to neurodegeneration in normal aging, as well as in age-related neurological disorders. Reactive microglia are found in increased numbers in aging brain and are prominently associated with lesions in such age-related degenerative conditions as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). In vitro, stimulated microglia or microglial-like cells secrete neurotoxic materials and are generators of free radicals through their respiratory burst system. Agents that suppress microglial activation are therefore candidates for neuroprotection. We have developed quantitative in vitro assays for measuring neurotoxicity of microglia or other mononuclear phagocytes. Neuronal like SH-SY5Y cells are cultured in supernatants from activated cells of the human monocytic THP-1 line and their survival is followed. Respiratory burst is directly measured on the activated cells. We tested inhibitors of the cyclooxygenase (COX) or the 5-lipoxygenase (5-LOX) pathways as possible neuroprotective agents. The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes. We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion. They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886. The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin. Combinations of COX and 5-LOX inhibitors were more effective than single inhibitors. The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class.	[ "Cyclooxygenase", "and", "5-lipoxygenase", "inhibitors", "protect", "against", "mononuclear", "phagocyte", "neurotoxicity", ".", "\n", "Neuroinflammation", "and", "oxidative", "stress", "are", "believed", "to", "be", "contributing", "factors", "to", "neurodegeneration", "in", "normal", "aging", ",", "as", "well", "as", "in", "age", "-", "related", "neurological", "disorders", ".", "Reactive", "microglia", "are", "found", "in", "increased", "numbers", "in", "aging", "brain", "and", "are", "prominently", "associated", "with", "lesions", "in", "such", "age", "-", "related", "degenerative", "conditions", "as", "Alzheimer", "'s", "disease", "(", "AD", ")", ",", "Parkinson", "'s", "disease", "(", "PD", ")", "and", "amyotrophic", "lateral", "sclerosis", "(", "ALS", ")", ".", "In", "vitro", ",", "stimulated", "microglia", "or", "microglial", "-", "like", "cells", "secrete", "neurotoxic", "materials", "and", "are", "generators", "of", "free", "radicals", "through", "their", "respiratory", "burst", "system", ".", "Agents", "that", "suppress", "microglial", "activation", "are", "therefore", "candidates", "for", "neuroprotection", ".", "We", "have", "developed", "quantitative", "in", "vitro", "assays", "for", "measuring", "neurotoxicity", "of", "microglia", "or", "other", "mononuclear", "phagocytes", ".", "Neuronal", "like", "SH", "-", "SY5Y", "cells", "are", "cultured", "in", "supernatants", "from", "activated", "cells", "of", "the", "human", "monocytic", "THP-1", "line", "and", "their", "survival", "is", "followed", ".", "Respiratory", "burst", "is", "directly", "measured", "on", "the", "activated", "cells", ".", "We", "tested", "inhibitors", "of", "the", "cyclooxygenase", "(", "COX", ")", "or", "the", "5-lipoxygenase", "(", "5-LOX", ")", "pathways", "as", "possible", "neuroprotective", "agents", ".", "The", "COX", "pathway", "generates", "inflammatory", "prostaglandins", ",", "while", "the", "5-LOX", "pathway", "generates", "inflammatory", "leukotrienes", ".", "We", "found", "that", "inhibitors", "of", "both", "these", "pathways", "suppressed", "neurotoxicity", "in", "a", "dose", "-", "dependent", "fashion", ".", "They", "included", "the", "COX-1", "inhibitor", "indomethacin", ";", "the", "COX-2", "inhibitor", "NS-398", ";", "the", "mixed", "COX-1", "/", "COX-2", "inhibitor", "ibuprofen", ";", "the", "nitric", "oxide", "(", "NO", ")", "derivatives", "of", "indomethacin", ",", "ibuprofen", "and", "flurbiprofen", ";", "the", "5-LOX", "inhibitor", "REV", "5901", ";", "and", "the", "5-LOX", "activating", "protein", "(", "FLAP", ")", "inhibitor", "MK-886", ".", "The", "FLAP", "inhibitor", "also", "reduced", "respiratory", "burst", "activity", "in", "a", "more", "potent", "manner", "than", "indomethacin", ".", "Combinations", "of", "COX", "and", "5-LOX", "inhibitors", "were", "more", "effective", "than", "single", "inhibitors", ".", "The", "data", "suggest", "that", "both", "COX", "inhibitors", "and", "5-LOX", "inhibitors", "may", "be", "neuroprotective", "in", "vivo", "by", "suppressing", "toxic", "actions", "of", "microglia", "/", "macrophages", ",", "and", "that", "combinations", "of", "the", "two", "might", "have", "greater", "therapeutic", "potential", "than", "single", "inhibitors", "of", "either", "class", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
Cyclooxygenase, 5-lipoxygenase, cyclooxygenase, COX, 5-lipoxygenase, 5-LOX, COX, prostaglandins, 5-LOX, leukotrienes, COX-1, COX-2, NS-398, COX-1, COX-2, ibuprofen, nitric oxide, NO, indomethacin, ibuprofen, flurbiprofen, 5-LOX, REV 5901, 5-LOX activating protein, FLAP, MK-886, FLAP, COX, 5-LOX, COX, 5-LOX	33469_task2	Sentence: Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neuroinflammation and oxidative stress are believed to be contributing factors to neurodegeneration in normal aging, as well as in age-related neurological disorders. Reactive microglia are found in increased numbers in aging brain and are prominently associated with lesions in such age-related degenerative conditions as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). In vitro, stimulated microglia or microglial-like cells secrete neurotoxic materials and are generators of free radicals through their respiratory burst system. Agents that suppress microglial activation are therefore candidates for neuroprotection. We have developed quantitative in vitro assays for measuring neurotoxicity of microglia or other mononuclear phagocytes. Neuronal like SH-SY5Y cells are cultured in supernatants from activated cells of the human monocytic THP-1 line and their survival is followed. Respiratory burst is directly measured on the activated cells. We tested inhibitors of the cyclooxygenase (COX) or the 5-lipoxygenase (5-LOX) pathways as possible neuroprotective agents. The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes. We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion. They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886. The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin. Combinations of COX and 5-LOX inhibitors were more effective than single inhibitors. The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class. Instructions: please extract entity words from the input sentence	[ "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neuroinflammation and oxidative stress are believed to be contributing factors to neurodegeneration in normal aging, as well as in age-related neurological disorders. Reactive microglia are found in increased numbers in aging brain and are prominently associated with lesions in such age-related degenerative conditions as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). In vitro, stimulated microglia or microglial-like cells secrete neurotoxic materials and are generators of free radicals through their respiratory burst system. Agents that suppress microglial activation are therefore candidates for neuroprotection. We have developed quantitative in vitro assays for measuring neurotoxicity of microglia or other mononuclear phagocytes. Neuronal like SH-SY5Y cells are cultured in supernatants from activated cells of the human monocytic THP-1 line and their survival is followed. Respiratory burst is directly measured on the activated cells. We tested inhibitors of the cyclooxygenase (COX) or the 5-lipoxygenase (5-LOX) pathways as possible neuroprotective agents. The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes. We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion. They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886. The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin. Combinations of COX and 5-LOX inhibitors were more effective than single inhibitors. The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class.	[ "Cyclooxygenase", "and", "5-lipoxygenase", "inhibitors", "protect", "against", "mononuclear", "phagocyte", "neurotoxicity", ".", "\n", "Neuroinflammation", "and", "oxidative", "stress", "are", "believed", "to", "be", "contributing", "factors", "to", "neurodegeneration", "in", "normal", "aging", ",", "as", "well", "as", "in", "age", "-", "related", "neurological", "disorders", ".", "Reactive", "microglia", "are", "found", "in", "increased", "numbers", "in", "aging", "brain", "and", "are", "prominently", "associated", "with", "lesions", "in", "such", "age", "-", "related", "degenerative", "conditions", "as", "Alzheimer", "'s", "disease", "(", "AD", ")", ",", "Parkinson", "'s", "disease", "(", "PD", ")", "and", "amyotrophic", "lateral", "sclerosis", "(", "ALS", ")", ".", "In", "vitro", ",", "stimulated", "microglia", "or", "microglial", "-", "like", "cells", "secrete", "neurotoxic", "materials", "and", "are", "generators", "of", "free", "radicals", "through", "their", "respiratory", "burst", "system", ".", "Agents", "that", "suppress", "microglial", "activation", "are", "therefore", "candidates", "for", "neuroprotection", ".", "We", "have", "developed", "quantitative", "in", "vitro", "assays", "for", "measuring", "neurotoxicity", "of", "microglia", "or", "other", "mononuclear", "phagocytes", ".", "Neuronal", "like", "SH", "-", "SY5Y", "cells", "are", "cultured", "in", "supernatants", "from", "activated", "cells", "of", "the", "human", "monocytic", "THP-1", "line", "and", "their", "survival", "is", "followed", ".", "Respiratory", "burst", "is", "directly", "measured", "on", "the", "activated", "cells", ".", "We", "tested", "inhibitors", "of", "the", "cyclooxygenase", "(", "COX", ")", "or", "the", "5-lipoxygenase", "(", "5-LOX", ")", "pathways", "as", "possible", "neuroprotective", "agents", ".", "The", "COX", "pathway", "generates", "inflammatory", "prostaglandins", ",", "while", "the", "5-LOX", "pathway", "generates", "inflammatory", "leukotrienes", ".", "We", "found", "that", "inhibitors", "of", "both", "these", "pathways", "suppressed", "neurotoxicity", "in", "a", "dose", "-", "dependent", "fashion", ".", "They", "included", "the", "COX-1", "inhibitor", "indomethacin", ";", "the", "COX-2", "inhibitor", "NS-398", ";", "the", "mixed", "COX-1", "/", "COX-2", "inhibitor", "ibuprofen", ";", "the", "nitric", "oxide", "(", "NO", ")", "derivatives", "of", "indomethacin", ",", "ibuprofen", "and", "flurbiprofen", ";", "the", "5-LOX", "inhibitor", "REV", "5901", ";", "and", "the", "5-LOX", "activating", "protein", "(", "FLAP", ")", "inhibitor", "MK-886", ".", "The", "FLAP", "inhibitor", "also", "reduced", "respiratory", "burst", "activity", "in", "a", "more", "potent", "manner", "than", "indomethacin", ".", "Combinations", "of", "COX", "and", "5-LOX", "inhibitors", "were", "more", "effective", "than", "single", "inhibitors", ".", "The", "data", "suggest", "that", "both", "COX", "inhibitors", "and", "5-LOX", "inhibitors", "may", "be", "neuroprotective", "in", "vivo", "by", "suppressing", "toxic", "actions", "of", "microglia", "/", "macrophages", ",", "and", "that", "combinations", "of", "the", "two", "might", "have", "greater", "therapeutic", "potential", "than", "single", "inhibitors", "of", "either", "class", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
role is an umlsterm, pathogenesis is an umlsterm, syndromes is an umlsterm, C - reactive protein is an umlsterm, CRP is an umlsterm, acute phase protein is an umlsterm, markers is an umlsterm, troponin T is an umlsterm, TnT is an umlsterm, determination is an umlsterm, CRP is an umlsterm, patients is an umlsterm, diagnosis is an umlsterm, prognosis is an umlsterm, Patients is an umlsterm, Methods is an umlsterm, patients is an umlsterm, TnT is an umlsterm, Diagnostics is an umlsterm, CRP is an umlsterm, CRP is an umlsterm, sensitivity is an umlsterm, patients is an umlsterm, unstable angina is an umlsterm, All is an umlsterm, patients is an umlsterm, discharge is an umlsterm, death is an umlsterm, discharge is an umlsterm, patients is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, patients is an umlsterm, TnT is an umlsterm, patients is an umlsterm, CRP is an umlsterm, test is an umlsterm, patients is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, discharge is an umlsterm, Logistic regression is an umlsterm, analysis is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, values is an umlsterm, age is an umlsterm, gender is an umlsterm, diagnosis is an umlsterm, death is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, AMI is an umlsterm, diagnosis is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, sensitivity is an umlsterm, CRP is an umlsterm, determination is an umlsterm, value is an umlsterm, AMI is an umlsterm, diagnosis is an umlsterm, prognosis is an umlsterm, patients is an umlsterm, CRP is an umlsterm, measurements is an umlsterm, troponin is an umlsterm	ZfuerKardiologie.00890658.eng.abstr_task0	Sentence: Background : It has been suggested that inflammatory processes play a role in the pathogenesis of acute coronary syndromes ( ACS ) . C-reactive protein ( CRP ) is a classic acute phase protein . It is yet unclear whether , in addition to established markers as troponin T ( TnT ) , determination of CRP in patients admitted for ACS contributes significantly to the diagnosis and prognosis of ACS . Patients and Methods : We investigated 50 patients with ACS ( 59.4 SD 13.9 years ) in the first hour after admission and 4-24h later with respect to TnT ( Elecsys , Roche Diagnostics ) and CRP ( biokit , modified Quantex CRP plus , analytical sensitivity 0.02mg/dL). Fifty percent of the patients were classified as having unstable angina retrospectively . All patients were followed in the 6 weeks post discharge regarding death and recurrent ACS . Results : The cumulative event rate at 6 weeks after discharge was 62.5% for patients being CRP and TnT positive compared to 35.3% in TnT positive and CRP negative patients . In TnT negative patients a positive CRP test predicted 33.3% of events and 28.8% of patients negative for CRP and TnT had events at 42 days post discharge . Logistic regression analysis regarding the primary endpoint including TnT and CRP ( 4-24h values ) , age , gender and diagnosis resulted in independent prediction of ACS or death by TnT ( cutoff 0.1µg/L, p=0.048, odds ratio=7.5) and CRP ( cutoff 0.862mg/dL, p=0.026, odds ratio=5.3). Sensitivity/specificity for AMI diagnosis were 69.6%/75% for TnT and 12%/72% for CRP in the first hour and 91.3%/68.2% for TnT and 68%/72% for CRP 4-24h later . Conclusions : Besides TnT , high sensitivity CRP determination has no additional value for early AMI diagnosis . The prognosis of these patients during the first 24 hours is significantly and independently predicted by CRP measurements in addition to troponin T. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Background : It has been suggested that inflammatory processes play a role in the pathogenesis of acute coronary syndromes ( ACS ) . C-reactive protein ( CRP ) is a classic acute phase protein . It is yet unclear whether , in addition to established markers as troponin T ( TnT ) , determination of CRP in patients admitted for ACS contributes significantly to the diagnosis and prognosis of ACS . Patients and Methods : We investigated 50 patients with ACS ( 59.4 SD 13.9 years ) in the first hour after admission and 4-24h later with respect to TnT ( Elecsys , Roche Diagnostics ) and CRP ( biokit , modified Quantex CRP plus , analytical sensitivity 0.02mg/dL). Fifty percent of the patients were classified as having unstable angina retrospectively . All patients were followed in the 6 weeks post discharge regarding death and recurrent ACS . Results : The cumulative event rate at 6 weeks after discharge was 62.5% for patients being CRP and TnT positive compared to 35.3% in TnT positive and CRP negative patients . In TnT negative patients a positive CRP test predicted 33.3% of events and 28.8% of patients negative for CRP and TnT had events at 42 days post discharge . Logistic regression analysis regarding the primary endpoint including TnT and CRP ( 4-24h values ) , age , gender and diagnosis resulted in independent prediction of ACS or death by TnT ( cutoff 0.1µg/L, p=0.048, odds ratio=7.5) and CRP ( cutoff 0.862mg/dL, p=0.026, odds ratio=5.3). Sensitivity/specificity for AMI diagnosis were 69.6%/75% for TnT and 12%/72% for CRP in the first hour and 91.3%/68.2% for TnT and 68%/72% for CRP 4-24h later . Conclusions : Besides TnT , high sensitivity CRP determination has no additional value for early AMI diagnosis . The prognosis of these patients during the first 24 hours is significantly and independently predicted by CRP measurements in addition to troponin T.	[ "Background", ":", "It", "has", "been", "suggested", "that", "inflammatory", "processes", "play", "a", "role", "in", "the", "pathogenesis", "of", "acute", "coronary", "syndromes", "(", "ACS", ")", ".", "C", "-", "reactive", "protein", "(", "CRP", ")", "is", "a", "classic", "acute", "phase", "protein", ".", "It", "is", "yet", "unclear", "whether", ",", "in", "addition", "to", "established", "markers", "as", "troponin", "T", "(", "TnT", ")", ",", "determination", "of", "CRP", "in", "patients", "admitted", "for", "ACS", "contributes", "significantly", "to", "the", "diagnosis", "and", "prognosis", "of", "ACS", ".", "Patients", "and", "Methods", ":", "We", "investigated", "50", "patients", "with", "ACS", "(", "59.4", "SD", "13.9", "years", ")", "in", "the", "first", "hour", "after", "admission", "and", "4", "-", "24h", "later", "with", "respect", "to", "TnT", "(", "Elecsys", ",", "Roche", "Diagnostics", ")", "and", "CRP", "(", "biokit", ",", "modified", "Quantex", "CRP", "plus", ",", "analytical", "sensitivity", "0.02mg", "/", "dL", ")", ".", "Fifty", "percent", "of", "the", "patients", "were", "classified", "as", "having", "unstable", "angina", "retrospectively", ".", "All", "patients", "were", "followed", "in", "the", "6", "weeks", "post", "discharge", "regarding", "death", "and", "recurrent", "ACS", ".", "Results", ":", "The", "cumulative", "event", "rate", "at", "6", "weeks", "after", "discharge", "was", "62.5", "%", "for", "patients", "being", "CRP", "and", "TnT", "positive", "compared", "to", "35.3", "%", "in", "TnT", "positive", "and", "CRP", "negative", "patients", ".", "In", "TnT", "negative", "patients", "a", "positive", "CRP", "test", "predicted", "33.3", "%", "of", "events", "and", "28.8", "%", "of", "patients", "negative", "for", "CRP", "and", "TnT", "had", "events", "at", "42", "days", "post", "discharge", ".", "Logistic", "regression", "analysis", "regarding", "the", "primary", "endpoint", "including", "TnT", "and", "CRP", "(", "4", "-", "24h", "values", ")", ",", "age", ",", "gender", "and", "diagnosis", "resulted", "in", "independent", "prediction", "of", "ACS", "or", "death", "by", "TnT", "(", "cutoff", "0.1µg", "/", "L", ",", "p=0.048", ",", "odds", "ratio=7.5", ")", "and", "CRP", "(", "cutoff", "0.862mg", "/", "dL", ",", "p=0.026", ",", "odds", "ratio=5.3", ")", ".", "Sensitivity", "/", "specificity", "for", "AMI", "diagnosis", "were", "69.6%/75", "%", "for", "TnT", "and", "12%/72", "%", "for", "CRP", "in", "the", "first", "hour", "and", "91.3%/68.2", "%", "for", "TnT", "and", "68%/72", "%", "for", "CRP", "4", "-", "24h", "later", ".", "Conclusions", ":", "Besides", "TnT", ",", "high", "sensitivity", "CRP", "determination", "has", "no", "additional", "value", "for", "early", "AMI", "diagnosis", ".", "The", "prognosis", "of", "these", "patients", "during", "the", "first", "24", "hours", "is", "significantly", "and", "independently", "predicted", "by", "CRP", "measurements", "in", "addition", "to", "troponin", "T." ]	[ "umlsterm" ]
role is an umlsterm, pathogenesis is an umlsterm, syndromes is an umlsterm, C - reactive protein is an umlsterm, CRP is an umlsterm, acute phase protein is an umlsterm, markers is an umlsterm, troponin T is an umlsterm, TnT is an umlsterm, determination is an umlsterm, CRP is an umlsterm, patients is an umlsterm, diagnosis is an umlsterm, prognosis is an umlsterm, Patients is an umlsterm, Methods is an umlsterm, patients is an umlsterm, TnT is an umlsterm, Diagnostics is an umlsterm, CRP is an umlsterm, CRP is an umlsterm, sensitivity is an umlsterm, patients is an umlsterm, unstable angina is an umlsterm, All is an umlsterm, patients is an umlsterm, discharge is an umlsterm, death is an umlsterm, discharge is an umlsterm, patients is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, patients is an umlsterm, TnT is an umlsterm, patients is an umlsterm, CRP is an umlsterm, test is an umlsterm, patients is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, discharge is an umlsterm, Logistic regression is an umlsterm, analysis is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, values is an umlsterm, age is an umlsterm, gender is an umlsterm, diagnosis is an umlsterm, death is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, AMI is an umlsterm, diagnosis is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, sensitivity is an umlsterm, CRP is an umlsterm, determination is an umlsterm, value is an umlsterm, AMI is an umlsterm, diagnosis is an umlsterm, prognosis is an umlsterm, patients is an umlsterm, CRP is an umlsterm, measurements is an umlsterm, troponin is an umlsterm	ZfuerKardiologie.00890658.eng.abstr_task1	Sentence: Background : It has been suggested that inflammatory processes play a role in the pathogenesis of acute coronary syndromes ( ACS ) . C-reactive protein ( CRP ) is a classic acute phase protein . It is yet unclear whether , in addition to established markers as troponin T ( TnT ) , determination of CRP in patients admitted for ACS contributes significantly to the diagnosis and prognosis of ACS . Patients and Methods : We investigated 50 patients with ACS ( 59.4 SD 13.9 years ) in the first hour after admission and 4-24h later with respect to TnT ( Elecsys , Roche Diagnostics ) and CRP ( biokit , modified Quantex CRP plus , analytical sensitivity 0.02mg/dL). Fifty percent of the patients were classified as having unstable angina retrospectively . All patients were followed in the 6 weeks post discharge regarding death and recurrent ACS . Results : The cumulative event rate at 6 weeks after discharge was 62.5% for patients being CRP and TnT positive compared to 35.3% in TnT positive and CRP negative patients . In TnT negative patients a positive CRP test predicted 33.3% of events and 28.8% of patients negative for CRP and TnT had events at 42 days post discharge . Logistic regression analysis regarding the primary endpoint including TnT and CRP ( 4-24h values ) , age , gender and diagnosis resulted in independent prediction of ACS or death by TnT ( cutoff 0.1µg/L, p=0.048, odds ratio=7.5) and CRP ( cutoff 0.862mg/dL, p=0.026, odds ratio=5.3). Sensitivity/specificity for AMI diagnosis were 69.6%/75% for TnT and 12%/72% for CRP in the first hour and 91.3%/68.2% for TnT and 68%/72% for CRP 4-24h later . Conclusions : Besides TnT , high sensitivity CRP determination has no additional value for early AMI diagnosis . The prognosis of these patients during the first 24 hours is significantly and independently predicted by CRP measurements in addition to troponin T. Instructions: please typing these entity words according to sentence: role, pathogenesis, syndromes, C - reactive protein, CRP, acute phase protein, markers, troponin T, TnT, determination, CRP, patients, diagnosis, prognosis, Patients, Methods, patients, TnT, Diagnostics, CRP, CRP, sensitivity, patients, unstable angina, All, patients, discharge, death, discharge, patients, CRP, TnT, TnT, CRP, patients, TnT, patients, CRP, test, patients, CRP, TnT, discharge, Logistic regression, analysis, TnT, CRP, values, age, gender, diagnosis, death, TnT, CRP, AMI, diagnosis, TnT, CRP, TnT, CRP, TnT, sensitivity, CRP, determination, value, AMI, diagnosis, prognosis, patients, CRP, measurements, troponin Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Background : It has been suggested that inflammatory processes play a role in the pathogenesis of acute coronary syndromes ( ACS ) . C-reactive protein ( CRP ) is a classic acute phase protein . It is yet unclear whether , in addition to established markers as troponin T ( TnT ) , determination of CRP in patients admitted for ACS contributes significantly to the diagnosis and prognosis of ACS . Patients and Methods : We investigated 50 patients with ACS ( 59.4 SD 13.9 years ) in the first hour after admission and 4-24h later with respect to TnT ( Elecsys , Roche Diagnostics ) and CRP ( biokit , modified Quantex CRP plus , analytical sensitivity 0.02mg/dL). Fifty percent of the patients were classified as having unstable angina retrospectively . All patients were followed in the 6 weeks post discharge regarding death and recurrent ACS . Results : The cumulative event rate at 6 weeks after discharge was 62.5% for patients being CRP and TnT positive compared to 35.3% in TnT positive and CRP negative patients . In TnT negative patients a positive CRP test predicted 33.3% of events and 28.8% of patients negative for CRP and TnT had events at 42 days post discharge . Logistic regression analysis regarding the primary endpoint including TnT and CRP ( 4-24h values ) , age , gender and diagnosis resulted in independent prediction of ACS or death by TnT ( cutoff 0.1µg/L, p=0.048, odds ratio=7.5) and CRP ( cutoff 0.862mg/dL, p=0.026, odds ratio=5.3). Sensitivity/specificity for AMI diagnosis were 69.6%/75% for TnT and 12%/72% for CRP in the first hour and 91.3%/68.2% for TnT and 68%/72% for CRP 4-24h later . Conclusions : Besides TnT , high sensitivity CRP determination has no additional value for early AMI diagnosis . The prognosis of these patients during the first 24 hours is significantly and independently predicted by CRP measurements in addition to troponin T.	[ "Background", ":", "It", "has", "been", "suggested", "that", "inflammatory", "processes", "play", "a", "role", "in", "the", "pathogenesis", "of", "acute", "coronary", "syndromes", "(", "ACS", ")", ".", "C", "-", "reactive", "protein", "(", "CRP", ")", "is", "a", "classic", "acute", "phase", "protein", ".", "It", "is", "yet", "unclear", "whether", ",", "in", "addition", "to", "established", "markers", "as", "troponin", "T", "(", "TnT", ")", ",", "determination", "of", "CRP", "in", "patients", "admitted", "for", "ACS", "contributes", "significantly", "to", "the", "diagnosis", "and", "prognosis", "of", "ACS", ".", "Patients", "and", "Methods", ":", "We", "investigated", "50", "patients", "with", "ACS", "(", "59.4", "SD", "13.9", "years", ")", "in", "the", "first", "hour", "after", "admission", "and", "4", "-", "24h", "later", "with", "respect", "to", "TnT", "(", "Elecsys", ",", "Roche", "Diagnostics", ")", "and", "CRP", "(", "biokit", ",", "modified", "Quantex", "CRP", "plus", ",", "analytical", "sensitivity", "0.02mg", "/", "dL", ")", ".", "Fifty", "percent", "of", "the", "patients", "were", "classified", "as", "having", "unstable", "angina", "retrospectively", ".", "All", "patients", "were", "followed", "in", "the", "6", "weeks", "post", "discharge", "regarding", "death", "and", "recurrent", "ACS", ".", "Results", ":", "The", "cumulative", "event", "rate", "at", "6", "weeks", "after", "discharge", "was", "62.5", "%", "for", "patients", "being", "CRP", "and", "TnT", "positive", "compared", "to", "35.3", "%", "in", "TnT", "positive", "and", "CRP", "negative", "patients", ".", "In", "TnT", "negative", "patients", "a", "positive", "CRP", "test", "predicted", "33.3", "%", "of", "events", "and", "28.8", "%", "of", "patients", "negative", "for", "CRP", "and", "TnT", "had", "events", "at", "42", "days", "post", "discharge", ".", "Logistic", "regression", "analysis", "regarding", "the", "primary", "endpoint", "including", "TnT", "and", "CRP", "(", "4", "-", "24h", "values", ")", ",", "age", ",", "gender", "and", "diagnosis", "resulted", "in", "independent", "prediction", "of", "ACS", "or", "death", "by", "TnT", "(", "cutoff", "0.1µg", "/", "L", ",", "p=0.048", ",", "odds", "ratio=7.5", ")", "and", "CRP", "(", "cutoff", "0.862mg", "/", "dL", ",", "p=0.026", ",", "odds", "ratio=5.3", ")", ".", "Sensitivity", "/", "specificity", "for", "AMI", "diagnosis", "were", "69.6%/75", "%", "for", "TnT", "and", "12%/72", "%", "for", "CRP", "in", "the", "first", "hour", "and", "91.3%/68.2", "%", "for", "TnT", "and", "68%/72", "%", "for", "CRP", "4", "-", "24h", "later", ".", "Conclusions", ":", "Besides", "TnT", ",", "high", "sensitivity", "CRP", "determination", "has", "no", "additional", "value", "for", "early", "AMI", "diagnosis", ".", "The", "prognosis", "of", "these", "patients", "during", "the", "first", "24", "hours", "is", "significantly", "and", "independently", "predicted", "by", "CRP", "measurements", "in", "addition", "to", "troponin", "T." ]	[ "umlsterm" ]
role, pathogenesis, syndromes, C - reactive protein, CRP, acute phase protein, markers, troponin T, TnT, determination, CRP, patients, diagnosis, prognosis, Patients, Methods, patients, TnT, Diagnostics, CRP, CRP, sensitivity, patients, unstable angina, All, patients, discharge, death, discharge, patients, CRP, TnT, TnT, CRP, patients, TnT, patients, CRP, test, patients, CRP, TnT, discharge, Logistic regression, analysis, TnT, CRP, values, age, gender, diagnosis, death, TnT, CRP, AMI, diagnosis, TnT, CRP, TnT, CRP, TnT, sensitivity, CRP, determination, value, AMI, diagnosis, prognosis, patients, CRP, measurements, troponin	ZfuerKardiologie.00890658.eng.abstr_task2	Sentence: Background : It has been suggested that inflammatory processes play a role in the pathogenesis of acute coronary syndromes ( ACS ) . C-reactive protein ( CRP ) is a classic acute phase protein . It is yet unclear whether , in addition to established markers as troponin T ( TnT ) , determination of CRP in patients admitted for ACS contributes significantly to the diagnosis and prognosis of ACS . Patients and Methods : We investigated 50 patients with ACS ( 59.4 SD 13.9 years ) in the first hour after admission and 4-24h later with respect to TnT ( Elecsys , Roche Diagnostics ) and CRP ( biokit , modified Quantex CRP plus , analytical sensitivity 0.02mg/dL). Fifty percent of the patients were classified as having unstable angina retrospectively . All patients were followed in the 6 weeks post discharge regarding death and recurrent ACS . Results : The cumulative event rate at 6 weeks after discharge was 62.5% for patients being CRP and TnT positive compared to 35.3% in TnT positive and CRP negative patients . In TnT negative patients a positive CRP test predicted 33.3% of events and 28.8% of patients negative for CRP and TnT had events at 42 days post discharge . Logistic regression analysis regarding the primary endpoint including TnT and CRP ( 4-24h values ) , age , gender and diagnosis resulted in independent prediction of ACS or death by TnT ( cutoff 0.1µg/L, p=0.048, odds ratio=7.5) and CRP ( cutoff 0.862mg/dL, p=0.026, odds ratio=5.3). Sensitivity/specificity for AMI diagnosis were 69.6%/75% for TnT and 12%/72% for CRP in the first hour and 91.3%/68.2% for TnT and 68%/72% for CRP 4-24h later . Conclusions : Besides TnT , high sensitivity CRP determination has no additional value for early AMI diagnosis . The prognosis of these patients during the first 24 hours is significantly and independently predicted by CRP measurements in addition to troponin T. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Background : It has been suggested that inflammatory processes play a role in the pathogenesis of acute coronary syndromes ( ACS ) . C-reactive protein ( CRP ) is a classic acute phase protein . It is yet unclear whether , in addition to established markers as troponin T ( TnT ) , determination of CRP in patients admitted for ACS contributes significantly to the diagnosis and prognosis of ACS . Patients and Methods : We investigated 50 patients with ACS ( 59.4 SD 13.9 years ) in the first hour after admission and 4-24h later with respect to TnT ( Elecsys , Roche Diagnostics ) and CRP ( biokit , modified Quantex CRP plus , analytical sensitivity 0.02mg/dL). Fifty percent of the patients were classified as having unstable angina retrospectively . All patients were followed in the 6 weeks post discharge regarding death and recurrent ACS . Results : The cumulative event rate at 6 weeks after discharge was 62.5% for patients being CRP and TnT positive compared to 35.3% in TnT positive and CRP negative patients . In TnT negative patients a positive CRP test predicted 33.3% of events and 28.8% of patients negative for CRP and TnT had events at 42 days post discharge . Logistic regression analysis regarding the primary endpoint including TnT and CRP ( 4-24h values ) , age , gender and diagnosis resulted in independent prediction of ACS or death by TnT ( cutoff 0.1µg/L, p=0.048, odds ratio=7.5) and CRP ( cutoff 0.862mg/dL, p=0.026, odds ratio=5.3). Sensitivity/specificity for AMI diagnosis were 69.6%/75% for TnT and 12%/72% for CRP in the first hour and 91.3%/68.2% for TnT and 68%/72% for CRP 4-24h later . Conclusions : Besides TnT , high sensitivity CRP determination has no additional value for early AMI diagnosis . The prognosis of these patients during the first 24 hours is significantly and independently predicted by CRP measurements in addition to troponin T.	[ "Background", ":", "It", "has", "been", "suggested", "that", "inflammatory", "processes", "play", "a", "role", "in", "the", "pathogenesis", "of", "acute", "coronary", "syndromes", "(", "ACS", ")", ".", "C", "-", "reactive", "protein", "(", "CRP", ")", "is", "a", "classic", "acute", "phase", "protein", ".", "It", "is", "yet", "unclear", "whether", ",", "in", "addition", "to", "established", "markers", "as", "troponin", "T", "(", "TnT", ")", ",", "determination", "of", "CRP", "in", "patients", "admitted", "for", "ACS", "contributes", "significantly", "to", "the", "diagnosis", "and", "prognosis", "of", "ACS", ".", "Patients", "and", "Methods", ":", "We", "investigated", "50", "patients", "with", "ACS", "(", "59.4", "SD", "13.9", "years", ")", "in", "the", "first", "hour", "after", "admission", "and", "4", "-", "24h", "later", "with", "respect", "to", "TnT", "(", "Elecsys", ",", "Roche", "Diagnostics", ")", "and", "CRP", "(", "biokit", ",", "modified", "Quantex", "CRP", "plus", ",", "analytical", "sensitivity", "0.02mg", "/", "dL", ")", ".", "Fifty", "percent", "of", "the", "patients", "were", "classified", "as", "having", "unstable", "angina", "retrospectively", ".", "All", "patients", "were", "followed", "in", "the", "6", "weeks", "post", "discharge", "regarding", "death", "and", "recurrent", "ACS", ".", "Results", ":", "The", "cumulative", "event", "rate", "at", "6", "weeks", "after", "discharge", "was", "62.5", "%", "for", "patients", "being", "CRP", "and", "TnT", "positive", "compared", "to", "35.3", "%", "in", "TnT", "positive", "and", "CRP", "negative", "patients", ".", "In", "TnT", "negative", "patients", "a", "positive", "CRP", "test", "predicted", "33.3", "%", "of", "events", "and", "28.8", "%", "of", "patients", "negative", "for", "CRP", "and", "TnT", "had", "events", "at", "42", "days", "post", "discharge", ".", "Logistic", "regression", "analysis", "regarding", "the", "primary", "endpoint", "including", "TnT", "and", "CRP", "(", "4", "-", "24h", "values", ")", ",", "age", ",", "gender", "and", "diagnosis", "resulted", "in", "independent", "prediction", "of", "ACS", "or", "death", "by", "TnT", "(", "cutoff", "0.1µg", "/", "L", ",", "p=0.048", ",", "odds", "ratio=7.5", ")", "and", "CRP", "(", "cutoff", "0.862mg", "/", "dL", ",", "p=0.026", ",", "odds", "ratio=5.3", ")", ".", "Sensitivity", "/", "specificity", "for", "AMI", "diagnosis", "were", "69.6%/75", "%", "for", "TnT", "and", "12%/72", "%", "for", "CRP", "in", "the", "first", "hour", "and", "91.3%/68.2", "%", "for", "TnT", "and", "68%/72", "%", "for", "CRP", "4", "-", "24h", "later", ".", "Conclusions", ":", "Besides", "TnT", ",", "high", "sensitivity", "CRP", "determination", "has", "no", "additional", "value", "for", "early", "AMI", "diagnosis", ".", "The", "prognosis", "of", "these", "patients", "during", "the", "first", "24", "hours", "is", "significantly", "and", "independently", "predicted", "by", "CRP", "measurements", "in", "addition", "to", "troponin", "T." ]	[ "umlsterm" ]
sarcoidosis is a Diseases & Disorders, etanercept is a Chemicals & Drugs, rheumatoid arthritis is a Diseases & Disorders	1675_task0	Sentence: Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Chemicals & Drugs, Diseases & Disorders	[ "O", "O", "B-Diseases & Disorders", "O", "B-Chemicals & Drugs", "O", "O", "B-Diseases & Disorders", "I-Diseases & Disorders", "O", "O" ]	Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.	[ "Development", "of", "sarcoidosis", "in", "etanercept", "-", "treated", "rheumatoid", "arthritis", "patients", "." ]	[ "Diseases & Disorders", "", "Chemicals & Drugs" ]
sarcoidosis is a Diseases & Disorders, etanercept is a Chemicals & Drugs, rheumatoid arthritis is a Diseases & Disorders	1675_task1	Sentence: Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Instructions: please typing these entity words according to sentence: sarcoidosis, etanercept, rheumatoid arthritis Options: Chemicals & Drugs, Diseases & Disorders	[ "O", "O", "B-Diseases & Disorders", "O", "B-Chemicals & Drugs", "O", "O", "B-Diseases & Disorders", "I-Diseases & Disorders", "O", "O" ]	Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.	[ "Development", "of", "sarcoidosis", "in", "etanercept", "-", "treated", "rheumatoid", "arthritis", "patients", "." ]	[ "Diseases & Disorders", "", "Chemicals & Drugs" ]
sarcoidosis, etanercept, rheumatoid arthritis	1675_task2	Sentence: Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Diseases & Disorders", "O", "B-Chemicals & Drugs", "O", "O", "B-Diseases & Disorders", "I-Diseases & Disorders", "O", "O" ]	Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.	[ "Development", "of", "sarcoidosis", "in", "etanercept", "-", "treated", "rheumatoid", "arthritis", "patients", "." ]	[ "Diseases & Disorders", "", "Chemicals & Drugs" ]
Alejandra is a NOMBRE_SUJETO_ASISTENCIA, Irías Arias is a NOMBRE_SUJETO_ASISTENCIA, 3738763 is a ID_SUJETO_ASISTENCIA, 74 65745652 32 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 28010 is a TERRITORIO, 05/02/1965 is a FECHAS, España is a PAIS, 52 años is a EDAD_SUJETO_ASISTENCIA, 18/01/2018 is a FECHAS, Esther Campos Mollo is a NOMBRE_PERSONAL_SANITARIO, 28 28 50312 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 52 años is a EDAD_SUJETO_ASISTENCIA, Esther Campos Mollo is a NOMBRE_PERSONAL_SANITARIO, esthercm@hotmail.com is a CORREO_ELECTRONICO	229_task0	Sentence: Datos del paciente. Nombre: Alejandra. Apellidos: Irías Arias. NHC: 3738763. NASS: 74 65745652 32. Domicilio: C/ Principe de Vergara, 29, 5 A. Localidad/ Provincia: Madrid. CP: 28010. Datos asistenciales. Fecha de nacimiento: 05/02/1965. País de nacimiento: España. Edad: 52 años Sexo: M. Fecha de Ingreso: 18/01/2018. Médico: Esther Campos Mollo NºCol: 28 28 50312. Informe clínico del paciente: Mujer de 52 años que refirió disminución de agudeza visual (AV) espontánea en su ojo izquierdo (OI) ambliope. No tenía el antecedente de parto prematuro, ni historia familiar de enfermedad ocular. En la primera exploración, la mejor AV corregida fue de 1 en el ojo derecho (OD) (-1 cilindro 150o +3 esfera; longitud axial de 22,5mm) y de 0,025 en el ojo izquierdo (OI) (-0,75 cilindro 25o -13,25 esfera; longitud axial de 25,3mm). El estudio biomicroscópico del OI permitió identificar la mancha de Mittendorf localizada en el cuadrante nasal inferior de la cápsula posterior del cristalino y el extremo anterior de la AHP con contenido hemático en su interior. El ojo adelfo era normal. Los diámetros corneales horizontales midieron 12mm en ambos ojos (AO) y la tonometría de aplanación fue de 18mm Hg en AO. La oftalmoscopia indirecta del OI mostró una hemorragia intravítrea leve difusa. El trayecto de la AHP se pudo seguir desde el nervio óptico hasta la cristaloides posterior. La arteria, fijada en sus dos extremos, se desplazaba libremente con los movimientos oculares. El vítreo posterior estaba desprendido parcialmente de la retina. No se hallaron anomalías retinianas periféricas, ni signos de tracción vitreorretiniana o desprendimiento de retina. El fondo del OD era normal. La hemorragia se reabsorbió gradualmente en el transcurso de una semana. La AHP se pudo distinguir con más claridad permitiendo un mejor estudio anatómico. En la tomografía de coherencia óptica (TCO) se apreciaron las características morfológicas de la papila de Bergmeister. De esta, surgía la AHP que mostró una estructura tubular con un interior hiporreflectivo. En la ecografía en modo B se evidenció una imagen lineal hiperecogénica respecto al vítreo que se correspondía con la AHP y un desprendimiento parcial de vítreo posterior. El eco-doppler demostró el flujo sanguíneo normal de la arteria central de la retina y de las arterias ciliares posteriores aunque no se objetivó la presencia de flujo sanguíneo activo en la AHP. El hemograma y las pruebas específicas de coagulación fueron normales. El hemovítreo se reabsorbió completamente y la paciente recuperó la visión de 0,2 que presentaba antes de sobrevenir la hemorragia a causa de una ambliopía por anisometropía. No hubo recurrencia de sangrado en 6 meses de seguimiento. Responsable clínico: Dra. Esther Campos Mollo Correo electrónico: esthercm@hotmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Alejandra. Apellidos: Irías Arias. NHC: 3738763. NASS: 74 65745652 32. Domicilio: C/ Principe de Vergara, 29, 5 A. Localidad/ Provincia: Madrid. CP: 28010. Datos asistenciales. Fecha de nacimiento: 05/02/1965. País de nacimiento: España. Edad: 52 años Sexo: M. Fecha de Ingreso: 18/01/2018. Médico: Esther Campos Mollo NºCol: 28 28 50312. Informe clínico del paciente: Mujer de 52 años que refirió disminución de agudeza visual (AV) espontánea en su ojo izquierdo (OI) ambliope. No tenía el antecedente de parto prematuro, ni historia familiar de enfermedad ocular. En la primera exploración, la mejor AV corregida fue de 1 en el ojo derecho (OD) (-1 cilindro 150o +3 esfera; longitud axial de 22,5mm) y de 0,025 en el ojo izquierdo (OI) (-0,75 cilindro 25o -13,25 esfera; longitud axial de 25,3mm). El estudio biomicroscópico del OI permitió identificar la mancha de Mittendorf localizada en el cuadrante nasal inferior de la cápsula posterior del cristalino y el extremo anterior de la AHP con contenido hemático en su interior. El ojo adelfo era normal. Los diámetros corneales horizontales midieron 12mm en ambos ojos (AO) y la tonometría de aplanación fue de 18mm Hg en AO. La oftalmoscopia indirecta del OI mostró una hemorragia intravítrea leve difusa. El trayecto de la AHP se pudo seguir desde el nervio óptico hasta la cristaloides posterior. La arteria, fijada en sus dos extremos, se desplazaba libremente con los movimientos oculares. El vítreo posterior estaba desprendido parcialmente de la retina. No se hallaron anomalías retinianas periféricas, ni signos de tracción vitreorretiniana o desprendimiento de retina. El fondo del OD era normal. La hemorragia se reabsorbió gradualmente en el transcurso de una semana. La AHP se pudo distinguir con más claridad permitiendo un mejor estudio anatómico. En la tomografía de coherencia óptica (TCO) se apreciaron las características morfológicas de la papila de Bergmeister. De esta, surgía la AHP que mostró una estructura tubular con un interior hiporreflectivo. En la ecografía en modo B se evidenció una imagen lineal hiperecogénica respecto al vítreo que se correspondía con la AHP y un desprendimiento parcial de vítreo posterior. El eco-doppler demostró el flujo sanguíneo normal de la arteria central de la retina y de las arterias ciliares posteriores aunque no se objetivó la presencia de flujo sanguíneo activo en la AHP. El hemograma y las pruebas específicas de coagulación fueron normales. El hemovítreo se reabsorbió completamente y la paciente recuperó la visión de 0,2 que presentaba antes de sobrevenir la hemorragia a causa de una ambliopía por anisometropía. No hubo recurrencia de sangrado en 6 meses de seguimiento. Responsable clínico: Dra. Esther Campos Mollo Correo electrónico: esthercm@hotmail.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Alejandra", ".", "\n", "Apellidos", ":", "Irías", "Arias", ".", "\n", "NHC", ":", "3738763", ".", "\n", "NASS", ":", "74", "65745652", "32", ".", "\n", "Domicilio", ":", "C/", "Principe", "de", "Vergara", ",", "29", ",", "5", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28010", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "05/02/1965", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "52", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "18/01/2018", ".", "\n", "Médico", ":", "Esther", "Campos", "Mollo", "NºCol", ":", "28", "28", "50312", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "52", "años", "que", "refirió", "disminución", "de", "agudeza", "visual", "(", "AV", ")", "espontánea", "en", "su", "ojo", "izquierdo", "(", "OI", ")", "ambliope", ".", "No", "tenía", "el", "antecedente", "de", "parto", "prematuro", ",", "ni", "historia", "familiar", "de", "enfermedad", "ocular", ".", "\n", "En", "la", "primera", "exploración", ",", "la", "mejor", "AV", "corregida", "fue", "de", "1", "en", "el", "ojo", "derecho", "(", "OD", ")", "(", "-1", "cilindro", "150o", "+3", "esfera", ";", "longitud", "axial", "de", "22,5", "mm", ")", "y", "de", "0,025", "en", "el", "ojo", "izquierdo", "(", "OI", ")", "(", "-0,75", "cilindro", "25o", "-13,25", "esfera", ";", "longitud", "axial", "de", "25,3", "mm", ")", ".", "\n", "El", "estudio", "biomicroscópico", "del", "OI", "permitió", "identificar", "la", "mancha", "de", "Mittendorf", "localizada", "en", "el", "cuadrante", "nasal", "inferior", "de", "la", "cápsula", "posterior", "del", "cristalino", "y", "el", "extremo", "anterior", "de", "la", "AHP", "con", "contenido", "hemático", "en", "su", "interior", ".", "El", "ojo", "adelfo", "era", "normal", ".", "Los", "diámetros", "corneales", "horizontales", "midieron", "12", "mm", "en", "ambos", "ojos", "(", "AO", ")", "y", "la", "tonometría", "de", "aplanación", "fue", "de", "18", "mm", "Hg", "en", "AO", ".", "\n", "La", "oftalmoscopia", "indirecta", "del", "OI", "mostró", "una", "hemorragia", "intravítrea", "leve", "difusa", ".", "El", "trayecto", "de", "la", "AHP", "se", "pudo", "seguir", "desde", "el", "nervio", "óptico", "hasta", "la", "cristaloides", "posterior", ".", "La", "arteria", ",", "fijada", "en", "sus", "dos", "extremos", ",", "se", "desplazaba", "libremente", "con", "los", "movimientos", "oculares", ".", "El", "vítreo", "posterior", "estaba", "desprendido", "parcialmente", "de", "la", "retina", ".", "No", "se", "hallaron", "anomalías", "retinianas", "periféricas", ",", "ni", "signos", "de", "tracción", "vitreorretiniana", "o", "desprendimiento", "de", "retina", ".", "El", "fondo", "del", "OD", "era", "normal", ".", "\n", "La", "hemorragia", "se", "reabsorbió", "gradualmente", "en", "el", "transcurso", "de", "una", "semana", ".", "La", "AHP", "se", "pudo", "distinguir", "con", "más", "claridad", "permitiendo", "un", "mejor", "estudio", "anatómico", ".", "En", "la", "tomografía", "de", "coherencia", "óptica", "(", "TCO", ")", "se", "apreciaron", "las", "características", "morfológicas", "de", "la", "papila", "de", "Bergmeister", ".", "De", "esta", ",", "surgía", "la", "AHP", "que", "mostró", "una", "estructura", "tubular", "con", "un", "interior", "hiporreflectivo", ".", "\n", "En", "la", "ecografía", "en", "modo", "B", "se", "evidenció", "una", "imagen", "lineal", "hiperecogénica", "respecto", "al", "vítreo", "que", "se", "correspondía", "con", "la", "AHP", "y", "un", "desprendimiento", "parcial", "de", "vítreo", "posterior", ".", "El", "eco", "-", "doppler", "demostró", "el", "flujo", "sanguíneo", "normal", "de", "la", "arteria", "central", "de", "la", "retina", "y", "de", "las", "arterias", "ciliares", "posteriores", "aunque", "no", "se", "objetivó", "la", "presencia", "de", "flujo", "sanguíneo", "activo", "en", "la", "AHP", ".", "\n", "El", "hemograma", "y", "las", "pruebas", "específicas", "de", "coagulación", "fueron", "normales", ".", "El", "hemovítreo", "se", "reabsorbió", "completamente", "y", "la", "paciente", "recuperó", "la", "visión", "de", "0,2", "que", "presentaba", "antes", "de", "sobrevenir", "la", "hemorragia", "a", "causa", "de", "una", "ambliopía", "por", "anisometropía", ".", "No", "hubo", "recurrencia", "de", "sangrado", "en", "6", "meses", "de", "seguimiento", ".", "\n", "Responsable", "clínico", ":", "Dra", ".", "Esther", "Campos", "Mollo", "Correo", "electrónico", ":", "esthercm@hotmail.com", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Alejandra is a NOMBRE_SUJETO_ASISTENCIA, Irías Arias is a NOMBRE_SUJETO_ASISTENCIA, 3738763 is a ID_SUJETO_ASISTENCIA, 74 65745652 32 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 28010 is a TERRITORIO, 05/02/1965 is a FECHAS, España is a PAIS, 52 años is a EDAD_SUJETO_ASISTENCIA, 18/01/2018 is a FECHAS, Esther Campos Mollo is a NOMBRE_PERSONAL_SANITARIO, 28 28 50312 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 52 años is a EDAD_SUJETO_ASISTENCIA, Esther Campos Mollo is a NOMBRE_PERSONAL_SANITARIO, esthercm@hotmail.com is a CORREO_ELECTRONICO	229_task1	Sentence: Datos del paciente. Nombre: Alejandra. Apellidos: Irías Arias. NHC: 3738763. NASS: 74 65745652 32. Domicilio: C/ Principe de Vergara, 29, 5 A. Localidad/ Provincia: Madrid. CP: 28010. Datos asistenciales. Fecha de nacimiento: 05/02/1965. País de nacimiento: España. Edad: 52 años Sexo: M. Fecha de Ingreso: 18/01/2018. Médico: Esther Campos Mollo NºCol: 28 28 50312. Informe clínico del paciente: Mujer de 52 años que refirió disminución de agudeza visual (AV) espontánea en su ojo izquierdo (OI) ambliope. No tenía el antecedente de parto prematuro, ni historia familiar de enfermedad ocular. En la primera exploración, la mejor AV corregida fue de 1 en el ojo derecho (OD) (-1 cilindro 150o +3 esfera; longitud axial de 22,5mm) y de 0,025 en el ojo izquierdo (OI) (-0,75 cilindro 25o -13,25 esfera; longitud axial de 25,3mm). El estudio biomicroscópico del OI permitió identificar la mancha de Mittendorf localizada en el cuadrante nasal inferior de la cápsula posterior del cristalino y el extremo anterior de la AHP con contenido hemático en su interior. El ojo adelfo era normal. Los diámetros corneales horizontales midieron 12mm en ambos ojos (AO) y la tonometría de aplanación fue de 18mm Hg en AO. La oftalmoscopia indirecta del OI mostró una hemorragia intravítrea leve difusa. El trayecto de la AHP se pudo seguir desde el nervio óptico hasta la cristaloides posterior. La arteria, fijada en sus dos extremos, se desplazaba libremente con los movimientos oculares. El vítreo posterior estaba desprendido parcialmente de la retina. No se hallaron anomalías retinianas periféricas, ni signos de tracción vitreorretiniana o desprendimiento de retina. El fondo del OD era normal. La hemorragia se reabsorbió gradualmente en el transcurso de una semana. La AHP se pudo distinguir con más claridad permitiendo un mejor estudio anatómico. En la tomografía de coherencia óptica (TCO) se apreciaron las características morfológicas de la papila de Bergmeister. De esta, surgía la AHP que mostró una estructura tubular con un interior hiporreflectivo. En la ecografía en modo B se evidenció una imagen lineal hiperecogénica respecto al vítreo que se correspondía con la AHP y un desprendimiento parcial de vítreo posterior. El eco-doppler demostró el flujo sanguíneo normal de la arteria central de la retina y de las arterias ciliares posteriores aunque no se objetivó la presencia de flujo sanguíneo activo en la AHP. El hemograma y las pruebas específicas de coagulación fueron normales. El hemovítreo se reabsorbió completamente y la paciente recuperó la visión de 0,2 que presentaba antes de sobrevenir la hemorragia a causa de una ambliopía por anisometropía. No hubo recurrencia de sangrado en 6 meses de seguimiento. Responsable clínico: Dra. Esther Campos Mollo Correo electrónico: esthercm@hotmail.com Instructions: please typing these entity words according to sentence: Alejandra, Irías Arias, 3738763, 74 65745652 32, Madrid, 28010, 05/02/1965, España, 52 años, 18/01/2018, Esther Campos Mollo, 28 28 50312, Mujer, 52 años, Esther Campos Mollo, esthercm@hotmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Alejandra. Apellidos: Irías Arias. NHC: 3738763. NASS: 74 65745652 32. Domicilio: C/ Principe de Vergara, 29, 5 A. Localidad/ Provincia: Madrid. CP: 28010. Datos asistenciales. Fecha de nacimiento: 05/02/1965. País de nacimiento: España. Edad: 52 años Sexo: M. Fecha de Ingreso: 18/01/2018. Médico: Esther Campos Mollo NºCol: 28 28 50312. Informe clínico del paciente: Mujer de 52 años que refirió disminución de agudeza visual (AV) espontánea en su ojo izquierdo (OI) ambliope. No tenía el antecedente de parto prematuro, ni historia familiar de enfermedad ocular. En la primera exploración, la mejor AV corregida fue de 1 en el ojo derecho (OD) (-1 cilindro 150o +3 esfera; longitud axial de 22,5mm) y de 0,025 en el ojo izquierdo (OI) (-0,75 cilindro 25o -13,25 esfera; longitud axial de 25,3mm). El estudio biomicroscópico del OI permitió identificar la mancha de Mittendorf localizada en el cuadrante nasal inferior de la cápsula posterior del cristalino y el extremo anterior de la AHP con contenido hemático en su interior. El ojo adelfo era normal. Los diámetros corneales horizontales midieron 12mm en ambos ojos (AO) y la tonometría de aplanación fue de 18mm Hg en AO. La oftalmoscopia indirecta del OI mostró una hemorragia intravítrea leve difusa. El trayecto de la AHP se pudo seguir desde el nervio óptico hasta la cristaloides posterior. La arteria, fijada en sus dos extremos, se desplazaba libremente con los movimientos oculares. El vítreo posterior estaba desprendido parcialmente de la retina. No se hallaron anomalías retinianas periféricas, ni signos de tracción vitreorretiniana o desprendimiento de retina. El fondo del OD era normal. La hemorragia se reabsorbió gradualmente en el transcurso de una semana. La AHP se pudo distinguir con más claridad permitiendo un mejor estudio anatómico. En la tomografía de coherencia óptica (TCO) se apreciaron las características morfológicas de la papila de Bergmeister. De esta, surgía la AHP que mostró una estructura tubular con un interior hiporreflectivo. En la ecografía en modo B se evidenció una imagen lineal hiperecogénica respecto al vítreo que se correspondía con la AHP y un desprendimiento parcial de vítreo posterior. El eco-doppler demostró el flujo sanguíneo normal de la arteria central de la retina y de las arterias ciliares posteriores aunque no se objetivó la presencia de flujo sanguíneo activo en la AHP. El hemograma y las pruebas específicas de coagulación fueron normales. El hemovítreo se reabsorbió completamente y la paciente recuperó la visión de 0,2 que presentaba antes de sobrevenir la hemorragia a causa de una ambliopía por anisometropía. No hubo recurrencia de sangrado en 6 meses de seguimiento. Responsable clínico: Dra. Esther Campos Mollo Correo electrónico: esthercm@hotmail.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Alejandra", ".", "\n", "Apellidos", ":", "Irías", "Arias", ".", "\n", "NHC", ":", "3738763", ".", "\n", "NASS", ":", "74", "65745652", "32", ".", "\n", "Domicilio", ":", "C/", "Principe", "de", "Vergara", ",", "29", ",", "5", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28010", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "05/02/1965", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "52", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "18/01/2018", ".", "\n", "Médico", ":", "Esther", "Campos", "Mollo", "NºCol", ":", "28", "28", "50312", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "52", "años", "que", "refirió", "disminución", "de", "agudeza", "visual", "(", "AV", ")", "espontánea", "en", "su", "ojo", "izquierdo", "(", "OI", ")", "ambliope", ".", "No", "tenía", "el", "antecedente", "de", "parto", "prematuro", ",", "ni", "historia", "familiar", "de", "enfermedad", "ocular", ".", "\n", "En", "la", "primera", "exploración", ",", "la", "mejor", "AV", "corregida", "fue", "de", "1", "en", "el", "ojo", "derecho", "(", "OD", ")", "(", "-1", "cilindro", "150o", "+3", "esfera", ";", "longitud", "axial", "de", "22,5", "mm", ")", "y", "de", "0,025", "en", "el", "ojo", "izquierdo", "(", "OI", ")", "(", "-0,75", "cilindro", "25o", "-13,25", "esfera", ";", "longitud", "axial", "de", "25,3", "mm", ")", ".", "\n", "El", "estudio", "biomicroscópico", "del", "OI", "permitió", "identificar", "la", "mancha", "de", "Mittendorf", "localizada", "en", "el", "cuadrante", "nasal", "inferior", "de", "la", "cápsula", "posterior", "del", "cristalino", "y", "el", "extremo", "anterior", "de", "la", "AHP", "con", "contenido", "hemático", "en", "su", "interior", ".", "El", "ojo", "adelfo", "era", "normal", ".", "Los", "diámetros", "corneales", "horizontales", "midieron", "12", "mm", "en", "ambos", "ojos", "(", "AO", ")", "y", "la", "tonometría", "de", "aplanación", "fue", "de", "18", "mm", "Hg", "en", "AO", ".", "\n", "La", "oftalmoscopia", "indirecta", "del", "OI", "mostró", "una", "hemorragia", "intravítrea", "leve", "difusa", ".", "El", "trayecto", "de", "la", "AHP", "se", "pudo", "seguir", "desde", "el", "nervio", "óptico", "hasta", "la", "cristaloides", "posterior", ".", "La", "arteria", ",", "fijada", "en", "sus", "dos", "extremos", ",", "se", "desplazaba", "libremente", "con", "los", "movimientos", "oculares", ".", "El", "vítreo", "posterior", "estaba", "desprendido", "parcialmente", "de", "la", "retina", ".", "No", "se", "hallaron", "anomalías", "retinianas", "periféricas", ",", "ni", "signos", "de", "tracción", "vitreorretiniana", "o", "desprendimiento", "de", "retina", ".", "El", "fondo", "del", "OD", "era", "normal", ".", "\n", "La", "hemorragia", "se", "reabsorbió", "gradualmente", "en", "el", "transcurso", "de", "una", "semana", ".", "La", "AHP", "se", "pudo", "distinguir", "con", "más", "claridad", "permitiendo", "un", "mejor", "estudio", "anatómico", ".", "En", "la", "tomografía", "de", "coherencia", "óptica", "(", "TCO", ")", "se", "apreciaron", "las", "características", "morfológicas", "de", "la", "papila", "de", "Bergmeister", ".", "De", "esta", ",", "surgía", "la", "AHP", "que", "mostró", "una", "estructura", "tubular", "con", "un", "interior", "hiporreflectivo", ".", "\n", "En", "la", "ecografía", "en", "modo", "B", "se", "evidenció", "una", "imagen", "lineal", "hiperecogénica", "respecto", "al", "vítreo", "que", "se", "correspondía", "con", "la", "AHP", "y", "un", "desprendimiento", "parcial", "de", "vítreo", "posterior", ".", "El", "eco", "-", "doppler", "demostró", "el", "flujo", "sanguíneo", "normal", "de", "la", "arteria", "central", "de", "la", "retina", "y", "de", "las", "arterias", "ciliares", "posteriores", "aunque", "no", "se", "objetivó", "la", "presencia", "de", "flujo", "sanguíneo", "activo", "en", "la", "AHP", ".", "\n", "El", "hemograma", "y", "las", "pruebas", "específicas", "de", "coagulación", "fueron", "normales", ".", "El", "hemovítreo", "se", "reabsorbió", "completamente", "y", "la", "paciente", "recuperó", "la", "visión", "de", "0,2", "que", "presentaba", "antes", "de", "sobrevenir", "la", "hemorragia", "a", "causa", "de", "una", "ambliopía", "por", "anisometropía", ".", "No", "hubo", "recurrencia", "de", "sangrado", "en", "6", "meses", "de", "seguimiento", ".", "\n", "Responsable", "clínico", ":", "Dra", ".", "Esther", "Campos", "Mollo", "Correo", "electrónico", ":", "esthercm@hotmail.com", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Alejandra, Irías Arias, 3738763, 74 65745652 32, Madrid, 28010, 05/02/1965, España, 52 años, 18/01/2018, Esther Campos Mollo, 28 28 50312, Mujer, 52 años, Esther Campos Mollo, esthercm@hotmail.com	229_task2	Sentence: Datos del paciente. Nombre: Alejandra. Apellidos: Irías Arias. NHC: 3738763. NASS: 74 65745652 32. Domicilio: C/ Principe de Vergara, 29, 5 A. Localidad/ Provincia: Madrid. CP: 28010. Datos asistenciales. Fecha de nacimiento: 05/02/1965. País de nacimiento: España. Edad: 52 años Sexo: M. Fecha de Ingreso: 18/01/2018. Médico: Esther Campos Mollo NºCol: 28 28 50312. Informe clínico del paciente: Mujer de 52 años que refirió disminución de agudeza visual (AV) espontánea en su ojo izquierdo (OI) ambliope. No tenía el antecedente de parto prematuro, ni historia familiar de enfermedad ocular. En la primera exploración, la mejor AV corregida fue de 1 en el ojo derecho (OD) (-1 cilindro 150o +3 esfera; longitud axial de 22,5mm) y de 0,025 en el ojo izquierdo (OI) (-0,75 cilindro 25o -13,25 esfera; longitud axial de 25,3mm). El estudio biomicroscópico del OI permitió identificar la mancha de Mittendorf localizada en el cuadrante nasal inferior de la cápsula posterior del cristalino y el extremo anterior de la AHP con contenido hemático en su interior. El ojo adelfo era normal. Los diámetros corneales horizontales midieron 12mm en ambos ojos (AO) y la tonometría de aplanación fue de 18mm Hg en AO. La oftalmoscopia indirecta del OI mostró una hemorragia intravítrea leve difusa. El trayecto de la AHP se pudo seguir desde el nervio óptico hasta la cristaloides posterior. La arteria, fijada en sus dos extremos, se desplazaba libremente con los movimientos oculares. El vítreo posterior estaba desprendido parcialmente de la retina. No se hallaron anomalías retinianas periféricas, ni signos de tracción vitreorretiniana o desprendimiento de retina. El fondo del OD era normal. La hemorragia se reabsorbió gradualmente en el transcurso de una semana. La AHP se pudo distinguir con más claridad permitiendo un mejor estudio anatómico. En la tomografía de coherencia óptica (TCO) se apreciaron las características morfológicas de la papila de Bergmeister. De esta, surgía la AHP que mostró una estructura tubular con un interior hiporreflectivo. En la ecografía en modo B se evidenció una imagen lineal hiperecogénica respecto al vítreo que se correspondía con la AHP y un desprendimiento parcial de vítreo posterior. El eco-doppler demostró el flujo sanguíneo normal de la arteria central de la retina y de las arterias ciliares posteriores aunque no se objetivó la presencia de flujo sanguíneo activo en la AHP. El hemograma y las pruebas específicas de coagulación fueron normales. El hemovítreo se reabsorbió completamente y la paciente recuperó la visión de 0,2 que presentaba antes de sobrevenir la hemorragia a causa de una ambliopía por anisometropía. No hubo recurrencia de sangrado en 6 meses de seguimiento. Responsable clínico: Dra. Esther Campos Mollo Correo electrónico: esthercm@hotmail.com Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Alejandra. Apellidos: Irías Arias. NHC: 3738763. NASS: 74 65745652 32. Domicilio: C/ Principe de Vergara, 29, 5 A. Localidad/ Provincia: Madrid. CP: 28010. Datos asistenciales. Fecha de nacimiento: 05/02/1965. País de nacimiento: España. Edad: 52 años Sexo: M. Fecha de Ingreso: 18/01/2018. Médico: Esther Campos Mollo NºCol: 28 28 50312. Informe clínico del paciente: Mujer de 52 años que refirió disminución de agudeza visual (AV) espontánea en su ojo izquierdo (OI) ambliope. No tenía el antecedente de parto prematuro, ni historia familiar de enfermedad ocular. En la primera exploración, la mejor AV corregida fue de 1 en el ojo derecho (OD) (-1 cilindro 150o +3 esfera; longitud axial de 22,5mm) y de 0,025 en el ojo izquierdo (OI) (-0,75 cilindro 25o -13,25 esfera; longitud axial de 25,3mm). El estudio biomicroscópico del OI permitió identificar la mancha de Mittendorf localizada en el cuadrante nasal inferior de la cápsula posterior del cristalino y el extremo anterior de la AHP con contenido hemático en su interior. El ojo adelfo era normal. Los diámetros corneales horizontales midieron 12mm en ambos ojos (AO) y la tonometría de aplanación fue de 18mm Hg en AO. La oftalmoscopia indirecta del OI mostró una hemorragia intravítrea leve difusa. El trayecto de la AHP se pudo seguir desde el nervio óptico hasta la cristaloides posterior. La arteria, fijada en sus dos extremos, se desplazaba libremente con los movimientos oculares. El vítreo posterior estaba desprendido parcialmente de la retina. No se hallaron anomalías retinianas periféricas, ni signos de tracción vitreorretiniana o desprendimiento de retina. El fondo del OD era normal. La hemorragia se reabsorbió gradualmente en el transcurso de una semana. La AHP se pudo distinguir con más claridad permitiendo un mejor estudio anatómico. En la tomografía de coherencia óptica (TCO) se apreciaron las características morfológicas de la papila de Bergmeister. De esta, surgía la AHP que mostró una estructura tubular con un interior hiporreflectivo. En la ecografía en modo B se evidenció una imagen lineal hiperecogénica respecto al vítreo que se correspondía con la AHP y un desprendimiento parcial de vítreo posterior. El eco-doppler demostró el flujo sanguíneo normal de la arteria central de la retina y de las arterias ciliares posteriores aunque no se objetivó la presencia de flujo sanguíneo activo en la AHP. El hemograma y las pruebas específicas de coagulación fueron normales. El hemovítreo se reabsorbió completamente y la paciente recuperó la visión de 0,2 que presentaba antes de sobrevenir la hemorragia a causa de una ambliopía por anisometropía. No hubo recurrencia de sangrado en 6 meses de seguimiento. Responsable clínico: Dra. Esther Campos Mollo Correo electrónico: esthercm@hotmail.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Alejandra", ".", "\n", "Apellidos", ":", "Irías", "Arias", ".", "\n", "NHC", ":", "3738763", ".", "\n", "NASS", ":", "74", "65745652", "32", ".", "\n", "Domicilio", ":", "C/", "Principe", "de", "Vergara", ",", "29", ",", "5", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28010", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "05/02/1965", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "52", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "18/01/2018", ".", "\n", "Médico", ":", "Esther", "Campos", "Mollo", "NºCol", ":", "28", "28", "50312", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "52", "años", "que", "refirió", "disminución", "de", "agudeza", "visual", "(", "AV", ")", "espontánea", "en", "su", "ojo", "izquierdo", "(", "OI", ")", "ambliope", ".", "No", "tenía", "el", "antecedente", "de", "parto", "prematuro", ",", "ni", "historia", "familiar", "de", "enfermedad", "ocular", ".", "\n", "En", "la", "primera", "exploración", ",", "la", "mejor", "AV", "corregida", "fue", "de", "1", "en", "el", "ojo", "derecho", "(", "OD", ")", "(", "-1", "cilindro", "150o", "+3", "esfera", ";", "longitud", "axial", "de", "22,5", "mm", ")", "y", "de", "0,025", "en", "el", "ojo", "izquierdo", "(", "OI", ")", "(", "-0,75", "cilindro", "25o", "-13,25", "esfera", ";", "longitud", "axial", "de", "25,3", "mm", ")", ".", "\n", "El", "estudio", "biomicroscópico", "del", "OI", "permitió", "identificar", "la", "mancha", "de", "Mittendorf", "localizada", "en", "el", "cuadrante", "nasal", "inferior", "de", "la", "cápsula", "posterior", "del", "cristalino", "y", "el", "extremo", "anterior", "de", "la", "AHP", "con", "contenido", "hemático", "en", "su", "interior", ".", "El", "ojo", "adelfo", "era", "normal", ".", "Los", "diámetros", "corneales", "horizontales", "midieron", "12", "mm", "en", "ambos", "ojos", "(", "AO", ")", "y", "la", "tonometría", "de", "aplanación", "fue", "de", "18", "mm", "Hg", "en", "AO", ".", "\n", "La", "oftalmoscopia", "indirecta", "del", "OI", "mostró", "una", "hemorragia", "intravítrea", "leve", "difusa", ".", "El", "trayecto", "de", "la", "AHP", "se", "pudo", "seguir", "desde", "el", "nervio", "óptico", "hasta", "la", "cristaloides", "posterior", ".", "La", "arteria", ",", "fijada", "en", "sus", "dos", "extremos", ",", "se", "desplazaba", "libremente", "con", "los", "movimientos", "oculares", ".", "El", "vítreo", "posterior", "estaba", "desprendido", "parcialmente", "de", "la", "retina", ".", "No", "se", "hallaron", "anomalías", "retinianas", "periféricas", ",", "ni", "signos", "de", "tracción", "vitreorretiniana", "o", "desprendimiento", "de", "retina", ".", "El", "fondo", "del", "OD", "era", "normal", ".", "\n", "La", "hemorragia", "se", "reabsorbió", "gradualmente", "en", "el", "transcurso", "de", "una", "semana", ".", "La", "AHP", "se", "pudo", "distinguir", "con", "más", "claridad", "permitiendo", "un", "mejor", "estudio", "anatómico", ".", "En", "la", "tomografía", "de", "coherencia", "óptica", "(", "TCO", ")", "se", "apreciaron", "las", "características", "morfológicas", "de", "la", "papila", "de", "Bergmeister", ".", "De", "esta", ",", "surgía", "la", "AHP", "que", "mostró", "una", "estructura", "tubular", "con", "un", "interior", "hiporreflectivo", ".", "\n", "En", "la", "ecografía", "en", "modo", "B", "se", "evidenció", "una", "imagen", "lineal", "hiperecogénica", "respecto", "al", "vítreo", "que", "se", "correspondía", "con", "la", "AHP", "y", "un", "desprendimiento", "parcial", "de", "vítreo", "posterior", ".", "El", "eco", "-", "doppler", "demostró", "el", "flujo", "sanguíneo", "normal", "de", "la", "arteria", "central", "de", "la", "retina", "y", "de", "las", "arterias", "ciliares", "posteriores", "aunque", "no", "se", "objetivó", "la", "presencia", "de", "flujo", "sanguíneo", "activo", "en", "la", "AHP", ".", "\n", "El", "hemograma", "y", "las", "pruebas", "específicas", "de", "coagulación", "fueron", "normales", ".", "El", "hemovítreo", "se", "reabsorbió", "completamente", "y", "la", "paciente", "recuperó", "la", "visión", "de", "0,2", "que", "presentaba", "antes", "de", "sobrevenir", "la", "hemorragia", "a", "causa", "de", "una", "ambliopía", "por", "anisometropía", ".", "No", "hubo", "recurrencia", "de", "sangrado", "en", "6", "meses", "de", "seguimiento", ".", "\n", "Responsable", "clínico", ":", "Dra", ".", "Esther", "Campos", "Mollo", "Correo", "electrónico", ":", "esthercm@hotmail.com", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Morphological is an umlsterm, joints is an umlsterm, surgical treatment is an umlsterm, pain is an umlsterm, symptoms is an umlsterm, treatment is an umlsterm, diagnostic is an umlsterm, treatment is an umlsterm, forms is an umlsterm	ManuelleMedizin.80360072.eng.abstr_task0	Sentence: Morphological changes in the peripheral joints are an indication for the necessity of surgical treatment , particularly when said changes lead to pain and functional disturbances . However , in the absence of either one , or both , of these symptoms conservative orthopaedic treatment should be considered . Taking into consideration the actuality diagnostic factors , conservative orthopaedic treatment forms which should be considered , either singly or in combination with each other , will be described . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Morphological changes in the peripheral joints are an indication for the necessity of surgical treatment , particularly when said changes lead to pain and functional disturbances . However , in the absence of either one , or both , of these symptoms conservative orthopaedic treatment should be considered . Taking into consideration the actuality diagnostic factors , conservative orthopaedic treatment forms which should be considered , either singly or in combination with each other , will be described .	[ "Morphological", "changes", "in", "the", "peripheral", "joints", "are", "an", "indication", "for", "the", "necessity", "of", "surgical", "treatment", ",", "particularly", "when", "said", "changes", "lead", "to", "pain", "and", "functional", "disturbances", ".", "However", ",", "in", "the", "absence", "of", "either", "one", ",", "or", "both", ",", "of", "these", "symptoms", "conservative", "orthopaedic", "treatment", "should", "be", "considered", ".", "Taking", "into", "consideration", "the", "actuality", "diagnostic", "factors", ",", "conservative", "orthopaedic", "treatment", "forms", "which", "should", "be", "considered", ",", "either", "singly", "or", "in", "combination", "with", "each", "other", ",", "will", "be", "described", "." ]	[ "umlsterm" ]
Morphological is an umlsterm, joints is an umlsterm, surgical treatment is an umlsterm, pain is an umlsterm, symptoms is an umlsterm, treatment is an umlsterm, diagnostic is an umlsterm, treatment is an umlsterm, forms is an umlsterm	ManuelleMedizin.80360072.eng.abstr_task1	Sentence: Morphological changes in the peripheral joints are an indication for the necessity of surgical treatment , particularly when said changes lead to pain and functional disturbances . However , in the absence of either one , or both , of these symptoms conservative orthopaedic treatment should be considered . Taking into consideration the actuality diagnostic factors , conservative orthopaedic treatment forms which should be considered , either singly or in combination with each other , will be described . Instructions: please typing these entity words according to sentence: Morphological, joints, surgical treatment, pain, symptoms, treatment, diagnostic, treatment, forms Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Morphological changes in the peripheral joints are an indication for the necessity of surgical treatment , particularly when said changes lead to pain and functional disturbances . However , in the absence of either one , or both , of these symptoms conservative orthopaedic treatment should be considered . Taking into consideration the actuality diagnostic factors , conservative orthopaedic treatment forms which should be considered , either singly or in combination with each other , will be described .	[ "Morphological", "changes", "in", "the", "peripheral", "joints", "are", "an", "indication", "for", "the", "necessity", "of", "surgical", "treatment", ",", "particularly", "when", "said", "changes", "lead", "to", "pain", "and", "functional", "disturbances", ".", "However", ",", "in", "the", "absence", "of", "either", "one", ",", "or", "both", ",", "of", "these", "symptoms", "conservative", "orthopaedic", "treatment", "should", "be", "considered", ".", "Taking", "into", "consideration", "the", "actuality", "diagnostic", "factors", ",", "conservative", "orthopaedic", "treatment", "forms", "which", "should", "be", "considered", ",", "either", "singly", "or", "in", "combination", "with", "each", "other", ",", "will", "be", "described", "." ]	[ "umlsterm" ]
Morphological, joints, surgical treatment, pain, symptoms, treatment, diagnostic, treatment, forms	ManuelleMedizin.80360072.eng.abstr_task2	Sentence: Morphological changes in the peripheral joints are an indication for the necessity of surgical treatment , particularly when said changes lead to pain and functional disturbances . However , in the absence of either one , or both , of these symptoms conservative orthopaedic treatment should be considered . Taking into consideration the actuality diagnostic factors , conservative orthopaedic treatment forms which should be considered , either singly or in combination with each other , will be described . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Morphological changes in the peripheral joints are an indication for the necessity of surgical treatment , particularly when said changes lead to pain and functional disturbances . However , in the absence of either one , or both , of these symptoms conservative orthopaedic treatment should be considered . Taking into consideration the actuality diagnostic factors , conservative orthopaedic treatment forms which should be considered , either singly or in combination with each other , will be described .	[ "Morphological", "changes", "in", "the", "peripheral", "joints", "are", "an", "indication", "for", "the", "necessity", "of", "surgical", "treatment", ",", "particularly", "when", "said", "changes", "lead", "to", "pain", "and", "functional", "disturbances", ".", "However", ",", "in", "the", "absence", "of", "either", "one", ",", "or", "both", ",", "of", "these", "symptoms", "conservative", "orthopaedic", "treatment", "should", "be", "considered", ".", "Taking", "into", "consideration", "the", "actuality", "diagnostic", "factors", ",", "conservative", "orthopaedic", "treatment", "forms", "which", "should", "be", "considered", ",", "either", "singly", "or", "in", "combination", "with", "each", "other", ",", "will", "be", "described", "." ]	[ "umlsterm" ]
Chinese herbal medicine is a Intervention_Pharmacological, Chinese herbal medicine ( CHM ) is a Intervention_Pharmacological, wait - list control ( WLC ) is a Intervention_Control, individualized CHM decoctions is a Intervention_Pharmacological, therapeutically inert placebo decoction is a Intervention_Control, measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; is a Outcome_Pain, Endometriosis Health Profile-30 ( EHP-30 ) endometriosis - specific quality - of - life questionnaire is a Outcome_Other, Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient - centered health questionnaire is a Outcome_Physical, Liver and renal function is a Outcome_Physical, EHP-30 and MYMOP scores is a Outcome_Physical, VAS scores is a Outcome_Physical	50976_task0	Sentence: A feasibility study exploring the role of Chinese herbal medicine in the treatment of endometriosis . BACKGROUND Endometriosis is a common and disabling gynecologic condition affecting between 5 % and 15 % of women of childbearing age . Conventional medical intervention has unpleasant side-effects , and symptoms frequently return after treatment . Preliminary evidence suggests Chinese herbal medicine ( CHM ) may contribute to the treatment of endometriosis . OBJECTIVES The aims of this study were to test the feasibility of a novel methodology for investigating individualized decoctions of CHM rigorously and to gather preliminary data on the treatment effect of CHM for a larger definitive trial . DESIGN This was a 16-week prospective , double blinded , randomized controlled trial of 40 women with laparoscopically confirmed endometriosis . SETTINGS The trial was conducted at a private CHM clinic in Hove ( U.K. ) and at a National Health Service outpatient clinic in London ( U.K. ) . INTERVENTIONS Participants were initially randomized to either wait-list control ( WLC ) or treatment groups to receive either individualized CHM decoctions or a therapeutically inert placebo decoction . OUTCOME MEASURES Four 10-cm visual analogue scales ( VAS ) were used to measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; these measurements were recorded weekly . The Endometriosis Health Profile-30 ( EHP-30 ) endometriosis-specific quality-of-life questionnaire was completed at the beginning and at the end of the trial . The Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient-centered health questionnaire was completed monthly . Liver and renal function was measured at 0 , 4 , 8 , and 16 weeks . RESULTS Twenty-eight ( 28 ) women completed the trial . High dropout rates led to the suspension of the WLC . Randomization , double blinding , and allocation concealment was achieved successfully . Adjusted mean differences favored the active treatment in the EHP-30 and MYMOP scores . VAS scores favored the active treatment for relief of menstrual pain and the placebo group for reduction of daily pain . CONCLUSIONS the methodology successfully allowed individualized CHM decoctions to be tested rigorously . There are nonspecific contextual effects from CHM that require further investigation . Provisional data were generated to warrant a larger , more-definitive study . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Outcome_Physical, Outcome_Pain, Outcome_Other	[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A feasibility study exploring the role of Chinese herbal medicine in the treatment of endometriosis . BACKGROUND Endometriosis is a common and disabling gynecologic condition affecting between 5 % and 15 % of women of childbearing age . Conventional medical intervention has unpleasant side-effects , and symptoms frequently return after treatment . Preliminary evidence suggests Chinese herbal medicine ( CHM ) may contribute to the treatment of endometriosis . OBJECTIVES The aims of this study were to test the feasibility of a novel methodology for investigating individualized decoctions of CHM rigorously and to gather preliminary data on the treatment effect of CHM for a larger definitive trial . DESIGN This was a 16-week prospective , double blinded , randomized controlled trial of 40 women with laparoscopically confirmed endometriosis . SETTINGS The trial was conducted at a private CHM clinic in Hove ( U.K. ) and at a National Health Service outpatient clinic in London ( U.K. ) . INTERVENTIONS Participants were initially randomized to either wait-list control ( WLC ) or treatment groups to receive either individualized CHM decoctions or a therapeutically inert placebo decoction . OUTCOME MEASURES Four 10-cm visual analogue scales ( VAS ) were used to measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; these measurements were recorded weekly . The Endometriosis Health Profile-30 ( EHP-30 ) endometriosis-specific quality-of-life questionnaire was completed at the beginning and at the end of the trial . The Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient-centered health questionnaire was completed monthly . Liver and renal function was measured at 0 , 4 , 8 , and 16 weeks . RESULTS Twenty-eight ( 28 ) women completed the trial . High dropout rates led to the suspension of the WLC . Randomization , double blinding , and allocation concealment was achieved successfully . Adjusted mean differences favored the active treatment in the EHP-30 and MYMOP scores . VAS scores favored the active treatment for relief of menstrual pain and the placebo group for reduction of daily pain . CONCLUSIONS the methodology successfully allowed individualized CHM decoctions to be tested rigorously . There are nonspecific contextual effects from CHM that require further investigation . Provisional data were generated to warrant a larger , more-definitive study .	[ "A", "feasibility", "study", "exploring", "the", "role", "of", "Chinese", "herbal", "medicine", "in", "the", "treatment", "of", "endometriosis", ".", "BACKGROUND", "Endometriosis", "is", "a", "common", "and", "disabling", "gynecologic", "condition", "affecting", "between", "5", "%", "and", "15", "%", "of", "women", "of", "childbearing", "age", ".", "Conventional", "medical", "intervention", "has", "unpleasant", "side", "-", "effects", ",", "and", "symptoms", "frequently", "return", "after", "treatment", ".", "Preliminary", "evidence", "suggests", "Chinese", "herbal", "medicine", "(", "CHM", ")", "may", "contribute", "to", "the", "treatment", "of", "endometriosis", ".", "OBJECTIVES", "The", "aims", "of", "this", "study", "were", "to", "test", "the", "feasibility", "of", "a", "novel", "methodology", "for", "investigating", "individualized", "decoctions", "of", "CHM", "rigorously", "and", "to", "gather", "preliminary", "data", "on", "the", "treatment", "effect", "of", "CHM", "for", "a", "larger", "definitive", "trial", ".", "DESIGN", "This", "was", "a", "16-week", "prospective", ",", "double", "blinded", ",", "randomized", "controlled", "trial", "of", "40", "women", "with", "laparoscopically", "confirmed", "endometriosis", ".", "SETTINGS", "The", "trial", "was", "conducted", "at", "a", "private", "CHM", "clinic", "in", "Hove", "(", "U.K.", ")", "and", "at", "a", "National", "Health", "Service", "outpatient", "clinic", "in", "London", "(", "U.K.", ")", ".", "INTERVENTIONS", "Participants", "were", "initially", "randomized", "to", "either", "wait", "-", "list", "control", "(", "WLC", ")", "or", "treatment", "groups", "to", "receive", "either", "individualized", "CHM", "decoctions", "or", "a", "therapeutically", "inert", "placebo", "decoction", ".", "OUTCOME", "MEASURES", "Four", "10-cm", "visual", "analogue", "scales", "(", "VAS", ")", "were", "used", "to", "measure", "menstrual", "pain", ",", "daily", "pain", ",", "and", "pain", "on", "intercourse", "and", "bowel", "movement", ";", "these", "measurements", "were", "recorded", "weekly", ".", "The", "Endometriosis", "Health", "Profile-30", "(", "EHP-30", ")", "endometriosis", "-", "specific", "quality", "-", "of", "-", "life", "questionnaire", "was", "completed", "at", "the", "beginning", "and", "at", "the", "end", "of", "the", "trial", ".", "The", "Measure", "Yourself", "Medical", "Outcomes", "Profile", "(", "MYMOP", ")", "a", "patient", "-", "centered", "health", "questionnaire", "was", "completed", "monthly", ".", "Liver", "and", "renal", "function", "was", "measured", "at", "0", ",", "4", ",", "8", ",", "and", "16", "weeks", ".", "RESULTS", "Twenty", "-", "eight", "(", "28", ")", "women", "completed", "the", "trial", ".", "High", "dropout", "rates", "led", "to", "the", "suspension", "of", "the", "WLC", ".", "Randomization", ",", "double", "blinding", ",", "and", "allocation", "concealment", "was", "achieved", "successfully", ".", "Adjusted", "mean", "differences", "favored", "the", "active", "treatment", "in", "the", "EHP-30", "and", "MYMOP", "scores", ".", "VAS", "scores", "favored", "the", "active", "treatment", "for", "relief", "of", "menstrual", "pain", "and", "the", "placebo", "group", "for", "reduction", "of", "daily", "pain", ".", "CONCLUSIONS", "the", "methodology", "successfully", "allowed", "individualized", "CHM", "decoctions", "to", "be", "tested", "rigorously", ".", "There", "are", "nonspecific", "contextual", "effects", "from", "CHM", "that", "require", "further", "investigation", ".", "Provisional", "data", "were", "generated", "to", "warrant", "a", "larger", ",", "more", "-", "definitive", "study", "." ]	[ "Outcome_Other", "Outcome_Physical", "Outcome_Pain", "Intervention_Control", "Intervention_Pharmacological" ]
Chinese herbal medicine is a Intervention_Pharmacological, Chinese herbal medicine ( CHM ) is a Intervention_Pharmacological, wait - list control ( WLC ) is a Intervention_Control, individualized CHM decoctions is a Intervention_Pharmacological, therapeutically inert placebo decoction is a Intervention_Control, measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; is a Outcome_Pain, Endometriosis Health Profile-30 ( EHP-30 ) endometriosis - specific quality - of - life questionnaire is a Outcome_Other, Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient - centered health questionnaire is a Outcome_Physical, Liver and renal function is a Outcome_Physical, EHP-30 and MYMOP scores is a Outcome_Physical, VAS scores is a Outcome_Physical	50976_task1	Sentence: A feasibility study exploring the role of Chinese herbal medicine in the treatment of endometriosis . BACKGROUND Endometriosis is a common and disabling gynecologic condition affecting between 5 % and 15 % of women of childbearing age . Conventional medical intervention has unpleasant side-effects , and symptoms frequently return after treatment . Preliminary evidence suggests Chinese herbal medicine ( CHM ) may contribute to the treatment of endometriosis . OBJECTIVES The aims of this study were to test the feasibility of a novel methodology for investigating individualized decoctions of CHM rigorously and to gather preliminary data on the treatment effect of CHM for a larger definitive trial . DESIGN This was a 16-week prospective , double blinded , randomized controlled trial of 40 women with laparoscopically confirmed endometriosis . SETTINGS The trial was conducted at a private CHM clinic in Hove ( U.K. ) and at a National Health Service outpatient clinic in London ( U.K. ) . INTERVENTIONS Participants were initially randomized to either wait-list control ( WLC ) or treatment groups to receive either individualized CHM decoctions or a therapeutically inert placebo decoction . OUTCOME MEASURES Four 10-cm visual analogue scales ( VAS ) were used to measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; these measurements were recorded weekly . The Endometriosis Health Profile-30 ( EHP-30 ) endometriosis-specific quality-of-life questionnaire was completed at the beginning and at the end of the trial . The Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient-centered health questionnaire was completed monthly . Liver and renal function was measured at 0 , 4 , 8 , and 16 weeks . RESULTS Twenty-eight ( 28 ) women completed the trial . High dropout rates led to the suspension of the WLC . Randomization , double blinding , and allocation concealment was achieved successfully . Adjusted mean differences favored the active treatment in the EHP-30 and MYMOP scores . VAS scores favored the active treatment for relief of menstrual pain and the placebo group for reduction of daily pain . CONCLUSIONS the methodology successfully allowed individualized CHM decoctions to be tested rigorously . There are nonspecific contextual effects from CHM that require further investigation . Provisional data were generated to warrant a larger , more-definitive study . Instructions: please typing these entity words according to sentence: Chinese herbal medicine, Chinese herbal medicine ( CHM ), wait - list control ( WLC ), individualized CHM decoctions, therapeutically inert placebo decoction, measure menstrual pain , daily pain , and pain on intercourse and bowel movement ;, Endometriosis Health Profile-30 ( EHP-30 ) endometriosis - specific quality - of - life questionnaire, Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient - centered health questionnaire, Liver and renal function, EHP-30 and MYMOP scores, VAS scores Options: Intervention_Pharmacological, Intervention_Control, Outcome_Physical, Outcome_Pain, Outcome_Other	[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A feasibility study exploring the role of Chinese herbal medicine in the treatment of endometriosis . BACKGROUND Endometriosis is a common and disabling gynecologic condition affecting between 5 % and 15 % of women of childbearing age . Conventional medical intervention has unpleasant side-effects , and symptoms frequently return after treatment . Preliminary evidence suggests Chinese herbal medicine ( CHM ) may contribute to the treatment of endometriosis . OBJECTIVES The aims of this study were to test the feasibility of a novel methodology for investigating individualized decoctions of CHM rigorously and to gather preliminary data on the treatment effect of CHM for a larger definitive trial . DESIGN This was a 16-week prospective , double blinded , randomized controlled trial of 40 women with laparoscopically confirmed endometriosis . SETTINGS The trial was conducted at a private CHM clinic in Hove ( U.K. ) and at a National Health Service outpatient clinic in London ( U.K. ) . INTERVENTIONS Participants were initially randomized to either wait-list control ( WLC ) or treatment groups to receive either individualized CHM decoctions or a therapeutically inert placebo decoction . OUTCOME MEASURES Four 10-cm visual analogue scales ( VAS ) were used to measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; these measurements were recorded weekly . The Endometriosis Health Profile-30 ( EHP-30 ) endometriosis-specific quality-of-life questionnaire was completed at the beginning and at the end of the trial . The Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient-centered health questionnaire was completed monthly . Liver and renal function was measured at 0 , 4 , 8 , and 16 weeks . RESULTS Twenty-eight ( 28 ) women completed the trial . High dropout rates led to the suspension of the WLC . Randomization , double blinding , and allocation concealment was achieved successfully . Adjusted mean differences favored the active treatment in the EHP-30 and MYMOP scores . VAS scores favored the active treatment for relief of menstrual pain and the placebo group for reduction of daily pain . CONCLUSIONS the methodology successfully allowed individualized CHM decoctions to be tested rigorously . There are nonspecific contextual effects from CHM that require further investigation . Provisional data were generated to warrant a larger , more-definitive study .	[ "A", "feasibility", "study", "exploring", "the", "role", "of", "Chinese", "herbal", "medicine", "in", "the", "treatment", "of", "endometriosis", ".", "BACKGROUND", "Endometriosis", "is", "a", "common", "and", "disabling", "gynecologic", "condition", "affecting", "between", "5", "%", "and", "15", "%", "of", "women", "of", "childbearing", "age", ".", "Conventional", "medical", "intervention", "has", "unpleasant", "side", "-", "effects", ",", "and", "symptoms", "frequently", "return", "after", "treatment", ".", "Preliminary", "evidence", "suggests", "Chinese", "herbal", "medicine", "(", "CHM", ")", "may", "contribute", "to", "the", "treatment", "of", "endometriosis", ".", "OBJECTIVES", "The", "aims", "of", "this", "study", "were", "to", "test", "the", "feasibility", "of", "a", "novel", "methodology", "for", "investigating", "individualized", "decoctions", "of", "CHM", "rigorously", "and", "to", "gather", "preliminary", "data", "on", "the", "treatment", "effect", "of", "CHM", "for", "a", "larger", "definitive", "trial", ".", "DESIGN", "This", "was", "a", "16-week", "prospective", ",", "double", "blinded", ",", "randomized", "controlled", "trial", "of", "40", "women", "with", "laparoscopically", "confirmed", "endometriosis", ".", "SETTINGS", "The", "trial", "was", "conducted", "at", "a", "private", "CHM", "clinic", "in", "Hove", "(", "U.K.", ")", "and", "at", "a", "National", "Health", "Service", "outpatient", "clinic", "in", "London", "(", "U.K.", ")", ".", "INTERVENTIONS", "Participants", "were", "initially", "randomized", "to", "either", "wait", "-", "list", "control", "(", "WLC", ")", "or", "treatment", "groups", "to", "receive", "either", "individualized", "CHM", "decoctions", "or", "a", "therapeutically", "inert", "placebo", "decoction", ".", "OUTCOME", "MEASURES", "Four", "10-cm", "visual", "analogue", "scales", "(", "VAS", ")", "were", "used", "to", "measure", "menstrual", "pain", ",", "daily", "pain", ",", "and", "pain", "on", "intercourse", "and", "bowel", "movement", ";", "these", "measurements", "were", "recorded", "weekly", ".", "The", "Endometriosis", "Health", "Profile-30", "(", "EHP-30", ")", "endometriosis", "-", "specific", "quality", "-", "of", "-", "life", "questionnaire", "was", "completed", "at", "the", "beginning", "and", "at", "the", "end", "of", "the", "trial", ".", "The", "Measure", "Yourself", "Medical", "Outcomes", "Profile", "(", "MYMOP", ")", "a", "patient", "-", "centered", "health", "questionnaire", "was", "completed", "monthly", ".", "Liver", "and", "renal", "function", "was", "measured", "at", "0", ",", "4", ",", "8", ",", "and", "16", "weeks", ".", "RESULTS", "Twenty", "-", "eight", "(", "28", ")", "women", "completed", "the", "trial", ".", "High", "dropout", "rates", "led", "to", "the", "suspension", "of", "the", "WLC", ".", "Randomization", ",", "double", "blinding", ",", "and", "allocation", "concealment", "was", "achieved", "successfully", ".", "Adjusted", "mean", "differences", "favored", "the", "active", "treatment", "in", "the", "EHP-30", "and", "MYMOP", "scores", ".", "VAS", "scores", "favored", "the", "active", "treatment", "for", "relief", "of", "menstrual", "pain", "and", "the", "placebo", "group", "for", "reduction", "of", "daily", "pain", ".", "CONCLUSIONS", "the", "methodology", "successfully", "allowed", "individualized", "CHM", "decoctions", "to", "be", "tested", "rigorously", ".", "There", "are", "nonspecific", "contextual", "effects", "from", "CHM", "that", "require", "further", "investigation", ".", "Provisional", "data", "were", "generated", "to", "warrant", "a", "larger", ",", "more", "-", "definitive", "study", "." ]	[ "Outcome_Other", "Outcome_Physical", "Outcome_Pain", "Intervention_Control", "Intervention_Pharmacological" ]
Chinese herbal medicine, Chinese herbal medicine ( CHM ), wait - list control ( WLC ), individualized CHM decoctions, therapeutically inert placebo decoction, measure menstrual pain , daily pain , and pain on intercourse and bowel movement ;, Endometriosis Health Profile-30 ( EHP-30 ) endometriosis - specific quality - of - life questionnaire, Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient - centered health questionnaire, Liver and renal function, EHP-30 and MYMOP scores, VAS scores	50976_task2	Sentence: A feasibility study exploring the role of Chinese herbal medicine in the treatment of endometriosis . BACKGROUND Endometriosis is a common and disabling gynecologic condition affecting between 5 % and 15 % of women of childbearing age . Conventional medical intervention has unpleasant side-effects , and symptoms frequently return after treatment . Preliminary evidence suggests Chinese herbal medicine ( CHM ) may contribute to the treatment of endometriosis . OBJECTIVES The aims of this study were to test the feasibility of a novel methodology for investigating individualized decoctions of CHM rigorously and to gather preliminary data on the treatment effect of CHM for a larger definitive trial . DESIGN This was a 16-week prospective , double blinded , randomized controlled trial of 40 women with laparoscopically confirmed endometriosis . SETTINGS The trial was conducted at a private CHM clinic in Hove ( U.K. ) and at a National Health Service outpatient clinic in London ( U.K. ) . INTERVENTIONS Participants were initially randomized to either wait-list control ( WLC ) or treatment groups to receive either individualized CHM decoctions or a therapeutically inert placebo decoction . OUTCOME MEASURES Four 10-cm visual analogue scales ( VAS ) were used to measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; these measurements were recorded weekly . The Endometriosis Health Profile-30 ( EHP-30 ) endometriosis-specific quality-of-life questionnaire was completed at the beginning and at the end of the trial . The Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient-centered health questionnaire was completed monthly . Liver and renal function was measured at 0 , 4 , 8 , and 16 weeks . RESULTS Twenty-eight ( 28 ) women completed the trial . High dropout rates led to the suspension of the WLC . Randomization , double blinding , and allocation concealment was achieved successfully . Adjusted mean differences favored the active treatment in the EHP-30 and MYMOP scores . VAS scores favored the active treatment for relief of menstrual pain and the placebo group for reduction of daily pain . CONCLUSIONS the methodology successfully allowed individualized CHM decoctions to be tested rigorously . There are nonspecific contextual effects from CHM that require further investigation . Provisional data were generated to warrant a larger , more-definitive study . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A feasibility study exploring the role of Chinese herbal medicine in the treatment of endometriosis . BACKGROUND Endometriosis is a common and disabling gynecologic condition affecting between 5 % and 15 % of women of childbearing age . Conventional medical intervention has unpleasant side-effects , and symptoms frequently return after treatment . Preliminary evidence suggests Chinese herbal medicine ( CHM ) may contribute to the treatment of endometriosis . OBJECTIVES The aims of this study were to test the feasibility of a novel methodology for investigating individualized decoctions of CHM rigorously and to gather preliminary data on the treatment effect of CHM for a larger definitive trial . DESIGN This was a 16-week prospective , double blinded , randomized controlled trial of 40 women with laparoscopically confirmed endometriosis . SETTINGS The trial was conducted at a private CHM clinic in Hove ( U.K. ) and at a National Health Service outpatient clinic in London ( U.K. ) . INTERVENTIONS Participants were initially randomized to either wait-list control ( WLC ) or treatment groups to receive either individualized CHM decoctions or a therapeutically inert placebo decoction . OUTCOME MEASURES Four 10-cm visual analogue scales ( VAS ) were used to measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; these measurements were recorded weekly . The Endometriosis Health Profile-30 ( EHP-30 ) endometriosis-specific quality-of-life questionnaire was completed at the beginning and at the end of the trial . The Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient-centered health questionnaire was completed monthly . Liver and renal function was measured at 0 , 4 , 8 , and 16 weeks . RESULTS Twenty-eight ( 28 ) women completed the trial . High dropout rates led to the suspension of the WLC . Randomization , double blinding , and allocation concealment was achieved successfully . Adjusted mean differences favored the active treatment in the EHP-30 and MYMOP scores . VAS scores favored the active treatment for relief of menstrual pain and the placebo group for reduction of daily pain . CONCLUSIONS the methodology successfully allowed individualized CHM decoctions to be tested rigorously . There are nonspecific contextual effects from CHM that require further investigation . Provisional data were generated to warrant a larger , more-definitive study .	[ "A", "feasibility", "study", "exploring", "the", "role", "of", "Chinese", "herbal", "medicine", "in", "the", "treatment", "of", "endometriosis", ".", "BACKGROUND", "Endometriosis", "is", "a", "common", "and", "disabling", "gynecologic", "condition", "affecting", "between", "5", "%", "and", "15", "%", "of", "women", "of", "childbearing", "age", ".", "Conventional", "medical", "intervention", "has", "unpleasant", "side", "-", "effects", ",", "and", "symptoms", "frequently", "return", "after", "treatment", ".", "Preliminary", "evidence", "suggests", "Chinese", "herbal", "medicine", "(", "CHM", ")", "may", "contribute", "to", "the", "treatment", "of", "endometriosis", ".", "OBJECTIVES", "The", "aims", "of", "this", "study", "were", "to", "test", "the", "feasibility", "of", "a", "novel", "methodology", "for", "investigating", "individualized", "decoctions", "of", "CHM", "rigorously", "and", "to", "gather", "preliminary", "data", "on", "the", "treatment", "effect", "of", "CHM", "for", "a", "larger", "definitive", "trial", ".", "DESIGN", "This", "was", "a", "16-week", "prospective", ",", "double", "blinded", ",", "randomized", "controlled", "trial", "of", "40", "women", "with", "laparoscopically", "confirmed", "endometriosis", ".", "SETTINGS", "The", "trial", "was", "conducted", "at", "a", "private", "CHM", "clinic", "in", "Hove", "(", "U.K.", ")", "and", "at", "a", "National", "Health", "Service", "outpatient", "clinic", "in", "London", "(", "U.K.", ")", ".", "INTERVENTIONS", "Participants", "were", "initially", "randomized", "to", "either", "wait", "-", "list", "control", "(", "WLC", ")", "or", "treatment", "groups", "to", "receive", "either", "individualized", "CHM", "decoctions", "or", "a", "therapeutically", "inert", "placebo", "decoction", ".", "OUTCOME", "MEASURES", "Four", "10-cm", "visual", "analogue", "scales", "(", "VAS", ")", "were", "used", "to", "measure", "menstrual", "pain", ",", "daily", "pain", ",", "and", "pain", "on", "intercourse", "and", "bowel", "movement", ";", "these", "measurements", "were", "recorded", "weekly", ".", "The", "Endometriosis", "Health", "Profile-30", "(", "EHP-30", ")", "endometriosis", "-", "specific", "quality", "-", "of", "-", "life", "questionnaire", "was", "completed", "at", "the", "beginning", "and", "at", "the", "end", "of", "the", "trial", ".", "The", "Measure", "Yourself", "Medical", "Outcomes", "Profile", "(", "MYMOP", ")", "a", "patient", "-", "centered", "health", "questionnaire", "was", "completed", "monthly", ".", "Liver", "and", "renal", "function", "was", "measured", "at", "0", ",", "4", ",", "8", ",", "and", "16", "weeks", ".", "RESULTS", "Twenty", "-", "eight", "(", "28", ")", "women", "completed", "the", "trial", ".", "High", "dropout", "rates", "led", "to", "the", "suspension", "of", "the", "WLC", ".", "Randomization", ",", "double", "blinding", ",", "and", "allocation", "concealment", "was", "achieved", "successfully", ".", "Adjusted", "mean", "differences", "favored", "the", "active", "treatment", "in", "the", "EHP-30", "and", "MYMOP", "scores", ".", "VAS", "scores", "favored", "the", "active", "treatment", "for", "relief", "of", "menstrual", "pain", "and", "the", "placebo", "group", "for", "reduction", "of", "daily", "pain", ".", "CONCLUSIONS", "the", "methodology", "successfully", "allowed", "individualized", "CHM", "decoctions", "to", "be", "tested", "rigorously", ".", "There", "are", "nonspecific", "contextual", "effects", "from", "CHM", "that", "require", "further", "investigation", ".", "Provisional", "data", "were", "generated", "to", "warrant", "a", "larger", ",", "more", "-", "definitive", "study", "." ]	[ "Outcome_Other", "Outcome_Physical", "Outcome_Pain", "Intervention_Control", "Intervention_Pharmacological" ]
reflex is an umlsterm, causes is an umlsterm, arrhythmias is an umlsterm, complication is an umlsterm, surgical is an umlsterm, rectus muscle is an umlsterm, lidocaine is an umlsterm, muscle is an umlsterm, incidence is an umlsterm, reflex is an umlsterm	DerOpthalmologe.70940354.eng.abstr_task0	Sentence: Introduction : The oculocardiac reflex causes severe bradycardic arrhythmias and is a frequent complication during surgical manipulation at the medial rectus muscle . The purpose of this study was to evaluate the influence of lidocaine administered topically on the muscle on the incidence of the oculocardiac reflex . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Introduction : The oculocardiac reflex causes severe bradycardic arrhythmias and is a frequent complication during surgical manipulation at the medial rectus muscle . The purpose of this study was to evaluate the influence of lidocaine administered topically on the muscle on the incidence of the oculocardiac reflex .	[ "Introduction", ":", "The", "oculocardiac", "reflex", "causes", "severe", "bradycardic", "arrhythmias", "and", "is", "a", "frequent", "complication", "during", "surgical", "manipulation", "at", "the", "medial", "rectus", "muscle", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "influence", "of", "lidocaine", "administered", "topically", "on", "the", "muscle", "on", "the", "incidence", "of", "the", "oculocardiac", "reflex", "." ]	[ "umlsterm" ]
reflex is an umlsterm, causes is an umlsterm, arrhythmias is an umlsterm, complication is an umlsterm, surgical is an umlsterm, rectus muscle is an umlsterm, lidocaine is an umlsterm, muscle is an umlsterm, incidence is an umlsterm, reflex is an umlsterm	DerOpthalmologe.70940354.eng.abstr_task1	Sentence: Introduction : The oculocardiac reflex causes severe bradycardic arrhythmias and is a frequent complication during surgical manipulation at the medial rectus muscle . The purpose of this study was to evaluate the influence of lidocaine administered topically on the muscle on the incidence of the oculocardiac reflex . Instructions: please typing these entity words according to sentence: reflex, causes, arrhythmias, complication, surgical, rectus muscle, lidocaine, muscle, incidence, reflex Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Introduction : The oculocardiac reflex causes severe bradycardic arrhythmias and is a frequent complication during surgical manipulation at the medial rectus muscle . The purpose of this study was to evaluate the influence of lidocaine administered topically on the muscle on the incidence of the oculocardiac reflex .	[ "Introduction", ":", "The", "oculocardiac", "reflex", "causes", "severe", "bradycardic", "arrhythmias", "and", "is", "a", "frequent", "complication", "during", "surgical", "manipulation", "at", "the", "medial", "rectus", "muscle", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "influence", "of", "lidocaine", "administered", "topically", "on", "the", "muscle", "on", "the", "incidence", "of", "the", "oculocardiac", "reflex", "." ]	[ "umlsterm" ]
reflex, causes, arrhythmias, complication, surgical, rectus muscle, lidocaine, muscle, incidence, reflex	DerOpthalmologe.70940354.eng.abstr_task2	Sentence: Introduction : The oculocardiac reflex causes severe bradycardic arrhythmias and is a frequent complication during surgical manipulation at the medial rectus muscle . The purpose of this study was to evaluate the influence of lidocaine administered topically on the muscle on the incidence of the oculocardiac reflex . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Introduction : The oculocardiac reflex causes severe bradycardic arrhythmias and is a frequent complication during surgical manipulation at the medial rectus muscle . The purpose of this study was to evaluate the influence of lidocaine administered topically on the muscle on the incidence of the oculocardiac reflex .	[ "Introduction", ":", "The", "oculocardiac", "reflex", "causes", "severe", "bradycardic", "arrhythmias", "and", "is", "a", "frequent", "complication", "during", "surgical", "manipulation", "at", "the", "medial", "rectus", "muscle", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "influence", "of", "lidocaine", "administered", "topically", "on", "the", "muscle", "on", "the", "incidence", "of", "the", "oculocardiac", "reflex", "." ]	[ "umlsterm" ]
detrusor overactivity is an outcome, bladder capacity is an outcome	1634_task0	Sentence: Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased bladder capacity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O" ]	Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased bladder capacity .	[ "Overall", ",", "13", "patients", "(", "46.4", "%", ")", "had", "detrusor", "overactivity", "and", "14", "(", "50", "%", ")", "had", "decreased", "bladder", "capacity", "." ]	[ "outcome" ]
detrusor overactivity is an outcome, bladder capacity is an outcome	1634_task1	Sentence: Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased bladder capacity . Instructions: please typing these entity words according to sentence: detrusor overactivity, bladder capacity Options: outcome	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O" ]	Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased bladder capacity .	[ "Overall", ",", "13", "patients", "(", "46.4", "%", ")", "had", "detrusor", "overactivity", "and", "14", "(", "50", "%", ")", "had", "decreased", "bladder", "capacity", "." ]	[ "outcome" ]
detrusor overactivity, bladder capacity	1634_task2	Sentence: Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased bladder capacity . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O" ]	Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased bladder capacity .	[ "Overall", ",", "13", "patients", "(", "46.4", "%", ")", "had", "detrusor", "overactivity", "and", "14", "(", "50", "%", ")", "had", "decreased", "bladder", "capacity", "." ]	[ "outcome" ]
calcium bioavailability is an outcome	376_task0	Sentence: In accordance , calcium bioavailability in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , BD % = 38.2 +/- 3.6 ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome	[ "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In accordance , calcium bioavailability in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , BD % = 38.2 +/- 3.6 ) .	[ "In", "accordance", ",", "calcium", "bioavailability", "in", "adolescents", "did", "not", "vary", "between", "the", "diets", "(", "%", "WD", "=", "40.4", "+", "/-", "5.1", ",", "BD", "%", "=", "38.2", "+", "/-", "3.6", ")", "." ]	[ "outcome" ]
calcium bioavailability is an outcome	376_task1	Sentence: In accordance , calcium bioavailability in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , BD % = 38.2 +/- 3.6 ) . Instructions: please typing these entity words according to sentence: calcium bioavailability Options: outcome	[ "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In accordance , calcium bioavailability in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , BD % = 38.2 +/- 3.6 ) .	[ "In", "accordance", ",", "calcium", "bioavailability", "in", "adolescents", "did", "not", "vary", "between", "the", "diets", "(", "%", "WD", "=", "40.4", "+", "/-", "5.1", ",", "BD", "%", "=", "38.2", "+", "/-", "3.6", ")", "." ]	[ "outcome" ]
calcium bioavailability	376_task2	Sentence: In accordance , calcium bioavailability in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , BD % = 38.2 +/- 3.6 ) . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In accordance , calcium bioavailability in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , BD % = 38.2 +/- 3.6 ) .	[ "In", "accordance", ",", "calcium", "bioavailability", "in", "adolescents", "did", "not", "vary", "between", "the", "diets", "(", "%", "WD", "=", "40.4", "+", "/-", "5.1", ",", "BD", "%", "=", "38.2", "+", "/-", "3.6", ")", "." ]	[ "outcome" ]
Prognose is an umlsterm, krankenhausepidemiologische is an umlsterm, Interventionsstudien is an umlsterm	ZfuerKardiologie.90880014.ger.abstr_task0	Sentence: Einleitung : Daten zur Prognose der Herzinsuffizienz stuetzen sich bislang auf bevoelkerungsepidemiologische und retrospektive krankenhausepidemiologische Untersuchungen sowie klinische Interventionsstudien . Alle diese Quellen sind nur eingeschraenkt auf den klinischen Alltag uebertragbar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Einleitung : Daten zur Prognose der Herzinsuffizienz stuetzen sich bislang auf bevoelkerungsepidemiologische und retrospektive krankenhausepidemiologische Untersuchungen sowie klinische Interventionsstudien . Alle diese Quellen sind nur eingeschraenkt auf den klinischen Alltag uebertragbar .	[ "Einleitung", ":", "Daten", "zur", "Prognose", "der", "Herzinsuffizienz", "stuetzen", "sich", "bislang", "auf", "bevoelkerungsepidemiologische", "und", "retrospektive", "krankenhausepidemiologische", "Untersuchungen", "sowie", "klinische", "Interventionsstudien", ".", "Alle", "diese", "Quellen", "sind", "nur", "eingeschraenkt", "auf", "den", "klinischen", "Alltag", "uebertragbar", "." ]	[ "umlsterm" ]
Prognose is an umlsterm, krankenhausepidemiologische is an umlsterm, Interventionsstudien is an umlsterm	ZfuerKardiologie.90880014.ger.abstr_task1	Sentence: Einleitung : Daten zur Prognose der Herzinsuffizienz stuetzen sich bislang auf bevoelkerungsepidemiologische und retrospektive krankenhausepidemiologische Untersuchungen sowie klinische Interventionsstudien . Alle diese Quellen sind nur eingeschraenkt auf den klinischen Alltag uebertragbar . Instructions: please typing these entity words according to sentence: Prognose, krankenhausepidemiologische, Interventionsstudien Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Einleitung : Daten zur Prognose der Herzinsuffizienz stuetzen sich bislang auf bevoelkerungsepidemiologische und retrospektive krankenhausepidemiologische Untersuchungen sowie klinische Interventionsstudien . Alle diese Quellen sind nur eingeschraenkt auf den klinischen Alltag uebertragbar .	[ "Einleitung", ":", "Daten", "zur", "Prognose", "der", "Herzinsuffizienz", "stuetzen", "sich", "bislang", "auf", "bevoelkerungsepidemiologische", "und", "retrospektive", "krankenhausepidemiologische", "Untersuchungen", "sowie", "klinische", "Interventionsstudien", ".", "Alle", "diese", "Quellen", "sind", "nur", "eingeschraenkt", "auf", "den", "klinischen", "Alltag", "uebertragbar", "." ]	[ "umlsterm" ]
Prognose, krankenhausepidemiologische, Interventionsstudien	ZfuerKardiologie.90880014.ger.abstr_task2	Sentence: Einleitung : Daten zur Prognose der Herzinsuffizienz stuetzen sich bislang auf bevoelkerungsepidemiologische und retrospektive krankenhausepidemiologische Untersuchungen sowie klinische Interventionsstudien . Alle diese Quellen sind nur eingeschraenkt auf den klinischen Alltag uebertragbar . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Einleitung : Daten zur Prognose der Herzinsuffizienz stuetzen sich bislang auf bevoelkerungsepidemiologische und retrospektive krankenhausepidemiologische Untersuchungen sowie klinische Interventionsstudien . Alle diese Quellen sind nur eingeschraenkt auf den klinischen Alltag uebertragbar .	[ "Einleitung", ":", "Daten", "zur", "Prognose", "der", "Herzinsuffizienz", "stuetzen", "sich", "bislang", "auf", "bevoelkerungsepidemiologische", "und", "retrospektive", "krankenhausepidemiologische", "Untersuchungen", "sowie", "klinische", "Interventionsstudien", ".", "Alle", "diese", "Quellen", "sind", "nur", "eingeschraenkt", "auf", "den", "klinischen", "Alltag", "uebertragbar", "." ]	[ "umlsterm" ]
Clonidine clearance is a Outcome_Physical, newborns is a Participant_Age, neonatal abstinence syndrome is a Participant_Condition, pharmacokinetic ( PK ) profile is a Outcome_Physical, oral clonidine is a Intervention_Pharmacological, Plasma clonidine concentration data is a Outcome_Other, 36 is a Participant_Sample-size, 1 to 25 days is a Participant_Age, PK model of clonidine is a Outcome_Other, plasma concentrations of clonidine is a Outcome_Other, body weight and PNA is a Outcome_Physical, apparent clearance is a Outcome_Other	45736_task0	Sentence: Clonidine clearance matures rapidly during the early postnatal period : a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome . The population pharmacokinetic ( PK ) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome , and significant covariates affecting its PK parameters were identified . Plasma clonidine concentration data were obtained from a clinical trial in which 36 newborns , aged 1 to 25 days ( postnatal age , PNA ) and weighing 2.1 to 3.9 kg , were enrolled to take multiple oral doses of clonidine . The population PK model of clonidine was developed by NONMEM , and significant covariates were identified , followed by nonparametric bootstraps ( 2000 replicates ) and simulation experiments . A 1-compartment open linear PK model was chosen to describe plasma concentrations of clonidine , and body weight and PNA were significant covariates for apparent clearance ( CL/F ) as follows : CL/F ( L/h ) = 15.2 × [ body weight ( kg ) /70 ] ( 0.75 ) × [ PNA ( day ) ( 0.441 ) / ( 4.06 ( 0.441 ) + PNA ( day ) ( 0.441 ) ) ] . Furthermore , CL/F of clonidine increased rapidly with PNA during the first month of life after body weight was adjusted . Any optimal dosage regimen for clonidine in term neonates should be based on infant 's age and body weight , and 1.5 µg/kg every 4 hours is proposed starting the second week of life based on the simulation results . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Clonidine clearance matures rapidly during the early postnatal period : a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome . The population pharmacokinetic ( PK ) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome , and significant covariates affecting its PK parameters were identified . Plasma clonidine concentration data were obtained from a clinical trial in which 36 newborns , aged 1 to 25 days ( postnatal age , PNA ) and weighing 2.1 to 3.9 kg , were enrolled to take multiple oral doses of clonidine . The population PK model of clonidine was developed by NONMEM , and significant covariates were identified , followed by nonparametric bootstraps ( 2000 replicates ) and simulation experiments . A 1-compartment open linear PK model was chosen to describe plasma concentrations of clonidine , and body weight and PNA were significant covariates for apparent clearance ( CL/F ) as follows : CL/F ( L/h ) = 15.2 × [ body weight ( kg ) /70 ] ( 0.75 ) × [ PNA ( day ) ( 0.441 ) / ( 4.06 ( 0.441 ) + PNA ( day ) ( 0.441 ) ) ] . Furthermore , CL/F of clonidine increased rapidly with PNA during the first month of life after body weight was adjusted . Any optimal dosage regimen for clonidine in term neonates should be based on infant 's age and body weight , and 1.5 µg/kg every 4 hours is proposed starting the second week of life based on the simulation results .	[ "Clonidine", "clearance", "matures", "rapidly", "during", "the", "early", "postnatal", "period", ":", "a", "population", "pharmacokinetic", "analysis", "in", "newborns", "with", "neonatal", "abstinence", "syndrome", ".", "The", "population", "pharmacokinetic", "(", "PK", ")", "profile", "of", "oral", "clonidine", "was", "characterized", "in", "newborns", "with", "neonatal", "abstinence", "syndrome", ",", "and", "significant", "covariates", "affecting", "its", "PK", "parameters", "were", "identified", ".", "Plasma", "clonidine", "concentration", "data", "were", "obtained", "from", "a", "clinical", "trial", "in", "which", "36", "newborns", ",", "aged", "1", "to", "25", "days", "(", "postnatal", "age", ",", "PNA", ")", "and", "weighing", "2.1", "to", "3.9", "kg", ",", "were", "enrolled", "to", "take", "multiple", "oral", "doses", "of", "clonidine", ".", "The", "population", "PK", "model", "of", "clonidine", "was", "developed", "by", "NONMEM", ",", "and", "significant", "covariates", "were", "identified", ",", "followed", "by", "nonparametric", "bootstraps", "(", "2000", "replicates", ")", "and", "simulation", "experiments", ".", "A", "1-compartment", "open", "linear", "PK", "model", "was", "chosen", "to", "describe", "plasma", "concentrations", "of", "clonidine", ",", "and", "body", "weight", "and", "PNA", "were", "significant", "covariates", "for", "apparent", "clearance", "(", "CL", "/", "F", ")", "as", "follows", ":", "CL", "/", "F", "(", "L", "/", "h", ")", "=", "15.2", "×", "[", "body", "weight", "(", "kg", ")", "/70", "]", "(", "0.75", ")", "×", "[", "PNA", "(", "day", ")", "(", "0.441", ")", "/", "(", "4.06", "(", "0.441", ")", "+", "PNA", "(", "day", ")", "(", "0.441", ")", ")", "]", ".", "Furthermore", ",", "CL", "/", "F", "of", "clonidine", "increased", "rapidly", "with", "PNA", "during", "the", "first", "month", "of", "life", "after", "body", "weight", "was", "adjusted", ".", "Any", "optimal", "dosage", "regimen", "for", "clonidine", "in", "term", "neonates", "should", "be", "based", "on", "infant", "'", "s", "age", "and", "body", "weight", ",", "and", "1.5", "µg", "/", "kg", "every", "4", "hours", "is", "proposed", "starting", "the", "second", "week", "of", "life", "based", "on", "the", "simulation", "results", "." ]	[ "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Age", "Participant_Sample-size" ]
Clonidine clearance is a Outcome_Physical, newborns is a Participant_Age, neonatal abstinence syndrome is a Participant_Condition, pharmacokinetic ( PK ) profile is a Outcome_Physical, oral clonidine is a Intervention_Pharmacological, Plasma clonidine concentration data is a Outcome_Other, 36 is a Participant_Sample-size, 1 to 25 days is a Participant_Age, PK model of clonidine is a Outcome_Other, plasma concentrations of clonidine is a Outcome_Other, body weight and PNA is a Outcome_Physical, apparent clearance is a Outcome_Other	45736_task1	Sentence: Clonidine clearance matures rapidly during the early postnatal period : a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome . The population pharmacokinetic ( PK ) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome , and significant covariates affecting its PK parameters were identified . Plasma clonidine concentration data were obtained from a clinical trial in which 36 newborns , aged 1 to 25 days ( postnatal age , PNA ) and weighing 2.1 to 3.9 kg , were enrolled to take multiple oral doses of clonidine . The population PK model of clonidine was developed by NONMEM , and significant covariates were identified , followed by nonparametric bootstraps ( 2000 replicates ) and simulation experiments . A 1-compartment open linear PK model was chosen to describe plasma concentrations of clonidine , and body weight and PNA were significant covariates for apparent clearance ( CL/F ) as follows : CL/F ( L/h ) = 15.2 × [ body weight ( kg ) /70 ] ( 0.75 ) × [ PNA ( day ) ( 0.441 ) / ( 4.06 ( 0.441 ) + PNA ( day ) ( 0.441 ) ) ] . Furthermore , CL/F of clonidine increased rapidly with PNA during the first month of life after body weight was adjusted . Any optimal dosage regimen for clonidine in term neonates should be based on infant 's age and body weight , and 1.5 µg/kg every 4 hours is proposed starting the second week of life based on the simulation results . Instructions: please typing these entity words according to sentence: Clonidine clearance, newborns, neonatal abstinence syndrome, pharmacokinetic ( PK ) profile, oral clonidine, Plasma clonidine concentration data, 36, 1 to 25 days, PK model of clonidine, plasma concentrations of clonidine, body weight and PNA, apparent clearance Options: Intervention_Pharmacological, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Clonidine clearance matures rapidly during the early postnatal period : a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome . The population pharmacokinetic ( PK ) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome , and significant covariates affecting its PK parameters were identified . Plasma clonidine concentration data were obtained from a clinical trial in which 36 newborns , aged 1 to 25 days ( postnatal age , PNA ) and weighing 2.1 to 3.9 kg , were enrolled to take multiple oral doses of clonidine . The population PK model of clonidine was developed by NONMEM , and significant covariates were identified , followed by nonparametric bootstraps ( 2000 replicates ) and simulation experiments . A 1-compartment open linear PK model was chosen to describe plasma concentrations of clonidine , and body weight and PNA were significant covariates for apparent clearance ( CL/F ) as follows : CL/F ( L/h ) = 15.2 × [ body weight ( kg ) /70 ] ( 0.75 ) × [ PNA ( day ) ( 0.441 ) / ( 4.06 ( 0.441 ) + PNA ( day ) ( 0.441 ) ) ] . Furthermore , CL/F of clonidine increased rapidly with PNA during the first month of life after body weight was adjusted . Any optimal dosage regimen for clonidine in term neonates should be based on infant 's age and body weight , and 1.5 µg/kg every 4 hours is proposed starting the second week of life based on the simulation results .	[ "Clonidine", "clearance", "matures", "rapidly", "during", "the", "early", "postnatal", "period", ":", "a", "population", "pharmacokinetic", "analysis", "in", "newborns", "with", "neonatal", "abstinence", "syndrome", ".", "The", "population", "pharmacokinetic", "(", "PK", ")", "profile", "of", "oral", "clonidine", "was", "characterized", "in", "newborns", "with", "neonatal", "abstinence", "syndrome", ",", "and", "significant", "covariates", "affecting", "its", "PK", "parameters", "were", "identified", ".", "Plasma", "clonidine", "concentration", "data", "were", "obtained", "from", "a", "clinical", "trial", "in", "which", "36", "newborns", ",", "aged", "1", "to", "25", "days", "(", "postnatal", "age", ",", "PNA", ")", "and", "weighing", "2.1", "to", "3.9", "kg", ",", "were", "enrolled", "to", "take", "multiple", "oral", "doses", "of", "clonidine", ".", "The", "population", "PK", "model", "of", "clonidine", "was", "developed", "by", "NONMEM", ",", "and", "significant", "covariates", "were", "identified", ",", "followed", "by", "nonparametric", "bootstraps", "(", "2000", "replicates", ")", "and", "simulation", "experiments", ".", "A", "1-compartment", "open", "linear", "PK", "model", "was", "chosen", "to", "describe", "plasma", "concentrations", "of", "clonidine", ",", "and", "body", "weight", "and", "PNA", "were", "significant", "covariates", "for", "apparent", "clearance", "(", "CL", "/", "F", ")", "as", "follows", ":", "CL", "/", "F", "(", "L", "/", "h", ")", "=", "15.2", "×", "[", "body", "weight", "(", "kg", ")", "/70", "]", "(", "0.75", ")", "×", "[", "PNA", "(", "day", ")", "(", "0.441", ")", "/", "(", "4.06", "(", "0.441", ")", "+", "PNA", "(", "day", ")", "(", "0.441", ")", ")", "]", ".", "Furthermore", ",", "CL", "/", "F", "of", "clonidine", "increased", "rapidly", "with", "PNA", "during", "the", "first", "month", "of", "life", "after", "body", "weight", "was", "adjusted", ".", "Any", "optimal", "dosage", "regimen", "for", "clonidine", "in", "term", "neonates", "should", "be", "based", "on", "infant", "'", "s", "age", "and", "body", "weight", ",", "and", "1.5", "µg", "/", "kg", "every", "4", "hours", "is", "proposed", "starting", "the", "second", "week", "of", "life", "based", "on", "the", "simulation", "results", "." ]	[ "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Age", "Participant_Sample-size" ]
Clonidine clearance, newborns, neonatal abstinence syndrome, pharmacokinetic ( PK ) profile, oral clonidine, Plasma clonidine concentration data, 36, 1 to 25 days, PK model of clonidine, plasma concentrations of clonidine, body weight and PNA, apparent clearance	45736_task2	Sentence: Clonidine clearance matures rapidly during the early postnatal period : a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome . The population pharmacokinetic ( PK ) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome , and significant covariates affecting its PK parameters were identified . Plasma clonidine concentration data were obtained from a clinical trial in which 36 newborns , aged 1 to 25 days ( postnatal age , PNA ) and weighing 2.1 to 3.9 kg , were enrolled to take multiple oral doses of clonidine . The population PK model of clonidine was developed by NONMEM , and significant covariates were identified , followed by nonparametric bootstraps ( 2000 replicates ) and simulation experiments . A 1-compartment open linear PK model was chosen to describe plasma concentrations of clonidine , and body weight and PNA were significant covariates for apparent clearance ( CL/F ) as follows : CL/F ( L/h ) = 15.2 × [ body weight ( kg ) /70 ] ( 0.75 ) × [ PNA ( day ) ( 0.441 ) / ( 4.06 ( 0.441 ) + PNA ( day ) ( 0.441 ) ) ] . Furthermore , CL/F of clonidine increased rapidly with PNA during the first month of life after body weight was adjusted . Any optimal dosage regimen for clonidine in term neonates should be based on infant 's age and body weight , and 1.5 µg/kg every 4 hours is proposed starting the second week of life based on the simulation results . Instructions: please extract entity words from the input sentence	[ "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Clonidine clearance matures rapidly during the early postnatal period : a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome . The population pharmacokinetic ( PK ) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome , and significant covariates affecting its PK parameters were identified . Plasma clonidine concentration data were obtained from a clinical trial in which 36 newborns , aged 1 to 25 days ( postnatal age , PNA ) and weighing 2.1 to 3.9 kg , were enrolled to take multiple oral doses of clonidine . The population PK model of clonidine was developed by NONMEM , and significant covariates were identified , followed by nonparametric bootstraps ( 2000 replicates ) and simulation experiments . A 1-compartment open linear PK model was chosen to describe plasma concentrations of clonidine , and body weight and PNA were significant covariates for apparent clearance ( CL/F ) as follows : CL/F ( L/h ) = 15.2 × [ body weight ( kg ) /70 ] ( 0.75 ) × [ PNA ( day ) ( 0.441 ) / ( 4.06 ( 0.441 ) + PNA ( day ) ( 0.441 ) ) ] . Furthermore , CL/F of clonidine increased rapidly with PNA during the first month of life after body weight was adjusted . Any optimal dosage regimen for clonidine in term neonates should be based on infant 's age and body weight , and 1.5 µg/kg every 4 hours is proposed starting the second week of life based on the simulation results .	[ "Clonidine", "clearance", "matures", "rapidly", "during", "the", "early", "postnatal", "period", ":", "a", "population", "pharmacokinetic", "analysis", "in", "newborns", "with", "neonatal", "abstinence", "syndrome", ".", "The", "population", "pharmacokinetic", "(", "PK", ")", "profile", "of", "oral", "clonidine", "was", "characterized", "in", "newborns", "with", "neonatal", "abstinence", "syndrome", ",", "and", "significant", "covariates", "affecting", "its", "PK", "parameters", "were", "identified", ".", "Plasma", "clonidine", "concentration", "data", "were", "obtained", "from", "a", "clinical", "trial", "in", "which", "36", "newborns", ",", "aged", "1", "to", "25", "days", "(", "postnatal", "age", ",", "PNA", ")", "and", "weighing", "2.1", "to", "3.9", "kg", ",", "were", "enrolled", "to", "take", "multiple", "oral", "doses", "of", "clonidine", ".", "The", "population", "PK", "model", "of", "clonidine", "was", "developed", "by", "NONMEM", ",", "and", "significant", "covariates", "were", "identified", ",", "followed", "by", "nonparametric", "bootstraps", "(", "2000", "replicates", ")", "and", "simulation", "experiments", ".", "A", "1-compartment", "open", "linear", "PK", "model", "was", "chosen", "to", "describe", "plasma", "concentrations", "of", "clonidine", ",", "and", "body", "weight", "and", "PNA", "were", "significant", "covariates", "for", "apparent", "clearance", "(", "CL", "/", "F", ")", "as", "follows", ":", "CL", "/", "F", "(", "L", "/", "h", ")", "=", "15.2", "×", "[", "body", "weight", "(", "kg", ")", "/70", "]", "(", "0.75", ")", "×", "[", "PNA", "(", "day", ")", "(", "0.441", ")", "/", "(", "4.06", "(", "0.441", ")", "+", "PNA", "(", "day", ")", "(", "0.441", ")", ")", "]", ".", "Furthermore", ",", "CL", "/", "F", "of", "clonidine", "increased", "rapidly", "with", "PNA", "during", "the", "first", "month", "of", "life", "after", "body", "weight", "was", "adjusted", ".", "Any", "optimal", "dosage", "regimen", "for", "clonidine", "in", "term", "neonates", "should", "be", "based", "on", "infant", "'", "s", "age", "and", "body", "weight", ",", "and", "1.5", "µg", "/", "kg", "every", "4", "hours", "is", "proposed", "starting", "the", "second", "week", "of", "life", "based", "on", "the", "simulation", "results", "." ]	[ "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Age", "Participant_Sample-size" ]
patients is an umlsterm, sport activities is an umlsterm, total knee replacement is an umlsterm, recommendations is an umlsterm	DerOrthopaede.00290739.eng.abstr_task0	Sentence: Many patients would like to resume some sport activities after total knee replacement ; however , most recommendations are based on subjective opinion rather than scientific evidence . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Many patients would like to resume some sport activities after total knee replacement ; however , most recommendations are based on subjective opinion rather than scientific evidence .	[ "Many", "patients", "would", "like", "to", "resume", "some", "sport", "activities", "after", "total", "knee", "replacement", ";", "however", ",", "most", "recommendations", "are", "based", "on", "subjective", "opinion", "rather", "than", "scientific", "evidence", "." ]	[ "umlsterm" ]
patients is an umlsterm, sport activities is an umlsterm, total knee replacement is an umlsterm, recommendations is an umlsterm	DerOrthopaede.00290739.eng.abstr_task1	Sentence: Many patients would like to resume some sport activities after total knee replacement ; however , most recommendations are based on subjective opinion rather than scientific evidence . Instructions: please typing these entity words according to sentence: patients, sport activities, total knee replacement, recommendations Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Many patients would like to resume some sport activities after total knee replacement ; however , most recommendations are based on subjective opinion rather than scientific evidence .	[ "Many", "patients", "would", "like", "to", "resume", "some", "sport", "activities", "after", "total", "knee", "replacement", ";", "however", ",", "most", "recommendations", "are", "based", "on", "subjective", "opinion", "rather", "than", "scientific", "evidence", "." ]	[ "umlsterm" ]
patients, sport activities, total knee replacement, recommendations	DerOrthopaede.00290739.eng.abstr_task2	Sentence: Many patients would like to resume some sport activities after total knee replacement ; however , most recommendations are based on subjective opinion rather than scientific evidence . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Many patients would like to resume some sport activities after total knee replacement ; however , most recommendations are based on subjective opinion rather than scientific evidence .	[ "Many", "patients", "would", "like", "to", "resume", "some", "sport", "activities", "after", "total", "knee", "replacement", ";", "however", ",", "most", "recommendations", "are", "based", "on", "subjective", "opinion", "rather", "than", "scientific", "evidence", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Morbiditaet is an umlsterm, Patientenkollektiv is an umlsterm	DerChirurg.90701475.ger.abstr_task0	Sentence: Zusammenfassung . Proktologische Erkrankungen werden bei HIV-Infizierten ueberaus haeufig beobachtet . Dennoch herrscht Unsicherheit , wie diese Patienten behandelt werden sollen . Im Rahmen einer retrospektiven Untersuchung von 29 HIV-Infizierten , die sich einem operativen Eingriff der Anorectalregion unterziehen mussten , konnte gezeigt werden , dass Fortgeschritten-HIV-Infizierte eine hoehere postoperative Letalitaet und Morbiditaet haben . Daraus ergibt sich , dass die Indikation zu einem anorectalen Eingriff bei diesem Patientenkollektiv anders zu stellen ist als bei HIV-Negativen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Proktologische Erkrankungen werden bei HIV-Infizierten ueberaus haeufig beobachtet . Dennoch herrscht Unsicherheit , wie diese Patienten behandelt werden sollen . Im Rahmen einer retrospektiven Untersuchung von 29 HIV-Infizierten , die sich einem operativen Eingriff der Anorectalregion unterziehen mussten , konnte gezeigt werden , dass Fortgeschritten-HIV-Infizierte eine hoehere postoperative Letalitaet und Morbiditaet haben . Daraus ergibt sich , dass die Indikation zu einem anorectalen Eingriff bei diesem Patientenkollektiv anders zu stellen ist als bei HIV-Negativen .	[ "Zusammenfassung", ".", "Proktologische", "Erkrankungen", "werden", "bei", "HIV", "-", "Infizierten", "ueberaus", "haeufig", "beobachtet", ".", "Dennoch", "herrscht", "Unsicherheit", ",", "wie", "diese", "Patienten", "behandelt", "werden", "sollen", ".", "Im", "Rahmen", "einer", "retrospektiven", "Untersuchung", "von", "29", "HIV", "-", "Infizierten", ",", "die", "sich", "einem", "operativen", "Eingriff", "der", "Anorectalregion", "unterziehen", "mussten", ",", "konnte", "gezeigt", "werden", ",", "dass", "Fortgeschritten", "-", "HIV", "-", "Infizierte", "eine", "hoehere", "postoperative", "Letalitaet", "und", "Morbiditaet", "haben", ".", "Daraus", "ergibt", "sich", ",", "dass", "die", "Indikation", "zu", "einem", "anorectalen", "Eingriff", "bei", "diesem", "Patientenkollektiv", "anders", "zu", "stellen", "ist", "als", "bei", "HIV", "-", "Negativen", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Morbiditaet is an umlsterm, Patientenkollektiv is an umlsterm	DerChirurg.90701475.ger.abstr_task1	Sentence: Zusammenfassung . Proktologische Erkrankungen werden bei HIV-Infizierten ueberaus haeufig beobachtet . Dennoch herrscht Unsicherheit , wie diese Patienten behandelt werden sollen . Im Rahmen einer retrospektiven Untersuchung von 29 HIV-Infizierten , die sich einem operativen Eingriff der Anorectalregion unterziehen mussten , konnte gezeigt werden , dass Fortgeschritten-HIV-Infizierte eine hoehere postoperative Letalitaet und Morbiditaet haben . Daraus ergibt sich , dass die Indikation zu einem anorectalen Eingriff bei diesem Patientenkollektiv anders zu stellen ist als bei HIV-Negativen . Instructions: please typing these entity words according to sentence: Patienten, Morbiditaet, Patientenkollektiv Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Proktologische Erkrankungen werden bei HIV-Infizierten ueberaus haeufig beobachtet . Dennoch herrscht Unsicherheit , wie diese Patienten behandelt werden sollen . Im Rahmen einer retrospektiven Untersuchung von 29 HIV-Infizierten , die sich einem operativen Eingriff der Anorectalregion unterziehen mussten , konnte gezeigt werden , dass Fortgeschritten-HIV-Infizierte eine hoehere postoperative Letalitaet und Morbiditaet haben . Daraus ergibt sich , dass die Indikation zu einem anorectalen Eingriff bei diesem Patientenkollektiv anders zu stellen ist als bei HIV-Negativen .	[ "Zusammenfassung", ".", "Proktologische", "Erkrankungen", "werden", "bei", "HIV", "-", "Infizierten", "ueberaus", "haeufig", "beobachtet", ".", "Dennoch", "herrscht", "Unsicherheit", ",", "wie", "diese", "Patienten", "behandelt", "werden", "sollen", ".", "Im", "Rahmen", "einer", "retrospektiven", "Untersuchung", "von", "29", "HIV", "-", "Infizierten", ",", "die", "sich", "einem", "operativen", "Eingriff", "der", "Anorectalregion", "unterziehen", "mussten", ",", "konnte", "gezeigt", "werden", ",", "dass", "Fortgeschritten", "-", "HIV", "-", "Infizierte", "eine", "hoehere", "postoperative", "Letalitaet", "und", "Morbiditaet", "haben", ".", "Daraus", "ergibt", "sich", ",", "dass", "die", "Indikation", "zu", "einem", "anorectalen", "Eingriff", "bei", "diesem", "Patientenkollektiv", "anders", "zu", "stellen", "ist", "als", "bei", "HIV", "-", "Negativen", "." ]	[ "umlsterm" ]
Patienten, Morbiditaet, Patientenkollektiv	DerChirurg.90701475.ger.abstr_task2	Sentence: Zusammenfassung . Proktologische Erkrankungen werden bei HIV-Infizierten ueberaus haeufig beobachtet . Dennoch herrscht Unsicherheit , wie diese Patienten behandelt werden sollen . Im Rahmen einer retrospektiven Untersuchung von 29 HIV-Infizierten , die sich einem operativen Eingriff der Anorectalregion unterziehen mussten , konnte gezeigt werden , dass Fortgeschritten-HIV-Infizierte eine hoehere postoperative Letalitaet und Morbiditaet haben . Daraus ergibt sich , dass die Indikation zu einem anorectalen Eingriff bei diesem Patientenkollektiv anders zu stellen ist als bei HIV-Negativen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Proktologische Erkrankungen werden bei HIV-Infizierten ueberaus haeufig beobachtet . Dennoch herrscht Unsicherheit , wie diese Patienten behandelt werden sollen . Im Rahmen einer retrospektiven Untersuchung von 29 HIV-Infizierten , die sich einem operativen Eingriff der Anorectalregion unterziehen mussten , konnte gezeigt werden , dass Fortgeschritten-HIV-Infizierte eine hoehere postoperative Letalitaet und Morbiditaet haben . Daraus ergibt sich , dass die Indikation zu einem anorectalen Eingriff bei diesem Patientenkollektiv anders zu stellen ist als bei HIV-Negativen .	[ "Zusammenfassung", ".", "Proktologische", "Erkrankungen", "werden", "bei", "HIV", "-", "Infizierten", "ueberaus", "haeufig", "beobachtet", ".", "Dennoch", "herrscht", "Unsicherheit", ",", "wie", "diese", "Patienten", "behandelt", "werden", "sollen", ".", "Im", "Rahmen", "einer", "retrospektiven", "Untersuchung", "von", "29", "HIV", "-", "Infizierten", ",", "die", "sich", "einem", "operativen", "Eingriff", "der", "Anorectalregion", "unterziehen", "mussten", ",", "konnte", "gezeigt", "werden", ",", "dass", "Fortgeschritten", "-", "HIV", "-", "Infizierte", "eine", "hoehere", "postoperative", "Letalitaet", "und", "Morbiditaet", "haben", ".", "Daraus", "ergibt", "sich", ",", "dass", "die", "Indikation", "zu", "einem", "anorectalen", "Eingriff", "bei", "diesem", "Patientenkollektiv", "anders", "zu", "stellen", "ist", "als", "bei", "HIV", "-", "Negativen", "." ]	[ "umlsterm" ]
T cell - specific negative regulation is an other_name, human cytokine IL-4 is a protein_molecule	85804_task0	Sentence: T cell-specific negative regulation of transcription of the human cytokine IL-4. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_molecule, other_name	[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]	T cell-specific negative regulation of transcription of the human cytokine IL-4.	[ "T", "cell", "-", "specific", "negative", "regulation", "of", "transcription", "of", "the", "human", "cytokine", "IL-4", "." ]	[ "DNA_domain_or_region", "other_name", "protein_family_or_group", "polynucleotide", "protein_molecule", "cell_type" ]
T cell - specific negative regulation is an other_name, human cytokine IL-4 is a protein_molecule	85804_task1	Sentence: T cell-specific negative regulation of transcription of the human cytokine IL-4. Instructions: please typing these entity words according to sentence: T cell - specific negative regulation, human cytokine IL-4 Options: protein_molecule, other_name	[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]	T cell-specific negative regulation of transcription of the human cytokine IL-4.	[ "T", "cell", "-", "specific", "negative", "regulation", "of", "transcription", "of", "the", "human", "cytokine", "IL-4", "." ]	[ "DNA_domain_or_region", "other_name", "protein_family_or_group", "polynucleotide", "protein_molecule", "cell_type" ]
T cell - specific negative regulation, human cytokine IL-4	85804_task2	Sentence: T cell-specific negative regulation of transcription of the human cytokine IL-4. Instructions: please extract entity words from the input sentence	[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]	T cell-specific negative regulation of transcription of the human cytokine IL-4.	[ "T", "cell", "-", "specific", "negative", "regulation", "of", "transcription", "of", "the", "human", "cytokine", "IL-4", "." ]	[ "DNA_domain_or_region", "other_name", "protein_family_or_group", "polynucleotide", "protein_molecule", "cell_type" ]
Metastasis is an umlsterm, tumor is an umlsterm, cells is an umlsterm, stages is an umlsterm, adhesion is an umlsterm, extracellular matrix is an umlsterm, locomotion is an umlsterm, tumor is an umlsterm, cells is an umlsterm, cells is an umlsterm, endothelium is an umlsterm, metastases is an umlsterm, growth is an umlsterm, metastases is an umlsterm, tumor is an umlsterm, cells is an umlsterm, growth factors is an umlsterm, anti - proteolytic is an umlsterm, anti - angiogenic is an umlsterm, therapeutic is an umlsterm, control is an umlsterm, metastatic is an umlsterm, growth is an umlsterm, goal is an umlsterm, drugs is an umlsterm, clinical research is an umlsterm	DerChirurg.80691315.eng.abstr_task0	Sentence: Metastasis formation is a multistep process that requires tumor cells to progress through many different stages . One of the first steps is a disturbance of the epithelial integrity through a decrease in intercellular homotypic adhesion . Proteolysis of the extracellular matrix , as well as increased locomotion , leads to intravasation and dissemination of the tumor cells . In the target organs metastasizing cells adhere to the endothelium , extravasate and form metastases . Finally , neoangiogenesis is required for the initiation as well as the growth of the metastases , providing the tumor cells with both nutritive agents and growth factors . This leads to the conclusion that anti-proteolytic and anti-angiogenic substances could provide effective therapeutic approaches for the control of metastatic growth . Whether or not this goal can be accomplished by synthetic or endogenous drugs must still be demonstrated by basic and definitive clinical research . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Metastasis formation is a multistep process that requires tumor cells to progress through many different stages . One of the first steps is a disturbance of the epithelial integrity through a decrease in intercellular homotypic adhesion . Proteolysis of the extracellular matrix , as well as increased locomotion , leads to intravasation and dissemination of the tumor cells . In the target organs metastasizing cells adhere to the endothelium , extravasate and form metastases . Finally , neoangiogenesis is required for the initiation as well as the growth of the metastases , providing the tumor cells with both nutritive agents and growth factors . This leads to the conclusion that anti-proteolytic and anti-angiogenic substances could provide effective therapeutic approaches for the control of metastatic growth . Whether or not this goal can be accomplished by synthetic or endogenous drugs must still be demonstrated by basic and definitive clinical research .	[ "Metastasis", "formation", "is", "a", "multistep", "process", "that", "requires", "tumor", "cells", "to", "progress", "through", "many", "different", "stages", ".", "One", "of", "the", "first", "steps", "is", "a", "disturbance", "of", "the", "epithelial", "integrity", "through", "a", "decrease", "in", "intercellular", "homotypic", "adhesion", ".", "Proteolysis", "of", "the", "extracellular", "matrix", ",", "as", "well", "as", "increased", "locomotion", ",", "leads", "to", "intravasation", "and", "dissemination", "of", "the", "tumor", "cells", ".", "In", "the", "target", "organs", "metastasizing", "cells", "adhere", "to", "the", "endothelium", ",", "extravasate", "and", "form", "metastases", ".", "Finally", ",", "neoangiogenesis", "is", "required", "for", "the", "initiation", "as", "well", "as", "the", "growth", "of", "the", "metastases", ",", "providing", "the", "tumor", "cells", "with", "both", "nutritive", "agents", "and", "growth", "factors", ".", "This", "leads", "to", "the", "conclusion", "that", "anti", "-", "proteolytic", "and", "anti", "-", "angiogenic", "substances", "could", "provide", "effective", "therapeutic", "approaches", "for", "the", "control", "of", "metastatic", "growth", ".", "Whether", "or", "not", "this", "goal", "can", "be", "accomplished", "by", "synthetic", "or", "endogenous", "drugs", "must", "still", "be", "demonstrated", "by", "basic", "and", "definitive", "clinical", "research", "." ]	[ "umlsterm" ]
Metastasis is an umlsterm, tumor is an umlsterm, cells is an umlsterm, stages is an umlsterm, adhesion is an umlsterm, extracellular matrix is an umlsterm, locomotion is an umlsterm, tumor is an umlsterm, cells is an umlsterm, cells is an umlsterm, endothelium is an umlsterm, metastases is an umlsterm, growth is an umlsterm, metastases is an umlsterm, tumor is an umlsterm, cells is an umlsterm, growth factors is an umlsterm, anti - proteolytic is an umlsterm, anti - angiogenic is an umlsterm, therapeutic is an umlsterm, control is an umlsterm, metastatic is an umlsterm, growth is an umlsterm, goal is an umlsterm, drugs is an umlsterm, clinical research is an umlsterm	DerChirurg.80691315.eng.abstr_task1	Sentence: Metastasis formation is a multistep process that requires tumor cells to progress through many different stages . One of the first steps is a disturbance of the epithelial integrity through a decrease in intercellular homotypic adhesion . Proteolysis of the extracellular matrix , as well as increased locomotion , leads to intravasation and dissemination of the tumor cells . In the target organs metastasizing cells adhere to the endothelium , extravasate and form metastases . Finally , neoangiogenesis is required for the initiation as well as the growth of the metastases , providing the tumor cells with both nutritive agents and growth factors . This leads to the conclusion that anti-proteolytic and anti-angiogenic substances could provide effective therapeutic approaches for the control of metastatic growth . Whether or not this goal can be accomplished by synthetic or endogenous drugs must still be demonstrated by basic and definitive clinical research . Instructions: please typing these entity words according to sentence: Metastasis, tumor, cells, stages, adhesion, extracellular matrix, locomotion, tumor, cells, cells, endothelium, metastases, growth, metastases, tumor, cells, growth factors, anti - proteolytic, anti - angiogenic, therapeutic, control, metastatic, growth, goal, drugs, clinical research Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Metastasis formation is a multistep process that requires tumor cells to progress through many different stages . One of the first steps is a disturbance of the epithelial integrity through a decrease in intercellular homotypic adhesion . Proteolysis of the extracellular matrix , as well as increased locomotion , leads to intravasation and dissemination of the tumor cells . In the target organs metastasizing cells adhere to the endothelium , extravasate and form metastases . Finally , neoangiogenesis is required for the initiation as well as the growth of the metastases , providing the tumor cells with both nutritive agents and growth factors . This leads to the conclusion that anti-proteolytic and anti-angiogenic substances could provide effective therapeutic approaches for the control of metastatic growth . Whether or not this goal can be accomplished by synthetic or endogenous drugs must still be demonstrated by basic and definitive clinical research .	[ "Metastasis", "formation", "is", "a", "multistep", "process", "that", "requires", "tumor", "cells", "to", "progress", "through", "many", "different", "stages", ".", "One", "of", "the", "first", "steps", "is", "a", "disturbance", "of", "the", "epithelial", "integrity", "through", "a", "decrease", "in", "intercellular", "homotypic", "adhesion", ".", "Proteolysis", "of", "the", "extracellular", "matrix", ",", "as", "well", "as", "increased", "locomotion", ",", "leads", "to", "intravasation", "and", "dissemination", "of", "the", "tumor", "cells", ".", "In", "the", "target", "organs", "metastasizing", "cells", "adhere", "to", "the", "endothelium", ",", "extravasate", "and", "form", "metastases", ".", "Finally", ",", "neoangiogenesis", "is", "required", "for", "the", "initiation", "as", "well", "as", "the", "growth", "of", "the", "metastases", ",", "providing", "the", "tumor", "cells", "with", "both", "nutritive", "agents", "and", "growth", "factors", ".", "This", "leads", "to", "the", "conclusion", "that", "anti", "-", "proteolytic", "and", "anti", "-", "angiogenic", "substances", "could", "provide", "effective", "therapeutic", "approaches", "for", "the", "control", "of", "metastatic", "growth", ".", "Whether", "or", "not", "this", "goal", "can", "be", "accomplished", "by", "synthetic", "or", "endogenous", "drugs", "must", "still", "be", "demonstrated", "by", "basic", "and", "definitive", "clinical", "research", "." ]	[ "umlsterm" ]
Metastasis, tumor, cells, stages, adhesion, extracellular matrix, locomotion, tumor, cells, cells, endothelium, metastases, growth, metastases, tumor, cells, growth factors, anti - proteolytic, anti - angiogenic, therapeutic, control, metastatic, growth, goal, drugs, clinical research	DerChirurg.80691315.eng.abstr_task2	Sentence: Metastasis formation is a multistep process that requires tumor cells to progress through many different stages . One of the first steps is a disturbance of the epithelial integrity through a decrease in intercellular homotypic adhesion . Proteolysis of the extracellular matrix , as well as increased locomotion , leads to intravasation and dissemination of the tumor cells . In the target organs metastasizing cells adhere to the endothelium , extravasate and form metastases . Finally , neoangiogenesis is required for the initiation as well as the growth of the metastases , providing the tumor cells with both nutritive agents and growth factors . This leads to the conclusion that anti-proteolytic and anti-angiogenic substances could provide effective therapeutic approaches for the control of metastatic growth . Whether or not this goal can be accomplished by synthetic or endogenous drugs must still be demonstrated by basic and definitive clinical research . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Metastasis formation is a multistep process that requires tumor cells to progress through many different stages . One of the first steps is a disturbance of the epithelial integrity through a decrease in intercellular homotypic adhesion . Proteolysis of the extracellular matrix , as well as increased locomotion , leads to intravasation and dissemination of the tumor cells . In the target organs metastasizing cells adhere to the endothelium , extravasate and form metastases . Finally , neoangiogenesis is required for the initiation as well as the growth of the metastases , providing the tumor cells with both nutritive agents and growth factors . This leads to the conclusion that anti-proteolytic and anti-angiogenic substances could provide effective therapeutic approaches for the control of metastatic growth . Whether or not this goal can be accomplished by synthetic or endogenous drugs must still be demonstrated by basic and definitive clinical research .	[ "Metastasis", "formation", "is", "a", "multistep", "process", "that", "requires", "tumor", "cells", "to", "progress", "through", "many", "different", "stages", ".", "One", "of", "the", "first", "steps", "is", "a", "disturbance", "of", "the", "epithelial", "integrity", "through", "a", "decrease", "in", "intercellular", "homotypic", "adhesion", ".", "Proteolysis", "of", "the", "extracellular", "matrix", ",", "as", "well", "as", "increased", "locomotion", ",", "leads", "to", "intravasation", "and", "dissemination", "of", "the", "tumor", "cells", ".", "In", "the", "target", "organs", "metastasizing", "cells", "adhere", "to", "the", "endothelium", ",", "extravasate", "and", "form", "metastases", ".", "Finally", ",", "neoangiogenesis", "is", "required", "for", "the", "initiation", "as", "well", "as", "the", "growth", "of", "the", "metastases", ",", "providing", "the", "tumor", "cells", "with", "both", "nutritive", "agents", "and", "growth", "factors", ".", "This", "leads", "to", "the", "conclusion", "that", "anti", "-", "proteolytic", "and", "anti", "-", "angiogenic", "substances", "could", "provide", "effective", "therapeutic", "approaches", "for", "the", "control", "of", "metastatic", "growth", ".", "Whether", "or", "not", "this", "goal", "can", "be", "accomplished", "by", "synthetic", "or", "endogenous", "drugs", "must", "still", "be", "demonstrated", "by", "basic", "and", "definitive", "clinical", "research", "." ]	[ "umlsterm" ]
coenzyme A is an umlsterm, reductase is an umlsterm, inhibitors is an umlsterm, role is an umlsterm, heart is an umlsterm, adverse effect is an umlsterm, myopathies is an umlsterm, interactions is an umlsterm, drugs is an umlsterm, patients is an umlsterm, myoglobinuria is an umlsterm, rhabdomyolysis is an umlsterm, operations is an umlsterm, aortic valve is an umlsterm, defect is an umlsterm, coronary artery bypass is an umlsterm, grafting is an umlsterm, coronary heart disease is an umlsterm, patients is an umlsterm, HMG - CoA reductase inhibitors is an umlsterm, operation is an umlsterm, diuresis is an umlsterm, concentrations is an umlsterm, kinase is an umlsterm, myoglobin is an umlsterm	ZfuerHerzThoraxGefaesschirurgie.80120201.eng.abstr_task0	Sentence: Hydroxymethylglutaryl coenzyme A reductase inhibitors play an important role in the propyhlaxis of coronary heart desease . A possible adverse effect is the induction of myopathies , which are described predominantly as interactions with other drugs . Two patients suffered myoglobinuria caused by rhabdomyolysis after cardiosurgical operations . In one case , a mechanical aortic valve prothesis was implanted for a combined valvular defect ; in a second case , a coronary artery bypass grafting was performed for coronary heart disease . Both patients had taken HMG-CoA reductase inhibitors before the operation . Under forced diuresis , the elevated serum concentrations of creatin kinase and myoglobin decreased continuously . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	Hydroxymethylglutaryl coenzyme A reductase inhibitors play an important role in the propyhlaxis of coronary heart desease . A possible adverse effect is the induction of myopathies , which are described predominantly as interactions with other drugs . Two patients suffered myoglobinuria caused by rhabdomyolysis after cardiosurgical operations . In one case , a mechanical aortic valve prothesis was implanted for a combined valvular defect ; in a second case , a coronary artery bypass grafting was performed for coronary heart disease . Both patients had taken HMG-CoA reductase inhibitors before the operation . Under forced diuresis , the elevated serum concentrations of creatin kinase and myoglobin decreased continuously .	[ "Hydroxymethylglutaryl", "coenzyme", "A", "reductase", "inhibitors", "play", "an", "important", "role", "in", "the", "propyhlaxis", "of", "coronary", "heart", "desease", ".", "A", "possible", "adverse", "effect", "is", "the", "induction", "of", "myopathies", ",", "which", "are", "described", "predominantly", "as", "interactions", "with", "other", "drugs", ".", "Two", "patients", "suffered", "myoglobinuria", "caused", "by", "rhabdomyolysis", "after", "cardiosurgical", "operations", ".", "In", "one", "case", ",", "a", "mechanical", "aortic", "valve", "prothesis", "was", "implanted", "for", "a", "combined", "valvular", "defect", ";", "in", "a", "second", "case", ",", "a", "coronary", "artery", "bypass", "grafting", "was", "performed", "for", "coronary", "heart", "disease", ".", "Both", "patients", "had", "taken", "HMG", "-", "CoA", "reductase", "inhibitors", "before", "the", "operation", ".", "Under", "forced", "diuresis", ",", "the", "elevated", "serum", "concentrations", "of", "creatin", "kinase", "and", "myoglobin", "decreased", "continuously", "." ]	[ "umlsterm" ]
coenzyme A is an umlsterm, reductase is an umlsterm, inhibitors is an umlsterm, role is an umlsterm, heart is an umlsterm, adverse effect is an umlsterm, myopathies is an umlsterm, interactions is an umlsterm, drugs is an umlsterm, patients is an umlsterm, myoglobinuria is an umlsterm, rhabdomyolysis is an umlsterm, operations is an umlsterm, aortic valve is an umlsterm, defect is an umlsterm, coronary artery bypass is an umlsterm, grafting is an umlsterm, coronary heart disease is an umlsterm, patients is an umlsterm, HMG - CoA reductase inhibitors is an umlsterm, operation is an umlsterm, diuresis is an umlsterm, concentrations is an umlsterm, kinase is an umlsterm, myoglobin is an umlsterm	ZfuerHerzThoraxGefaesschirurgie.80120201.eng.abstr_task1	Sentence: Hydroxymethylglutaryl coenzyme A reductase inhibitors play an important role in the propyhlaxis of coronary heart desease . A possible adverse effect is the induction of myopathies , which are described predominantly as interactions with other drugs . Two patients suffered myoglobinuria caused by rhabdomyolysis after cardiosurgical operations . In one case , a mechanical aortic valve prothesis was implanted for a combined valvular defect ; in a second case , a coronary artery bypass grafting was performed for coronary heart disease . Both patients had taken HMG-CoA reductase inhibitors before the operation . Under forced diuresis , the elevated serum concentrations of creatin kinase and myoglobin decreased continuously . Instructions: please typing these entity words according to sentence: coenzyme A, reductase, inhibitors, role, heart, adverse effect, myopathies, interactions, drugs, patients, myoglobinuria, rhabdomyolysis, operations, aortic valve, defect, coronary artery bypass, grafting, coronary heart disease, patients, HMG - CoA reductase inhibitors, operation, diuresis, concentrations, kinase, myoglobin Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	Hydroxymethylglutaryl coenzyme A reductase inhibitors play an important role in the propyhlaxis of coronary heart desease . A possible adverse effect is the induction of myopathies , which are described predominantly as interactions with other drugs . Two patients suffered myoglobinuria caused by rhabdomyolysis after cardiosurgical operations . In one case , a mechanical aortic valve prothesis was implanted for a combined valvular defect ; in a second case , a coronary artery bypass grafting was performed for coronary heart disease . Both patients had taken HMG-CoA reductase inhibitors before the operation . Under forced diuresis , the elevated serum concentrations of creatin kinase and myoglobin decreased continuously .	[ "Hydroxymethylglutaryl", "coenzyme", "A", "reductase", "inhibitors", "play", "an", "important", "role", "in", "the", "propyhlaxis", "of", "coronary", "heart", "desease", ".", "A", "possible", "adverse", "effect", "is", "the", "induction", "of", "myopathies", ",", "which", "are", "described", "predominantly", "as", "interactions", "with", "other", "drugs", ".", "Two", "patients", "suffered", "myoglobinuria", "caused", "by", "rhabdomyolysis", "after", "cardiosurgical", "operations", ".", "In", "one", "case", ",", "a", "mechanical", "aortic", "valve", "prothesis", "was", "implanted", "for", "a", "combined", "valvular", "defect", ";", "in", "a", "second", "case", ",", "a", "coronary", "artery", "bypass", "grafting", "was", "performed", "for", "coronary", "heart", "disease", ".", "Both", "patients", "had", "taken", "HMG", "-", "CoA", "reductase", "inhibitors", "before", "the", "operation", ".", "Under", "forced", "diuresis", ",", "the", "elevated", "serum", "concentrations", "of", "creatin", "kinase", "and", "myoglobin", "decreased", "continuously", "." ]	[ "umlsterm" ]
coenzyme A, reductase, inhibitors, role, heart, adverse effect, myopathies, interactions, drugs, patients, myoglobinuria, rhabdomyolysis, operations, aortic valve, defect, coronary artery bypass, grafting, coronary heart disease, patients, HMG - CoA reductase inhibitors, operation, diuresis, concentrations, kinase, myoglobin	ZfuerHerzThoraxGefaesschirurgie.80120201.eng.abstr_task2	Sentence: Hydroxymethylglutaryl coenzyme A reductase inhibitors play an important role in the propyhlaxis of coronary heart desease . A possible adverse effect is the induction of myopathies , which are described predominantly as interactions with other drugs . Two patients suffered myoglobinuria caused by rhabdomyolysis after cardiosurgical operations . In one case , a mechanical aortic valve prothesis was implanted for a combined valvular defect ; in a second case , a coronary artery bypass grafting was performed for coronary heart disease . Both patients had taken HMG-CoA reductase inhibitors before the operation . Under forced diuresis , the elevated serum concentrations of creatin kinase and myoglobin decreased continuously . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	Hydroxymethylglutaryl coenzyme A reductase inhibitors play an important role in the propyhlaxis of coronary heart desease . A possible adverse effect is the induction of myopathies , which are described predominantly as interactions with other drugs . Two patients suffered myoglobinuria caused by rhabdomyolysis after cardiosurgical operations . In one case , a mechanical aortic valve prothesis was implanted for a combined valvular defect ; in a second case , a coronary artery bypass grafting was performed for coronary heart disease . Both patients had taken HMG-CoA reductase inhibitors before the operation . Under forced diuresis , the elevated serum concentrations of creatin kinase and myoglobin decreased continuously .	[ "Hydroxymethylglutaryl", "coenzyme", "A", "reductase", "inhibitors", "play", "an", "important", "role", "in", "the", "propyhlaxis", "of", "coronary", "heart", "desease", ".", "A", "possible", "adverse", "effect", "is", "the", "induction", "of", "myopathies", ",", "which", "are", "described", "predominantly", "as", "interactions", "with", "other", "drugs", ".", "Two", "patients", "suffered", "myoglobinuria", "caused", "by", "rhabdomyolysis", "after", "cardiosurgical", "operations", ".", "In", "one", "case", ",", "a", "mechanical", "aortic", "valve", "prothesis", "was", "implanted", "for", "a", "combined", "valvular", "defect", ";", "in", "a", "second", "case", ",", "a", "coronary", "artery", "bypass", "grafting", "was", "performed", "for", "coronary", "heart", "disease", ".", "Both", "patients", "had", "taken", "HMG", "-", "CoA", "reductase", "inhibitors", "before", "the", "operation", ".", "Under", "forced", "diuresis", ",", "the", "elevated", "serum", "concentrations", "of", "creatin", "kinase", "and", "myoglobin", "decreased", "continuously", "." ]	[ "umlsterm" ]
E2F1 is a Gene_or_gene_product, p53 is a Gene_or_gene_product, hepatitis B viral X protein is a Gene_or_gene_product, Hbx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, hepatitis B virus X protein is a Gene_or_gene_product, HBx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, chloramphenicol acetyl transferase is a Gene_or_gene_product, CAT is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, thymidine kinase is a Gene_or_gene_product, tk is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, GAL4 is a Gene_or_gene_product, pRb is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product	94_task0	Sentence: E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. The functional effect of the interaction of E2F1 and hepatitis B virus X protein (HBx) on the promoter of human p53 gene was studied using chloramphenicol acetyl transferase (CAT) assay. E2F1 activated the p53 promoter through E2F1 binding site. As previously reported, HBx repressed the p53 promoter through E-box. When E2F1 was cotransfected with HBx, E2F1 overcame the repressive effect of HBx on the p53 promoter through the E2F1 site. However, in the thymidine kinase (tk) heterologous promoter system with the E2F1 binding sites, cotransfection of E2F1 and HBx showed a strong synergistic activation. An in vitro interaction assay showed that E2F1 and HBx physically bind with each other. Analyses of the interaction domain with the GAL4 fusion protein showed that the pRb-binding domain of E2F1 was necessary for the functional interaction of these two proteins. Taken together, these results imply the functional inhibitory action of E2F1 on the HBV life cycle and HBV-mediated hepatocellular carcinogenesis (HCC). Therefore, the normal or enhanced function of E2F1 gene would be important in controlling the HBx function in HCC. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene_or_gene_product	[ "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O" ]	E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. The functional effect of the interaction of E2F1 and hepatitis B virus X protein (HBx) on the promoter of human p53 gene was studied using chloramphenicol acetyl transferase (CAT) assay. E2F1 activated the p53 promoter through E2F1 binding site. As previously reported, HBx repressed the p53 promoter through E-box. When E2F1 was cotransfected with HBx, E2F1 overcame the repressive effect of HBx on the p53 promoter through the E2F1 site. However, in the thymidine kinase (tk) heterologous promoter system with the E2F1 binding sites, cotransfection of E2F1 and HBx showed a strong synergistic activation. An in vitro interaction assay showed that E2F1 and HBx physically bind with each other. Analyses of the interaction domain with the GAL4 fusion protein showed that the pRb-binding domain of E2F1 was necessary for the functional interaction of these two proteins. Taken together, these results imply the functional inhibitory action of E2F1 on the HBV life cycle and HBV-mediated hepatocellular carcinogenesis (HCC). Therefore, the normal or enhanced function of E2F1 gene would be important in controlling the HBx function in HCC.	[ "E2F1", "activates", "the", "human", "p53", "promoter", "and", "overcomes", "the", "repressive", "effect", "of", "hepatitis", "B", "viral", "X", "protein", "(", "Hbx", ")", "on", "the", "p53", "promoter", ".", "\n", "The", "functional", "effect", "of", "the", "interaction", "of", "E2F1", "and", "hepatitis", "B", "virus", "X", "protein", "(", "HBx", ")", "on", "the", "promoter", "of", "human", "p53", "gene", "was", "studied", "using", "chloramphenicol", "acetyl", "transferase", "(", "CAT", ")", "assay", ".", "E2F1", "activated", "the", "p53", "promoter", "through", "E2F1", "binding", "site", ".", "As", "previously", "reported", ",", "HBx", "repressed", "the", "p53", "promoter", "through", "E", "-", "box", ".", "When", "E2F1", "was", "cotransfected", "with", "HBx", ",", "E2F1", "overcame", "the", "repressive", "effect", "of", "HBx", "on", "the", "p53", "promoter", "through", "the", "E2F1", "site", ".", "However", ",", "in", "the", "thymidine", "kinase", "(", "tk", ")", "heterologous", "promoter", "system", "with", "the", "E2F1", "binding", "sites", ",", "cotransfection", "of", "E2F1", "and", "HBx", "showed", "a", "strong", "synergistic", "activation", ".", "An", "in", "vitro", "interaction", "assay", "showed", "that", "E2F1", "and", "HBx", "physically", "bind", "with", "each", "other", ".", "Analyses", "of", "the", "interaction", "domain", "with", "the", "GAL4", "fusion", "protein", "showed", "that", "the", "pRb", "-", "binding", "domain", "of", "E2F1", "was", "necessary", "for", "the", "functional", "interaction", "of", "these", "two", "proteins", ".", "Taken", "together", ",", "these", "results", "imply", "the", "functional", "inhibitory", "action", "of", "E2F1", "on", "the", "HBV", "life", "cycle", "and", "HBV", "-", "mediated", "hepatocellular", "carcinogenesis", "(", "HCC", ")", ".", "Therefore", ",", "the", "normal", "or", "enhanced", "function", "of", "E2F1", "gene", "would", "be", "important", "in", "controlling", "the", "HBx", "function", "in", "HCC", ".", "\n" ]	[ "Gene_or_gene_product" ]
E2F1 is a Gene_or_gene_product, p53 is a Gene_or_gene_product, hepatitis B viral X protein is a Gene_or_gene_product, Hbx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, hepatitis B virus X protein is a Gene_or_gene_product, HBx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, chloramphenicol acetyl transferase is a Gene_or_gene_product, CAT is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, thymidine kinase is a Gene_or_gene_product, tk is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, GAL4 is a Gene_or_gene_product, pRb is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product	94_task1	Sentence: E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. The functional effect of the interaction of E2F1 and hepatitis B virus X protein (HBx) on the promoter of human p53 gene was studied using chloramphenicol acetyl transferase (CAT) assay. E2F1 activated the p53 promoter through E2F1 binding site. As previously reported, HBx repressed the p53 promoter through E-box. When E2F1 was cotransfected with HBx, E2F1 overcame the repressive effect of HBx on the p53 promoter through the E2F1 site. However, in the thymidine kinase (tk) heterologous promoter system with the E2F1 binding sites, cotransfection of E2F1 and HBx showed a strong synergistic activation. An in vitro interaction assay showed that E2F1 and HBx physically bind with each other. Analyses of the interaction domain with the GAL4 fusion protein showed that the pRb-binding domain of E2F1 was necessary for the functional interaction of these two proteins. Taken together, these results imply the functional inhibitory action of E2F1 on the HBV life cycle and HBV-mediated hepatocellular carcinogenesis (HCC). Therefore, the normal or enhanced function of E2F1 gene would be important in controlling the HBx function in HCC. Instructions: please typing these entity words according to sentence: E2F1, p53, hepatitis B viral X protein, Hbx, p53, E2F1, hepatitis B virus X protein, HBx, p53, chloramphenicol acetyl transferase, CAT, E2F1, p53, E2F1, HBx, p53, E2F1, HBx, E2F1, HBx, p53, E2F1, thymidine kinase, tk, E2F1, E2F1, HBx, E2F1, HBx, GAL4, pRb, E2F1, E2F1, E2F1, HBx Options: Gene_or_gene_product	[ "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O" ]	E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. The functional effect of the interaction of E2F1 and hepatitis B virus X protein (HBx) on the promoter of human p53 gene was studied using chloramphenicol acetyl transferase (CAT) assay. E2F1 activated the p53 promoter through E2F1 binding site. As previously reported, HBx repressed the p53 promoter through E-box. When E2F1 was cotransfected with HBx, E2F1 overcame the repressive effect of HBx on the p53 promoter through the E2F1 site. However, in the thymidine kinase (tk) heterologous promoter system with the E2F1 binding sites, cotransfection of E2F1 and HBx showed a strong synergistic activation. An in vitro interaction assay showed that E2F1 and HBx physically bind with each other. Analyses of the interaction domain with the GAL4 fusion protein showed that the pRb-binding domain of E2F1 was necessary for the functional interaction of these two proteins. Taken together, these results imply the functional inhibitory action of E2F1 on the HBV life cycle and HBV-mediated hepatocellular carcinogenesis (HCC). Therefore, the normal or enhanced function of E2F1 gene would be important in controlling the HBx function in HCC.	[ "E2F1", "activates", "the", "human", "p53", "promoter", "and", "overcomes", "the", "repressive", "effect", "of", "hepatitis", "B", "viral", "X", "protein", "(", "Hbx", ")", "on", "the", "p53", "promoter", ".", "\n", "The", "functional", "effect", "of", "the", "interaction", "of", "E2F1", "and", "hepatitis", "B", "virus", "X", "protein", "(", "HBx", ")", "on", "the", "promoter", "of", "human", "p53", "gene", "was", "studied", "using", "chloramphenicol", "acetyl", "transferase", "(", "CAT", ")", "assay", ".", "E2F1", "activated", "the", "p53", "promoter", "through", "E2F1", "binding", "site", ".", "As", "previously", "reported", ",", "HBx", "repressed", "the", "p53", "promoter", "through", "E", "-", "box", ".", "When", "E2F1", "was", "cotransfected", "with", "HBx", ",", "E2F1", "overcame", "the", "repressive", "effect", "of", "HBx", "on", "the", "p53", "promoter", "through", "the", "E2F1", "site", ".", "However", ",", "in", "the", "thymidine", "kinase", "(", "tk", ")", "heterologous", "promoter", "system", "with", "the", "E2F1", "binding", "sites", ",", "cotransfection", "of", "E2F1", "and", "HBx", "showed", "a", "strong", "synergistic", "activation", ".", "An", "in", "vitro", "interaction", "assay", "showed", "that", "E2F1", "and", "HBx", "physically", "bind", "with", "each", "other", ".", "Analyses", "of", "the", "interaction", "domain", "with", "the", "GAL4", "fusion", "protein", "showed", "that", "the", "pRb", "-", "binding", "domain", "of", "E2F1", "was", "necessary", "for", "the", "functional", "interaction", "of", "these", "two", "proteins", ".", "Taken", "together", ",", "these", "results", "imply", "the", "functional", "inhibitory", "action", "of", "E2F1", "on", "the", "HBV", "life", "cycle", "and", "HBV", "-", "mediated", "hepatocellular", "carcinogenesis", "(", "HCC", ")", ".", "Therefore", ",", "the", "normal", "or", "enhanced", "function", "of", "E2F1", "gene", "would", "be", "important", "in", "controlling", "the", "HBx", "function", "in", "HCC", ".", "\n" ]	[ "Gene_or_gene_product" ]
E2F1, p53, hepatitis B viral X protein, Hbx, p53, E2F1, hepatitis B virus X protein, HBx, p53, chloramphenicol acetyl transferase, CAT, E2F1, p53, E2F1, HBx, p53, E2F1, HBx, E2F1, HBx, p53, E2F1, thymidine kinase, tk, E2F1, E2F1, HBx, E2F1, HBx, GAL4, pRb, E2F1, E2F1, E2F1, HBx	94_task2	Sentence: E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. The functional effect of the interaction of E2F1 and hepatitis B virus X protein (HBx) on the promoter of human p53 gene was studied using chloramphenicol acetyl transferase (CAT) assay. E2F1 activated the p53 promoter through E2F1 binding site. As previously reported, HBx repressed the p53 promoter through E-box. When E2F1 was cotransfected with HBx, E2F1 overcame the repressive effect of HBx on the p53 promoter through the E2F1 site. However, in the thymidine kinase (tk) heterologous promoter system with the E2F1 binding sites, cotransfection of E2F1 and HBx showed a strong synergistic activation. An in vitro interaction assay showed that E2F1 and HBx physically bind with each other. Analyses of the interaction domain with the GAL4 fusion protein showed that the pRb-binding domain of E2F1 was necessary for the functional interaction of these two proteins. Taken together, these results imply the functional inhibitory action of E2F1 on the HBV life cycle and HBV-mediated hepatocellular carcinogenesis (HCC). Therefore, the normal or enhanced function of E2F1 gene would be important in controlling the HBx function in HCC. Instructions: please extract entity words from the input sentence	[ "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O" ]	E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. The functional effect of the interaction of E2F1 and hepatitis B virus X protein (HBx) on the promoter of human p53 gene was studied using chloramphenicol acetyl transferase (CAT) assay. E2F1 activated the p53 promoter through E2F1 binding site. As previously reported, HBx repressed the p53 promoter through E-box. When E2F1 was cotransfected with HBx, E2F1 overcame the repressive effect of HBx on the p53 promoter through the E2F1 site. However, in the thymidine kinase (tk) heterologous promoter system with the E2F1 binding sites, cotransfection of E2F1 and HBx showed a strong synergistic activation. An in vitro interaction assay showed that E2F1 and HBx physically bind with each other. Analyses of the interaction domain with the GAL4 fusion protein showed that the pRb-binding domain of E2F1 was necessary for the functional interaction of these two proteins. Taken together, these results imply the functional inhibitory action of E2F1 on the HBV life cycle and HBV-mediated hepatocellular carcinogenesis (HCC). Therefore, the normal or enhanced function of E2F1 gene would be important in controlling the HBx function in HCC.	[ "E2F1", "activates", "the", "human", "p53", "promoter", "and", "overcomes", "the", "repressive", "effect", "of", "hepatitis", "B", "viral", "X", "protein", "(", "Hbx", ")", "on", "the", "p53", "promoter", ".", "\n", "The", "functional", "effect", "of", "the", "interaction", "of", "E2F1", "and", "hepatitis", "B", "virus", "X", "protein", "(", "HBx", ")", "on", "the", "promoter", "of", "human", "p53", "gene", "was", "studied", "using", "chloramphenicol", "acetyl", "transferase", "(", "CAT", ")", "assay", ".", "E2F1", "activated", "the", "p53", "promoter", "through", "E2F1", "binding", "site", ".", "As", "previously", "reported", ",", "HBx", "repressed", "the", "p53", "promoter", "through", "E", "-", "box", ".", "When", "E2F1", "was", "cotransfected", "with", "HBx", ",", "E2F1", "overcame", "the", "repressive", "effect", "of", "HBx", "on", "the", "p53", "promoter", "through", "the", "E2F1", "site", ".", "However", ",", "in", "the", "thymidine", "kinase", "(", "tk", ")", "heterologous", "promoter", "system", "with", "the", "E2F1", "binding", "sites", ",", "cotransfection", "of", "E2F1", "and", "HBx", "showed", "a", "strong", "synergistic", "activation", ".", "An", "in", "vitro", "interaction", "assay", "showed", "that", "E2F1", "and", "HBx", "physically", "bind", "with", "each", "other", ".", "Analyses", "of", "the", "interaction", "domain", "with", "the", "GAL4", "fusion", "protein", "showed", "that", "the", "pRb", "-", "binding", "domain", "of", "E2F1", "was", "necessary", "for", "the", "functional", "interaction", "of", "these", "two", "proteins", ".", "Taken", "together", ",", "these", "results", "imply", "the", "functional", "inhibitory", "action", "of", "E2F1", "on", "the", "HBV", "life", "cycle", "and", "HBV", "-", "mediated", "hepatocellular", "carcinogenesis", "(", "HCC", ")", ".", "Therefore", ",", "the", "normal", "or", "enhanced", "function", "of", "E2F1", "gene", "would", "be", "important", "in", "controlling", "the", "HBx", "function", "in", "HCC", ".", "\n" ]	[ "Gene_or_gene_product" ]
cuffs -- is a Outcome_Physical, efficacy is a Outcome_Other, cuff pressure release valve is a Intervention_Other, performance is a Outcome_Other, ( is a Intervention_Physical, CPRV is a Intervention_Other, paediatric cuffed tracheal tubes is a Participant_Condition, with is a Intervention_Other, and without is a Intervention_Physical, 50 is a Participant_Sample-size, children is a Participant_Age, general anaesthesia with tracheal intubation and standardized anaesthesia technique is a Participant_Condition, reliable cuff pressure release is a Outcome_Physical	23067_task0	Sentence: Nitrous oxide diffusion into tracheal tube cuffs -- efficacy of a new prototype cuff pressure release valve . BACKGROUND The aim of this study was to evaluate the performance of a new cuff pressure release valve ( CPRV ) , in which the release pressure can be adjusted from 10 to 25 cmH2O , particularly intended to control pressure in paediatric cuffed tracheal tubes and to avoid cuff hyperinflation caused by N2O diffusion . METHODS In vitro : the PRV was set to 10 , 15 , 20 or 25 cmH2O release pressure and connected to a cuffed tube placed into a box flushed with 66 % N2O in O2 . The cuff pressure was monitored with and without CPRV for 60 min . Experiments were performed four times using two different CPRVs . In vivo : with Institutional Review Board approval , CPRV was studied in 50 children undergoing general anaesthesia with tracheal intubation and standardized anaesthesia technique ( including 66 % N2O in O2 ) and ventilator settings . Patients were randomized into two groups ( with and without CPRV ) . The cuff pressure baseline was 20 cmH2O and CPRV was set to 25 cmH2O . If the cuff pressure exceeded 25 cmH2O , it was manually released to 20 cmH2O . The numbers of deflations in both groups were noted and compared by Mann-Whitney U-test ( P < 0.05 ) . RESULTS In vitro : the cuff pressure exceeded 50 cmH2O after 60 min without CPRV , but did not exceed the settings with CPRV . In vivo : there was no need to manually deflate the cuff in the CPRV group but , in every patient in the control group , three ( two to seven ) deflating manoeuvres were required within the first hour of anaesthesia ( P < 0.0001 ) . CONCLUSION The CPRV allows reliable cuff pressure release at various pressure levels and reliably prevents cuff pressure increases caused by N2O . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition, Intervention_Other, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other	[ "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nitrous oxide diffusion into tracheal tube cuffs -- efficacy of a new prototype cuff pressure release valve . BACKGROUND The aim of this study was to evaluate the performance of a new cuff pressure release valve ( CPRV ) , in which the release pressure can be adjusted from 10 to 25 cmH2O , particularly intended to control pressure in paediatric cuffed tracheal tubes and to avoid cuff hyperinflation caused by N2O diffusion . METHODS In vitro : the PRV was set to 10 , 15 , 20 or 25 cmH2O release pressure and connected to a cuffed tube placed into a box flushed with 66 % N2O in O2 . The cuff pressure was monitored with and without CPRV for 60 min . Experiments were performed four times using two different CPRVs . In vivo : with Institutional Review Board approval , CPRV was studied in 50 children undergoing general anaesthesia with tracheal intubation and standardized anaesthesia technique ( including 66 % N2O in O2 ) and ventilator settings . Patients were randomized into two groups ( with and without CPRV ) . The cuff pressure baseline was 20 cmH2O and CPRV was set to 25 cmH2O . If the cuff pressure exceeded 25 cmH2O , it was manually released to 20 cmH2O . The numbers of deflations in both groups were noted and compared by Mann-Whitney U-test ( P < 0.05 ) . RESULTS In vitro : the cuff pressure exceeded 50 cmH2O after 60 min without CPRV , but did not exceed the settings with CPRV . In vivo : there was no need to manually deflate the cuff in the CPRV group but , in every patient in the control group , three ( two to seven ) deflating manoeuvres were required within the first hour of anaesthesia ( P < 0.0001 ) . CONCLUSION The CPRV allows reliable cuff pressure release at various pressure levels and reliably prevents cuff pressure increases caused by N2O .	[ "Nitrous", "oxide", "diffusion", "into", "tracheal", "tube", "cuffs", "--", "efficacy", "of", "a", "new", "prototype", "cuff", "pressure", "release", "valve", ".", "BACKGROUND", "The", "aim", "of", "this", "study", "was", "to", "evaluate", "the", "performance", "of", "a", "new", "cuff", "pressure", "release", "valve", "(", "CPRV", ")", ",", "in", "which", "the", "release", "pressure", "can", "be", "adjusted", "from", "10", "to", "25", "cmH2O", ",", "particularly", "intended", "to", "control", "pressure", "in", "paediatric", "cuffed", "tracheal", "tubes", "and", "to", "avoid", "cuff", "hyperinflation", "caused", "by", "N2O", "diffusion", ".", "METHODS", "In", "vitro", ":", "the", "PRV", "was", "set", "to", "10", ",", "15", ",", "20", "or", "25", "cmH2O", "release", "pressure", "and", "connected", "to", "a", "cuffed", "tube", "placed", "into", "a", "box", "flushed", "with", "66", "%", "N2O", "in", "O2", ".", "The", "cuff", "pressure", "was", "monitored", "with", "and", "without", "CPRV", "for", "60", "min", ".", "Experiments", "were", "performed", "four", "times", "using", "two", "different", "CPRVs", ".", "In", "vivo", ":", "with", "Institutional", "Review", "Board", "approval", ",", "CPRV", "was", "studied", "in", "50", "children", "undergoing", "general", "anaesthesia", "with", "tracheal", "intubation", "and", "standardized", "anaesthesia", "technique", "(", "including", "66", "%", "N2O", "in", "O2", ")", "and", "ventilator", "settings", ".", "Patients", "were", "randomized", "into", "two", "groups", "(", "with", "and", "without", "CPRV", ")", ".", "The", "cuff", "pressure", "baseline", "was", "20", "cmH2O", "and", "CPRV", "was", "set", "to", "25", "cmH2O", ".", "If", "the", "cuff", "pressure", "exceeded", "25", "cmH2O", ",", "it", "was", "manually", "released", "to", "20", "cmH2O", ".", "The", "numbers", "of", "deflations", "in", "both", "groups", "were", "noted", "and", "compared", "by", "Mann", "-", "Whitney", "U", "-", "test", "(", "P", "<", "0.05", ")", ".", "RESULTS", "In", "vitro", ":", "the", "cuff", "pressure", "exceeded", "50", "cmH2O", "after", "60", "min", "without", "CPRV", ",", "but", "did", "not", "exceed", "the", "settings", "with", "CPRV", ".", "In", "vivo", ":", "there", "was", "no", "need", "to", "manually", "deflate", "the", "cuff", "in", "the", "CPRV", "group", "but", ",", "in", "every", "patient", "in", "the", "control", "group", ",", "three", "(", "two", "to", "seven", ")", "deflating", "manoeuvres", "were", "required", "within", "the", "first", "hour", "of", "anaesthesia", "(", "P", "<", "0.0001", ")", ".", "CONCLUSION", "The", "CPRV", "allows", "reliable", "cuff", "pressure", "release", "at", "various", "pressure", "levels", "and", "reliably", "prevents", "cuff", "pressure", "increases", "caused", "by", "N2O", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Other", "Intervention_Physical", "Outcome_Other", "Participant_Age", "Participant_Sample-size" ]
cuffs -- is a Outcome_Physical, efficacy is a Outcome_Other, cuff pressure release valve is a Intervention_Other, performance is a Outcome_Other, ( is a Intervention_Physical, CPRV is a Intervention_Other, paediatric cuffed tracheal tubes is a Participant_Condition, with is a Intervention_Other, and without is a Intervention_Physical, 50 is a Participant_Sample-size, children is a Participant_Age, general anaesthesia with tracheal intubation and standardized anaesthesia technique is a Participant_Condition, reliable cuff pressure release is a Outcome_Physical	23067_task1	Sentence: Nitrous oxide diffusion into tracheal tube cuffs -- efficacy of a new prototype cuff pressure release valve . BACKGROUND The aim of this study was to evaluate the performance of a new cuff pressure release valve ( CPRV ) , in which the release pressure can be adjusted from 10 to 25 cmH2O , particularly intended to control pressure in paediatric cuffed tracheal tubes and to avoid cuff hyperinflation caused by N2O diffusion . METHODS In vitro : the PRV was set to 10 , 15 , 20 or 25 cmH2O release pressure and connected to a cuffed tube placed into a box flushed with 66 % N2O in O2 . The cuff pressure was monitored with and without CPRV for 60 min . Experiments were performed four times using two different CPRVs . In vivo : with Institutional Review Board approval , CPRV was studied in 50 children undergoing general anaesthesia with tracheal intubation and standardized anaesthesia technique ( including 66 % N2O in O2 ) and ventilator settings . Patients were randomized into two groups ( with and without CPRV ) . The cuff pressure baseline was 20 cmH2O and CPRV was set to 25 cmH2O . If the cuff pressure exceeded 25 cmH2O , it was manually released to 20 cmH2O . The numbers of deflations in both groups were noted and compared by Mann-Whitney U-test ( P < 0.05 ) . RESULTS In vitro : the cuff pressure exceeded 50 cmH2O after 60 min without CPRV , but did not exceed the settings with CPRV . In vivo : there was no need to manually deflate the cuff in the CPRV group but , in every patient in the control group , three ( two to seven ) deflating manoeuvres were required within the first hour of anaesthesia ( P < 0.0001 ) . CONCLUSION The CPRV allows reliable cuff pressure release at various pressure levels and reliably prevents cuff pressure increases caused by N2O . Instructions: please typing these entity words according to sentence: cuffs --, efficacy, cuff pressure release valve, performance, (, CPRV, paediatric cuffed tracheal tubes, with, and without, 50, children, general anaesthesia with tracheal intubation and standardized anaesthesia technique, reliable cuff pressure release Options: Intervention_Physical, Participant_Condition, Intervention_Other, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other	[ "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nitrous oxide diffusion into tracheal tube cuffs -- efficacy of a new prototype cuff pressure release valve . BACKGROUND The aim of this study was to evaluate the performance of a new cuff pressure release valve ( CPRV ) , in which the release pressure can be adjusted from 10 to 25 cmH2O , particularly intended to control pressure in paediatric cuffed tracheal tubes and to avoid cuff hyperinflation caused by N2O diffusion . METHODS In vitro : the PRV was set to 10 , 15 , 20 or 25 cmH2O release pressure and connected to a cuffed tube placed into a box flushed with 66 % N2O in O2 . The cuff pressure was monitored with and without CPRV for 60 min . Experiments were performed four times using two different CPRVs . In vivo : with Institutional Review Board approval , CPRV was studied in 50 children undergoing general anaesthesia with tracheal intubation and standardized anaesthesia technique ( including 66 % N2O in O2 ) and ventilator settings . Patients were randomized into two groups ( with and without CPRV ) . The cuff pressure baseline was 20 cmH2O and CPRV was set to 25 cmH2O . If the cuff pressure exceeded 25 cmH2O , it was manually released to 20 cmH2O . The numbers of deflations in both groups were noted and compared by Mann-Whitney U-test ( P < 0.05 ) . RESULTS In vitro : the cuff pressure exceeded 50 cmH2O after 60 min without CPRV , but did not exceed the settings with CPRV . In vivo : there was no need to manually deflate the cuff in the CPRV group but , in every patient in the control group , three ( two to seven ) deflating manoeuvres were required within the first hour of anaesthesia ( P < 0.0001 ) . CONCLUSION The CPRV allows reliable cuff pressure release at various pressure levels and reliably prevents cuff pressure increases caused by N2O .	[ "Nitrous", "oxide", "diffusion", "into", "tracheal", "tube", "cuffs", "--", "efficacy", "of", "a", "new", "prototype", "cuff", "pressure", "release", "valve", ".", "BACKGROUND", "The", "aim", "of", "this", "study", "was", "to", "evaluate", "the", "performance", "of", "a", "new", "cuff", "pressure", "release", "valve", "(", "CPRV", ")", ",", "in", "which", "the", "release", "pressure", "can", "be", "adjusted", "from", "10", "to", "25", "cmH2O", ",", "particularly", "intended", "to", "control", "pressure", "in", "paediatric", "cuffed", "tracheal", "tubes", "and", "to", "avoid", "cuff", "hyperinflation", "caused", "by", "N2O", "diffusion", ".", "METHODS", "In", "vitro", ":", "the", "PRV", "was", "set", "to", "10", ",", "15", ",", "20", "or", "25", "cmH2O", "release", "pressure", "and", "connected", "to", "a", "cuffed", "tube", "placed", "into", "a", "box", "flushed", "with", "66", "%", "N2O", "in", "O2", ".", "The", "cuff", "pressure", "was", "monitored", "with", "and", "without", "CPRV", "for", "60", "min", ".", "Experiments", "were", "performed", "four", "times", "using", "two", "different", "CPRVs", ".", "In", "vivo", ":", "with", "Institutional", "Review", "Board", "approval", ",", "CPRV", "was", "studied", "in", "50", "children", "undergoing", "general", "anaesthesia", "with", "tracheal", "intubation", "and", "standardized", "anaesthesia", "technique", "(", "including", "66", "%", "N2O", "in", "O2", ")", "and", "ventilator", "settings", ".", "Patients", "were", "randomized", "into", "two", "groups", "(", "with", "and", "without", "CPRV", ")", ".", "The", "cuff", "pressure", "baseline", "was", "20", "cmH2O", "and", "CPRV", "was", "set", "to", "25", "cmH2O", ".", "If", "the", "cuff", "pressure", "exceeded", "25", "cmH2O", ",", "it", "was", "manually", "released", "to", "20", "cmH2O", ".", "The", "numbers", "of", "deflations", "in", "both", "groups", "were", "noted", "and", "compared", "by", "Mann", "-", "Whitney", "U", "-", "test", "(", "P", "<", "0.05", ")", ".", "RESULTS", "In", "vitro", ":", "the", "cuff", "pressure", "exceeded", "50", "cmH2O", "after", "60", "min", "without", "CPRV", ",", "but", "did", "not", "exceed", "the", "settings", "with", "CPRV", ".", "In", "vivo", ":", "there", "was", "no", "need", "to", "manually", "deflate", "the", "cuff", "in", "the", "CPRV", "group", "but", ",", "in", "every", "patient", "in", "the", "control", "group", ",", "three", "(", "two", "to", "seven", ")", "deflating", "manoeuvres", "were", "required", "within", "the", "first", "hour", "of", "anaesthesia", "(", "P", "<", "0.0001", ")", ".", "CONCLUSION", "The", "CPRV", "allows", "reliable", "cuff", "pressure", "release", "at", "various", "pressure", "levels", "and", "reliably", "prevents", "cuff", "pressure", "increases", "caused", "by", "N2O", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Other", "Intervention_Physical", "Outcome_Other", "Participant_Age", "Participant_Sample-size" ]
cuffs --, efficacy, cuff pressure release valve, performance, (, CPRV, paediatric cuffed tracheal tubes, with, and without, 50, children, general anaesthesia with tracheal intubation and standardized anaesthesia technique, reliable cuff pressure release	23067_task2	Sentence: Nitrous oxide diffusion into tracheal tube cuffs -- efficacy of a new prototype cuff pressure release valve . BACKGROUND The aim of this study was to evaluate the performance of a new cuff pressure release valve ( CPRV ) , in which the release pressure can be adjusted from 10 to 25 cmH2O , particularly intended to control pressure in paediatric cuffed tracheal tubes and to avoid cuff hyperinflation caused by N2O diffusion . METHODS In vitro : the PRV was set to 10 , 15 , 20 or 25 cmH2O release pressure and connected to a cuffed tube placed into a box flushed with 66 % N2O in O2 . The cuff pressure was monitored with and without CPRV for 60 min . Experiments were performed four times using two different CPRVs . In vivo : with Institutional Review Board approval , CPRV was studied in 50 children undergoing general anaesthesia with tracheal intubation and standardized anaesthesia technique ( including 66 % N2O in O2 ) and ventilator settings . Patients were randomized into two groups ( with and without CPRV ) . The cuff pressure baseline was 20 cmH2O and CPRV was set to 25 cmH2O . If the cuff pressure exceeded 25 cmH2O , it was manually released to 20 cmH2O . The numbers of deflations in both groups were noted and compared by Mann-Whitney U-test ( P < 0.05 ) . RESULTS In vitro : the cuff pressure exceeded 50 cmH2O after 60 min without CPRV , but did not exceed the settings with CPRV . In vivo : there was no need to manually deflate the cuff in the CPRV group but , in every patient in the control group , three ( two to seven ) deflating manoeuvres were required within the first hour of anaesthesia ( P < 0.0001 ) . CONCLUSION The CPRV allows reliable cuff pressure release at various pressure levels and reliably prevents cuff pressure increases caused by N2O . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nitrous oxide diffusion into tracheal tube cuffs -- efficacy of a new prototype cuff pressure release valve . BACKGROUND The aim of this study was to evaluate the performance of a new cuff pressure release valve ( CPRV ) , in which the release pressure can be adjusted from 10 to 25 cmH2O , particularly intended to control pressure in paediatric cuffed tracheal tubes and to avoid cuff hyperinflation caused by N2O diffusion . METHODS In vitro : the PRV was set to 10 , 15 , 20 or 25 cmH2O release pressure and connected to a cuffed tube placed into a box flushed with 66 % N2O in O2 . The cuff pressure was monitored with and without CPRV for 60 min . Experiments were performed four times using two different CPRVs . In vivo : with Institutional Review Board approval , CPRV was studied in 50 children undergoing general anaesthesia with tracheal intubation and standardized anaesthesia technique ( including 66 % N2O in O2 ) and ventilator settings . Patients were randomized into two groups ( with and without CPRV ) . The cuff pressure baseline was 20 cmH2O and CPRV was set to 25 cmH2O . If the cuff pressure exceeded 25 cmH2O , it was manually released to 20 cmH2O . The numbers of deflations in both groups were noted and compared by Mann-Whitney U-test ( P < 0.05 ) . RESULTS In vitro : the cuff pressure exceeded 50 cmH2O after 60 min without CPRV , but did not exceed the settings with CPRV . In vivo : there was no need to manually deflate the cuff in the CPRV group but , in every patient in the control group , three ( two to seven ) deflating manoeuvres were required within the first hour of anaesthesia ( P < 0.0001 ) . CONCLUSION The CPRV allows reliable cuff pressure release at various pressure levels and reliably prevents cuff pressure increases caused by N2O .	[ "Nitrous", "oxide", "diffusion", "into", "tracheal", "tube", "cuffs", "--", "efficacy", "of", "a", "new", "prototype", "cuff", "pressure", "release", "valve", ".", "BACKGROUND", "The", "aim", "of", "this", "study", "was", "to", "evaluate", "the", "performance", "of", "a", "new", "cuff", "pressure", "release", "valve", "(", "CPRV", ")", ",", "in", "which", "the", "release", "pressure", "can", "be", "adjusted", "from", "10", "to", "25", "cmH2O", ",", "particularly", "intended", "to", "control", "pressure", "in", "paediatric", "cuffed", "tracheal", "tubes", "and", "to", "avoid", "cuff", "hyperinflation", "caused", "by", "N2O", "diffusion", ".", "METHODS", "In", "vitro", ":", "the", "PRV", "was", "set", "to", "10", ",", "15", ",", "20", "or", "25", "cmH2O", "release", "pressure", "and", "connected", "to", "a", "cuffed", "tube", "placed", "into", "a", "box", "flushed", "with", "66", "%", "N2O", "in", "O2", ".", "The", "cuff", "pressure", "was", "monitored", "with", "and", "without", "CPRV", "for", "60", "min", ".", "Experiments", "were", "performed", "four", "times", "using", "two", "different", "CPRVs", ".", "In", "vivo", ":", "with", "Institutional", "Review", "Board", "approval", ",", "CPRV", "was", "studied", "in", "50", "children", "undergoing", "general", "anaesthesia", "with", "tracheal", "intubation", "and", "standardized", "anaesthesia", "technique", "(", "including", "66", "%", "N2O", "in", "O2", ")", "and", "ventilator", "settings", ".", "Patients", "were", "randomized", "into", "two", "groups", "(", "with", "and", "without", "CPRV", ")", ".", "The", "cuff", "pressure", "baseline", "was", "20", "cmH2O", "and", "CPRV", "was", "set", "to", "25", "cmH2O", ".", "If", "the", "cuff", "pressure", "exceeded", "25", "cmH2O", ",", "it", "was", "manually", "released", "to", "20", "cmH2O", ".", "The", "numbers", "of", "deflations", "in", "both", "groups", "were", "noted", "and", "compared", "by", "Mann", "-", "Whitney", "U", "-", "test", "(", "P", "<", "0.05", ")", ".", "RESULTS", "In", "vitro", ":", "the", "cuff", "pressure", "exceeded", "50", "cmH2O", "after", "60", "min", "without", "CPRV", ",", "but", "did", "not", "exceed", "the", "settings", "with", "CPRV", ".", "In", "vivo", ":", "there", "was", "no", "need", "to", "manually", "deflate", "the", "cuff", "in", "the", "CPRV", "group", "but", ",", "in", "every", "patient", "in", "the", "control", "group", ",", "three", "(", "two", "to", "seven", ")", "deflating", "manoeuvres", "were", "required", "within", "the", "first", "hour", "of", "anaesthesia", "(", "P", "<", "0.0001", ")", ".", "CONCLUSION", "The", "CPRV", "allows", "reliable", "cuff", "pressure", "release", "at", "various", "pressure", "levels", "and", "reliably", "prevents", "cuff", "pressure", "increases", "caused", "by", "N2O", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Other", "Intervention_Physical", "Outcome_Other", "Participant_Age", "Participant_Sample-size" ]
ulceration is an umlsterm, skin is an umlsterm, patients is an umlsterm, rheumatoid arthritis is an umlsterm, disease is an umlsterm, mortality is an umlsterm, pathogenesis is an umlsterm, ulceration is an umlsterm, causes is an umlsterm, development is an umlsterm, immune complex is an umlsterm, vasculitis is an umlsterm, treatment is an umlsterm, drugs is an umlsterm, side effects is an umlsterm, treatment is an umlsterm, venous insufficiency is an umlsterm, ulceration is an umlsterm, autoimmune disease is an umlsterm, immunosuppressive drugs is an umlsterm, plasmapheresis is an umlsterm, Adjuvant is an umlsterm, treatment is an umlsterm, pain is an umlsterm, analgesics is an umlsterm, blood is an umlsterm, perfusion is an umlsterm, drugs is an umlsterm, therapy is an umlsterm, ulcers is an umlsterm, inflammatory reaction is an umlsterm, surgical is an umlsterm, patients is an umlsterm, muscle is an umlsterm, flaps is an umlsterm, skin grafts is an umlsterm, ulceration is an umlsterm, rheumatoid arthritis is an umlsterm, treatment is an umlsterm, rheumatoid arthritis is an umlsterm, immunotherapy is an umlsterm, monoclonal antibodies is an umlsterm	DerHautarzt.50460406.eng.abstr_task0	Sentence: The appearance of severe ulceration of the skin in patients with rheumatoid arthritis is often associated with a tendency to progression of the underlying disease , involvement of internal organs and increased mortality . In the pathogenesis of such ulceration there are multiple causes for their development , persistence and tendency to poor healing . They include localized or generalized immune complex vasculitis , treatment with anti-inflammatory drugs and their side effects following the treatment , arterial and venous insufficiency , and mechanical factors . The management of severe ulceration requires stabilization of the underlying autoimmune disease , e.g. with high doses of glucocorticosteroids or other immunosuppressive drugs or plasmapheresis . Adjuvant treatment of pain with analgesics , improvement of blood perfusion and anti-inflammatory drugs should accompany the topical therapy of ulcers . After suppression of the local inflammatory reaction surgical intervention becomes necessary in most of the patients , and vascularized muscle flaps should be used in preference to meshgrafts or split skin grafts for extensive ulceration in rheumatoid arthritis . A hopeful perspective in the treatment of severe rheumatoid arthritis might be opened up with immunotherapy using monoclonal antibodies . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]	The appearance of severe ulceration of the skin in patients with rheumatoid arthritis is often associated with a tendency to progression of the underlying disease , involvement of internal organs and increased mortality . In the pathogenesis of such ulceration there are multiple causes for their development , persistence and tendency to poor healing . They include localized or generalized immune complex vasculitis , treatment with anti-inflammatory drugs and their side effects following the treatment , arterial and venous insufficiency , and mechanical factors . The management of severe ulceration requires stabilization of the underlying autoimmune disease , e.g. with high doses of glucocorticosteroids or other immunosuppressive drugs or plasmapheresis . Adjuvant treatment of pain with analgesics , improvement of blood perfusion and anti-inflammatory drugs should accompany the topical therapy of ulcers . After suppression of the local inflammatory reaction surgical intervention becomes necessary in most of the patients , and vascularized muscle flaps should be used in preference to meshgrafts or split skin grafts for extensive ulceration in rheumatoid arthritis . A hopeful perspective in the treatment of severe rheumatoid arthritis might be opened up with immunotherapy using monoclonal antibodies .	[ "The", "appearance", "of", "severe", "ulceration", "of", "the", "skin", "in", "patients", "with", "rheumatoid", "arthritis", "is", "often", "associated", "with", "a", "tendency", "to", "progression", "of", "the", "underlying", "disease", ",", "involvement", "of", "internal", "organs", "and", "increased", "mortality", ".", "In", "the", "pathogenesis", "of", "such", "ulceration", "there", "are", "multiple", "causes", "for", "their", "development", ",", "persistence", "and", "tendency", "to", "poor", "healing", ".", "They", "include", "localized", "or", "generalized", "immune", "complex", "vasculitis", ",", "treatment", "with", "anti", "-", "inflammatory", "drugs", "and", "their", "side", "effects", "following", "the", "treatment", ",", "arterial", "and", "venous", "insufficiency", ",", "and", "mechanical", "factors", ".", "The", "management", "of", "severe", "ulceration", "requires", "stabilization", "of", "the", "underlying", "autoimmune", "disease", ",", "e.g", ".", "with", "high", "doses", "of", "glucocorticosteroids", "or", "other", "immunosuppressive", "drugs", "or", "plasmapheresis", ".", "Adjuvant", "treatment", "of", "pain", "with", "analgesics", ",", "improvement", "of", "blood", "perfusion", "and", "anti", "-", "inflammatory", "drugs", "should", "accompany", "the", "topical", "therapy", "of", "ulcers", ".", "After", "suppression", "of", "the", "local", "inflammatory", "reaction", "surgical", "intervention", "becomes", "necessary", "in", "most", "of", "the", "patients", ",", "and", "vascularized", "muscle", "flaps", "should", "be", "used", "in", "preference", "to", "meshgrafts", "or", "split", "skin", "grafts", "for", "extensive", "ulceration", "in", "rheumatoid", "arthritis", ".", "A", "hopeful", "perspective", "in", "the", "treatment", "of", "severe", "rheumatoid", "arthritis", "might", "be", "opened", "up", "with", "immunotherapy", "using", "monoclonal", "antibodies", "." ]	[ "umlsterm" ]
ulceration is an umlsterm, skin is an umlsterm, patients is an umlsterm, rheumatoid arthritis is an umlsterm, disease is an umlsterm, mortality is an umlsterm, pathogenesis is an umlsterm, ulceration is an umlsterm, causes is an umlsterm, development is an umlsterm, immune complex is an umlsterm, vasculitis is an umlsterm, treatment is an umlsterm, drugs is an umlsterm, side effects is an umlsterm, treatment is an umlsterm, venous insufficiency is an umlsterm, ulceration is an umlsterm, autoimmune disease is an umlsterm, immunosuppressive drugs is an umlsterm, plasmapheresis is an umlsterm, Adjuvant is an umlsterm, treatment is an umlsterm, pain is an umlsterm, analgesics is an umlsterm, blood is an umlsterm, perfusion is an umlsterm, drugs is an umlsterm, therapy is an umlsterm, ulcers is an umlsterm, inflammatory reaction is an umlsterm, surgical is an umlsterm, patients is an umlsterm, muscle is an umlsterm, flaps is an umlsterm, skin grafts is an umlsterm, ulceration is an umlsterm, rheumatoid arthritis is an umlsterm, treatment is an umlsterm, rheumatoid arthritis is an umlsterm, immunotherapy is an umlsterm, monoclonal antibodies is an umlsterm	DerHautarzt.50460406.eng.abstr_task1	Sentence: The appearance of severe ulceration of the skin in patients with rheumatoid arthritis is often associated with a tendency to progression of the underlying disease , involvement of internal organs and increased mortality . In the pathogenesis of such ulceration there are multiple causes for their development , persistence and tendency to poor healing . They include localized or generalized immune complex vasculitis , treatment with anti-inflammatory drugs and their side effects following the treatment , arterial and venous insufficiency , and mechanical factors . The management of severe ulceration requires stabilization of the underlying autoimmune disease , e.g. with high doses of glucocorticosteroids or other immunosuppressive drugs or plasmapheresis . Adjuvant treatment of pain with analgesics , improvement of blood perfusion and anti-inflammatory drugs should accompany the topical therapy of ulcers . After suppression of the local inflammatory reaction surgical intervention becomes necessary in most of the patients , and vascularized muscle flaps should be used in preference to meshgrafts or split skin grafts for extensive ulceration in rheumatoid arthritis . A hopeful perspective in the treatment of severe rheumatoid arthritis might be opened up with immunotherapy using monoclonal antibodies . Instructions: please typing these entity words according to sentence: ulceration, skin, patients, rheumatoid arthritis, disease, mortality, pathogenesis, ulceration, causes, development, immune complex, vasculitis, treatment, drugs, side effects, treatment, venous insufficiency, ulceration, autoimmune disease, immunosuppressive drugs, plasmapheresis, Adjuvant, treatment, pain, analgesics, blood, perfusion, drugs, therapy, ulcers, inflammatory reaction, surgical, patients, muscle, flaps, skin grafts, ulceration, rheumatoid arthritis, treatment, rheumatoid arthritis, immunotherapy, monoclonal antibodies Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]	The appearance of severe ulceration of the skin in patients with rheumatoid arthritis is often associated with a tendency to progression of the underlying disease , involvement of internal organs and increased mortality . In the pathogenesis of such ulceration there are multiple causes for their development , persistence and tendency to poor healing . They include localized or generalized immune complex vasculitis , treatment with anti-inflammatory drugs and their side effects following the treatment , arterial and venous insufficiency , and mechanical factors . The management of severe ulceration requires stabilization of the underlying autoimmune disease , e.g. with high doses of glucocorticosteroids or other immunosuppressive drugs or plasmapheresis . Adjuvant treatment of pain with analgesics , improvement of blood perfusion and anti-inflammatory drugs should accompany the topical therapy of ulcers . After suppression of the local inflammatory reaction surgical intervention becomes necessary in most of the patients , and vascularized muscle flaps should be used in preference to meshgrafts or split skin grafts for extensive ulceration in rheumatoid arthritis . A hopeful perspective in the treatment of severe rheumatoid arthritis might be opened up with immunotherapy using monoclonal antibodies .	[ "The", "appearance", "of", "severe", "ulceration", "of", "the", "skin", "in", "patients", "with", "rheumatoid", "arthritis", "is", "often", "associated", "with", "a", "tendency", "to", "progression", "of", "the", "underlying", "disease", ",", "involvement", "of", "internal", "organs", "and", "increased", "mortality", ".", "In", "the", "pathogenesis", "of", "such", "ulceration", "there", "are", "multiple", "causes", "for", "their", "development", ",", "persistence", "and", "tendency", "to", "poor", "healing", ".", "They", "include", "localized", "or", "generalized", "immune", "complex", "vasculitis", ",", "treatment", "with", "anti", "-", "inflammatory", "drugs", "and", "their", "side", "effects", "following", "the", "treatment", ",", "arterial", "and", "venous", "insufficiency", ",", "and", "mechanical", "factors", ".", "The", "management", "of", "severe", "ulceration", "requires", "stabilization", "of", "the", "underlying", "autoimmune", "disease", ",", "e.g", ".", "with", "high", "doses", "of", "glucocorticosteroids", "or", "other", "immunosuppressive", "drugs", "or", "plasmapheresis", ".", "Adjuvant", "treatment", "of", "pain", "with", "analgesics", ",", "improvement", "of", "blood", "perfusion", "and", "anti", "-", "inflammatory", "drugs", "should", "accompany", "the", "topical", "therapy", "of", "ulcers", ".", "After", "suppression", "of", "the", "local", "inflammatory", "reaction", "surgical", "intervention", "becomes", "necessary", "in", "most", "of", "the", "patients", ",", "and", "vascularized", "muscle", "flaps", "should", "be", "used", "in", "preference", "to", "meshgrafts", "or", "split", "skin", "grafts", "for", "extensive", "ulceration", "in", "rheumatoid", "arthritis", ".", "A", "hopeful", "perspective", "in", "the", "treatment", "of", "severe", "rheumatoid", "arthritis", "might", "be", "opened", "up", "with", "immunotherapy", "using", "monoclonal", "antibodies", "." ]	[ "umlsterm" ]

Torsionskontrolle is an umlsterm, Unterschenkelfrakturen is an umlsterm, Torsionsabweichungen is an umlsterm, Analyse is an umlsterm, Beingeometrie is an umlsterm, Korrekturosteotomie is an umlsterm, -technik is an umlsterm, Torsionskorrekturen is an umlsterm, Marknagel is an umlsterm, Torsionsabweichungen is an umlsterm, Korrekturosteotomien is an umlsterm, Oberschenkel is an umlsterm, Korrekturosteotomien is an umlsterm, Torsionsabweichungen is an umlsterm, Oberschenkel is an umlsterm, Torsionstoleranz is an umlsterm, Patienten is an umlsterm, Mark - nagel is an umlsterm

DerUnfallchirurg.71000029.ger.abstr_task1

Sentence: Die mangelhafte intraoperative Torsionskontrolle gilt als typisches Problem von Marknagel-osteosynthesen von Ober- und Unterschenkelfrakturen . Posttraumatische Torsionsabweichungen fuehren zu klinischen Beschwerden , wenn der rotatorische 0-Durchgang , entsprechend der Neutral-0-Methode nicht erreicht oder durchschritten werden kann . Nur auf der Grundlage einer gewissenhaften klinischen , uebersichtsradiographischen und computertomographischen Analyse der Beingeometrie koennen Indikationsstellung und Planung einer Korrekturosteotomie erfolgen . Operationstaktik und -technik von Torsionskorrekturen ueber dem liegenden Marknagel werden beschrieben . Die intraindividuellen Torsionsabweichungen vor den 15 Korrekturosteotomien am Oberschenkel betrugen 33 Grad ( -37/+50 ) und vor den 7 Korrekturosteotomien am Unterschenkel 23 Grad ( -21/ +29 ) . Negative Vorzeichen beschreiben hierbei Innentorsionsabweichungen , positive Vorzeichen Aussentorsionsabweichungen . Postoperativ lagen die intraindividuellen Torsionsabweichungen am Oberschenkel bei 6 Grad ( -3/+14 ) und am Unterschenkel bei 7 Grad ( +3/+12 ) und somit im Bereich der physiologischen Torsionstoleranz von 15 Grad . Bei 4 Patienten mit Femurverkuerzung wurde zusaetzlich eine Laengenkorrektur ueber dem liegenden Mark-nagel durchgefuehrt , davon 3 mal einzeitig durch Interposition von allogener Spongiosa und einmal durch kontinuierliche Kallusdistraktion mittels Fixateur externe . Instructions: please typing these entity words according to sentence: Torsionskontrolle, Unterschenkelfrakturen, Torsionsabweichungen, Analyse, Beingeometrie, Korrekturosteotomie, -technik, Torsionskorrekturen, Marknagel, Torsionsabweichungen, Korrekturosteotomien, Oberschenkel, Korrekturosteotomien, Torsionsabweichungen, Oberschenkel, Torsionstoleranz, Patienten, Mark - nagel Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die mangelhafte intraoperative Torsionskontrolle gilt als typisches Problem von Marknagel-osteosynthesen von Ober- und Unterschenkelfrakturen . Posttraumatische Torsionsabweichungen fuehren zu klinischen Beschwerden , wenn der rotatorische 0-Durchgang , entsprechend der Neutral-0-Methode nicht erreicht oder durchschritten werden kann . Nur auf der Grundlage einer gewissenhaften klinischen , uebersichtsradiographischen und computertomographischen Analyse der Beingeometrie koennen Indikationsstellung und Planung einer Korrekturosteotomie erfolgen . Operationstaktik und -technik von Torsionskorrekturen ueber dem liegenden Marknagel werden beschrieben . Die intraindividuellen Torsionsabweichungen vor den 15 Korrekturosteotomien am Oberschenkel betrugen 33 Grad ( -37/+50 ) und vor den 7 Korrekturosteotomien am Unterschenkel 23 Grad ( -21/ +29 ) . Negative Vorzeichen beschreiben hierbei Innentorsionsabweichungen , positive Vorzeichen Aussentorsionsabweichungen . Postoperativ lagen die intraindividuellen Torsionsabweichungen am Oberschenkel bei 6 Grad ( -3/+14 ) und am Unterschenkel bei 7 Grad ( +3/+12 ) und somit im Bereich der physiologischen Torsionstoleranz von 15 Grad . Bei 4 Patienten mit Femurverkuerzung wurde zusaetzlich eine Laengenkorrektur ueber dem liegenden Mark-nagel durchgefuehrt , davon 3 mal einzeitig durch Interposition von allogener Spongiosa und einmal durch kontinuierliche Kallusdistraktion mittels Fixateur externe .

[ "Die", "mangelhafte", "intraoperative", "Torsionskontrolle", "gilt", "als", "typisches", "Problem", "von", "Marknagel", "-", "osteosynthesen", "von", "Ober-", "und", "Unterschenkelfrakturen", ".", "Posttraumatische", "Torsionsabweichungen", "fuehren", "zu", "klinischen", "Beschwerden", ",", "wenn", "der", "rotatorische", "0-Durchgang", ",", "entsprechend", "der", "Neutral-0-Methode", "nicht", "erreicht", "oder", "durchschritten", "werden", "kann", ".", "Nur", "auf", "der", "Grundlage", "einer", "gewissenhaften", "klinischen", ",", "uebersichtsradiographischen", "und", "computertomographischen", "Analyse", "der", "Beingeometrie", "koennen", "Indikationsstellung", "und", "Planung", "einer", "Korrekturosteotomie", "erfolgen", ".", "Operationstaktik", "und", "-technik", "von", "Torsionskorrekturen", "ueber", "dem", "liegenden", "Marknagel", "werden", "beschrieben", ".", "Die", "intraindividuellen", "Torsionsabweichungen", "vor", "den", "15", "Korrekturosteotomien", "am", "Oberschenkel", "betrugen", "33", "Grad", "(", "-37/+50", ")", "und", "vor", "den", "7", "Korrekturosteotomien", "am", "Unterschenkel", "23", "Grad", "(", "-21/", "+29", ")", ".", "Negative", "Vorzeichen", "beschreiben", "hierbei", "Innentorsionsabweichungen", ",", "positive", "Vorzeichen", "Aussentorsionsabweichungen", ".", "Postoperativ", "lagen", "die", "intraindividuellen", "Torsionsabweichungen", "am", "Oberschenkel", "bei", "6", "Grad", "(", "-3/+14", ")", "und", "am", "Unterschenkel", "bei", "7", "Grad", "(", "+3/+12", ")", "und", "somit", "im", "Bereich", "der", "physiologischen", "Torsionstoleranz", "von", "15", "Grad", ".", "Bei", "4", "Patienten", "mit", "Femurverkuerzung", "wurde", "zusaetzlich", "eine", "Laengenkorrektur", "ueber", "dem", "liegenden", "Mark", "-", "nagel", "durchgefuehrt", ",", "davon", "3", "mal", "einzeitig", "durch", "Interposition", "von", "allogener", "Spongiosa", "und", "einmal", "durch", "kontinuierliche", "Kallusdistraktion", "mittels", "Fixateur", "externe", "." ]

[ "umlsterm" ]

Torsionskontrolle, Unterschenkelfrakturen, Torsionsabweichungen, Analyse, Beingeometrie, Korrekturosteotomie, -technik, Torsionskorrekturen, Marknagel, Torsionsabweichungen, Korrekturosteotomien, Oberschenkel, Korrekturosteotomien, Torsionsabweichungen, Oberschenkel, Torsionstoleranz, Patienten, Mark - nagel

DerUnfallchirurg.71000029.ger.abstr_task2

Sentence: Die mangelhafte intraoperative Torsionskontrolle gilt als typisches Problem von Marknagel-osteosynthesen von Ober- und Unterschenkelfrakturen . Posttraumatische Torsionsabweichungen fuehren zu klinischen Beschwerden , wenn der rotatorische 0-Durchgang , entsprechend der Neutral-0-Methode nicht erreicht oder durchschritten werden kann . Nur auf der Grundlage einer gewissenhaften klinischen , uebersichtsradiographischen und computertomographischen Analyse der Beingeometrie koennen Indikationsstellung und Planung einer Korrekturosteotomie erfolgen . Operationstaktik und -technik von Torsionskorrekturen ueber dem liegenden Marknagel werden beschrieben . Die intraindividuellen Torsionsabweichungen vor den 15 Korrekturosteotomien am Oberschenkel betrugen 33 Grad ( -37/+50 ) und vor den 7 Korrekturosteotomien am Unterschenkel 23 Grad ( -21/ +29 ) . Negative Vorzeichen beschreiben hierbei Innentorsionsabweichungen , positive Vorzeichen Aussentorsionsabweichungen . Postoperativ lagen die intraindividuellen Torsionsabweichungen am Oberschenkel bei 6 Grad ( -3/+14 ) und am Unterschenkel bei 7 Grad ( +3/+12 ) und somit im Bereich der physiologischen Torsionstoleranz von 15 Grad . Bei 4 Patienten mit Femurverkuerzung wurde zusaetzlich eine Laengenkorrektur ueber dem liegenden Mark-nagel durchgefuehrt , davon 3 mal einzeitig durch Interposition von allogener Spongiosa und einmal durch kontinuierliche Kallusdistraktion mittels Fixateur externe . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die mangelhafte intraoperative Torsionskontrolle gilt als typisches Problem von Marknagel-osteosynthesen von Ober- und Unterschenkelfrakturen . Posttraumatische Torsionsabweichungen fuehren zu klinischen Beschwerden , wenn der rotatorische 0-Durchgang , entsprechend der Neutral-0-Methode nicht erreicht oder durchschritten werden kann . Nur auf der Grundlage einer gewissenhaften klinischen , uebersichtsradiographischen und computertomographischen Analyse der Beingeometrie koennen Indikationsstellung und Planung einer Korrekturosteotomie erfolgen . Operationstaktik und -technik von Torsionskorrekturen ueber dem liegenden Marknagel werden beschrieben . Die intraindividuellen Torsionsabweichungen vor den 15 Korrekturosteotomien am Oberschenkel betrugen 33 Grad ( -37/+50 ) und vor den 7 Korrekturosteotomien am Unterschenkel 23 Grad ( -21/ +29 ) . Negative Vorzeichen beschreiben hierbei Innentorsionsabweichungen , positive Vorzeichen Aussentorsionsabweichungen . Postoperativ lagen die intraindividuellen Torsionsabweichungen am Oberschenkel bei 6 Grad ( -3/+14 ) und am Unterschenkel bei 7 Grad ( +3/+12 ) und somit im Bereich der physiologischen Torsionstoleranz von 15 Grad . Bei 4 Patienten mit Femurverkuerzung wurde zusaetzlich eine Laengenkorrektur ueber dem liegenden Mark-nagel durchgefuehrt , davon 3 mal einzeitig durch Interposition von allogener Spongiosa und einmal durch kontinuierliche Kallusdistraktion mittels Fixateur externe .

[ "Die", "mangelhafte", "intraoperative", "Torsionskontrolle", "gilt", "als", "typisches", "Problem", "von", "Marknagel", "-", "osteosynthesen", "von", "Ober-", "und", "Unterschenkelfrakturen", ".", "Posttraumatische", "Torsionsabweichungen", "fuehren", "zu", "klinischen", "Beschwerden", ",", "wenn", "der", "rotatorische", "0-Durchgang", ",", "entsprechend", "der", "Neutral-0-Methode", "nicht", "erreicht", "oder", "durchschritten", "werden", "kann", ".", "Nur", "auf", "der", "Grundlage", "einer", "gewissenhaften", "klinischen", ",", "uebersichtsradiographischen", "und", "computertomographischen", "Analyse", "der", "Beingeometrie", "koennen", "Indikationsstellung", "und", "Planung", "einer", "Korrekturosteotomie", "erfolgen", ".", "Operationstaktik", "und", "-technik", "von", "Torsionskorrekturen", "ueber", "dem", "liegenden", "Marknagel", "werden", "beschrieben", ".", "Die", "intraindividuellen", "Torsionsabweichungen", "vor", "den", "15", "Korrekturosteotomien", "am", "Oberschenkel", "betrugen", "33", "Grad", "(", "-37/+50", ")", "und", "vor", "den", "7", "Korrekturosteotomien", "am", "Unterschenkel", "23", "Grad", "(", "-21/", "+29", ")", ".", "Negative", "Vorzeichen", "beschreiben", "hierbei", "Innentorsionsabweichungen", ",", "positive", "Vorzeichen", "Aussentorsionsabweichungen", ".", "Postoperativ", "lagen", "die", "intraindividuellen", "Torsionsabweichungen", "am", "Oberschenkel", "bei", "6", "Grad", "(", "-3/+14", ")", "und", "am", "Unterschenkel", "bei", "7", "Grad", "(", "+3/+12", ")", "und", "somit", "im", "Bereich", "der", "physiologischen", "Torsionstoleranz", "von", "15", "Grad", ".", "Bei", "4", "Patienten", "mit", "Femurverkuerzung", "wurde", "zusaetzlich", "eine", "Laengenkorrektur", "ueber", "dem", "liegenden", "Mark", "-", "nagel", "durchgefuehrt", ",", "davon", "3", "mal", "einzeitig", "durch", "Interposition", "von", "allogener", "Spongiosa", "und", "einmal", "durch", "kontinuierliche", "Kallusdistraktion", "mittels", "Fixateur", "externe", "." ]

[ "umlsterm" ]

Entscheidungsbaeume is an umlsterm, Radiologie is an umlsterm, Erwachsenenradiologie is an umlsterm, Computertomographie is an umlsterm, Nieren- is an umlsterm, Harnwegsuntersuchung is an umlsterm, Ultraschall is an umlsterm, Erwachsenenalter is an umlsterm, Szintigraphie is an umlsterm, Magnetresonanztomographie is an umlsterm, Standardsituationen is an umlsterm, Kinderradiologie is an umlsterm, Harnwegspathologie is an umlsterm, Harntransportstoerung is an umlsterm, Harnwegsinfektion is an umlsterm

DerRadiologe.90390415.ger.abstr_task0

Sentence: Die diagnostischen Entscheidungsbaeume in der Paediatrischen Radiologie unterscheiden sich oft erheblich von denen der Erwachsenenradiologie . Die Ursache hierfuer besteht im unterschiedlichen Erkrankungsspektrum , in den unterschiedlichen therapeutischen Konsequenzen , die aus einem erhobenen Befund gezogen werden und auch im unterschiedlichen Stellenwert der bildgebenden Verfahren . Abgesehen vom schweren Abdominaltrauma , das primaer mittels Computertomographie ( CT ) untersucht werden muss , beginnt jede Nieren- und Harnwegsuntersuchung mit einer Ultraschall ( US ) -untersuchung Die Entscheidung , ob ein normaler oder ein pathologischer Befund der Bildgebung vorliegt , ist fast immer mittels US zu treffen . Die Aussagekraft und damit der diagnostische Stellenwert des US unterscheiden sich infolge der Moeglichkeit , hoeherfrequente Schallsysteme mit exzellenter Aufloesung zu verwenden , erheblich von der Situation im Erwachsenenalter . Erst in Kenntnis des sonographischen Befundes wird der Ablauf der weiteren Bildgebung ( Szintigraphie Roentgen , Magnetresonanztomographie ( , MRT ) und sehr selten CT ) festgelegt . Nachfolgend sollen , ausgehend von den wichtigsten klinischen Symptomen , die diagnostischen Flussschemata fuer drei haeufige Standardsituationen in der Kinderradiologie dargestellt werden : Praenatal erkannte Harnwegspathologie Harntransportstoerung und Harnwegsinfektion . , Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Die diagnostischen Entscheidungsbaeume in der Paediatrischen Radiologie unterscheiden sich oft erheblich von denen der Erwachsenenradiologie . Die Ursache hierfuer besteht im unterschiedlichen Erkrankungsspektrum , in den unterschiedlichen therapeutischen Konsequenzen , die aus einem erhobenen Befund gezogen werden und auch im unterschiedlichen Stellenwert der bildgebenden Verfahren . Abgesehen vom schweren Abdominaltrauma , das primaer mittels Computertomographie ( CT ) untersucht werden muss , beginnt jede Nieren- und Harnwegsuntersuchung mit einer Ultraschall ( US ) -untersuchung Die Entscheidung , ob ein normaler oder ein pathologischer Befund der Bildgebung vorliegt , ist fast immer mittels US zu treffen . Die Aussagekraft und damit der diagnostische Stellenwert des US unterscheiden sich infolge der Moeglichkeit , hoeherfrequente Schallsysteme mit exzellenter Aufloesung zu verwenden , erheblich von der Situation im Erwachsenenalter . Erst in Kenntnis des sonographischen Befundes wird der Ablauf der weiteren Bildgebung ( Szintigraphie Roentgen , Magnetresonanztomographie ( , MRT ) und sehr selten CT ) festgelegt . Nachfolgend sollen , ausgehend von den wichtigsten klinischen Symptomen , die diagnostischen Flussschemata fuer drei haeufige Standardsituationen in der Kinderradiologie dargestellt werden : Praenatal erkannte Harnwegspathologie Harntransportstoerung und Harnwegsinfektion . ,

[ "Die", "diagnostischen", "Entscheidungsbaeume", "in", "der", "Paediatrischen", "Radiologie", "unterscheiden", "sich", "oft", "erheblich", "von", "denen", "der", "Erwachsenenradiologie", ".", "Die", "Ursache", "hierfuer", "besteht", "im", "unterschiedlichen", "Erkrankungsspektrum", ",", "in", "den", "unterschiedlichen", "therapeutischen", "Konsequenzen", ",", "die", "aus", "einem", "erhobenen", "Befund", "gezogen", "werden", "und", "auch", "im", "unterschiedlichen", "Stellenwert", "der", "bildgebenden", "Verfahren", ".", "Abgesehen", "vom", "schweren", "Abdominaltrauma", ",", "das", "primaer", "mittels", "Computertomographie", "(", "CT", ")", "untersucht", "werden", "muss", ",", "beginnt", "jede", "Nieren-", "und", "Harnwegsuntersuchung", "mit", "einer", "Ultraschall", "(", "US", ")", "-untersuchung", "Die", "Entscheidung", ",", "ob", "ein", "normaler", "oder", "ein", "pathologischer", "Befund", "der", "Bildgebung", "vorliegt", ",", "ist", "fast", "immer", "mittels", "US", "zu", "treffen", ".", "Die", "Aussagekraft", "und", "damit", "der", "diagnostische", "Stellenwert", "des", "US", "unterscheiden", "sich", "infolge", "der", "Moeglichkeit", ",", "hoeherfrequente", "Schallsysteme", "mit", "exzellenter", "Aufloesung", "zu", "verwenden", ",", "erheblich", "von", "der", "Situation", "im", "Erwachsenenalter", ".", "Erst", "in", "Kenntnis", "des", "sonographischen", "Befundes", "wird", "der", "Ablauf", "der", "weiteren", "Bildgebung", "(", "Szintigraphie", "Roentgen", ",", "Magnetresonanztomographie", "(", ",", "MRT", ")", "und", "sehr", "selten", "CT", ")", "festgelegt", ".", "Nachfolgend", "sollen", ",", "ausgehend", "von", "den", "wichtigsten", "klinischen", "Symptomen", ",", "die", "diagnostischen", "Flussschemata", "fuer", "drei", "haeufige", "Standardsituationen", "in", "der", "Kinderradiologie", "dargestellt", "werden", ":", "Praenatal", "erkannte", "Harnwegspathologie", "Harntransportstoerung", "und", "Harnwegsinfektion", ".", "," ]

[ "umlsterm" ]

Entscheidungsbaeume is an umlsterm, Radiologie is an umlsterm, Erwachsenenradiologie is an umlsterm, Computertomographie is an umlsterm, Nieren- is an umlsterm, Harnwegsuntersuchung is an umlsterm, Ultraschall is an umlsterm, Erwachsenenalter is an umlsterm, Szintigraphie is an umlsterm, Magnetresonanztomographie is an umlsterm, Standardsituationen is an umlsterm, Kinderradiologie is an umlsterm, Harnwegspathologie is an umlsterm, Harntransportstoerung is an umlsterm, Harnwegsinfektion is an umlsterm

DerRadiologe.90390415.ger.abstr_task1

Sentence: Die diagnostischen Entscheidungsbaeume in der Paediatrischen Radiologie unterscheiden sich oft erheblich von denen der Erwachsenenradiologie . Die Ursache hierfuer besteht im unterschiedlichen Erkrankungsspektrum , in den unterschiedlichen therapeutischen Konsequenzen , die aus einem erhobenen Befund gezogen werden und auch im unterschiedlichen Stellenwert der bildgebenden Verfahren . Abgesehen vom schweren Abdominaltrauma , das primaer mittels Computertomographie ( CT ) untersucht werden muss , beginnt jede Nieren- und Harnwegsuntersuchung mit einer Ultraschall ( US ) -untersuchung Die Entscheidung , ob ein normaler oder ein pathologischer Befund der Bildgebung vorliegt , ist fast immer mittels US zu treffen . Die Aussagekraft und damit der diagnostische Stellenwert des US unterscheiden sich infolge der Moeglichkeit , hoeherfrequente Schallsysteme mit exzellenter Aufloesung zu verwenden , erheblich von der Situation im Erwachsenenalter . Erst in Kenntnis des sonographischen Befundes wird der Ablauf der weiteren Bildgebung ( Szintigraphie Roentgen , Magnetresonanztomographie ( , MRT ) und sehr selten CT ) festgelegt . Nachfolgend sollen , ausgehend von den wichtigsten klinischen Symptomen , die diagnostischen Flussschemata fuer drei haeufige Standardsituationen in der Kinderradiologie dargestellt werden : Praenatal erkannte Harnwegspathologie Harntransportstoerung und Harnwegsinfektion . , Instructions: please typing these entity words according to sentence: Entscheidungsbaeume, Radiologie, Erwachsenenradiologie, Computertomographie, Nieren-, Harnwegsuntersuchung, Ultraschall, Erwachsenenalter, Szintigraphie, Magnetresonanztomographie, Standardsituationen, Kinderradiologie, Harnwegspathologie, Harntransportstoerung, Harnwegsinfektion Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Die diagnostischen Entscheidungsbaeume in der Paediatrischen Radiologie unterscheiden sich oft erheblich von denen der Erwachsenenradiologie . Die Ursache hierfuer besteht im unterschiedlichen Erkrankungsspektrum , in den unterschiedlichen therapeutischen Konsequenzen , die aus einem erhobenen Befund gezogen werden und auch im unterschiedlichen Stellenwert der bildgebenden Verfahren . Abgesehen vom schweren Abdominaltrauma , das primaer mittels Computertomographie ( CT ) untersucht werden muss , beginnt jede Nieren- und Harnwegsuntersuchung mit einer Ultraschall ( US ) -untersuchung Die Entscheidung , ob ein normaler oder ein pathologischer Befund der Bildgebung vorliegt , ist fast immer mittels US zu treffen . Die Aussagekraft und damit der diagnostische Stellenwert des US unterscheiden sich infolge der Moeglichkeit , hoeherfrequente Schallsysteme mit exzellenter Aufloesung zu verwenden , erheblich von der Situation im Erwachsenenalter . Erst in Kenntnis des sonographischen Befundes wird der Ablauf der weiteren Bildgebung ( Szintigraphie Roentgen , Magnetresonanztomographie ( , MRT ) und sehr selten CT ) festgelegt . Nachfolgend sollen , ausgehend von den wichtigsten klinischen Symptomen , die diagnostischen Flussschemata fuer drei haeufige Standardsituationen in der Kinderradiologie dargestellt werden : Praenatal erkannte Harnwegspathologie Harntransportstoerung und Harnwegsinfektion . ,

[ "Die", "diagnostischen", "Entscheidungsbaeume", "in", "der", "Paediatrischen", "Radiologie", "unterscheiden", "sich", "oft", "erheblich", "von", "denen", "der", "Erwachsenenradiologie", ".", "Die", "Ursache", "hierfuer", "besteht", "im", "unterschiedlichen", "Erkrankungsspektrum", ",", "in", "den", "unterschiedlichen", "therapeutischen", "Konsequenzen", ",", "die", "aus", "einem", "erhobenen", "Befund", "gezogen", "werden", "und", "auch", "im", "unterschiedlichen", "Stellenwert", "der", "bildgebenden", "Verfahren", ".", "Abgesehen", "vom", "schweren", "Abdominaltrauma", ",", "das", "primaer", "mittels", "Computertomographie", "(", "CT", ")", "untersucht", "werden", "muss", ",", "beginnt", "jede", "Nieren-", "und", "Harnwegsuntersuchung", "mit", "einer", "Ultraschall", "(", "US", ")", "-untersuchung", "Die", "Entscheidung", ",", "ob", "ein", "normaler", "oder", "ein", "pathologischer", "Befund", "der", "Bildgebung", "vorliegt", ",", "ist", "fast", "immer", "mittels", "US", "zu", "treffen", ".", "Die", "Aussagekraft", "und", "damit", "der", "diagnostische", "Stellenwert", "des", "US", "unterscheiden", "sich", "infolge", "der", "Moeglichkeit", ",", "hoeherfrequente", "Schallsysteme", "mit", "exzellenter", "Aufloesung", "zu", "verwenden", ",", "erheblich", "von", "der", "Situation", "im", "Erwachsenenalter", ".", "Erst", "in", "Kenntnis", "des", "sonographischen", "Befundes", "wird", "der", "Ablauf", "der", "weiteren", "Bildgebung", "(", "Szintigraphie", "Roentgen", ",", "Magnetresonanztomographie", "(", ",", "MRT", ")", "und", "sehr", "selten", "CT", ")", "festgelegt", ".", "Nachfolgend", "sollen", ",", "ausgehend", "von", "den", "wichtigsten", "klinischen", "Symptomen", ",", "die", "diagnostischen", "Flussschemata", "fuer", "drei", "haeufige", "Standardsituationen", "in", "der", "Kinderradiologie", "dargestellt", "werden", ":", "Praenatal", "erkannte", "Harnwegspathologie", "Harntransportstoerung", "und", "Harnwegsinfektion", ".", "," ]

[ "umlsterm" ]

Entscheidungsbaeume, Radiologie, Erwachsenenradiologie, Computertomographie, Nieren-, Harnwegsuntersuchung, Ultraschall, Erwachsenenalter, Szintigraphie, Magnetresonanztomographie, Standardsituationen, Kinderradiologie, Harnwegspathologie, Harntransportstoerung, Harnwegsinfektion

DerRadiologe.90390415.ger.abstr_task2

Sentence: Die diagnostischen Entscheidungsbaeume in der Paediatrischen Radiologie unterscheiden sich oft erheblich von denen der Erwachsenenradiologie . Die Ursache hierfuer besteht im unterschiedlichen Erkrankungsspektrum , in den unterschiedlichen therapeutischen Konsequenzen , die aus einem erhobenen Befund gezogen werden und auch im unterschiedlichen Stellenwert der bildgebenden Verfahren . Abgesehen vom schweren Abdominaltrauma , das primaer mittels Computertomographie ( CT ) untersucht werden muss , beginnt jede Nieren- und Harnwegsuntersuchung mit einer Ultraschall ( US ) -untersuchung Die Entscheidung , ob ein normaler oder ein pathologischer Befund der Bildgebung vorliegt , ist fast immer mittels US zu treffen . Die Aussagekraft und damit der diagnostische Stellenwert des US unterscheiden sich infolge der Moeglichkeit , hoeherfrequente Schallsysteme mit exzellenter Aufloesung zu verwenden , erheblich von der Situation im Erwachsenenalter . Erst in Kenntnis des sonographischen Befundes wird der Ablauf der weiteren Bildgebung ( Szintigraphie Roentgen , Magnetresonanztomographie ( , MRT ) und sehr selten CT ) festgelegt . Nachfolgend sollen , ausgehend von den wichtigsten klinischen Symptomen , die diagnostischen Flussschemata fuer drei haeufige Standardsituationen in der Kinderradiologie dargestellt werden : Praenatal erkannte Harnwegspathologie Harntransportstoerung und Harnwegsinfektion . , Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Die diagnostischen Entscheidungsbaeume in der Paediatrischen Radiologie unterscheiden sich oft erheblich von denen der Erwachsenenradiologie . Die Ursache hierfuer besteht im unterschiedlichen Erkrankungsspektrum , in den unterschiedlichen therapeutischen Konsequenzen , die aus einem erhobenen Befund gezogen werden und auch im unterschiedlichen Stellenwert der bildgebenden Verfahren . Abgesehen vom schweren Abdominaltrauma , das primaer mittels Computertomographie ( CT ) untersucht werden muss , beginnt jede Nieren- und Harnwegsuntersuchung mit einer Ultraschall ( US ) -untersuchung Die Entscheidung , ob ein normaler oder ein pathologischer Befund der Bildgebung vorliegt , ist fast immer mittels US zu treffen . Die Aussagekraft und damit der diagnostische Stellenwert des US unterscheiden sich infolge der Moeglichkeit , hoeherfrequente Schallsysteme mit exzellenter Aufloesung zu verwenden , erheblich von der Situation im Erwachsenenalter . Erst in Kenntnis des sonographischen Befundes wird der Ablauf der weiteren Bildgebung ( Szintigraphie Roentgen , Magnetresonanztomographie ( , MRT ) und sehr selten CT ) festgelegt . Nachfolgend sollen , ausgehend von den wichtigsten klinischen Symptomen , die diagnostischen Flussschemata fuer drei haeufige Standardsituationen in der Kinderradiologie dargestellt werden : Praenatal erkannte Harnwegspathologie Harntransportstoerung und Harnwegsinfektion . ,

[ "Die", "diagnostischen", "Entscheidungsbaeume", "in", "der", "Paediatrischen", "Radiologie", "unterscheiden", "sich", "oft", "erheblich", "von", "denen", "der", "Erwachsenenradiologie", ".", "Die", "Ursache", "hierfuer", "besteht", "im", "unterschiedlichen", "Erkrankungsspektrum", ",", "in", "den", "unterschiedlichen", "therapeutischen", "Konsequenzen", ",", "die", "aus", "einem", "erhobenen", "Befund", "gezogen", "werden", "und", "auch", "im", "unterschiedlichen", "Stellenwert", "der", "bildgebenden", "Verfahren", ".", "Abgesehen", "vom", "schweren", "Abdominaltrauma", ",", "das", "primaer", "mittels", "Computertomographie", "(", "CT", ")", "untersucht", "werden", "muss", ",", "beginnt", "jede", "Nieren-", "und", "Harnwegsuntersuchung", "mit", "einer", "Ultraschall", "(", "US", ")", "-untersuchung", "Die", "Entscheidung", ",", "ob", "ein", "normaler", "oder", "ein", "pathologischer", "Befund", "der", "Bildgebung", "vorliegt", ",", "ist", "fast", "immer", "mittels", "US", "zu", "treffen", ".", "Die", "Aussagekraft", "und", "damit", "der", "diagnostische", "Stellenwert", "des", "US", "unterscheiden", "sich", "infolge", "der", "Moeglichkeit", ",", "hoeherfrequente", "Schallsysteme", "mit", "exzellenter", "Aufloesung", "zu", "verwenden", ",", "erheblich", "von", "der", "Situation", "im", "Erwachsenenalter", ".", "Erst", "in", "Kenntnis", "des", "sonographischen", "Befundes", "wird", "der", "Ablauf", "der", "weiteren", "Bildgebung", "(", "Szintigraphie", "Roentgen", ",", "Magnetresonanztomographie", "(", ",", "MRT", ")", "und", "sehr", "selten", "CT", ")", "festgelegt", ".", "Nachfolgend", "sollen", ",", "ausgehend", "von", "den", "wichtigsten", "klinischen", "Symptomen", ",", "die", "diagnostischen", "Flussschemata", "fuer", "drei", "haeufige", "Standardsituationen", "in", "der", "Kinderradiologie", "dargestellt", "werden", ":", "Praenatal", "erkannte", "Harnwegspathologie", "Harntransportstoerung", "und", "Harnwegsinfektion", ".", "," ]

[ "umlsterm" ]

FEV1 is a Measurement, > = 80 % is a Value, FEV1 is a Measurement, < 20 % of predicted value is a Value, post - bronchodilator is a Qualifier, History is a Observation, lung transplant is a Procedure, lung surgery is a Procedure, within the past two years is a Temporal, thoracic surgery waiting list is a Observation, exacerbation is a Condition, less than 6 weeks prior to screening / re - screening visit is a Temporal, Clinically significant is a Qualifier, intercurrent illnesses is a Condition, except for is a Negation, respiratory or liver disease is a Scope, secondary to AAT deficiency is a Qualifier, cardiac , hepatic , renal , endocrine , neurological , hematological , neoplastic , immunological , skeletal or other is a Scope, Active smoking is a Condition, during the last 12 months from screening date is a Temporal, Pregnancy is a Condition, lactation is a Condition, Woman is a Person, child - bearing potential is a Condition, not is a Negation, adequate is a Qualifier, contraception is a Procedure, deemed reliable by the investigator is a Qualifier, psychiatric/ mental disorder or any other medical disorder is a Scope, impair the patient 's ability to give informed consent is a Observation, ongoing is a Temporal, viral infection is a Condition, HCV , HBV and / or HIV is a Scope, alcohol abuse is a Condition, history is a Observation, alcohol abuse or illegal and / or legally prescribed drugs is a Scope, IgA Deficiency is a Condition, History is a Observation, life threatening allergy , anaphylactic reaction , or systemic response to human plasma derived products is a Scope

NCT01217671_exc_task0

Sentence: FEV1 >= 80% or FEV1 < 20% of predicted value post-bronchodilator. FEV1/SVC>=70% History of lung transplant. Any lung surgery within the past two years. On any thoracic surgery waiting list. End of last exacerbation less than 6 weeks prior to screening/re-screening visit. Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor. Active smoking during the last 12 months from screening date. Pregnancy or lactation. Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. Evidence of ongoing viral infection with HCV, HBV and/or HIV. Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs. IgA Deficiency History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. Participation in another clinical trial within 30 days prior to baseline visit. Inability to attend scheduled clinic visits and/or comply with the study protocol. Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Observation, Procedure, Negation, Scope, Measurement

[ "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "O", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Condition", "O", "B-Condition", "O", "O", "B-Person", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "B-Negation", "O", "B-Qualifier", "B-Procedure", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

FEV1 >= 80% or FEV1 < 20% of predicted value post-bronchodilator. FEV1/SVC>=70% History of lung transplant. Any lung surgery within the past two years. On any thoracic surgery waiting list. End of last exacerbation less than 6 weeks prior to screening/re-screening visit. Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor. Active smoking during the last 12 months from screening date. Pregnancy or lactation. Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. Evidence of ongoing viral infection with HCV, HBV and/or HIV. Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs. IgA Deficiency History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. Participation in another clinical trial within 30 days prior to baseline visit. Inability to attend scheduled clinic visits and/or comply with the study protocol. Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol.

[ "FEV1", ">", "=", "80", "%", "or", "FEV1", "<", "20", "%", "of", "predicted", "value", "post", "-", "bronchodilator", ".", "\n", "FEV1", "/", "SVC>=70", "%", "\n", "History", "of", "lung", "transplant", ".", "\n", "Any", "lung", "surgery", "within", "the", "past", "two", "years", ".", "\n", "On", "any", "thoracic", "surgery", "waiting", "list", ".", "\n", "End", "of", "last", "exacerbation", "less", "than", "6", "weeks", "prior", "to", "screening", "/", "re", "-", "screening", "visit", ".", "\n", "Clinically", "significant", "intercurrent", "illnesses", "(", "except", "for", "respiratory", "or", "liver", "disease", "secondary", "to", "AAT", "deficiency", ")", ",", "including", ":", "cardiac", ",", "hepatic", ",", "renal", ",", "endocrine", ",", "neurological", ",", "hematological", ",", "neoplastic", ",", "immunological", ",", "skeletal", "or", "other", ")", "that", "in", "the", "opinion", "of", "the", "investigator", ",", "could", "interfere", "with", "the", "safety", ",", "compliance", "or", "other", "aspects", "of", "this", "study", ".", "Patients", "with", "well", "-", "controlled", ",", "chronic", "diseases", "could", "possibly", "be", "included", "after", "consultation", "with", "the", "treating", "physician", "and", "the", "sponsor", ".", "\n", "Active", "smoking", "during", "the", "last", "12", "months", "from", "screening", "date", ".", "\n", "Pregnancy", "or", "lactation", ".", "\n", "Woman", "of", "child", "-", "bearing", "potential", "not", "taking", "adequate", "contraception", "deemed", "reliable", "by", "the", "investigator", ".", "\n", "Presence", "of", "psychiatric/", "mental", "disorder", "or", "any", "other", "medical", "disorder", "which", "might", "impair", "the", "patient", "'s", "ability", "to", "give", "informed", "consent", "or", "to", "comply", "with", "the", "requirements", "of", "the", "study", "protocol", ".", "\n", "Evidence", "of", "ongoing", "viral", "infection", "with", "HCV", ",", "HBV", "and", "/", "or", "HIV", ".", "\n", "Evidence", "of", "alcohol", "abuse", "or", "history", "of", "alcohol", "abuse", "or", "illegal", "and", "/", "or", "legally", "prescribed", "drugs", ".", "\n", "IgA", "Deficiency", "\n", "History", "of", "life", "threatening", "allergy", ",", "anaphylactic", "reaction", ",", "or", "systemic", "response", "to", "human", "plasma", "derived", "products", ".", "\n", "Participation", "in", "another", "clinical", "trial", "within", "30", "days", "prior", "to", "baseline", "visit", ".", "\n", "Inability", "to", "attend", "scheduled", "clinic", "visits", "and", "/", "or", "comply", "with", "the", "study", "protocol", ".", "\n", "Any", "other", "factor", "that", ",", "in", "the", "opinion", "of", "the", "investigator", ",", "would", "prevent", "the", "patient", "from", "complying", "with", "the", "requirements", "of", "the", "protocol", ".", " \n \n" ]

[ "Scope", "Temporal", "Observation", "Condition", "Qualifier", "Reference_point", "Value", "Procedure", "Drug", "Negation", "Measurement", "Person" ]

FEV1 is a Measurement, > = 80 % is a Value, FEV1 is a Measurement, < 20 % of predicted value is a Value, post - bronchodilator is a Qualifier, History is a Observation, lung transplant is a Procedure, lung surgery is a Procedure, within the past two years is a Temporal, thoracic surgery waiting list is a Observation, exacerbation is a Condition, less than 6 weeks prior to screening / re - screening visit is a Temporal, Clinically significant is a Qualifier, intercurrent illnesses is a Condition, except for is a Negation, respiratory or liver disease is a Scope, secondary to AAT deficiency is a Qualifier, cardiac , hepatic , renal , endocrine , neurological , hematological , neoplastic , immunological , skeletal or other is a Scope, Active smoking is a Condition, during the last 12 months from screening date is a Temporal, Pregnancy is a Condition, lactation is a Condition, Woman is a Person, child - bearing potential is a Condition, not is a Negation, adequate is a Qualifier, contraception is a Procedure, deemed reliable by the investigator is a Qualifier, psychiatric/ mental disorder or any other medical disorder is a Scope, impair the patient 's ability to give informed consent is a Observation, ongoing is a Temporal, viral infection is a Condition, HCV , HBV and / or HIV is a Scope, alcohol abuse is a Condition, history is a Observation, alcohol abuse or illegal and / or legally prescribed drugs is a Scope, IgA Deficiency is a Condition, History is a Observation, life threatening allergy , anaphylactic reaction , or systemic response to human plasma derived products is a Scope

NCT01217671_exc_task1

Sentence: FEV1 >= 80% or FEV1 < 20% of predicted value post-bronchodilator. FEV1/SVC>=70% History of lung transplant. Any lung surgery within the past two years. On any thoracic surgery waiting list. End of last exacerbation less than 6 weeks prior to screening/re-screening visit. Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor. Active smoking during the last 12 months from screening date. Pregnancy or lactation. Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. Evidence of ongoing viral infection with HCV, HBV and/or HIV. Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs. IgA Deficiency History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. Participation in another clinical trial within 30 days prior to baseline visit. Inability to attend scheduled clinic visits and/or comply with the study protocol. Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol. Instructions: please typing these entity words according to sentence: FEV1, > = 80 %, FEV1, < 20 % of predicted value, post - bronchodilator, History, lung transplant, lung surgery, within the past two years, thoracic surgery waiting list, exacerbation, less than 6 weeks prior to screening / re - screening visit, Clinically significant, intercurrent illnesses, except for, respiratory or liver disease, secondary to AAT deficiency, cardiac , hepatic , renal , endocrine , neurological , hematological , neoplastic , immunological , skeletal or other, Active smoking, during the last 12 months from screening date, Pregnancy, lactation, Woman, child - bearing potential, not, adequate, contraception, deemed reliable by the investigator, psychiatric/ mental disorder or any other medical disorder, impair the patient 's ability to give informed consent, ongoing, viral infection, HCV , HBV and / or HIV, alcohol abuse, history, alcohol abuse or illegal and / or legally prescribed drugs, IgA Deficiency, History, life threatening allergy , anaphylactic reaction , or systemic response to human plasma derived products Options: Temporal, Condition, Qualifier, Value, Person, Observation, Procedure, Negation, Scope, Measurement

[ "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "O", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Condition", "O", "B-Condition", "O", "O", "B-Person", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "B-Negation", "O", "B-Qualifier", "B-Procedure", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

FEV1 >= 80% or FEV1 < 20% of predicted value post-bronchodilator. FEV1/SVC>=70% History of lung transplant. Any lung surgery within the past two years. On any thoracic surgery waiting list. End of last exacerbation less than 6 weeks prior to screening/re-screening visit. Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor. Active smoking during the last 12 months from screening date. Pregnancy or lactation. Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. Evidence of ongoing viral infection with HCV, HBV and/or HIV. Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs. IgA Deficiency History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. Participation in another clinical trial within 30 days prior to baseline visit. Inability to attend scheduled clinic visits and/or comply with the study protocol. Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol.

[ "FEV1", ">", "=", "80", "%", "or", "FEV1", "<", "20", "%", "of", "predicted", "value", "post", "-", "bronchodilator", ".", "\n", "FEV1", "/", "SVC>=70", "%", "\n", "History", "of", "lung", "transplant", ".", "\n", "Any", "lung", "surgery", "within", "the", "past", "two", "years", ".", "\n", "On", "any", "thoracic", "surgery", "waiting", "list", ".", "\n", "End", "of", "last", "exacerbation", "less", "than", "6", "weeks", "prior", "to", "screening", "/", "re", "-", "screening", "visit", ".", "\n", "Clinically", "significant", "intercurrent", "illnesses", "(", "except", "for", "respiratory", "or", "liver", "disease", "secondary", "to", "AAT", "deficiency", ")", ",", "including", ":", "cardiac", ",", "hepatic", ",", "renal", ",", "endocrine", ",", "neurological", ",", "hematological", ",", "neoplastic", ",", "immunological", ",", "skeletal", "or", "other", ")", "that", "in", "the", "opinion", "of", "the", "investigator", ",", "could", "interfere", "with", "the", "safety", ",", "compliance", "or", "other", "aspects", "of", "this", "study", ".", "Patients", "with", "well", "-", "controlled", ",", "chronic", "diseases", "could", "possibly", "be", "included", "after", "consultation", "with", "the", "treating", "physician", "and", "the", "sponsor", ".", "\n", "Active", "smoking", "during", "the", "last", "12", "months", "from", "screening", "date", ".", "\n", "Pregnancy", "or", "lactation", ".", "\n", "Woman", "of", "child", "-", "bearing", "potential", "not", "taking", "adequate", "contraception", "deemed", "reliable", "by", "the", "investigator", ".", "\n", "Presence", "of", "psychiatric/", "mental", "disorder", "or", "any", "other", "medical", "disorder", "which", "might", "impair", "the", "patient", "'s", "ability", "to", "give", "informed", "consent", "or", "to", "comply", "with", "the", "requirements", "of", "the", "study", "protocol", ".", "\n", "Evidence", "of", "ongoing", "viral", "infection", "with", "HCV", ",", "HBV", "and", "/", "or", "HIV", ".", "\n", "Evidence", "of", "alcohol", "abuse", "or", "history", "of", "alcohol", "abuse", "or", "illegal", "and", "/", "or", "legally", "prescribed", "drugs", ".", "\n", "IgA", "Deficiency", "\n", "History", "of", "life", "threatening", "allergy", ",", "anaphylactic", "reaction", ",", "or", "systemic", "response", "to", "human", "plasma", "derived", "products", ".", "\n", "Participation", "in", "another", "clinical", "trial", "within", "30", "days", "prior", "to", "baseline", "visit", ".", "\n", "Inability", "to", "attend", "scheduled", "clinic", "visits", "and", "/", "or", "comply", "with", "the", "study", "protocol", ".", "\n", "Any", "other", "factor", "that", ",", "in", "the", "opinion", "of", "the", "investigator", ",", "would", "prevent", "the", "patient", "from", "complying", "with", "the", "requirements", "of", "the", "protocol", ".", " \n \n" ]

[ "Scope", "Temporal", "Observation", "Condition", "Qualifier", "Reference_point", "Value", "Procedure", "Drug", "Negation", "Measurement", "Person" ]

FEV1, > = 80 %, FEV1, < 20 % of predicted value, post - bronchodilator, History, lung transplant, lung surgery, within the past two years, thoracic surgery waiting list, exacerbation, less than 6 weeks prior to screening / re - screening visit, Clinically significant, intercurrent illnesses, except for, respiratory or liver disease, secondary to AAT deficiency, cardiac , hepatic , renal , endocrine , neurological , hematological , neoplastic , immunological , skeletal or other, Active smoking, during the last 12 months from screening date, Pregnancy, lactation, Woman, child - bearing potential, not, adequate, contraception, deemed reliable by the investigator, psychiatric/ mental disorder or any other medical disorder, impair the patient 's ability to give informed consent, ongoing, viral infection, HCV , HBV and / or HIV, alcohol abuse, history, alcohol abuse or illegal and / or legally prescribed drugs, IgA Deficiency, History, life threatening allergy , anaphylactic reaction , or systemic response to human plasma derived products

NCT01217671_exc_task2

Sentence: FEV1 >= 80% or FEV1 < 20% of predicted value post-bronchodilator. FEV1/SVC>=70% History of lung transplant. Any lung surgery within the past two years. On any thoracic surgery waiting list. End of last exacerbation less than 6 weeks prior to screening/re-screening visit. Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor. Active smoking during the last 12 months from screening date. Pregnancy or lactation. Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. Evidence of ongoing viral infection with HCV, HBV and/or HIV. Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs. IgA Deficiency History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. Participation in another clinical trial within 30 days prior to baseline visit. Inability to attend scheduled clinic visits and/or comply with the study protocol. Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol. Instructions: please extract entity words from the input sentence

[ "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "B-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "O", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Condition", "O", "B-Condition", "O", "O", "B-Person", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "B-Negation", "O", "B-Qualifier", "B-Procedure", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

FEV1 >= 80% or FEV1 < 20% of predicted value post-bronchodilator. FEV1/SVC>=70% History of lung transplant. Any lung surgery within the past two years. On any thoracic surgery waiting list. End of last exacerbation less than 6 weeks prior to screening/re-screening visit. Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor. Active smoking during the last 12 months from screening date. Pregnancy or lactation. Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. Evidence of ongoing viral infection with HCV, HBV and/or HIV. Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs. IgA Deficiency History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. Participation in another clinical trial within 30 days prior to baseline visit. Inability to attend scheduled clinic visits and/or comply with the study protocol. Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol.

[ "FEV1", ">", "=", "80", "%", "or", "FEV1", "<", "20", "%", "of", "predicted", "value", "post", "-", "bronchodilator", ".", "\n", "FEV1", "/", "SVC>=70", "%", "\n", "History", "of", "lung", "transplant", ".", "\n", "Any", "lung", "surgery", "within", "the", "past", "two", "years", ".", "\n", "On", "any", "thoracic", "surgery", "waiting", "list", ".", "\n", "End", "of", "last", "exacerbation", "less", "than", "6", "weeks", "prior", "to", "screening", "/", "re", "-", "screening", "visit", ".", "\n", "Clinically", "significant", "intercurrent", "illnesses", "(", "except", "for", "respiratory", "or", "liver", "disease", "secondary", "to", "AAT", "deficiency", ")", ",", "including", ":", "cardiac", ",", "hepatic", ",", "renal", ",", "endocrine", ",", "neurological", ",", "hematological", ",", "neoplastic", ",", "immunological", ",", "skeletal", "or", "other", ")", "that", "in", "the", "opinion", "of", "the", "investigator", ",", "could", "interfere", "with", "the", "safety", ",", "compliance", "or", "other", "aspects", "of", "this", "study", ".", "Patients", "with", "well", "-", "controlled", ",", "chronic", "diseases", "could", "possibly", "be", "included", "after", "consultation", "with", "the", "treating", "physician", "and", "the", "sponsor", ".", "\n", "Active", "smoking", "during", "the", "last", "12", "months", "from", "screening", "date", ".", "\n", "Pregnancy", "or", "lactation", ".", "\n", "Woman", "of", "child", "-", "bearing", "potential", "not", "taking", "adequate", "contraception", "deemed", "reliable", "by", "the", "investigator", ".", "\n", "Presence", "of", "psychiatric/", "mental", "disorder", "or", "any", "other", "medical", "disorder", "which", "might", "impair", "the", "patient", "'s", "ability", "to", "give", "informed", "consent", "or", "to", "comply", "with", "the", "requirements", "of", "the", "study", "protocol", ".", "\n", "Evidence", "of", "ongoing", "viral", "infection", "with", "HCV", ",", "HBV", "and", "/", "or", "HIV", ".", "\n", "Evidence", "of", "alcohol", "abuse", "or", "history", "of", "alcohol", "abuse", "or", "illegal", "and", "/", "or", "legally", "prescribed", "drugs", ".", "\n", "IgA", "Deficiency", "\n", "History", "of", "life", "threatening", "allergy", ",", "anaphylactic", "reaction", ",", "or", "systemic", "response", "to", "human", "plasma", "derived", "products", ".", "\n", "Participation", "in", "another", "clinical", "trial", "within", "30", "days", "prior", "to", "baseline", "visit", ".", "\n", "Inability", "to", "attend", "scheduled", "clinic", "visits", "and", "/", "or", "comply", "with", "the", "study", "protocol", ".", "\n", "Any", "other", "factor", "that", ",", "in", "the", "opinion", "of", "the", "investigator", ",", "would", "prevent", "the", "patient", "from", "complying", "with", "the", "requirements", "of", "the", "protocol", ".", " \n \n" ]

[ "Scope", "Temporal", "Observation", "Condition", "Qualifier", "Reference_point", "Value", "Procedure", "Drug", "Negation", "Measurement", "Person" ]

ARE - containing genes is a DNA_family_or_group, AU - motif - directed display is an other_name

71773_task0

Sentence: Cloning of ARE-containing genes by AU-motif-directed display. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_family_or_group, other_name

[ "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]

Cloning of ARE-containing genes by AU-motif-directed display.

[ "Cloning", "of", "ARE", "-", "containing", "genes", "by", "AU", "-", "motif", "-", "directed", "display", "." ]

[ "DNA_domain_or_region", "protein_family_or_group", "cell_type", "other_name", "DNA_family_or_group", "RNA_family_or_group", "tissue", "cell_line", "RNA_substructure" ]

ARE - containing genes is a DNA_family_or_group, AU - motif - directed display is an other_name

71773_task1

Sentence: Cloning of ARE-containing genes by AU-motif-directed display. Instructions: please typing these entity words according to sentence: ARE - containing genes, AU - motif - directed display Options: DNA_family_or_group, other_name

[ "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]

Cloning of ARE-containing genes by AU-motif-directed display.

[ "Cloning", "of", "ARE", "-", "containing", "genes", "by", "AU", "-", "motif", "-", "directed", "display", "." ]

[ "DNA_domain_or_region", "protein_family_or_group", "cell_type", "other_name", "DNA_family_or_group", "RNA_family_or_group", "tissue", "cell_line", "RNA_substructure" ]

ARE - containing genes, AU - motif - directed display

71773_task2

Sentence: Cloning of ARE-containing genes by AU-motif-directed display. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]

Cloning of ARE-containing genes by AU-motif-directed display.

[ "Cloning", "of", "ARE", "-", "containing", "genes", "by", "AU", "-", "motif", "-", "directed", "display", "." ]

[ "DNA_domain_or_region", "protein_family_or_group", "cell_type", "other_name", "DNA_family_or_group", "RNA_family_or_group", "tissue", "cell_line", "RNA_substructure" ]

Consensus is an umlsterm, -adrenoceptor is an umlsterm, antagonists is an umlsterm, therapy is an umlsterm, benign prostatic hyperplasia is an umlsterm, BPH is an umlsterm, review is an umlsterm, double - blind studies is an umlsterm, patients is an umlsterm, clinical studies is an umlsterm, patients is an umlsterm, treatment is an umlsterm, -adrenoceptor is an umlsterm, antagonists is an umlsterm, BPH is an umlsterm, therapeutic is an umlsterm, -adrenoceptor is an umlsterm, antagonists is an umlsterm, symptom is an umlsterm, quality of life is an umlsterm, antagonists is an umlsterm, side effects is an umlsterm, side effects is an umlsterm, development is an umlsterm, antagonists is an umlsterm, treatment is an umlsterm, BPH is an umlsterm, side effects is an umlsterm, vasodilatation is an umlsterm, therapy is an umlsterm, antagonists is an umlsterm, phytotherapy is an umlsterm, treatment is an umlsterm, inhibitors is an umlsterm, combination therapy is an umlsterm, antagonists is an umlsterm, BPH is an umlsterm, patients is an umlsterm, prostatectomy is an umlsterm, patients is an umlsterm, surgical treatment is an umlsterm, therapy is an umlsterm, antagonists is an umlsterm, choice is an umlsterm, clinical trials is an umlsterm, choice is an umlsterm, antagonists is an umlsterm, safety is an umlsterm, costs is an umlsterm

DerUrologeA.70360018.eng.abstr_task0

Sentence: The International Consensus Committee recommends -adrenoceptor antagonists for medical therapy of benign prostatic hyperplasia ( BPH ) . This review evaluates 52 randomized , placebo-controlled , double-blind studies , including 10 399 patients and , moreover , 40 clinical studies including 33 600 patients undergoing treatment with -adrenoceptor antagonists because of BPH . The therapeutic efficacy of all -adrenoceptor antagonists is more or less the same . There is an average improvement of symptom scores of about 35 % and a mean increase in maximum flow rate of between 1.8 and 2.5 ml/s . Studies investigating long-term efficacy and quality of life tend to show a long-term benefit . The introduction of selective 1-adrenoceptor antagonists led to a significant reduction of side effects . These side effects are primarily caused by the vasodilatatory qualities of -blockers . The development of so-called uroselective 1A-adrenoceptor antagonists in the treatment of BPH possibly leads to further reduction of side effects related to vasodilatation . Medical therapy by 1-adrenoceptor antagonists seems to be superior to phytotherapy or treatment with 5-reductase inhibitors , as shown in a few studies . So far , it is not clear whether there is any advantage of combination therapy . The application of 1-adrenoceptor antagonists is indicated in all cases of symptomatic BPH , excluding patients who need TUR-P ( e . g . , middle lobe ) or prostatectomy . If patients are either willing or eligible to have surgical treatment , therapy by 1-adrenoceptor antagonists is a rational choice . Comparative clinical trials have to be conducted to provide additional information and to clarify which -blocker may be recommended as the first choice . Until then , those 1-adrenoceptor antagonists should be used for which safety and efficacy are well documented and which can be prescribed at reasonable costs . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

The International Consensus Committee recommends -adrenoceptor antagonists for medical therapy of benign prostatic hyperplasia ( BPH ) . This review evaluates 52 randomized , placebo-controlled , double-blind studies , including 10 399 patients and , moreover , 40 clinical studies including 33 600 patients undergoing treatment with -adrenoceptor antagonists because of BPH . The therapeutic efficacy of all -adrenoceptor antagonists is more or less the same . There is an average improvement of symptom scores of about 35 % and a mean increase in maximum flow rate of between 1.8 and 2.5 ml/s . Studies investigating long-term efficacy and quality of life tend to show a long-term benefit . The introduction of selective 1-adrenoceptor antagonists led to a significant reduction of side effects . These side effects are primarily caused by the vasodilatatory qualities of -blockers . The development of so-called uroselective 1A-adrenoceptor antagonists in the treatment of BPH possibly leads to further reduction of side effects related to vasodilatation . Medical therapy by 1-adrenoceptor antagonists seems to be superior to phytotherapy or treatment with 5-reductase inhibitors , as shown in a few studies . So far , it is not clear whether there is any advantage of combination therapy . The application of 1-adrenoceptor antagonists is indicated in all cases of symptomatic BPH , excluding patients who need TUR-P ( e . g . , middle lobe ) or prostatectomy . If patients are either willing or eligible to have surgical treatment , therapy by 1-adrenoceptor antagonists is a rational choice . Comparative clinical trials have to be conducted to provide additional information and to clarify which -blocker may be recommended as the first choice . Until then , those 1-adrenoceptor antagonists should be used for which safety and efficacy are well documented and which can be prescribed at reasonable costs .

[ "The", "International", "Consensus", "Committee", "recommends", "-adrenoceptor", "antagonists", "for", "medical", "therapy", "of", "benign", "prostatic", "hyperplasia", "(", "BPH", ")", ".", "This", "review", "evaluates", "52", "randomized", ",", "placebo", "-", "controlled", ",", "double", "-", "blind", "studies", ",", "including", "10", "399", "patients", "and", ",", "moreover", ",", "40", "clinical", "studies", "including", "33", "600", "patients", "undergoing", "treatment", "with", "-adrenoceptor", "antagonists", "because", "of", "BPH", ".", "The", "therapeutic", "efficacy", "of", "all", "-adrenoceptor", "antagonists", "is", "more", "or", "less", "the", "same", ".", "There", "is", "an", "average", "improvement", "of", "symptom", "scores", "of", "about", "35", "%", "and", "a", "mean", "increase", "in", "maximum", "flow", "rate", "of", "between", "1.8", "and", "2.5", "ml", "/", "s", ".", "Studies", "investigating", "long", "-", "term", "efficacy", "and", "quality", "of", "life", "tend", "to", "show", "a", "long", "-", "term", "benefit", ".", "The", "introduction", "of", "selective", "1-adrenoceptor", "antagonists", "led", "to", "a", "significant", "reduction", "of", "side", "effects", ".", "These", "side", "effects", "are", "primarily", "caused", "by", "the", "vasodilatatory", "qualities", "of", "-blockers", ".", "The", "development", "of", "so", "-", "called", "uroselective", "1A", "-", "adrenoceptor", "antagonists", "in", "the", "treatment", "of", "BPH", "possibly", "leads", "to", "further", "reduction", "of", "side", "effects", "related", "to", "vasodilatation", ".", "Medical", "therapy", "by", "1-adrenoceptor", "antagonists", "seems", "to", "be", "superior", "to", "phytotherapy", "or", "treatment", "with", "5-reductase", "inhibitors", ",", "as", "shown", "in", "a", "few", "studies", ".", "So", "far", ",", "it", "is", "not", "clear", "whether", "there", "is", "any", "advantage", "of", "combination", "therapy", ".", "The", "application", "of", "1-adrenoceptor", "antagonists", "is", "indicated", "in", "all", "cases", "of", "symptomatic", "BPH", ",", "excluding", "patients", "who", "need", "TUR", "-", "P", "(", "e", ".", "g", ".", ",", "middle", "lobe", ")", "or", "prostatectomy", ".", "If", "patients", "are", "either", "willing", "or", "eligible", "to", "have", "surgical", "treatment", ",", "therapy", "by", "1-adrenoceptor", "antagonists", "is", "a", "rational", "choice", ".", "Comparative", "clinical", "trials", "have", "to", "be", "conducted", "to", "provide", "additional", "information", "and", "to", "clarify", "which", "-blocker", "may", "be", "recommended", "as", "the", "first", "choice", ".", "Until", "then", ",", "those", "1-adrenoceptor", "antagonists", "should", "be", "used", "for", "which", "safety", "and", "efficacy", "are", "well", "documented", "and", "which", "can", "be", "prescribed", "at", "reasonable", "costs", "." ]

[ "umlsterm" ]

Consensus is an umlsterm, -adrenoceptor is an umlsterm, antagonists is an umlsterm, therapy is an umlsterm, benign prostatic hyperplasia is an umlsterm, BPH is an umlsterm, review is an umlsterm, double - blind studies is an umlsterm, patients is an umlsterm, clinical studies is an umlsterm, patients is an umlsterm, treatment is an umlsterm, -adrenoceptor is an umlsterm, antagonists is an umlsterm, BPH is an umlsterm, therapeutic is an umlsterm, -adrenoceptor is an umlsterm, antagonists is an umlsterm, symptom is an umlsterm, quality of life is an umlsterm, antagonists is an umlsterm, side effects is an umlsterm, side effects is an umlsterm, development is an umlsterm, antagonists is an umlsterm, treatment is an umlsterm, BPH is an umlsterm, side effects is an umlsterm, vasodilatation is an umlsterm, therapy is an umlsterm, antagonists is an umlsterm, phytotherapy is an umlsterm, treatment is an umlsterm, inhibitors is an umlsterm, combination therapy is an umlsterm, antagonists is an umlsterm, BPH is an umlsterm, patients is an umlsterm, prostatectomy is an umlsterm, patients is an umlsterm, surgical treatment is an umlsterm, therapy is an umlsterm, antagonists is an umlsterm, choice is an umlsterm, clinical trials is an umlsterm, choice is an umlsterm, antagonists is an umlsterm, safety is an umlsterm, costs is an umlsterm

DerUrologeA.70360018.eng.abstr_task1

Sentence: The International Consensus Committee recommends -adrenoceptor antagonists for medical therapy of benign prostatic hyperplasia ( BPH ) . This review evaluates 52 randomized , placebo-controlled , double-blind studies , including 10 399 patients and , moreover , 40 clinical studies including 33 600 patients undergoing treatment with -adrenoceptor antagonists because of BPH . The therapeutic efficacy of all -adrenoceptor antagonists is more or less the same . There is an average improvement of symptom scores of about 35 % and a mean increase in maximum flow rate of between 1.8 and 2.5 ml/s . Studies investigating long-term efficacy and quality of life tend to show a long-term benefit . The introduction of selective 1-adrenoceptor antagonists led to a significant reduction of side effects . These side effects are primarily caused by the vasodilatatory qualities of -blockers . The development of so-called uroselective 1A-adrenoceptor antagonists in the treatment of BPH possibly leads to further reduction of side effects related to vasodilatation . Medical therapy by 1-adrenoceptor antagonists seems to be superior to phytotherapy or treatment with 5-reductase inhibitors , as shown in a few studies . So far , it is not clear whether there is any advantage of combination therapy . The application of 1-adrenoceptor antagonists is indicated in all cases of symptomatic BPH , excluding patients who need TUR-P ( e . g . , middle lobe ) or prostatectomy . If patients are either willing or eligible to have surgical treatment , therapy by 1-adrenoceptor antagonists is a rational choice . Comparative clinical trials have to be conducted to provide additional information and to clarify which -blocker may be recommended as the first choice . Until then , those 1-adrenoceptor antagonists should be used for which safety and efficacy are well documented and which can be prescribed at reasonable costs . Instructions: please typing these entity words according to sentence: Consensus, -adrenoceptor, antagonists, therapy, benign prostatic hyperplasia, BPH, review, double - blind studies, patients, clinical studies, patients, treatment, -adrenoceptor, antagonists, BPH, therapeutic, -adrenoceptor, antagonists, symptom, quality of life, antagonists, side effects, side effects, development, antagonists, treatment, BPH, side effects, vasodilatation, therapy, antagonists, phytotherapy, treatment, inhibitors, combination therapy, antagonists, BPH, patients, prostatectomy, patients, surgical treatment, therapy, antagonists, choice, clinical trials, choice, antagonists, safety, costs Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

The International Consensus Committee recommends -adrenoceptor antagonists for medical therapy of benign prostatic hyperplasia ( BPH ) . This review evaluates 52 randomized , placebo-controlled , double-blind studies , including 10 399 patients and , moreover , 40 clinical studies including 33 600 patients undergoing treatment with -adrenoceptor antagonists because of BPH . The therapeutic efficacy of all -adrenoceptor antagonists is more or less the same . There is an average improvement of symptom scores of about 35 % and a mean increase in maximum flow rate of between 1.8 and 2.5 ml/s . Studies investigating long-term efficacy and quality of life tend to show a long-term benefit . The introduction of selective 1-adrenoceptor antagonists led to a significant reduction of side effects . These side effects are primarily caused by the vasodilatatory qualities of -blockers . The development of so-called uroselective 1A-adrenoceptor antagonists in the treatment of BPH possibly leads to further reduction of side effects related to vasodilatation . Medical therapy by 1-adrenoceptor antagonists seems to be superior to phytotherapy or treatment with 5-reductase inhibitors , as shown in a few studies . So far , it is not clear whether there is any advantage of combination therapy . The application of 1-adrenoceptor antagonists is indicated in all cases of symptomatic BPH , excluding patients who need TUR-P ( e . g . , middle lobe ) or prostatectomy . If patients are either willing or eligible to have surgical treatment , therapy by 1-adrenoceptor antagonists is a rational choice . Comparative clinical trials have to be conducted to provide additional information and to clarify which -blocker may be recommended as the first choice . Until then , those 1-adrenoceptor antagonists should be used for which safety and efficacy are well documented and which can be prescribed at reasonable costs .

[ "The", "International", "Consensus", "Committee", "recommends", "-adrenoceptor", "antagonists", "for", "medical", "therapy", "of", "benign", "prostatic", "hyperplasia", "(", "BPH", ")", ".", "This", "review", "evaluates", "52", "randomized", ",", "placebo", "-", "controlled", ",", "double", "-", "blind", "studies", ",", "including", "10", "399", "patients", "and", ",", "moreover", ",", "40", "clinical", "studies", "including", "33", "600", "patients", "undergoing", "treatment", "with", "-adrenoceptor", "antagonists", "because", "of", "BPH", ".", "The", "therapeutic", "efficacy", "of", "all", "-adrenoceptor", "antagonists", "is", "more", "or", "less", "the", "same", ".", "There", "is", "an", "average", "improvement", "of", "symptom", "scores", "of", "about", "35", "%", "and", "a", "mean", "increase", "in", "maximum", "flow", "rate", "of", "between", "1.8", "and", "2.5", "ml", "/", "s", ".", "Studies", "investigating", "long", "-", "term", "efficacy", "and", "quality", "of", "life", "tend", "to", "show", "a", "long", "-", "term", "benefit", ".", "The", "introduction", "of", "selective", "1-adrenoceptor", "antagonists", "led", "to", "a", "significant", "reduction", "of", "side", "effects", ".", "These", "side", "effects", "are", "primarily", "caused", "by", "the", "vasodilatatory", "qualities", "of", "-blockers", ".", "The", "development", "of", "so", "-", "called", "uroselective", "1A", "-", "adrenoceptor", "antagonists", "in", "the", "treatment", "of", "BPH", "possibly", "leads", "to", "further", "reduction", "of", "side", "effects", "related", "to", "vasodilatation", ".", "Medical", "therapy", "by", "1-adrenoceptor", "antagonists", "seems", "to", "be", "superior", "to", "phytotherapy", "or", "treatment", "with", "5-reductase", "inhibitors", ",", "as", "shown", "in", "a", "few", "studies", ".", "So", "far", ",", "it", "is", "not", "clear", "whether", "there", "is", "any", "advantage", "of", "combination", "therapy", ".", "The", "application", "of", "1-adrenoceptor", "antagonists", "is", "indicated", "in", "all", "cases", "of", "symptomatic", "BPH", ",", "excluding", "patients", "who", "need", "TUR", "-", "P", "(", "e", ".", "g", ".", ",", "middle", "lobe", ")", "or", "prostatectomy", ".", "If", "patients", "are", "either", "willing", "or", "eligible", "to", "have", "surgical", "treatment", ",", "therapy", "by", "1-adrenoceptor", "antagonists", "is", "a", "rational", "choice", ".", "Comparative", "clinical", "trials", "have", "to", "be", "conducted", "to", "provide", "additional", "information", "and", "to", "clarify", "which", "-blocker", "may", "be", "recommended", "as", "the", "first", "choice", ".", "Until", "then", ",", "those", "1-adrenoceptor", "antagonists", "should", "be", "used", "for", "which", "safety", "and", "efficacy", "are", "well", "documented", "and", "which", "can", "be", "prescribed", "at", "reasonable", "costs", "." ]

[ "umlsterm" ]

Consensus, -adrenoceptor, antagonists, therapy, benign prostatic hyperplasia, BPH, review, double - blind studies, patients, clinical studies, patients, treatment, -adrenoceptor, antagonists, BPH, therapeutic, -adrenoceptor, antagonists, symptom, quality of life, antagonists, side effects, side effects, development, antagonists, treatment, BPH, side effects, vasodilatation, therapy, antagonists, phytotherapy, treatment, inhibitors, combination therapy, antagonists, BPH, patients, prostatectomy, patients, surgical treatment, therapy, antagonists, choice, clinical trials, choice, antagonists, safety, costs

DerUrologeA.70360018.eng.abstr_task2

Sentence: The International Consensus Committee recommends -adrenoceptor antagonists for medical therapy of benign prostatic hyperplasia ( BPH ) . This review evaluates 52 randomized , placebo-controlled , double-blind studies , including 10 399 patients and , moreover , 40 clinical studies including 33 600 patients undergoing treatment with -adrenoceptor antagonists because of BPH . The therapeutic efficacy of all -adrenoceptor antagonists is more or less the same . There is an average improvement of symptom scores of about 35 % and a mean increase in maximum flow rate of between 1.8 and 2.5 ml/s . Studies investigating long-term efficacy and quality of life tend to show a long-term benefit . The introduction of selective 1-adrenoceptor antagonists led to a significant reduction of side effects . These side effects are primarily caused by the vasodilatatory qualities of -blockers . The development of so-called uroselective 1A-adrenoceptor antagonists in the treatment of BPH possibly leads to further reduction of side effects related to vasodilatation . Medical therapy by 1-adrenoceptor antagonists seems to be superior to phytotherapy or treatment with 5-reductase inhibitors , as shown in a few studies . So far , it is not clear whether there is any advantage of combination therapy . The application of 1-adrenoceptor antagonists is indicated in all cases of symptomatic BPH , excluding patients who need TUR-P ( e . g . , middle lobe ) or prostatectomy . If patients are either willing or eligible to have surgical treatment , therapy by 1-adrenoceptor antagonists is a rational choice . Comparative clinical trials have to be conducted to provide additional information and to clarify which -blocker may be recommended as the first choice . Until then , those 1-adrenoceptor antagonists should be used for which safety and efficacy are well documented and which can be prescribed at reasonable costs . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

The International Consensus Committee recommends -adrenoceptor antagonists for medical therapy of benign prostatic hyperplasia ( BPH ) . This review evaluates 52 randomized , placebo-controlled , double-blind studies , including 10 399 patients and , moreover , 40 clinical studies including 33 600 patients undergoing treatment with -adrenoceptor antagonists because of BPH . The therapeutic efficacy of all -adrenoceptor antagonists is more or less the same . There is an average improvement of symptom scores of about 35 % and a mean increase in maximum flow rate of between 1.8 and 2.5 ml/s . Studies investigating long-term efficacy and quality of life tend to show a long-term benefit . The introduction of selective 1-adrenoceptor antagonists led to a significant reduction of side effects . These side effects are primarily caused by the vasodilatatory qualities of -blockers . The development of so-called uroselective 1A-adrenoceptor antagonists in the treatment of BPH possibly leads to further reduction of side effects related to vasodilatation . Medical therapy by 1-adrenoceptor antagonists seems to be superior to phytotherapy or treatment with 5-reductase inhibitors , as shown in a few studies . So far , it is not clear whether there is any advantage of combination therapy . The application of 1-adrenoceptor antagonists is indicated in all cases of symptomatic BPH , excluding patients who need TUR-P ( e . g . , middle lobe ) or prostatectomy . If patients are either willing or eligible to have surgical treatment , therapy by 1-adrenoceptor antagonists is a rational choice . Comparative clinical trials have to be conducted to provide additional information and to clarify which -blocker may be recommended as the first choice . Until then , those 1-adrenoceptor antagonists should be used for which safety and efficacy are well documented and which can be prescribed at reasonable costs .

[ "The", "International", "Consensus", "Committee", "recommends", "-adrenoceptor", "antagonists", "for", "medical", "therapy", "of", "benign", "prostatic", "hyperplasia", "(", "BPH", ")", ".", "This", "review", "evaluates", "52", "randomized", ",", "placebo", "-", "controlled", ",", "double", "-", "blind", "studies", ",", "including", "10", "399", "patients", "and", ",", "moreover", ",", "40", "clinical", "studies", "including", "33", "600", "patients", "undergoing", "treatment", "with", "-adrenoceptor", "antagonists", "because", "of", "BPH", ".", "The", "therapeutic", "efficacy", "of", "all", "-adrenoceptor", "antagonists", "is", "more", "or", "less", "the", "same", ".", "There", "is", "an", "average", "improvement", "of", "symptom", "scores", "of", "about", "35", "%", "and", "a", "mean", "increase", "in", "maximum", "flow", "rate", "of", "between", "1.8", "and", "2.5", "ml", "/", "s", ".", "Studies", "investigating", "long", "-", "term", "efficacy", "and", "quality", "of", "life", "tend", "to", "show", "a", "long", "-", "term", "benefit", ".", "The", "introduction", "of", "selective", "1-adrenoceptor", "antagonists", "led", "to", "a", "significant", "reduction", "of", "side", "effects", ".", "These", "side", "effects", "are", "primarily", "caused", "by", "the", "vasodilatatory", "qualities", "of", "-blockers", ".", "The", "development", "of", "so", "-", "called", "uroselective", "1A", "-", "adrenoceptor", "antagonists", "in", "the", "treatment", "of", "BPH", "possibly", "leads", "to", "further", "reduction", "of", "side", "effects", "related", "to", "vasodilatation", ".", "Medical", "therapy", "by", "1-adrenoceptor", "antagonists", "seems", "to", "be", "superior", "to", "phytotherapy", "or", "treatment", "with", "5-reductase", "inhibitors", ",", "as", "shown", "in", "a", "few", "studies", ".", "So", "far", ",", "it", "is", "not", "clear", "whether", "there", "is", "any", "advantage", "of", "combination", "therapy", ".", "The", "application", "of", "1-adrenoceptor", "antagonists", "is", "indicated", "in", "all", "cases", "of", "symptomatic", "BPH", ",", "excluding", "patients", "who", "need", "TUR", "-", "P", "(", "e", ".", "g", ".", ",", "middle", "lobe", ")", "or", "prostatectomy", ".", "If", "patients", "are", "either", "willing", "or", "eligible", "to", "have", "surgical", "treatment", ",", "therapy", "by", "1-adrenoceptor", "antagonists", "is", "a", "rational", "choice", ".", "Comparative", "clinical", "trials", "have", "to", "be", "conducted", "to", "provide", "additional", "information", "and", "to", "clarify", "which", "-blocker", "may", "be", "recommended", "as", "the", "first", "choice", ".", "Until", "then", ",", "those", "1-adrenoceptor", "antagonists", "should", "be", "used", "for", "which", "safety", "and", "efficacy", "are", "well", "documented", "and", "which", "can", "be", "prescribed", "at", "reasonable", "costs", "." ]

[ "umlsterm" ]

relapses is an umlsterm, surgical is an umlsterm, maxilla is an umlsterm, osteotomy is an umlsterm, patients is an umlsterm, complications is an umlsterm, aim is an umlsterm, technique is an umlsterm, distraction osteogenesis is an umlsterm, patients is an umlsterm, maxillary is an umlsterm, Maxillary is an umlsterm, patients is an umlsterm, mask is an umlsterm, maxilla is an umlsterm, patients is an umlsterm, device designed is an umlsterm, patients is an umlsterm, maxilla is an umlsterm, distraction osteogenesis is an umlsterm, maxilla is an umlsterm, technique is an umlsterm, minor surgical procedure is an umlsterm

MundKieferGesichtschirurgie.0004s438.eng.abstr_task0

Sentence: Total or partial relapses after conventional surgical advancement of the maxilla following Le Fort I osteotomy in CLP patients are frequent and major complications . The aim of this investigation was to find out whether the technique of distraction osteogenesis in these patients shows more stability and whether maxillary distraction is able to replace conventional advancement . Maxillary distraction was performed in 12 patients . In two cases , a Delaire mask was used to bring the maxilla forward , ten patients were treated with the extraoral distraction device designed by Polley . In all patients , planned advancement of the maxilla could be achieved ; one partial relapse occurred . The results indicate that distraction osteogenesis offers the possibility of advancement of the maxilla with the required stability . The technique presents a major improvement which is achieved with a relatively minor surgical procedure . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]

Total or partial relapses after conventional surgical advancement of the maxilla following Le Fort I osteotomy in CLP patients are frequent and major complications . The aim of this investigation was to find out whether the technique of distraction osteogenesis in these patients shows more stability and whether maxillary distraction is able to replace conventional advancement . Maxillary distraction was performed in 12 patients . In two cases , a Delaire mask was used to bring the maxilla forward , ten patients were treated with the extraoral distraction device designed by Polley . In all patients , planned advancement of the maxilla could be achieved ; one partial relapse occurred . The results indicate that distraction osteogenesis offers the possibility of advancement of the maxilla with the required stability . The technique presents a major improvement which is achieved with a relatively minor surgical procedure .

[ "Total", "or", "partial", "relapses", "after", "conventional", "surgical", "advancement", "of", "the", "maxilla", "following", "Le", "Fort", "I", "osteotomy", "in", "CLP", "patients", "are", "frequent", "and", "major", "complications", ".", "The", "aim", "of", "this", "investigation", "was", "to", "find", "out", "whether", "the", "technique", "of", "distraction", "osteogenesis", "in", "these", "patients", "shows", "more", "stability", "and", "whether", "maxillary", "distraction", "is", "able", "to", "replace", "conventional", "advancement", ".", "Maxillary", "distraction", "was", "performed", "in", "12", "patients", ".", "In", "two", "cases", ",", "a", "Delaire", "mask", "was", "used", "to", "bring", "the", "maxilla", "forward", ",", "ten", "patients", "were", "treated", "with", "the", "extraoral", "distraction", "device", "designed", "by", "Polley", ".", "In", "all", "patients", ",", "planned", "advancement", "of", "the", "maxilla", "could", "be", "achieved", ";", "one", "partial", "relapse", "occurred", ".", "The", "results", "indicate", "that", "distraction", "osteogenesis", "offers", "the", "possibility", "of", "advancement", "of", "the", "maxilla", "with", "the", "required", "stability", ".", "The", "technique", "presents", "a", "major", "improvement", "which", "is", "achieved", "with", "a", "relatively", "minor", "surgical", "procedure", "." ]

[ "umlsterm" ]

relapses is an umlsterm, surgical is an umlsterm, maxilla is an umlsterm, osteotomy is an umlsterm, patients is an umlsterm, complications is an umlsterm, aim is an umlsterm, technique is an umlsterm, distraction osteogenesis is an umlsterm, patients is an umlsterm, maxillary is an umlsterm, Maxillary is an umlsterm, patients is an umlsterm, mask is an umlsterm, maxilla is an umlsterm, patients is an umlsterm, device designed is an umlsterm, patients is an umlsterm, maxilla is an umlsterm, distraction osteogenesis is an umlsterm, maxilla is an umlsterm, technique is an umlsterm, minor surgical procedure is an umlsterm

MundKieferGesichtschirurgie.0004s438.eng.abstr_task1

Sentence: Total or partial relapses after conventional surgical advancement of the maxilla following Le Fort I osteotomy in CLP patients are frequent and major complications . The aim of this investigation was to find out whether the technique of distraction osteogenesis in these patients shows more stability and whether maxillary distraction is able to replace conventional advancement . Maxillary distraction was performed in 12 patients . In two cases , a Delaire mask was used to bring the maxilla forward , ten patients were treated with the extraoral distraction device designed by Polley . In all patients , planned advancement of the maxilla could be achieved ; one partial relapse occurred . The results indicate that distraction osteogenesis offers the possibility of advancement of the maxilla with the required stability . The technique presents a major improvement which is achieved with a relatively minor surgical procedure . Instructions: please typing these entity words according to sentence: relapses, surgical, maxilla, osteotomy, patients, complications, aim, technique, distraction osteogenesis, patients, maxillary, Maxillary, patients, mask, maxilla, patients, device designed, patients, maxilla, distraction osteogenesis, maxilla, technique, minor surgical procedure Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]

Total or partial relapses after conventional surgical advancement of the maxilla following Le Fort I osteotomy in CLP patients are frequent and major complications . The aim of this investigation was to find out whether the technique of distraction osteogenesis in these patients shows more stability and whether maxillary distraction is able to replace conventional advancement . Maxillary distraction was performed in 12 patients . In two cases , a Delaire mask was used to bring the maxilla forward , ten patients were treated with the extraoral distraction device designed by Polley . In all patients , planned advancement of the maxilla could be achieved ; one partial relapse occurred . The results indicate that distraction osteogenesis offers the possibility of advancement of the maxilla with the required stability . The technique presents a major improvement which is achieved with a relatively minor surgical procedure .

[ "Total", "or", "partial", "relapses", "after", "conventional", "surgical", "advancement", "of", "the", "maxilla", "following", "Le", "Fort", "I", "osteotomy", "in", "CLP", "patients", "are", "frequent", "and", "major", "complications", ".", "The", "aim", "of", "this", "investigation", "was", "to", "find", "out", "whether", "the", "technique", "of", "distraction", "osteogenesis", "in", "these", "patients", "shows", "more", "stability", "and", "whether", "maxillary", "distraction", "is", "able", "to", "replace", "conventional", "advancement", ".", "Maxillary", "distraction", "was", "performed", "in", "12", "patients", ".", "In", "two", "cases", ",", "a", "Delaire", "mask", "was", "used", "to", "bring", "the", "maxilla", "forward", ",", "ten", "patients", "were", "treated", "with", "the", "extraoral", "distraction", "device", "designed", "by", "Polley", ".", "In", "all", "patients", ",", "planned", "advancement", "of", "the", "maxilla", "could", "be", "achieved", ";", "one", "partial", "relapse", "occurred", ".", "The", "results", "indicate", "that", "distraction", "osteogenesis", "offers", "the", "possibility", "of", "advancement", "of", "the", "maxilla", "with", "the", "required", "stability", ".", "The", "technique", "presents", "a", "major", "improvement", "which", "is", "achieved", "with", "a", "relatively", "minor", "surgical", "procedure", "." ]

[ "umlsterm" ]

relapses, surgical, maxilla, osteotomy, patients, complications, aim, technique, distraction osteogenesis, patients, maxillary, Maxillary, patients, mask, maxilla, patients, device designed, patients, maxilla, distraction osteogenesis, maxilla, technique, minor surgical procedure

MundKieferGesichtschirurgie.0004s438.eng.abstr_task2

Sentence: Total or partial relapses after conventional surgical advancement of the maxilla following Le Fort I osteotomy in CLP patients are frequent and major complications . The aim of this investigation was to find out whether the technique of distraction osteogenesis in these patients shows more stability and whether maxillary distraction is able to replace conventional advancement . Maxillary distraction was performed in 12 patients . In two cases , a Delaire mask was used to bring the maxilla forward , ten patients were treated with the extraoral distraction device designed by Polley . In all patients , planned advancement of the maxilla could be achieved ; one partial relapse occurred . The results indicate that distraction osteogenesis offers the possibility of advancement of the maxilla with the required stability . The technique presents a major improvement which is achieved with a relatively minor surgical procedure . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]

Total or partial relapses after conventional surgical advancement of the maxilla following Le Fort I osteotomy in CLP patients are frequent and major complications . The aim of this investigation was to find out whether the technique of distraction osteogenesis in these patients shows more stability and whether maxillary distraction is able to replace conventional advancement . Maxillary distraction was performed in 12 patients . In two cases , a Delaire mask was used to bring the maxilla forward , ten patients were treated with the extraoral distraction device designed by Polley . In all patients , planned advancement of the maxilla could be achieved ; one partial relapse occurred . The results indicate that distraction osteogenesis offers the possibility of advancement of the maxilla with the required stability . The technique presents a major improvement which is achieved with a relatively minor surgical procedure .

[ "Total", "or", "partial", "relapses", "after", "conventional", "surgical", "advancement", "of", "the", "maxilla", "following", "Le", "Fort", "I", "osteotomy", "in", "CLP", "patients", "are", "frequent", "and", "major", "complications", ".", "The", "aim", "of", "this", "investigation", "was", "to", "find", "out", "whether", "the", "technique", "of", "distraction", "osteogenesis", "in", "these", "patients", "shows", "more", "stability", "and", "whether", "maxillary", "distraction", "is", "able", "to", "replace", "conventional", "advancement", ".", "Maxillary", "distraction", "was", "performed", "in", "12", "patients", ".", "In", "two", "cases", ",", "a", "Delaire", "mask", "was", "used", "to", "bring", "the", "maxilla", "forward", ",", "ten", "patients", "were", "treated", "with", "the", "extraoral", "distraction", "device", "designed", "by", "Polley", ".", "In", "all", "patients", ",", "planned", "advancement", "of", "the", "maxilla", "could", "be", "achieved", ";", "one", "partial", "relapse", "occurred", ".", "The", "results", "indicate", "that", "distraction", "osteogenesis", "offers", "the", "possibility", "of", "advancement", "of", "the", "maxilla", "with", "the", "required", "stability", ".", "The", "technique", "presents", "a", "major", "improvement", "which", "is", "achieved", "with", "a", "relatively", "minor", "surgical", "procedure", "." ]

[ "umlsterm" ]

lymphotoxin promoter is a DNA_domain_or_region, HTLV - I tax activation is an other_name, NF - kappa B is a protein_molecule, human T - cell lines is a cell_line

83714_task0

Sentence: The lymphotoxin promoter is stimulated by HTLV-I tax activation of NF-kappa B in human T-cell lines. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, cell_line, protein_molecule, other_name

[ "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

The lymphotoxin promoter is stimulated by HTLV-I tax activation of NF-kappa B in human T-cell lines.

[ "The", "lymphotoxin", "promoter", "is", "stimulated", "by", "HTLV", "-", "I", "tax", "activation", "of", "NF", "-", "kappa", "B", "in", "human", "T", "-", "cell", "lines", "." ]

[ "other_name", "protein_molecule", "DNA_molecule", "cell_line", "DNA_domain_or_region", "protein_family_or_group", "virus", "DNA_family_or_group" ]

lymphotoxin promoter is a DNA_domain_or_region, HTLV - I tax activation is an other_name, NF - kappa B is a protein_molecule, human T - cell lines is a cell_line

83714_task1

Sentence: The lymphotoxin promoter is stimulated by HTLV-I tax activation of NF-kappa B in human T-cell lines. Instructions: please typing these entity words according to sentence: lymphotoxin promoter, HTLV - I tax activation, NF - kappa B, human T - cell lines Options: DNA_domain_or_region, cell_line, protein_molecule, other_name

[ "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

The lymphotoxin promoter is stimulated by HTLV-I tax activation of NF-kappa B in human T-cell lines.

[ "The", "lymphotoxin", "promoter", "is", "stimulated", "by", "HTLV", "-", "I", "tax", "activation", "of", "NF", "-", "kappa", "B", "in", "human", "T", "-", "cell", "lines", "." ]

[ "other_name", "protein_molecule", "DNA_molecule", "cell_line", "DNA_domain_or_region", "protein_family_or_group", "virus", "DNA_family_or_group" ]

lymphotoxin promoter, HTLV - I tax activation, NF - kappa B, human T - cell lines

83714_task2

Sentence: The lymphotoxin promoter is stimulated by HTLV-I tax activation of NF-kappa B in human T-cell lines. Instructions: please extract entity words from the input sentence

[ "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

The lymphotoxin promoter is stimulated by HTLV-I tax activation of NF-kappa B in human T-cell lines.

[ "The", "lymphotoxin", "promoter", "is", "stimulated", "by", "HTLV", "-", "I", "tax", "activation", "of", "NF", "-", "kappa", "B", "in", "human", "T", "-", "cell", "lines", "." ]

[ "other_name", "protein_molecule", "DNA_molecule", "cell_line", "DNA_domain_or_region", "protein_family_or_group", "virus", "DNA_family_or_group" ]

cardiac myosin heavy chain is a Gene/protein/RNA, actin is a Gene/protein/RNA

269_task0

Sentence: Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA

[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families.

[ "Exclusion", "of", "cardiac", "myosin", "heavy", "chain", "and", "actin", "gene", "involvement", "in", "hypertrophic", "cardiomyopathy", "of", "several", "French", "families", "." ]

[ "Gene/protein/RNA" ]

cardiac myosin heavy chain is a Gene/protein/RNA, actin is a Gene/protein/RNA

269_task1

Sentence: Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families. Instructions: please typing these entity words according to sentence: cardiac myosin heavy chain, actin Options: Gene/protein/RNA

[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families.

[ "Exclusion", "of", "cardiac", "myosin", "heavy", "chain", "and", "actin", "gene", "involvement", "in", "hypertrophic", "cardiomyopathy", "of", "several", "French", "families", "." ]

[ "Gene/protein/RNA" ]

cardiac myosin heavy chain, actin

269_task2

Sentence: Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families.

[ "Exclusion", "of", "cardiac", "myosin", "heavy", "chain", "and", "actin", "gene", "involvement", "in", "hypertrophic", "cardiomyopathy", "of", "several", "French", "families", "." ]

[ "Gene/protein/RNA" ]

Abstract is an umlsterm, software is an umlsterm, vascular surgery is an umlsterm, database is an umlsterm, vascular surgery is an umlsterm, life is an umlsterm, procedures is an umlsterm, Instruments is an umlsterm, organization is an umlsterm, functions is an umlsterm, program is an umlsterm, surgery is an umlsterm, Society is an umlsterm, Vascular Surgery is an umlsterm, program is an umlsterm, documentation is an umlsterm, computer systems is an umlsterm, budgets is an umlsterm, resources is an umlsterm, time is an umlsterm, controls is an umlsterm

Gefaesschirurgie.00050166.eng.abstr_task0

Sentence: Abstract There is little commercial medical software available for department management in the field of vascular surgery . The database VasoDat was created as an eventual study of vascular surgery 10 years ago . In the meantime it has been autonomously developed into an integral part of daily life in our department . With its relational structure it covers all routine procedures in the department with an intense working stability . Instruments have been developed for optimizing the department's organization and for supporting scientific works . Statistical functions have been added . Data exchange with other systems at the moment is restricted to the program " Quality management in carotid surgery " of the DGG ( German Society of Vascular Surgery ) , and linking to the practising program PatiO and the accompanying private liquidation . Adding tools for image storing , visual report documentation , and linking with other computer systems is possible . Extensions for supporting the management of budgets and resources , e.g. , in managing operative capacity , were developed in order to provide adequate time results and department controls . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Abstract There is little commercial medical software available for department management in the field of vascular surgery . The database VasoDat was created as an eventual study of vascular surgery 10 years ago . In the meantime it has been autonomously developed into an integral part of daily life in our department . With its relational structure it covers all routine procedures in the department with an intense working stability . Instruments have been developed for optimizing the department's organization and for supporting scientific works . Statistical functions have been added . Data exchange with other systems at the moment is restricted to the program " Quality management in carotid surgery " of the DGG ( German Society of Vascular Surgery ) , and linking to the practising program PatiO and the accompanying private liquidation . Adding tools for image storing , visual report documentation , and linking with other computer systems is possible . Extensions for supporting the management of budgets and resources , e.g. , in managing operative capacity , were developed in order to provide adequate time results and department controls .

[ "Abstract", "There", "is", "little", "commercial", "medical", "software", "available", "for", "department", "management", "in", "the", "field", "of", "vascular", "surgery", ".", "The", "database", "VasoDat", "was", "created", "as", "an", "eventual", "study", "of", "vascular", "surgery", "10", "years", "ago", ".", "In", "the", "meantime", "it", "has", "been", "autonomously", "developed", "into", "an", "integral", "part", "of", "daily", "life", "in", "our", "department", ".", "With", "its", "relational", "structure", "it", "covers", "all", "routine", "procedures", "in", "the", "department", "with", "an", "intense", "working", "stability", ".", "Instruments", "have", "been", "developed", "for", "optimizing", "the", "department", "'s", "organization", "and", "for", "supporting", "scientific", "works", ".", "Statistical", "functions", "have", "been", "added", ".", "Data", "exchange", "with", "other", "systems", "at", "the", "moment", "is", "restricted", "to", "the", "program", "\"", "Quality", "management", "in", "carotid", "surgery", "\"", "of", "the", "DGG", "(", "German", "Society", "of", "Vascular", "Surgery", ")", ",", "and", "linking", "to", "the", "practising", "program", "PatiO", "and", "the", "accompanying", "private", "liquidation", ".", "Adding", "tools", "for", "image", "storing", ",", "visual", "report", "documentation", ",", "and", "linking", "with", "other", "computer", "systems", "is", "possible", ".", "Extensions", "for", "supporting", "the", "management", "of", "budgets", "and", "resources", ",", "e.g", ".", ",", "in", "managing", "operative", "capacity", ",", "were", "developed", "in", "order", "to", "provide", "adequate", "time", "results", "and", "department", "controls", "." ]

[ "umlsterm" ]

Abstract is an umlsterm, software is an umlsterm, vascular surgery is an umlsterm, database is an umlsterm, vascular surgery is an umlsterm, life is an umlsterm, procedures is an umlsterm, Instruments is an umlsterm, organization is an umlsterm, functions is an umlsterm, program is an umlsterm, surgery is an umlsterm, Society is an umlsterm, Vascular Surgery is an umlsterm, program is an umlsterm, documentation is an umlsterm, computer systems is an umlsterm, budgets is an umlsterm, resources is an umlsterm, time is an umlsterm, controls is an umlsterm

Gefaesschirurgie.00050166.eng.abstr_task1

Sentence: Abstract There is little commercial medical software available for department management in the field of vascular surgery . The database VasoDat was created as an eventual study of vascular surgery 10 years ago . In the meantime it has been autonomously developed into an integral part of daily life in our department . With its relational structure it covers all routine procedures in the department with an intense working stability . Instruments have been developed for optimizing the department's organization and for supporting scientific works . Statistical functions have been added . Data exchange with other systems at the moment is restricted to the program " Quality management in carotid surgery " of the DGG ( German Society of Vascular Surgery ) , and linking to the practising program PatiO and the accompanying private liquidation . Adding tools for image storing , visual report documentation , and linking with other computer systems is possible . Extensions for supporting the management of budgets and resources , e.g. , in managing operative capacity , were developed in order to provide adequate time results and department controls . Instructions: please typing these entity words according to sentence: Abstract, software, vascular surgery, database, vascular surgery, life, procedures, Instruments, organization, functions, program, surgery, Society, Vascular Surgery, program, documentation, computer systems, budgets, resources, time, controls Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Abstract There is little commercial medical software available for department management in the field of vascular surgery . The database VasoDat was created as an eventual study of vascular surgery 10 years ago . In the meantime it has been autonomously developed into an integral part of daily life in our department . With its relational structure it covers all routine procedures in the department with an intense working stability . Instruments have been developed for optimizing the department's organization and for supporting scientific works . Statistical functions have been added . Data exchange with other systems at the moment is restricted to the program " Quality management in carotid surgery " of the DGG ( German Society of Vascular Surgery ) , and linking to the practising program PatiO and the accompanying private liquidation . Adding tools for image storing , visual report documentation , and linking with other computer systems is possible . Extensions for supporting the management of budgets and resources , e.g. , in managing operative capacity , were developed in order to provide adequate time results and department controls .

[ "Abstract", "There", "is", "little", "commercial", "medical", "software", "available", "for", "department", "management", "in", "the", "field", "of", "vascular", "surgery", ".", "The", "database", "VasoDat", "was", "created", "as", "an", "eventual", "study", "of", "vascular", "surgery", "10", "years", "ago", ".", "In", "the", "meantime", "it", "has", "been", "autonomously", "developed", "into", "an", "integral", "part", "of", "daily", "life", "in", "our", "department", ".", "With", "its", "relational", "structure", "it", "covers", "all", "routine", "procedures", "in", "the", "department", "with", "an", "intense", "working", "stability", ".", "Instruments", "have", "been", "developed", "for", "optimizing", "the", "department", "'s", "organization", "and", "for", "supporting", "scientific", "works", ".", "Statistical", "functions", "have", "been", "added", ".", "Data", "exchange", "with", "other", "systems", "at", "the", "moment", "is", "restricted", "to", "the", "program", "\"", "Quality", "management", "in", "carotid", "surgery", "\"", "of", "the", "DGG", "(", "German", "Society", "of", "Vascular", "Surgery", ")", ",", "and", "linking", "to", "the", "practising", "program", "PatiO", "and", "the", "accompanying", "private", "liquidation", ".", "Adding", "tools", "for", "image", "storing", ",", "visual", "report", "documentation", ",", "and", "linking", "with", "other", "computer", "systems", "is", "possible", ".", "Extensions", "for", "supporting", "the", "management", "of", "budgets", "and", "resources", ",", "e.g", ".", ",", "in", "managing", "operative", "capacity", ",", "were", "developed", "in", "order", "to", "provide", "adequate", "time", "results", "and", "department", "controls", "." ]

[ "umlsterm" ]

Abstract, software, vascular surgery, database, vascular surgery, life, procedures, Instruments, organization, functions, program, surgery, Society, Vascular Surgery, program, documentation, computer systems, budgets, resources, time, controls

Gefaesschirurgie.00050166.eng.abstr_task2

Sentence: Abstract There is little commercial medical software available for department management in the field of vascular surgery . The database VasoDat was created as an eventual study of vascular surgery 10 years ago . In the meantime it has been autonomously developed into an integral part of daily life in our department . With its relational structure it covers all routine procedures in the department with an intense working stability . Instruments have been developed for optimizing the department's organization and for supporting scientific works . Statistical functions have been added . Data exchange with other systems at the moment is restricted to the program " Quality management in carotid surgery " of the DGG ( German Society of Vascular Surgery ) , and linking to the practising program PatiO and the accompanying private liquidation . Adding tools for image storing , visual report documentation , and linking with other computer systems is possible . Extensions for supporting the management of budgets and resources , e.g. , in managing operative capacity , were developed in order to provide adequate time results and department controls . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Abstract There is little commercial medical software available for department management in the field of vascular surgery . The database VasoDat was created as an eventual study of vascular surgery 10 years ago . In the meantime it has been autonomously developed into an integral part of daily life in our department . With its relational structure it covers all routine procedures in the department with an intense working stability . Instruments have been developed for optimizing the department's organization and for supporting scientific works . Statistical functions have been added . Data exchange with other systems at the moment is restricted to the program " Quality management in carotid surgery " of the DGG ( German Society of Vascular Surgery ) , and linking to the practising program PatiO and the accompanying private liquidation . Adding tools for image storing , visual report documentation , and linking with other computer systems is possible . Extensions for supporting the management of budgets and resources , e.g. , in managing operative capacity , were developed in order to provide adequate time results and department controls .

[ "Abstract", "There", "is", "little", "commercial", "medical", "software", "available", "for", "department", "management", "in", "the", "field", "of", "vascular", "surgery", ".", "The", "database", "VasoDat", "was", "created", "as", "an", "eventual", "study", "of", "vascular", "surgery", "10", "years", "ago", ".", "In", "the", "meantime", "it", "has", "been", "autonomously", "developed", "into", "an", "integral", "part", "of", "daily", "life", "in", "our", "department", ".", "With", "its", "relational", "structure", "it", "covers", "all", "routine", "procedures", "in", "the", "department", "with", "an", "intense", "working", "stability", ".", "Instruments", "have", "been", "developed", "for", "optimizing", "the", "department", "'s", "organization", "and", "for", "supporting", "scientific", "works", ".", "Statistical", "functions", "have", "been", "added", ".", "Data", "exchange", "with", "other", "systems", "at", "the", "moment", "is", "restricted", "to", "the", "program", "\"", "Quality", "management", "in", "carotid", "surgery", "\"", "of", "the", "DGG", "(", "German", "Society", "of", "Vascular", "Surgery", ")", ",", "and", "linking", "to", "the", "practising", "program", "PatiO", "and", "the", "accompanying", "private", "liquidation", ".", "Adding", "tools", "for", "image", "storing", ",", "visual", "report", "documentation", ",", "and", "linking", "with", "other", "computer", "systems", "is", "possible", ".", "Extensions", "for", "supporting", "the", "management", "of", "budgets", "and", "resources", ",", "e.g", ".", ",", "in", "managing", "operative", "capacity", ",", "were", "developed", "in", "order", "to", "provide", "adequate", "time", "results", "and", "department", "controls", "." ]

[ "umlsterm" ]

Pankreastumoren is an umlsterm, Patienten is an umlsterm, Pankreaskarzinom is an umlsterm, Kontrastmittel is an umlsterm, Pankreasparenchymphase is an umlsterm, Pankreasloge is an umlsterm, Tumorausdehnung is an umlsterm, Tumoren is an umlsterm, Fettgewebe is an umlsterm, Duodenum is an umlsterm, Magen is an umlsterm, Lymphknoten is an umlsterm, Pankreaskarzinomen is an umlsterm

DerRadiologe.90390958.ger.abstr_task0

Sentence: Ziel unserer Untersuchungen war es , die Moeglichkeiten der Mehrzeilen-Detektor-Spiral-CT und ihre Bedeutung fuer das Staging von Pankreastumoren zu evaluieren . Bei insgesamt 50 Patienten , bei denen der Verdacht auf ein Pankreaskarzinom bestand , wurde im Rahmen der Tumorstagings ein biphasisches hochaufgeloestes Mehrzeilen-Spiral-CT mit einer Schichtkollimation von 4x1 mm , einem Pitch von 3,5-4, 120 ml Kontrastmittel , 50 ml 0,9%NaCl-Bolus, 3,0 ml/s Fluss und einem Startdelay von durchschnittlich 40 s ( Pankreasparenchymphase ) und 80 s ( portalvenoese Phase ) durchgefuehrt . Die Mehrzeilen-Spiral-CT ist in der Lage die gesamte Pankreasloge und auch die angrenzenden Organe mit hoher Ortsaufloesung in allen Raumebenen abzubilden . Die nahezu isotrope multiplanare Bildgebung erlaubt die vollstaendige Erfassung der Tumorausdehnung in allen Raumebenen und eine bessere Abgrenzung der Tumoren gegenueber dem angrenzenden Fettgewebe , den benachbarten Organen ( Gefaesse Duodenum , Magen ) , und einen sichereren Nachweis von peripankreatischen Lymphknoten . Die Mehrzeilen-Spiral-CT und der Einsatz von interaktiven multiplanaren Rekonstruktionen verbessern nachhaltig die Bestimmung der Ausdehnung von Pankreaskarzinomen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Ziel unserer Untersuchungen war es , die Moeglichkeiten der Mehrzeilen-Detektor-Spiral-CT und ihre Bedeutung fuer das Staging von Pankreastumoren zu evaluieren . Bei insgesamt 50 Patienten , bei denen der Verdacht auf ein Pankreaskarzinom bestand , wurde im Rahmen der Tumorstagings ein biphasisches hochaufgeloestes Mehrzeilen-Spiral-CT mit einer Schichtkollimation von 4x1 mm , einem Pitch von 3,5-4, 120 ml Kontrastmittel , 50 ml 0,9%NaCl-Bolus, 3,0 ml/s Fluss und einem Startdelay von durchschnittlich 40 s ( Pankreasparenchymphase ) und 80 s ( portalvenoese Phase ) durchgefuehrt . Die Mehrzeilen-Spiral-CT ist in der Lage die gesamte Pankreasloge und auch die angrenzenden Organe mit hoher Ortsaufloesung in allen Raumebenen abzubilden . Die nahezu isotrope multiplanare Bildgebung erlaubt die vollstaendige Erfassung der Tumorausdehnung in allen Raumebenen und eine bessere Abgrenzung der Tumoren gegenueber dem angrenzenden Fettgewebe , den benachbarten Organen ( Gefaesse Duodenum , Magen ) , und einen sichereren Nachweis von peripankreatischen Lymphknoten . Die Mehrzeilen-Spiral-CT und der Einsatz von interaktiven multiplanaren Rekonstruktionen verbessern nachhaltig die Bestimmung der Ausdehnung von Pankreaskarzinomen .

[ "Ziel", "unserer", "Untersuchungen", "war", "es", ",", "die", "Moeglichkeiten", "der", "Mehrzeilen", "-", "Detektor", "-", "Spiral", "-", "CT", "und", "ihre", "Bedeutung", "fuer", "das", "Staging", "von", "Pankreastumoren", "zu", "evaluieren", ".", "Bei", "insgesamt", "50", "Patienten", ",", "bei", "denen", "der", "Verdacht", "auf", "ein", "Pankreaskarzinom", "bestand", ",", "wurde", "im", "Rahmen", "der", "Tumorstagings", "ein", "biphasisches", "hochaufgeloestes", "Mehrzeilen", "-", "Spiral", "-", "CT", "mit", "einer", "Schichtkollimation", "von", "4x1", "mm", ",", "einem", "Pitch", "von", "3,5", "-", "4", ",", "120", "ml", "Kontrastmittel", ",", "50", "ml", "0,9%NaCl", "-", "Bolus", ",", "3,0", "ml", "/", "s", "Fluss", "und", "einem", "Startdelay", "von", "durchschnittlich", "40", "s", "(", "Pankreasparenchymphase", ")", "und", "80", "s", "(", "portalvenoese", "Phase", ")", "durchgefuehrt", ".", "Die", "Mehrzeilen", "-", "Spiral", "-", "CT", "ist", "in", "der", "Lage", "die", "gesamte", "Pankreasloge", "und", "auch", "die", "angrenzenden", "Organe", "mit", "hoher", "Ortsaufloesung", "in", "allen", "Raumebenen", "abzubilden", ".", "Die", "nahezu", "isotrope", "multiplanare", "Bildgebung", "erlaubt", "die", "vollstaendige", "Erfassung", "der", "Tumorausdehnung", "in", "allen", "Raumebenen", "und", "eine", "bessere", "Abgrenzung", "der", "Tumoren", "gegenueber", "dem", "angrenzenden", "Fettgewebe", ",", "den", "benachbarten", "Organen", "(", "Gefaesse", "Duodenum", ",", "Magen", ")", ",", "und", "einen", "sichereren", "Nachweis", "von", "peripankreatischen", "Lymphknoten", ".", "Die", "Mehrzeilen", "-", "Spiral", "-", "CT", "und", "der", "Einsatz", "von", "interaktiven", "multiplanaren", "Rekonstruktionen", "verbessern", "nachhaltig", "die", "Bestimmung", "der", "Ausdehnung", "von", "Pankreaskarzinomen", "." ]

[ "umlsterm" ]

Pankreastumoren is an umlsterm, Patienten is an umlsterm, Pankreaskarzinom is an umlsterm, Kontrastmittel is an umlsterm, Pankreasparenchymphase is an umlsterm, Pankreasloge is an umlsterm, Tumorausdehnung is an umlsterm, Tumoren is an umlsterm, Fettgewebe is an umlsterm, Duodenum is an umlsterm, Magen is an umlsterm, Lymphknoten is an umlsterm, Pankreaskarzinomen is an umlsterm

DerRadiologe.90390958.ger.abstr_task1

Sentence: Ziel unserer Untersuchungen war es , die Moeglichkeiten der Mehrzeilen-Detektor-Spiral-CT und ihre Bedeutung fuer das Staging von Pankreastumoren zu evaluieren . Bei insgesamt 50 Patienten , bei denen der Verdacht auf ein Pankreaskarzinom bestand , wurde im Rahmen der Tumorstagings ein biphasisches hochaufgeloestes Mehrzeilen-Spiral-CT mit einer Schichtkollimation von 4x1 mm , einem Pitch von 3,5-4, 120 ml Kontrastmittel , 50 ml 0,9%NaCl-Bolus, 3,0 ml/s Fluss und einem Startdelay von durchschnittlich 40 s ( Pankreasparenchymphase ) und 80 s ( portalvenoese Phase ) durchgefuehrt . Die Mehrzeilen-Spiral-CT ist in der Lage die gesamte Pankreasloge und auch die angrenzenden Organe mit hoher Ortsaufloesung in allen Raumebenen abzubilden . Die nahezu isotrope multiplanare Bildgebung erlaubt die vollstaendige Erfassung der Tumorausdehnung in allen Raumebenen und eine bessere Abgrenzung der Tumoren gegenueber dem angrenzenden Fettgewebe , den benachbarten Organen ( Gefaesse Duodenum , Magen ) , und einen sichereren Nachweis von peripankreatischen Lymphknoten . Die Mehrzeilen-Spiral-CT und der Einsatz von interaktiven multiplanaren Rekonstruktionen verbessern nachhaltig die Bestimmung der Ausdehnung von Pankreaskarzinomen . Instructions: please typing these entity words according to sentence: Pankreastumoren, Patienten, Pankreaskarzinom, Kontrastmittel, Pankreasparenchymphase, Pankreasloge, Tumorausdehnung, Tumoren, Fettgewebe, Duodenum, Magen, Lymphknoten, Pankreaskarzinomen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Ziel unserer Untersuchungen war es , die Moeglichkeiten der Mehrzeilen-Detektor-Spiral-CT und ihre Bedeutung fuer das Staging von Pankreastumoren zu evaluieren . Bei insgesamt 50 Patienten , bei denen der Verdacht auf ein Pankreaskarzinom bestand , wurde im Rahmen der Tumorstagings ein biphasisches hochaufgeloestes Mehrzeilen-Spiral-CT mit einer Schichtkollimation von 4x1 mm , einem Pitch von 3,5-4, 120 ml Kontrastmittel , 50 ml 0,9%NaCl-Bolus, 3,0 ml/s Fluss und einem Startdelay von durchschnittlich 40 s ( Pankreasparenchymphase ) und 80 s ( portalvenoese Phase ) durchgefuehrt . Die Mehrzeilen-Spiral-CT ist in der Lage die gesamte Pankreasloge und auch die angrenzenden Organe mit hoher Ortsaufloesung in allen Raumebenen abzubilden . Die nahezu isotrope multiplanare Bildgebung erlaubt die vollstaendige Erfassung der Tumorausdehnung in allen Raumebenen und eine bessere Abgrenzung der Tumoren gegenueber dem angrenzenden Fettgewebe , den benachbarten Organen ( Gefaesse Duodenum , Magen ) , und einen sichereren Nachweis von peripankreatischen Lymphknoten . Die Mehrzeilen-Spiral-CT und der Einsatz von interaktiven multiplanaren Rekonstruktionen verbessern nachhaltig die Bestimmung der Ausdehnung von Pankreaskarzinomen .

[ "Ziel", "unserer", "Untersuchungen", "war", "es", ",", "die", "Moeglichkeiten", "der", "Mehrzeilen", "-", "Detektor", "-", "Spiral", "-", "CT", "und", "ihre", "Bedeutung", "fuer", "das", "Staging", "von", "Pankreastumoren", "zu", "evaluieren", ".", "Bei", "insgesamt", "50", "Patienten", ",", "bei", "denen", "der", "Verdacht", "auf", "ein", "Pankreaskarzinom", "bestand", ",", "wurde", "im", "Rahmen", "der", "Tumorstagings", "ein", "biphasisches", "hochaufgeloestes", "Mehrzeilen", "-", "Spiral", "-", "CT", "mit", "einer", "Schichtkollimation", "von", "4x1", "mm", ",", "einem", "Pitch", "von", "3,5", "-", "4", ",", "120", "ml", "Kontrastmittel", ",", "50", "ml", "0,9%NaCl", "-", "Bolus", ",", "3,0", "ml", "/", "s", "Fluss", "und", "einem", "Startdelay", "von", "durchschnittlich", "40", "s", "(", "Pankreasparenchymphase", ")", "und", "80", "s", "(", "portalvenoese", "Phase", ")", "durchgefuehrt", ".", "Die", "Mehrzeilen", "-", "Spiral", "-", "CT", "ist", "in", "der", "Lage", "die", "gesamte", "Pankreasloge", "und", "auch", "die", "angrenzenden", "Organe", "mit", "hoher", "Ortsaufloesung", "in", "allen", "Raumebenen", "abzubilden", ".", "Die", "nahezu", "isotrope", "multiplanare", "Bildgebung", "erlaubt", "die", "vollstaendige", "Erfassung", "der", "Tumorausdehnung", "in", "allen", "Raumebenen", "und", "eine", "bessere", "Abgrenzung", "der", "Tumoren", "gegenueber", "dem", "angrenzenden", "Fettgewebe", ",", "den", "benachbarten", "Organen", "(", "Gefaesse", "Duodenum", ",", "Magen", ")", ",", "und", "einen", "sichereren", "Nachweis", "von", "peripankreatischen", "Lymphknoten", ".", "Die", "Mehrzeilen", "-", "Spiral", "-", "CT", "und", "der", "Einsatz", "von", "interaktiven", "multiplanaren", "Rekonstruktionen", "verbessern", "nachhaltig", "die", "Bestimmung", "der", "Ausdehnung", "von", "Pankreaskarzinomen", "." ]

[ "umlsterm" ]

Pankreastumoren, Patienten, Pankreaskarzinom, Kontrastmittel, Pankreasparenchymphase, Pankreasloge, Tumorausdehnung, Tumoren, Fettgewebe, Duodenum, Magen, Lymphknoten, Pankreaskarzinomen

DerRadiologe.90390958.ger.abstr_task2

Sentence: Ziel unserer Untersuchungen war es , die Moeglichkeiten der Mehrzeilen-Detektor-Spiral-CT und ihre Bedeutung fuer das Staging von Pankreastumoren zu evaluieren . Bei insgesamt 50 Patienten , bei denen der Verdacht auf ein Pankreaskarzinom bestand , wurde im Rahmen der Tumorstagings ein biphasisches hochaufgeloestes Mehrzeilen-Spiral-CT mit einer Schichtkollimation von 4x1 mm , einem Pitch von 3,5-4, 120 ml Kontrastmittel , 50 ml 0,9%NaCl-Bolus, 3,0 ml/s Fluss und einem Startdelay von durchschnittlich 40 s ( Pankreasparenchymphase ) und 80 s ( portalvenoese Phase ) durchgefuehrt . Die Mehrzeilen-Spiral-CT ist in der Lage die gesamte Pankreasloge und auch die angrenzenden Organe mit hoher Ortsaufloesung in allen Raumebenen abzubilden . Die nahezu isotrope multiplanare Bildgebung erlaubt die vollstaendige Erfassung der Tumorausdehnung in allen Raumebenen und eine bessere Abgrenzung der Tumoren gegenueber dem angrenzenden Fettgewebe , den benachbarten Organen ( Gefaesse Duodenum , Magen ) , und einen sichereren Nachweis von peripankreatischen Lymphknoten . Die Mehrzeilen-Spiral-CT und der Einsatz von interaktiven multiplanaren Rekonstruktionen verbessern nachhaltig die Bestimmung der Ausdehnung von Pankreaskarzinomen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Ziel unserer Untersuchungen war es , die Moeglichkeiten der Mehrzeilen-Detektor-Spiral-CT und ihre Bedeutung fuer das Staging von Pankreastumoren zu evaluieren . Bei insgesamt 50 Patienten , bei denen der Verdacht auf ein Pankreaskarzinom bestand , wurde im Rahmen der Tumorstagings ein biphasisches hochaufgeloestes Mehrzeilen-Spiral-CT mit einer Schichtkollimation von 4x1 mm , einem Pitch von 3,5-4, 120 ml Kontrastmittel , 50 ml 0,9%NaCl-Bolus, 3,0 ml/s Fluss und einem Startdelay von durchschnittlich 40 s ( Pankreasparenchymphase ) und 80 s ( portalvenoese Phase ) durchgefuehrt . Die Mehrzeilen-Spiral-CT ist in der Lage die gesamte Pankreasloge und auch die angrenzenden Organe mit hoher Ortsaufloesung in allen Raumebenen abzubilden . Die nahezu isotrope multiplanare Bildgebung erlaubt die vollstaendige Erfassung der Tumorausdehnung in allen Raumebenen und eine bessere Abgrenzung der Tumoren gegenueber dem angrenzenden Fettgewebe , den benachbarten Organen ( Gefaesse Duodenum , Magen ) , und einen sichereren Nachweis von peripankreatischen Lymphknoten . Die Mehrzeilen-Spiral-CT und der Einsatz von interaktiven multiplanaren Rekonstruktionen verbessern nachhaltig die Bestimmung der Ausdehnung von Pankreaskarzinomen .

[ "Ziel", "unserer", "Untersuchungen", "war", "es", ",", "die", "Moeglichkeiten", "der", "Mehrzeilen", "-", "Detektor", "-", "Spiral", "-", "CT", "und", "ihre", "Bedeutung", "fuer", "das", "Staging", "von", "Pankreastumoren", "zu", "evaluieren", ".", "Bei", "insgesamt", "50", "Patienten", ",", "bei", "denen", "der", "Verdacht", "auf", "ein", "Pankreaskarzinom", "bestand", ",", "wurde", "im", "Rahmen", "der", "Tumorstagings", "ein", "biphasisches", "hochaufgeloestes", "Mehrzeilen", "-", "Spiral", "-", "CT", "mit", "einer", "Schichtkollimation", "von", "4x1", "mm", ",", "einem", "Pitch", "von", "3,5", "-", "4", ",", "120", "ml", "Kontrastmittel", ",", "50", "ml", "0,9%NaCl", "-", "Bolus", ",", "3,0", "ml", "/", "s", "Fluss", "und", "einem", "Startdelay", "von", "durchschnittlich", "40", "s", "(", "Pankreasparenchymphase", ")", "und", "80", "s", "(", "portalvenoese", "Phase", ")", "durchgefuehrt", ".", "Die", "Mehrzeilen", "-", "Spiral", "-", "CT", "ist", "in", "der", "Lage", "die", "gesamte", "Pankreasloge", "und", "auch", "die", "angrenzenden", "Organe", "mit", "hoher", "Ortsaufloesung", "in", "allen", "Raumebenen", "abzubilden", ".", "Die", "nahezu", "isotrope", "multiplanare", "Bildgebung", "erlaubt", "die", "vollstaendige", "Erfassung", "der", "Tumorausdehnung", "in", "allen", "Raumebenen", "und", "eine", "bessere", "Abgrenzung", "der", "Tumoren", "gegenueber", "dem", "angrenzenden", "Fettgewebe", ",", "den", "benachbarten", "Organen", "(", "Gefaesse", "Duodenum", ",", "Magen", ")", ",", "und", "einen", "sichereren", "Nachweis", "von", "peripankreatischen", "Lymphknoten", ".", "Die", "Mehrzeilen", "-", "Spiral", "-", "CT", "und", "der", "Einsatz", "von", "interaktiven", "multiplanaren", "Rekonstruktionen", "verbessern", "nachhaltig", "die", "Bestimmung", "der", "Ausdehnung", "von", "Pankreaskarzinomen", "." ]

[ "umlsterm" ]

glucose is a compound, IGF - I is a protein, PRL is a protein

DS.d388_task0

Sentence: Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL and TSH, seen in both Snell and Ames dwarf mice. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL and TSH, seen in both Snell and Ames dwarf mice.

[ "Hence", ",", "resistance", "to", "cancer", "in", "old", "Snell", "dwarf", "mice", "may", "be", "mediated", "by", "neuroendocrine", "factors", "that", "reduce", "glucose", "utilization", "besides", "elevated", "adiponectin", ",", "reduced", "IGF", "-", "I", "and", "a", "lack", "of", "GH", ",", "PRL", "and", "TSH", ",", "seen", "in", "both", "Snell", "and", "Ames", "dwarf", "mice", "." ]

[ "compound", "protein" ]

glucose is a compound, IGF - I is a protein, PRL is a protein

DS.d388_task1

Sentence: Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL and TSH, seen in both Snell and Ames dwarf mice. Instructions: please typing these entity words according to sentence: glucose, IGF - I, PRL Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL and TSH, seen in both Snell and Ames dwarf mice.

[ "Hence", ",", "resistance", "to", "cancer", "in", "old", "Snell", "dwarf", "mice", "may", "be", "mediated", "by", "neuroendocrine", "factors", "that", "reduce", "glucose", "utilization", "besides", "elevated", "adiponectin", ",", "reduced", "IGF", "-", "I", "and", "a", "lack", "of", "GH", ",", "PRL", "and", "TSH", ",", "seen", "in", "both", "Snell", "and", "Ames", "dwarf", "mice", "." ]

[ "compound", "protein" ]

glucose, IGF - I, PRL

DS.d388_task2

Sentence: Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL and TSH, seen in both Snell and Ames dwarf mice. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL and TSH, seen in both Snell and Ames dwarf mice.

[ "Hence", ",", "resistance", "to", "cancer", "in", "old", "Snell", "dwarf", "mice", "may", "be", "mediated", "by", "neuroendocrine", "factors", "that", "reduce", "glucose", "utilization", "besides", "elevated", "adiponectin", ",", "reduced", "IGF", "-", "I", "and", "a", "lack", "of", "GH", ",", "PRL", "and", "TSH", ",", "seen", "in", "both", "Snell", "and", "Ames", "dwarf", "mice", "." ]

[ "compound", "protein" ]

severe comorbidities is a Scope, cardiovascular disease , chronic obstructive pulmonary disease , diabetes mellitus , and chronic renal dysfunction is a Scope, bad compliance is a Condition, contraindication to enrollment is a Condition, Pregnant woman is a Scope, lactating woman is a Scope, contraindication is a Condition, adjuvant chemotherapy is a Procedure

NCT02466113_exc_task0

Sentence: With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. With bad compliance or contraindication to enrollment. Pregnant woman or lactating woman. With contraindication to receive adjuvant chemotherapy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Condition, Procedure

[ "O", "B-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "O", "O", "O", "B-Condition", "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]

With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. With bad compliance or contraindication to enrollment. Pregnant woman or lactating woman. With contraindication to receive adjuvant chemotherapy.

[ "With", "severe", "comorbidities", ",", "such", "as", "cardiovascular", "disease", ",", "chronic", "obstructive", "pulmonary", "disease", ",", "diabetes", "mellitus", ",", "and", "chronic", "renal", "dysfunction", ".", "\n", "With", "bad", "compliance", "or", "contraindication", "to", "enrollment", ".", "\n", "Pregnant", "woman", "or", "lactating", "woman", ".", "\n", "With", "contraindication", "to", "receive", "adjuvant", "chemotherapy", ".", " \n \n" ]

[ "Scope", "Condition", "Procedure", "Qualifier", "Person" ]

severe comorbidities is a Scope, cardiovascular disease , chronic obstructive pulmonary disease , diabetes mellitus , and chronic renal dysfunction is a Scope, bad compliance is a Condition, contraindication to enrollment is a Condition, Pregnant woman is a Scope, lactating woman is a Scope, contraindication is a Condition, adjuvant chemotherapy is a Procedure

NCT02466113_exc_task1

Sentence: With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. With bad compliance or contraindication to enrollment. Pregnant woman or lactating woman. With contraindication to receive adjuvant chemotherapy. Instructions: please typing these entity words according to sentence: severe comorbidities, cardiovascular disease , chronic obstructive pulmonary disease , diabetes mellitus , and chronic renal dysfunction, bad compliance, contraindication to enrollment, Pregnant woman, lactating woman, contraindication, adjuvant chemotherapy Options: Scope, Condition, Procedure

[ "O", "B-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "O", "O", "O", "B-Condition", "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]

With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. With bad compliance or contraindication to enrollment. Pregnant woman or lactating woman. With contraindication to receive adjuvant chemotherapy.

[ "With", "severe", "comorbidities", ",", "such", "as", "cardiovascular", "disease", ",", "chronic", "obstructive", "pulmonary", "disease", ",", "diabetes", "mellitus", ",", "and", "chronic", "renal", "dysfunction", ".", "\n", "With", "bad", "compliance", "or", "contraindication", "to", "enrollment", ".", "\n", "Pregnant", "woman", "or", "lactating", "woman", ".", "\n", "With", "contraindication", "to", "receive", "adjuvant", "chemotherapy", ".", " \n \n" ]

[ "Scope", "Condition", "Procedure", "Qualifier", "Person" ]

severe comorbidities, cardiovascular disease , chronic obstructive pulmonary disease , diabetes mellitus , and chronic renal dysfunction, bad compliance, contraindication to enrollment, Pregnant woman, lactating woman, contraindication, adjuvant chemotherapy

NCT02466113_exc_task2

Sentence: With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. With bad compliance or contraindication to enrollment. Pregnant woman or lactating woman. With contraindication to receive adjuvant chemotherapy. Instructions: please extract entity words from the input sentence

[ "O", "B-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "O", "O", "O", "B-Condition", "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]

With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. With bad compliance or contraindication to enrollment. Pregnant woman or lactating woman. With contraindication to receive adjuvant chemotherapy.

[ "With", "severe", "comorbidities", ",", "such", "as", "cardiovascular", "disease", ",", "chronic", "obstructive", "pulmonary", "disease", ",", "diabetes", "mellitus", ",", "and", "chronic", "renal", "dysfunction", ".", "\n", "With", "bad", "compliance", "or", "contraindication", "to", "enrollment", ".", "\n", "Pregnant", "woman", "or", "lactating", "woman", ".", "\n", "With", "contraindication", "to", "receive", "adjuvant", "chemotherapy", ".", " \n \n" ]

[ "Scope", "Condition", "Procedure", "Qualifier", "Person" ]

profilin is a Individual_protein, actin is a Individual_protein

789_task0

Sentence: These regions also interact with the physiologically relevant ligands of profilin, actin and proline-rich peptides. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O" ]

These regions also interact with the physiologically relevant ligands of profilin, actin and proline-rich peptides.

[ "These", "regions", "also", "interact", "with", "the", "physiologically", "relevant", "ligands", "of", "profilin", ",", "actin", "and", "proline", "-", "rich", "peptides", "." ]

[ "Individual_protein" ]

profilin is a Individual_protein, actin is a Individual_protein

789_task1

Sentence: These regions also interact with the physiologically relevant ligands of profilin, actin and proline-rich peptides. Instructions: please typing these entity words according to sentence: profilin, actin Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O" ]

These regions also interact with the physiologically relevant ligands of profilin, actin and proline-rich peptides.

[ "These", "regions", "also", "interact", "with", "the", "physiologically", "relevant", "ligands", "of", "profilin", ",", "actin", "and", "proline", "-", "rich", "peptides", "." ]

[ "Individual_protein" ]

profilin, actin

789_task2

Sentence: These regions also interact with the physiologically relevant ligands of profilin, actin and proline-rich peptides. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O" ]

These regions also interact with the physiologically relevant ligands of profilin, actin and proline-rich peptides.

[ "These", "regions", "also", "interact", "with", "the", "physiologically", "relevant", "ligands", "of", "profilin", ",", "actin", "and", "proline", "-", "rich", "peptides", "." ]

[ "Individual_protein" ]

giant cell granuloma is an umlsterm, middle aged is an umlsterm, women is an umlsterm, skin is an umlsterm, sunlight is an umlsterm, female is an umlsterm, patient is an umlsterm, abdomen is an umlsterm, criteria is an umlsterm, giant cell granuloma is an umlsterm, findings is an umlsterm, light is an umlsterm, transient is an umlsterm, Differential diagnosis is an umlsterm, skin disorders is an umlsterm, discrimination is an umlsterm

DerHautarzt.50460490.eng.abstr_task0

Sentence: Annular elastolytic giant cell granuloma is mostly found in middle aged women in skin areas exposed to sunlight . Our 17-year-old female patient had a widespread reddish-brown lesion on the abdomen that met the histological criteria for annular elastolytic giant cell granuloma . However , the clinical findings and the localization were uncommon . UV light was excluded as a trigger . Other , still unknown , factors that might change antigenicity of elastic fibres must be considered . Spontaneous resolution suggests a transient influence of such factors . Differential diagnosis includes skin disorders with elastolysis ; discrimination especially from mid-dermal elastolysis is not well defined . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Annular elastolytic giant cell granuloma is mostly found in middle aged women in skin areas exposed to sunlight . Our 17-year-old female patient had a widespread reddish-brown lesion on the abdomen that met the histological criteria for annular elastolytic giant cell granuloma . However , the clinical findings and the localization were uncommon . UV light was excluded as a trigger . Other , still unknown , factors that might change antigenicity of elastic fibres must be considered . Spontaneous resolution suggests a transient influence of such factors . Differential diagnosis includes skin disorders with elastolysis ; discrimination especially from mid-dermal elastolysis is not well defined .

[ "Annular", "elastolytic", "giant", "cell", "granuloma", "is", "mostly", "found", "in", "middle", "aged", "women", "in", "skin", "areas", "exposed", "to", "sunlight", ".", "Our", "17-year", "-", "old", "female", "patient", "had", "a", "widespread", "reddish", "-", "brown", "lesion", "on", "the", "abdomen", "that", "met", "the", "histological", "criteria", "for", "annular", "elastolytic", "giant", "cell", "granuloma", ".", "However", ",", "the", "clinical", "findings", "and", "the", "localization", "were", "uncommon", ".", "UV", "light", "was", "excluded", "as", "a", "trigger", ".", "Other", ",", "still", "unknown", ",", "factors", "that", "might", "change", "antigenicity", "of", "elastic", "fibres", "must", "be", "considered", ".", "Spontaneous", "resolution", "suggests", "a", "transient", "influence", "of", "such", "factors", ".", "Differential", "diagnosis", "includes", "skin", "disorders", "with", "elastolysis", ";", "discrimination", "especially", "from", "mid", "-", "dermal", "elastolysis", "is", "not", "well", "defined", "." ]

[ "umlsterm" ]

giant cell granuloma is an umlsterm, middle aged is an umlsterm, women is an umlsterm, skin is an umlsterm, sunlight is an umlsterm, female is an umlsterm, patient is an umlsterm, abdomen is an umlsterm, criteria is an umlsterm, giant cell granuloma is an umlsterm, findings is an umlsterm, light is an umlsterm, transient is an umlsterm, Differential diagnosis is an umlsterm, skin disorders is an umlsterm, discrimination is an umlsterm

DerHautarzt.50460490.eng.abstr_task1

Sentence: Annular elastolytic giant cell granuloma is mostly found in middle aged women in skin areas exposed to sunlight . Our 17-year-old female patient had a widespread reddish-brown lesion on the abdomen that met the histological criteria for annular elastolytic giant cell granuloma . However , the clinical findings and the localization were uncommon . UV light was excluded as a trigger . Other , still unknown , factors that might change antigenicity of elastic fibres must be considered . Spontaneous resolution suggests a transient influence of such factors . Differential diagnosis includes skin disorders with elastolysis ; discrimination especially from mid-dermal elastolysis is not well defined . Instructions: please typing these entity words according to sentence: giant cell granuloma, middle aged, women, skin, sunlight, female, patient, abdomen, criteria, giant cell granuloma, findings, light, transient, Differential diagnosis, skin disorders, discrimination Options: umlsterm

[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Annular elastolytic giant cell granuloma is mostly found in middle aged women in skin areas exposed to sunlight . Our 17-year-old female patient had a widespread reddish-brown lesion on the abdomen that met the histological criteria for annular elastolytic giant cell granuloma . However , the clinical findings and the localization were uncommon . UV light was excluded as a trigger . Other , still unknown , factors that might change antigenicity of elastic fibres must be considered . Spontaneous resolution suggests a transient influence of such factors . Differential diagnosis includes skin disorders with elastolysis ; discrimination especially from mid-dermal elastolysis is not well defined .

[ "Annular", "elastolytic", "giant", "cell", "granuloma", "is", "mostly", "found", "in", "middle", "aged", "women", "in", "skin", "areas", "exposed", "to", "sunlight", ".", "Our", "17-year", "-", "old", "female", "patient", "had", "a", "widespread", "reddish", "-", "brown", "lesion", "on", "the", "abdomen", "that", "met", "the", "histological", "criteria", "for", "annular", "elastolytic", "giant", "cell", "granuloma", ".", "However", ",", "the", "clinical", "findings", "and", "the", "localization", "were", "uncommon", ".", "UV", "light", "was", "excluded", "as", "a", "trigger", ".", "Other", ",", "still", "unknown", ",", "factors", "that", "might", "change", "antigenicity", "of", "elastic", "fibres", "must", "be", "considered", ".", "Spontaneous", "resolution", "suggests", "a", "transient", "influence", "of", "such", "factors", ".", "Differential", "diagnosis", "includes", "skin", "disorders", "with", "elastolysis", ";", "discrimination", "especially", "from", "mid", "-", "dermal", "elastolysis", "is", "not", "well", "defined", "." ]

[ "umlsterm" ]

giant cell granuloma, middle aged, women, skin, sunlight, female, patient, abdomen, criteria, giant cell granuloma, findings, light, transient, Differential diagnosis, skin disorders, discrimination

DerHautarzt.50460490.eng.abstr_task2

Sentence: Annular elastolytic giant cell granuloma is mostly found in middle aged women in skin areas exposed to sunlight . Our 17-year-old female patient had a widespread reddish-brown lesion on the abdomen that met the histological criteria for annular elastolytic giant cell granuloma . However , the clinical findings and the localization were uncommon . UV light was excluded as a trigger . Other , still unknown , factors that might change antigenicity of elastic fibres must be considered . Spontaneous resolution suggests a transient influence of such factors . Differential diagnosis includes skin disorders with elastolysis ; discrimination especially from mid-dermal elastolysis is not well defined . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Annular elastolytic giant cell granuloma is mostly found in middle aged women in skin areas exposed to sunlight . Our 17-year-old female patient had a widespread reddish-brown lesion on the abdomen that met the histological criteria for annular elastolytic giant cell granuloma . However , the clinical findings and the localization were uncommon . UV light was excluded as a trigger . Other , still unknown , factors that might change antigenicity of elastic fibres must be considered . Spontaneous resolution suggests a transient influence of such factors . Differential diagnosis includes skin disorders with elastolysis ; discrimination especially from mid-dermal elastolysis is not well defined .

[ "Annular", "elastolytic", "giant", "cell", "granuloma", "is", "mostly", "found", "in", "middle", "aged", "women", "in", "skin", "areas", "exposed", "to", "sunlight", ".", "Our", "17-year", "-", "old", "female", "patient", "had", "a", "widespread", "reddish", "-", "brown", "lesion", "on", "the", "abdomen", "that", "met", "the", "histological", "criteria", "for", "annular", "elastolytic", "giant", "cell", "granuloma", ".", "However", ",", "the", "clinical", "findings", "and", "the", "localization", "were", "uncommon", ".", "UV", "light", "was", "excluded", "as", "a", "trigger", ".", "Other", ",", "still", "unknown", ",", "factors", "that", "might", "change", "antigenicity", "of", "elastic", "fibres", "must", "be", "considered", ".", "Spontaneous", "resolution", "suggests", "a", "transient", "influence", "of", "such", "factors", ".", "Differential", "diagnosis", "includes", "skin", "disorders", "with", "elastolysis", ";", "discrimination", "especially", "from", "mid", "-", "dermal", "elastolysis", "is", "not", "well", "defined", "." ]

[ "umlsterm" ]

depression after admission for a cardiac condition is a Participant_Condition, general - practitioner - based interventions is a Intervention_Educational, identifying depression and offering an evidence - based intervention is a Intervention_Educational, multidisciplinary telephone case conferencing is a Intervention_Educational, economic costs . is a Outcome_Other, 1455 is a Participant_Sample-size, Center for Epidemiological Studies Depression Scale is a Outcome_Mental, Hospital Anxiety and Depression Scale is a Outcome_Mental, Center for Epidemiological Studies Depression Scale scores > 27 is a Outcome_Mental, depressive symptoms is a Outcome_Mental

15547_task0

Sentence: Identification , course , and treatment of depression after admission for a cardiac condition : rationale and patient characteristics for the Identifying Depression As a Comorbid Condition ( IDACC ) project . BACKGROUND Given the prevalence of cardiovascular disease and the high rates of depression among cardiac patients , there is a need to develop practical ways to identify this population and provide pragmatic general-practitioner-based interventions for managing depression as a comorbid condition . METHOD The Identifying Depression As a Comorbid Condition ( IDACC ) study employed a hybrid design , incorporating a randomized controlled trial nested within a prospective cohort study . IDACC screened for depression in patients hospitalized in South Australia for a range of cardiac conditions , with outcome measures monitored for 12 months after discharge . The subgroup identified as depressed was entered into the nested IDACC trial , which tests the hypothesis that identifying depression and offering an evidence-based intervention to general practitioners , incorporating multidisciplinary telephone case conferencing , will reduce levels of depression , improve quality of life , and reduce associated economic costs . RESULTS At baseline , 46.3 % of 1455 participants screened were classified as depression cases on the basis of their score on the Center for Epidemiological Studies Depression Scale ( > or =16 ) or the Hospital Anxiety and Depression Scale ( > or =8 ) . Elevated scores were associated with being younger , female , divorced or separated , not employed , living alone , having a lower level of education , and having poorer health and quality of life . Nearly one fifth ( 19.4 % ) of participants had Center for Epidemiological Studies Depression Scale scores > 27 , which is indicative of major depression . CONCLUSIONS This project confirms , in an Australian setting , the high prevalence of depressive symptoms among hospitalized cardiac patients . Follow-up over 12 months will enhance understanding of the natural history of depression in cardiac patients , while the nested trial will inform on effectiveness of an intervention involving tailored advice and support to general practitioners . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Educational, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Identification , course , and treatment of depression after admission for a cardiac condition : rationale and patient characteristics for the Identifying Depression As a Comorbid Condition ( IDACC ) project . BACKGROUND Given the prevalence of cardiovascular disease and the high rates of depression among cardiac patients , there is a need to develop practical ways to identify this population and provide pragmatic general-practitioner-based interventions for managing depression as a comorbid condition . METHOD The Identifying Depression As a Comorbid Condition ( IDACC ) study employed a hybrid design , incorporating a randomized controlled trial nested within a prospective cohort study . IDACC screened for depression in patients hospitalized in South Australia for a range of cardiac conditions , with outcome measures monitored for 12 months after discharge . The subgroup identified as depressed was entered into the nested IDACC trial , which tests the hypothesis that identifying depression and offering an evidence-based intervention to general practitioners , incorporating multidisciplinary telephone case conferencing , will reduce levels of depression , improve quality of life , and reduce associated economic costs . RESULTS At baseline , 46.3 % of 1455 participants screened were classified as depression cases on the basis of their score on the Center for Epidemiological Studies Depression Scale ( > or =16 ) or the Hospital Anxiety and Depression Scale ( > or =8 ) . Elevated scores were associated with being younger , female , divorced or separated , not employed , living alone , having a lower level of education , and having poorer health and quality of life . Nearly one fifth ( 19.4 % ) of participants had Center for Epidemiological Studies Depression Scale scores > 27 , which is indicative of major depression . CONCLUSIONS This project confirms , in an Australian setting , the high prevalence of depressive symptoms among hospitalized cardiac patients . Follow-up over 12 months will enhance understanding of the natural history of depression in cardiac patients , while the nested trial will inform on effectiveness of an intervention involving tailored advice and support to general practitioners .

[ "Identification", ",", "course", ",", "and", "treatment", "of", "depression", "after", "admission", "for", "a", "cardiac", "condition", ":", "rationale", "and", "patient", "characteristics", "for", "the", "Identifying", "Depression", "As", "a", "Comorbid", "Condition", "(", "IDACC", ")", "project", ".", "BACKGROUND", "Given", "the", "prevalence", "of", "cardiovascular", "disease", "and", "the", "high", "rates", "of", "depression", "among", "cardiac", "patients", ",", "there", "is", "a", "need", "to", "develop", "practical", "ways", "to", "identify", "this", "population", "and", "provide", "pragmatic", "general", "-", "practitioner", "-", "based", "interventions", "for", "managing", "depression", "as", "a", "comorbid", "condition", ".", "METHOD", "The", "Identifying", "Depression", "As", "a", "Comorbid", "Condition", "(", "IDACC", ")", "study", "employed", "a", "hybrid", "design", ",", "incorporating", "a", "randomized", "controlled", "trial", "nested", "within", "a", "prospective", "cohort", "study", ".", "IDACC", "screened", "for", "depression", "in", "patients", "hospitalized", "in", "South", "Australia", "for", "a", "range", "of", "cardiac", "conditions", ",", "with", "outcome", "measures", "monitored", "for", "12", "months", "after", "discharge", ".", "The", "subgroup", "identified", "as", "depressed", "was", "entered", "into", "the", "nested", "IDACC", "trial", ",", "which", "tests", "the", "hypothesis", "that", "identifying", "depression", "and", "offering", "an", "evidence", "-", "based", "intervention", "to", "general", "practitioners", ",", "incorporating", "multidisciplinary", "telephone", "case", "conferencing", ",", "will", "reduce", "levels", "of", "depression", ",", "improve", "quality", "of", "life", ",", "and", "reduce", "associated", "economic", "costs", ".", "RESULTS", "At", "baseline", ",", "46.3", "%", "of", "1455", "participants", "screened", "were", "classified", "as", "depression", "cases", "on", "the", "basis", "of", "their", "score", "on", "the", "Center", "for", "Epidemiological", "Studies", "Depression", "Scale", "(", ">", "or", "=", "16", ")", "or", "the", "Hospital", "Anxiety", "and", "Depression", "Scale", "(", ">", "or", "=", "8", ")", ".", "Elevated", "scores", "were", "associated", "with", "being", "younger", ",", "female", ",", "divorced", "or", "separated", ",", "not", "employed", ",", "living", "alone", ",", "having", "a", "lower", "level", "of", "education", ",", "and", "having", "poorer", "health", "and", "quality", "of", "life", ".", "Nearly", "one", "fifth", "(", "19.4", "%", ")", "of", "participants", "had", "Center", "for", "Epidemiological", "Studies", "Depression", "Scale", "scores", ">", "27", ",", "which", "is", "indicative", "of", "major", "depression", ".", "CONCLUSIONS", "This", "project", "confirms", ",", "in", "an", "Australian", "setting", ",", "the", "high", "prevalence", "of", "depressive", "symptoms", "among", "hospitalized", "cardiac", "patients", ".", "Follow", "-", "up", "over", "12", "months", "will", "enhance", "understanding", "of", "the", "natural", "history", "of", "depression", "in", "cardiac", "patients", ",", "while", "the", "nested", "trial", "will", "inform", "on", "effectiveness", "of", "an", "intervention", "involving", "tailored", "advice", "and", "support", "to", "general", "practitioners", "." ]

[ "Intervention_Educational", "Outcome_Mental", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]

depression after admission for a cardiac condition is a Participant_Condition, general - practitioner - based interventions is a Intervention_Educational, identifying depression and offering an evidence - based intervention is a Intervention_Educational, multidisciplinary telephone case conferencing is a Intervention_Educational, economic costs . is a Outcome_Other, 1455 is a Participant_Sample-size, Center for Epidemiological Studies Depression Scale is a Outcome_Mental, Hospital Anxiety and Depression Scale is a Outcome_Mental, Center for Epidemiological Studies Depression Scale scores > 27 is a Outcome_Mental, depressive symptoms is a Outcome_Mental

15547_task1

Sentence: Identification , course , and treatment of depression after admission for a cardiac condition : rationale and patient characteristics for the Identifying Depression As a Comorbid Condition ( IDACC ) project . BACKGROUND Given the prevalence of cardiovascular disease and the high rates of depression among cardiac patients , there is a need to develop practical ways to identify this population and provide pragmatic general-practitioner-based interventions for managing depression as a comorbid condition . METHOD The Identifying Depression As a Comorbid Condition ( IDACC ) study employed a hybrid design , incorporating a randomized controlled trial nested within a prospective cohort study . IDACC screened for depression in patients hospitalized in South Australia for a range of cardiac conditions , with outcome measures monitored for 12 months after discharge . The subgroup identified as depressed was entered into the nested IDACC trial , which tests the hypothesis that identifying depression and offering an evidence-based intervention to general practitioners , incorporating multidisciplinary telephone case conferencing , will reduce levels of depression , improve quality of life , and reduce associated economic costs . RESULTS At baseline , 46.3 % of 1455 participants screened were classified as depression cases on the basis of their score on the Center for Epidemiological Studies Depression Scale ( > or =16 ) or the Hospital Anxiety and Depression Scale ( > or =8 ) . Elevated scores were associated with being younger , female , divorced or separated , not employed , living alone , having a lower level of education , and having poorer health and quality of life . Nearly one fifth ( 19.4 % ) of participants had Center for Epidemiological Studies Depression Scale scores > 27 , which is indicative of major depression . CONCLUSIONS This project confirms , in an Australian setting , the high prevalence of depressive symptoms among hospitalized cardiac patients . Follow-up over 12 months will enhance understanding of the natural history of depression in cardiac patients , while the nested trial will inform on effectiveness of an intervention involving tailored advice and support to general practitioners . Instructions: please typing these entity words according to sentence: depression after admission for a cardiac condition, general - practitioner - based interventions, identifying depression and offering an evidence - based intervention, multidisciplinary telephone case conferencing, economic costs ., 1455, Center for Epidemiological Studies Depression Scale, Hospital Anxiety and Depression Scale, Center for Epidemiological Studies Depression Scale scores > 27, depressive symptoms Options: Participant_Condition, Intervention_Educational, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Identification , course , and treatment of depression after admission for a cardiac condition : rationale and patient characteristics for the Identifying Depression As a Comorbid Condition ( IDACC ) project . BACKGROUND Given the prevalence of cardiovascular disease and the high rates of depression among cardiac patients , there is a need to develop practical ways to identify this population and provide pragmatic general-practitioner-based interventions for managing depression as a comorbid condition . METHOD The Identifying Depression As a Comorbid Condition ( IDACC ) study employed a hybrid design , incorporating a randomized controlled trial nested within a prospective cohort study . IDACC screened for depression in patients hospitalized in South Australia for a range of cardiac conditions , with outcome measures monitored for 12 months after discharge . The subgroup identified as depressed was entered into the nested IDACC trial , which tests the hypothesis that identifying depression and offering an evidence-based intervention to general practitioners , incorporating multidisciplinary telephone case conferencing , will reduce levels of depression , improve quality of life , and reduce associated economic costs . RESULTS At baseline , 46.3 % of 1455 participants screened were classified as depression cases on the basis of their score on the Center for Epidemiological Studies Depression Scale ( > or =16 ) or the Hospital Anxiety and Depression Scale ( > or =8 ) . Elevated scores were associated with being younger , female , divorced or separated , not employed , living alone , having a lower level of education , and having poorer health and quality of life . Nearly one fifth ( 19.4 % ) of participants had Center for Epidemiological Studies Depression Scale scores > 27 , which is indicative of major depression . CONCLUSIONS This project confirms , in an Australian setting , the high prevalence of depressive symptoms among hospitalized cardiac patients . Follow-up over 12 months will enhance understanding of the natural history of depression in cardiac patients , while the nested trial will inform on effectiveness of an intervention involving tailored advice and support to general practitioners .

[ "Identification", ",", "course", ",", "and", "treatment", "of", "depression", "after", "admission", "for", "a", "cardiac", "condition", ":", "rationale", "and", "patient", "characteristics", "for", "the", "Identifying", "Depression", "As", "a", "Comorbid", "Condition", "(", "IDACC", ")", "project", ".", "BACKGROUND", "Given", "the", "prevalence", "of", "cardiovascular", "disease", "and", "the", "high", "rates", "of", "depression", "among", "cardiac", "patients", ",", "there", "is", "a", "need", "to", "develop", "practical", "ways", "to", "identify", "this", "population", "and", "provide", "pragmatic", "general", "-", "practitioner", "-", "based", "interventions", "for", "managing", "depression", "as", "a", "comorbid", "condition", ".", "METHOD", "The", "Identifying", "Depression", "As", "a", "Comorbid", "Condition", "(", "IDACC", ")", "study", "employed", "a", "hybrid", "design", ",", "incorporating", "a", "randomized", "controlled", "trial", "nested", "within", "a", "prospective", "cohort", "study", ".", "IDACC", "screened", "for", "depression", "in", "patients", "hospitalized", "in", "South", "Australia", "for", "a", "range", "of", "cardiac", "conditions", ",", "with", "outcome", "measures", "monitored", "for", "12", "months", "after", "discharge", ".", "The", "subgroup", "identified", "as", "depressed", "was", "entered", "into", "the", "nested", "IDACC", "trial", ",", "which", "tests", "the", "hypothesis", "that", "identifying", "depression", "and", "offering", "an", "evidence", "-", "based", "intervention", "to", "general", "practitioners", ",", "incorporating", "multidisciplinary", "telephone", "case", "conferencing", ",", "will", "reduce", "levels", "of", "depression", ",", "improve", "quality", "of", "life", ",", "and", "reduce", "associated", "economic", "costs", ".", "RESULTS", "At", "baseline", ",", "46.3", "%", "of", "1455", "participants", "screened", "were", "classified", "as", "depression", "cases", "on", "the", "basis", "of", "their", "score", "on", "the", "Center", "for", "Epidemiological", "Studies", "Depression", "Scale", "(", ">", "or", "=", "16", ")", "or", "the", "Hospital", "Anxiety", "and", "Depression", "Scale", "(", ">", "or", "=", "8", ")", ".", "Elevated", "scores", "were", "associated", "with", "being", "younger", ",", "female", ",", "divorced", "or", "separated", ",", "not", "employed", ",", "living", "alone", ",", "having", "a", "lower", "level", "of", "education", ",", "and", "having", "poorer", "health", "and", "quality", "of", "life", ".", "Nearly", "one", "fifth", "(", "19.4", "%", ")", "of", "participants", "had", "Center", "for", "Epidemiological", "Studies", "Depression", "Scale", "scores", ">", "27", ",", "which", "is", "indicative", "of", "major", "depression", ".", "CONCLUSIONS", "This", "project", "confirms", ",", "in", "an", "Australian", "setting", ",", "the", "high", "prevalence", "of", "depressive", "symptoms", "among", "hospitalized", "cardiac", "patients", ".", "Follow", "-", "up", "over", "12", "months", "will", "enhance", "understanding", "of", "the", "natural", "history", "of", "depression", "in", "cardiac", "patients", ",", "while", "the", "nested", "trial", "will", "inform", "on", "effectiveness", "of", "an", "intervention", "involving", "tailored", "advice", "and", "support", "to", "general", "practitioners", "." ]

[ "Intervention_Educational", "Outcome_Mental", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]

depression after admission for a cardiac condition, general - practitioner - based interventions, identifying depression and offering an evidence - based intervention, multidisciplinary telephone case conferencing, economic costs ., 1455, Center for Epidemiological Studies Depression Scale, Hospital Anxiety and Depression Scale, Center for Epidemiological Studies Depression Scale scores > 27, depressive symptoms

15547_task2

Sentence: Identification , course , and treatment of depression after admission for a cardiac condition : rationale and patient characteristics for the Identifying Depression As a Comorbid Condition ( IDACC ) project . BACKGROUND Given the prevalence of cardiovascular disease and the high rates of depression among cardiac patients , there is a need to develop practical ways to identify this population and provide pragmatic general-practitioner-based interventions for managing depression as a comorbid condition . METHOD The Identifying Depression As a Comorbid Condition ( IDACC ) study employed a hybrid design , incorporating a randomized controlled trial nested within a prospective cohort study . IDACC screened for depression in patients hospitalized in South Australia for a range of cardiac conditions , with outcome measures monitored for 12 months after discharge . The subgroup identified as depressed was entered into the nested IDACC trial , which tests the hypothesis that identifying depression and offering an evidence-based intervention to general practitioners , incorporating multidisciplinary telephone case conferencing , will reduce levels of depression , improve quality of life , and reduce associated economic costs . RESULTS At baseline , 46.3 % of 1455 participants screened were classified as depression cases on the basis of their score on the Center for Epidemiological Studies Depression Scale ( > or =16 ) or the Hospital Anxiety and Depression Scale ( > or =8 ) . Elevated scores were associated with being younger , female , divorced or separated , not employed , living alone , having a lower level of education , and having poorer health and quality of life . Nearly one fifth ( 19.4 % ) of participants had Center for Epidemiological Studies Depression Scale scores > 27 , which is indicative of major depression . CONCLUSIONS This project confirms , in an Australian setting , the high prevalence of depressive symptoms among hospitalized cardiac patients . Follow-up over 12 months will enhance understanding of the natural history of depression in cardiac patients , while the nested trial will inform on effectiveness of an intervention involving tailored advice and support to general practitioners . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Identification , course , and treatment of depression after admission for a cardiac condition : rationale and patient characteristics for the Identifying Depression As a Comorbid Condition ( IDACC ) project . BACKGROUND Given the prevalence of cardiovascular disease and the high rates of depression among cardiac patients , there is a need to develop practical ways to identify this population and provide pragmatic general-practitioner-based interventions for managing depression as a comorbid condition . METHOD The Identifying Depression As a Comorbid Condition ( IDACC ) study employed a hybrid design , incorporating a randomized controlled trial nested within a prospective cohort study . IDACC screened for depression in patients hospitalized in South Australia for a range of cardiac conditions , with outcome measures monitored for 12 months after discharge . The subgroup identified as depressed was entered into the nested IDACC trial , which tests the hypothesis that identifying depression and offering an evidence-based intervention to general practitioners , incorporating multidisciplinary telephone case conferencing , will reduce levels of depression , improve quality of life , and reduce associated economic costs . RESULTS At baseline , 46.3 % of 1455 participants screened were classified as depression cases on the basis of their score on the Center for Epidemiological Studies Depression Scale ( > or =16 ) or the Hospital Anxiety and Depression Scale ( > or =8 ) . Elevated scores were associated with being younger , female , divorced or separated , not employed , living alone , having a lower level of education , and having poorer health and quality of life . Nearly one fifth ( 19.4 % ) of participants had Center for Epidemiological Studies Depression Scale scores > 27 , which is indicative of major depression . CONCLUSIONS This project confirms , in an Australian setting , the high prevalence of depressive symptoms among hospitalized cardiac patients . Follow-up over 12 months will enhance understanding of the natural history of depression in cardiac patients , while the nested trial will inform on effectiveness of an intervention involving tailored advice and support to general practitioners .

[ "Identification", ",", "course", ",", "and", "treatment", "of", "depression", "after", "admission", "for", "a", "cardiac", "condition", ":", "rationale", "and", "patient", "characteristics", "for", "the", "Identifying", "Depression", "As", "a", "Comorbid", "Condition", "(", "IDACC", ")", "project", ".", "BACKGROUND", "Given", "the", "prevalence", "of", "cardiovascular", "disease", "and", "the", "high", "rates", "of", "depression", "among", "cardiac", "patients", ",", "there", "is", "a", "need", "to", "develop", "practical", "ways", "to", "identify", "this", "population", "and", "provide", "pragmatic", "general", "-", "practitioner", "-", "based", "interventions", "for", "managing", "depression", "as", "a", "comorbid", "condition", ".", "METHOD", "The", "Identifying", "Depression", "As", "a", "Comorbid", "Condition", "(", "IDACC", ")", "study", "employed", "a", "hybrid", "design", ",", "incorporating", "a", "randomized", "controlled", "trial", "nested", "within", "a", "prospective", "cohort", "study", ".", "IDACC", "screened", "for", "depression", "in", "patients", "hospitalized", "in", "South", "Australia", "for", "a", "range", "of", "cardiac", "conditions", ",", "with", "outcome", "measures", "monitored", "for", "12", "months", "after", "discharge", ".", "The", "subgroup", "identified", "as", "depressed", "was", "entered", "into", "the", "nested", "IDACC", "trial", ",", "which", "tests", "the", "hypothesis", "that", "identifying", "depression", "and", "offering", "an", "evidence", "-", "based", "intervention", "to", "general", "practitioners", ",", "incorporating", "multidisciplinary", "telephone", "case", "conferencing", ",", "will", "reduce", "levels", "of", "depression", ",", "improve", "quality", "of", "life", ",", "and", "reduce", "associated", "economic", "costs", ".", "RESULTS", "At", "baseline", ",", "46.3", "%", "of", "1455", "participants", "screened", "were", "classified", "as", "depression", "cases", "on", "the", "basis", "of", "their", "score", "on", "the", "Center", "for", "Epidemiological", "Studies", "Depression", "Scale", "(", ">", "or", "=", "16", ")", "or", "the", "Hospital", "Anxiety", "and", "Depression", "Scale", "(", ">", "or", "=", "8", ")", ".", "Elevated", "scores", "were", "associated", "with", "being", "younger", ",", "female", ",", "divorced", "or", "separated", ",", "not", "employed", ",", "living", "alone", ",", "having", "a", "lower", "level", "of", "education", ",", "and", "having", "poorer", "health", "and", "quality", "of", "life", ".", "Nearly", "one", "fifth", "(", "19.4", "%", ")", "of", "participants", "had", "Center", "for", "Epidemiological", "Studies", "Depression", "Scale", "scores", ">", "27", ",", "which", "is", "indicative", "of", "major", "depression", ".", "CONCLUSIONS", "This", "project", "confirms", ",", "in", "an", "Australian", "setting", ",", "the", "high", "prevalence", "of", "depressive", "symptoms", "among", "hospitalized", "cardiac", "patients", ".", "Follow", "-", "up", "over", "12", "months", "will", "enhance", "understanding", "of", "the", "natural", "history", "of", "depression", "in", "cardiac", "patients", ",", "while", "the", "nested", "trial", "will", "inform", "on", "effectiveness", "of", "an", "intervention", "involving", "tailored", "advice", "and", "support", "to", "general", "practitioners", "." ]

[ "Intervention_Educational", "Outcome_Mental", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]

Cyclooxygenase is a GENE-N, 5-lipoxygenase is a GENE-Y, cyclooxygenase is a GENE-N, COX is a GENE-N, 5-lipoxygenase is a GENE-Y, 5-LOX is a GENE-Y, COX is a GENE-N, prostaglandins is a CHEMICAL, 5-LOX is a GENE-Y, leukotrienes is a CHEMICAL, COX-1 is a GENE-Y, COX-2 is a GENE-Y, NS-398 is a CHEMICAL, COX-1 is a GENE-Y, COX-2 is a GENE-Y, ibuprofen is a CHEMICAL, nitric oxide is a CHEMICAL, NO is a CHEMICAL, indomethacin is a CHEMICAL, ibuprofen is a CHEMICAL, flurbiprofen is a CHEMICAL, 5-LOX is a GENE-Y, REV 5901 is a CHEMICAL, 5-LOX activating protein is a GENE-Y, FLAP is a GENE-Y, MK-886 is a CHEMICAL, FLAP is a GENE-Y, COX is a GENE-N, 5-LOX is a GENE-Y, COX is a GENE-N, 5-LOX is a GENE-Y

33469_task0

Sentence: Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neuroinflammation and oxidative stress are believed to be contributing factors to neurodegeneration in normal aging, as well as in age-related neurological disorders. Reactive microglia are found in increased numbers in aging brain and are prominently associated with lesions in such age-related degenerative conditions as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). In vitro, stimulated microglia or microglial-like cells secrete neurotoxic materials and are generators of free radicals through their respiratory burst system. Agents that suppress microglial activation are therefore candidates for neuroprotection. We have developed quantitative in vitro assays for measuring neurotoxicity of microglia or other mononuclear phagocytes. Neuronal like SH-SY5Y cells are cultured in supernatants from activated cells of the human monocytic THP-1 line and their survival is followed. Respiratory burst is directly measured on the activated cells. We tested inhibitors of the cyclooxygenase (COX) or the 5-lipoxygenase (5-LOX) pathways as possible neuroprotective agents. The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes. We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion. They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886. The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin. Combinations of COX and 5-LOX inhibitors were more effective than single inhibitors. The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL

[ "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neuroinflammation and oxidative stress are believed to be contributing factors to neurodegeneration in normal aging, as well as in age-related neurological disorders. Reactive microglia are found in increased numbers in aging brain and are prominently associated with lesions in such age-related degenerative conditions as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). In vitro, stimulated microglia or microglial-like cells secrete neurotoxic materials and are generators of free radicals through their respiratory burst system. Agents that suppress microglial activation are therefore candidates for neuroprotection. We have developed quantitative in vitro assays for measuring neurotoxicity of microglia or other mononuclear phagocytes. Neuronal like SH-SY5Y cells are cultured in supernatants from activated cells of the human monocytic THP-1 line and their survival is followed. Respiratory burst is directly measured on the activated cells. We tested inhibitors of the cyclooxygenase (COX) or the 5-lipoxygenase (5-LOX) pathways as possible neuroprotective agents. The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes. We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion. They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886. The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin. Combinations of COX and 5-LOX inhibitors were more effective than single inhibitors. The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class.

[ "Cyclooxygenase", "and", "5-lipoxygenase", "inhibitors", "protect", "against", "mononuclear", "phagocyte", "neurotoxicity", ".", "\n", "Neuroinflammation", "and", "oxidative", "stress", "are", "believed", "to", "be", "contributing", "factors", "to", "neurodegeneration", "in", "normal", "aging", ",", "as", "well", "as", "in", "age", "-", "related", "neurological", "disorders", ".", "Reactive", "microglia", "are", "found", "in", "increased", "numbers", "in", "aging", "brain", "and", "are", "prominently", "associated", "with", "lesions", "in", "such", "age", "-", "related", "degenerative", "conditions", "as", "Alzheimer", "'s", "disease", "(", "AD", ")", ",", "Parkinson", "'s", "disease", "(", "PD", ")", "and", "amyotrophic", "lateral", "sclerosis", "(", "ALS", ")", ".", "In", "vitro", ",", "stimulated", "microglia", "or", "microglial", "-", "like", "cells", "secrete", "neurotoxic", "materials", "and", "are", "generators", "of", "free", "radicals", "through", "their", "respiratory", "burst", "system", ".", "Agents", "that", "suppress", "microglial", "activation", "are", "therefore", "candidates", "for", "neuroprotection", ".", "We", "have", "developed", "quantitative", "in", "vitro", "assays", "for", "measuring", "neurotoxicity", "of", "microglia", "or", "other", "mononuclear", "phagocytes", ".", "Neuronal", "like", "SH", "-", "SY5Y", "cells", "are", "cultured", "in", "supernatants", "from", "activated", "cells", "of", "the", "human", "monocytic", "THP-1", "line", "and", "their", "survival", "is", "followed", ".", "Respiratory", "burst", "is", "directly", "measured", "on", "the", "activated", "cells", ".", "We", "tested", "inhibitors", "of", "the", "cyclooxygenase", "(", "COX", ")", "or", "the", "5-lipoxygenase", "(", "5-LOX", ")", "pathways", "as", "possible", "neuroprotective", "agents", ".", "The", "COX", "pathway", "generates", "inflammatory", "prostaglandins", ",", "while", "the", "5-LOX", "pathway", "generates", "inflammatory", "leukotrienes", ".", "We", "found", "that", "inhibitors", "of", "both", "these", "pathways", "suppressed", "neurotoxicity", "in", "a", "dose", "-", "dependent", "fashion", ".", "They", "included", "the", "COX-1", "inhibitor", "indomethacin", ";", "the", "COX-2", "inhibitor", "NS-398", ";", "the", "mixed", "COX-1", "/", "COX-2", "inhibitor", "ibuprofen", ";", "the", "nitric", "oxide", "(", "NO", ")", "derivatives", "of", "indomethacin", ",", "ibuprofen", "and", "flurbiprofen", ";", "the", "5-LOX", "inhibitor", "REV", "5901", ";", "and", "the", "5-LOX", "activating", "protein", "(", "FLAP", ")", "inhibitor", "MK-886", ".", "The", "FLAP", "inhibitor", "also", "reduced", "respiratory", "burst", "activity", "in", "a", "more", "potent", "manner", "than", "indomethacin", ".", "Combinations", "of", "COX", "and", "5-LOX", "inhibitors", "were", "more", "effective", "than", "single", "inhibitors", ".", "The", "data", "suggest", "that", "both", "COX", "inhibitors", "and", "5-LOX", "inhibitors", "may", "be", "neuroprotective", "in", "vivo", "by", "suppressing", "toxic", "actions", "of", "microglia", "/", "macrophages", ",", "and", "that", "combinations", "of", "the", "two", "might", "have", "greater", "therapeutic", "potential", "than", "single", "inhibitors", "of", "either", "class", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

Cyclooxygenase is a GENE-N, 5-lipoxygenase is a GENE-Y, cyclooxygenase is a GENE-N, COX is a GENE-N, 5-lipoxygenase is a GENE-Y, 5-LOX is a GENE-Y, COX is a GENE-N, prostaglandins is a CHEMICAL, 5-LOX is a GENE-Y, leukotrienes is a CHEMICAL, COX-1 is a GENE-Y, COX-2 is a GENE-Y, NS-398 is a CHEMICAL, COX-1 is a GENE-Y, COX-2 is a GENE-Y, ibuprofen is a CHEMICAL, nitric oxide is a CHEMICAL, NO is a CHEMICAL, indomethacin is a CHEMICAL, ibuprofen is a CHEMICAL, flurbiprofen is a CHEMICAL, 5-LOX is a GENE-Y, REV 5901 is a CHEMICAL, 5-LOX activating protein is a GENE-Y, FLAP is a GENE-Y, MK-886 is a CHEMICAL, FLAP is a GENE-Y, COX is a GENE-N, 5-LOX is a GENE-Y, COX is a GENE-N, 5-LOX is a GENE-Y

33469_task1

Sentence: Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neuroinflammation and oxidative stress are believed to be contributing factors to neurodegeneration in normal aging, as well as in age-related neurological disorders. Reactive microglia are found in increased numbers in aging brain and are prominently associated with lesions in such age-related degenerative conditions as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). In vitro, stimulated microglia or microglial-like cells secrete neurotoxic materials and are generators of free radicals through their respiratory burst system. Agents that suppress microglial activation are therefore candidates for neuroprotection. We have developed quantitative in vitro assays for measuring neurotoxicity of microglia or other mononuclear phagocytes. Neuronal like SH-SY5Y cells are cultured in supernatants from activated cells of the human monocytic THP-1 line and their survival is followed. Respiratory burst is directly measured on the activated cells. We tested inhibitors of the cyclooxygenase (COX) or the 5-lipoxygenase (5-LOX) pathways as possible neuroprotective agents. The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes. We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion. They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886. The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin. Combinations of COX and 5-LOX inhibitors were more effective than single inhibitors. The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class. Instructions: please typing these entity words according to sentence: Cyclooxygenase, 5-lipoxygenase, cyclooxygenase, COX, 5-lipoxygenase, 5-LOX, COX, prostaglandins, 5-LOX, leukotrienes, COX-1, COX-2, NS-398, COX-1, COX-2, ibuprofen, nitric oxide, NO, indomethacin, ibuprofen, flurbiprofen, 5-LOX, REV 5901, 5-LOX activating protein, FLAP, MK-886, FLAP, COX, 5-LOX, COX, 5-LOX Options: GENE-Y, GENE-N, CHEMICAL

[ "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neuroinflammation and oxidative stress are believed to be contributing factors to neurodegeneration in normal aging, as well as in age-related neurological disorders. Reactive microglia are found in increased numbers in aging brain and are prominently associated with lesions in such age-related degenerative conditions as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). In vitro, stimulated microglia or microglial-like cells secrete neurotoxic materials and are generators of free radicals through their respiratory burst system. Agents that suppress microglial activation are therefore candidates for neuroprotection. We have developed quantitative in vitro assays for measuring neurotoxicity of microglia or other mononuclear phagocytes. Neuronal like SH-SY5Y cells are cultured in supernatants from activated cells of the human monocytic THP-1 line and their survival is followed. Respiratory burst is directly measured on the activated cells. We tested inhibitors of the cyclooxygenase (COX) or the 5-lipoxygenase (5-LOX) pathways as possible neuroprotective agents. The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes. We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion. They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886. The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin. Combinations of COX and 5-LOX inhibitors were more effective than single inhibitors. The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class.

[ "Cyclooxygenase", "and", "5-lipoxygenase", "inhibitors", "protect", "against", "mononuclear", "phagocyte", "neurotoxicity", ".", "\n", "Neuroinflammation", "and", "oxidative", "stress", "are", "believed", "to", "be", "contributing", "factors", "to", "neurodegeneration", "in", "normal", "aging", ",", "as", "well", "as", "in", "age", "-", "related", "neurological", "disorders", ".", "Reactive", "microglia", "are", "found", "in", "increased", "numbers", "in", "aging", "brain", "and", "are", "prominently", "associated", "with", "lesions", "in", "such", "age", "-", "related", "degenerative", "conditions", "as", "Alzheimer", "'s", "disease", "(", "AD", ")", ",", "Parkinson", "'s", "disease", "(", "PD", ")", "and", "amyotrophic", "lateral", "sclerosis", "(", "ALS", ")", ".", "In", "vitro", ",", "stimulated", "microglia", "or", "microglial", "-", "like", "cells", "secrete", "neurotoxic", "materials", "and", "are", "generators", "of", "free", "radicals", "through", "their", "respiratory", "burst", "system", ".", "Agents", "that", "suppress", "microglial", "activation", "are", "therefore", "candidates", "for", "neuroprotection", ".", "We", "have", "developed", "quantitative", "in", "vitro", "assays", "for", "measuring", "neurotoxicity", "of", "microglia", "or", "other", "mononuclear", "phagocytes", ".", "Neuronal", "like", "SH", "-", "SY5Y", "cells", "are", "cultured", "in", "supernatants", "from", "activated", "cells", "of", "the", "human", "monocytic", "THP-1", "line", "and", "their", "survival", "is", "followed", ".", "Respiratory", "burst", "is", "directly", "measured", "on", "the", "activated", "cells", ".", "We", "tested", "inhibitors", "of", "the", "cyclooxygenase", "(", "COX", ")", "or", "the", "5-lipoxygenase", "(", "5-LOX", ")", "pathways", "as", "possible", "neuroprotective", "agents", ".", "The", "COX", "pathway", "generates", "inflammatory", "prostaglandins", ",", "while", "the", "5-LOX", "pathway", "generates", "inflammatory", "leukotrienes", ".", "We", "found", "that", "inhibitors", "of", "both", "these", "pathways", "suppressed", "neurotoxicity", "in", "a", "dose", "-", "dependent", "fashion", ".", "They", "included", "the", "COX-1", "inhibitor", "indomethacin", ";", "the", "COX-2", "inhibitor", "NS-398", ";", "the", "mixed", "COX-1", "/", "COX-2", "inhibitor", "ibuprofen", ";", "the", "nitric", "oxide", "(", "NO", ")", "derivatives", "of", "indomethacin", ",", "ibuprofen", "and", "flurbiprofen", ";", "the", "5-LOX", "inhibitor", "REV", "5901", ";", "and", "the", "5-LOX", "activating", "protein", "(", "FLAP", ")", "inhibitor", "MK-886", ".", "The", "FLAP", "inhibitor", "also", "reduced", "respiratory", "burst", "activity", "in", "a", "more", "potent", "manner", "than", "indomethacin", ".", "Combinations", "of", "COX", "and", "5-LOX", "inhibitors", "were", "more", "effective", "than", "single", "inhibitors", ".", "The", "data", "suggest", "that", "both", "COX", "inhibitors", "and", "5-LOX", "inhibitors", "may", "be", "neuroprotective", "in", "vivo", "by", "suppressing", "toxic", "actions", "of", "microglia", "/", "macrophages", ",", "and", "that", "combinations", "of", "the", "two", "might", "have", "greater", "therapeutic", "potential", "than", "single", "inhibitors", "of", "either", "class", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

Cyclooxygenase, 5-lipoxygenase, cyclooxygenase, COX, 5-lipoxygenase, 5-LOX, COX, prostaglandins, 5-LOX, leukotrienes, COX-1, COX-2, NS-398, COX-1, COX-2, ibuprofen, nitric oxide, NO, indomethacin, ibuprofen, flurbiprofen, 5-LOX, REV 5901, 5-LOX activating protein, FLAP, MK-886, FLAP, COX, 5-LOX, COX, 5-LOX

33469_task2

Sentence: Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neuroinflammation and oxidative stress are believed to be contributing factors to neurodegeneration in normal aging, as well as in age-related neurological disorders. Reactive microglia are found in increased numbers in aging brain and are prominently associated with lesions in such age-related degenerative conditions as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). In vitro, stimulated microglia or microglial-like cells secrete neurotoxic materials and are generators of free radicals through their respiratory burst system. Agents that suppress microglial activation are therefore candidates for neuroprotection. We have developed quantitative in vitro assays for measuring neurotoxicity of microglia or other mononuclear phagocytes. Neuronal like SH-SY5Y cells are cultured in supernatants from activated cells of the human monocytic THP-1 line and their survival is followed. Respiratory burst is directly measured on the activated cells. We tested inhibitors of the cyclooxygenase (COX) or the 5-lipoxygenase (5-LOX) pathways as possible neuroprotective agents. The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes. We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion. They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886. The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin. Combinations of COX and 5-LOX inhibitors were more effective than single inhibitors. The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class. Instructions: please extract entity words from the input sentence

[ "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neuroinflammation and oxidative stress are believed to be contributing factors to neurodegeneration in normal aging, as well as in age-related neurological disorders. Reactive microglia are found in increased numbers in aging brain and are prominently associated with lesions in such age-related degenerative conditions as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). In vitro, stimulated microglia or microglial-like cells secrete neurotoxic materials and are generators of free radicals through their respiratory burst system. Agents that suppress microglial activation are therefore candidates for neuroprotection. We have developed quantitative in vitro assays for measuring neurotoxicity of microglia or other mononuclear phagocytes. Neuronal like SH-SY5Y cells are cultured in supernatants from activated cells of the human monocytic THP-1 line and their survival is followed. Respiratory burst is directly measured on the activated cells. We tested inhibitors of the cyclooxygenase (COX) or the 5-lipoxygenase (5-LOX) pathways as possible neuroprotective agents. The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes. We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion. They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886. The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin. Combinations of COX and 5-LOX inhibitors were more effective than single inhibitors. The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class.

[ "Cyclooxygenase", "and", "5-lipoxygenase", "inhibitors", "protect", "against", "mononuclear", "phagocyte", "neurotoxicity", ".", "\n", "Neuroinflammation", "and", "oxidative", "stress", "are", "believed", "to", "be", "contributing", "factors", "to", "neurodegeneration", "in", "normal", "aging", ",", "as", "well", "as", "in", "age", "-", "related", "neurological", "disorders", ".", "Reactive", "microglia", "are", "found", "in", "increased", "numbers", "in", "aging", "brain", "and", "are", "prominently", "associated", "with", "lesions", "in", "such", "age", "-", "related", "degenerative", "conditions", "as", "Alzheimer", "'s", "disease", "(", "AD", ")", ",", "Parkinson", "'s", "disease", "(", "PD", ")", "and", "amyotrophic", "lateral", "sclerosis", "(", "ALS", ")", ".", "In", "vitro", ",", "stimulated", "microglia", "or", "microglial", "-", "like", "cells", "secrete", "neurotoxic", "materials", "and", "are", "generators", "of", "free", "radicals", "through", "their", "respiratory", "burst", "system", ".", "Agents", "that", "suppress", "microglial", "activation", "are", "therefore", "candidates", "for", "neuroprotection", ".", "We", "have", "developed", "quantitative", "in", "vitro", "assays", "for", "measuring", "neurotoxicity", "of", "microglia", "or", "other", "mononuclear", "phagocytes", ".", "Neuronal", "like", "SH", "-", "SY5Y", "cells", "are", "cultured", "in", "supernatants", "from", "activated", "cells", "of", "the", "human", "monocytic", "THP-1", "line", "and", "their", "survival", "is", "followed", ".", "Respiratory", "burst", "is", "directly", "measured", "on", "the", "activated", "cells", ".", "We", "tested", "inhibitors", "of", "the", "cyclooxygenase", "(", "COX", ")", "or", "the", "5-lipoxygenase", "(", "5-LOX", ")", "pathways", "as", "possible", "neuroprotective", "agents", ".", "The", "COX", "pathway", "generates", "inflammatory", "prostaglandins", ",", "while", "the", "5-LOX", "pathway", "generates", "inflammatory", "leukotrienes", ".", "We", "found", "that", "inhibitors", "of", "both", "these", "pathways", "suppressed", "neurotoxicity", "in", "a", "dose", "-", "dependent", "fashion", ".", "They", "included", "the", "COX-1", "inhibitor", "indomethacin", ";", "the", "COX-2", "inhibitor", "NS-398", ";", "the", "mixed", "COX-1", "/", "COX-2", "inhibitor", "ibuprofen", ";", "the", "nitric", "oxide", "(", "NO", ")", "derivatives", "of", "indomethacin", ",", "ibuprofen", "and", "flurbiprofen", ";", "the", "5-LOX", "inhibitor", "REV", "5901", ";", "and", "the", "5-LOX", "activating", "protein", "(", "FLAP", ")", "inhibitor", "MK-886", ".", "The", "FLAP", "inhibitor", "also", "reduced", "respiratory", "burst", "activity", "in", "a", "more", "potent", "manner", "than", "indomethacin", ".", "Combinations", "of", "COX", "and", "5-LOX", "inhibitors", "were", "more", "effective", "than", "single", "inhibitors", ".", "The", "data", "suggest", "that", "both", "COX", "inhibitors", "and", "5-LOX", "inhibitors", "may", "be", "neuroprotective", "in", "vivo", "by", "suppressing", "toxic", "actions", "of", "microglia", "/", "macrophages", ",", "and", "that", "combinations", "of", "the", "two", "might", "have", "greater", "therapeutic", "potential", "than", "single", "inhibitors", "of", "either", "class", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

role is an umlsterm, pathogenesis is an umlsterm, syndromes is an umlsterm, C - reactive protein is an umlsterm, CRP is an umlsterm, acute phase protein is an umlsterm, markers is an umlsterm, troponin T is an umlsterm, TnT is an umlsterm, determination is an umlsterm, CRP is an umlsterm, patients is an umlsterm, diagnosis is an umlsterm, prognosis is an umlsterm, Patients is an umlsterm, Methods is an umlsterm, patients is an umlsterm, TnT is an umlsterm, Diagnostics is an umlsterm, CRP is an umlsterm, CRP is an umlsterm, sensitivity is an umlsterm, patients is an umlsterm, unstable angina is an umlsterm, All is an umlsterm, patients is an umlsterm, discharge is an umlsterm, death is an umlsterm, discharge is an umlsterm, patients is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, patients is an umlsterm, TnT is an umlsterm, patients is an umlsterm, CRP is an umlsterm, test is an umlsterm, patients is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, discharge is an umlsterm, Logistic regression is an umlsterm, analysis is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, values is an umlsterm, age is an umlsterm, gender is an umlsterm, diagnosis is an umlsterm, death is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, AMI is an umlsterm, diagnosis is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, sensitivity is an umlsterm, CRP is an umlsterm, determination is an umlsterm, value is an umlsterm, AMI is an umlsterm, diagnosis is an umlsterm, prognosis is an umlsterm, patients is an umlsterm, CRP is an umlsterm, measurements is an umlsterm, troponin is an umlsterm

ZfuerKardiologie.00890658.eng.abstr_task0

Sentence: Background : It has been suggested that inflammatory processes play a role in the pathogenesis of acute coronary syndromes ( ACS ) . C-reactive protein ( CRP ) is a classic acute phase protein . It is yet unclear whether , in addition to established markers as troponin T ( TnT ) , determination of CRP in patients admitted for ACS contributes significantly to the diagnosis and prognosis of ACS . Patients and Methods : We investigated 50 patients with ACS ( 59.4 SD 13.9 years ) in the first hour after admission and 4-24h later with respect to TnT ( Elecsys , Roche Diagnostics ) and CRP ( biokit , modified Quantex CRP plus , analytical sensitivity 0.02mg/dL). Fifty percent of the patients were classified as having unstable angina retrospectively . All patients were followed in the 6 weeks post discharge regarding death and recurrent ACS . Results : The cumulative event rate at 6 weeks after discharge was 62.5% for patients being CRP and TnT positive compared to 35.3% in TnT positive and CRP negative patients . In TnT negative patients a positive CRP test predicted 33.3% of events and 28.8% of patients negative for CRP and TnT had events at 42 days post discharge . Logistic regression analysis regarding the primary endpoint including TnT and CRP ( 4-24h values ) , age , gender and diagnosis resulted in independent prediction of ACS or death by TnT ( cutoff 0.1µg/L, p=0.048, odds ratio=7.5) and CRP ( cutoff 0.862mg/dL, p=0.026, odds ratio=5.3). Sensitivity/specificity for AMI diagnosis were 69.6%/75% for TnT and 12%/72% for CRP in the first hour and 91.3%/68.2% for TnT and 68%/72% for CRP 4-24h later . Conclusions : Besides TnT , high sensitivity CRP determination has no additional value for early AMI diagnosis . The prognosis of these patients during the first 24 hours is significantly and independently predicted by CRP measurements in addition to troponin T. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Background : It has been suggested that inflammatory processes play a role in the pathogenesis of acute coronary syndromes ( ACS ) . C-reactive protein ( CRP ) is a classic acute phase protein . It is yet unclear whether , in addition to established markers as troponin T ( TnT ) , determination of CRP in patients admitted for ACS contributes significantly to the diagnosis and prognosis of ACS . Patients and Methods : We investigated 50 patients with ACS ( 59.4 SD 13.9 years ) in the first hour after admission and 4-24h later with respect to TnT ( Elecsys , Roche Diagnostics ) and CRP ( biokit , modified Quantex CRP plus , analytical sensitivity 0.02mg/dL). Fifty percent of the patients were classified as having unstable angina retrospectively . All patients were followed in the 6 weeks post discharge regarding death and recurrent ACS . Results : The cumulative event rate at 6 weeks after discharge was 62.5% for patients being CRP and TnT positive compared to 35.3% in TnT positive and CRP negative patients . In TnT negative patients a positive CRP test predicted 33.3% of events and 28.8% of patients negative for CRP and TnT had events at 42 days post discharge . Logistic regression analysis regarding the primary endpoint including TnT and CRP ( 4-24h values ) , age , gender and diagnosis resulted in independent prediction of ACS or death by TnT ( cutoff 0.1µg/L, p=0.048, odds ratio=7.5) and CRP ( cutoff 0.862mg/dL, p=0.026, odds ratio=5.3). Sensitivity/specificity for AMI diagnosis were 69.6%/75% for TnT and 12%/72% for CRP in the first hour and 91.3%/68.2% for TnT and 68%/72% for CRP 4-24h later . Conclusions : Besides TnT , high sensitivity CRP determination has no additional value for early AMI diagnosis . The prognosis of these patients during the first 24 hours is significantly and independently predicted by CRP measurements in addition to troponin T.

[ "Background", ":", "It", "has", "been", "suggested", "that", "inflammatory", "processes", "play", "a", "role", "in", "the", "pathogenesis", "of", "acute", "coronary", "syndromes", "(", "ACS", ")", ".", "C", "-", "reactive", "protein", "(", "CRP", ")", "is", "a", "classic", "acute", "phase", "protein", ".", "It", "is", "yet", "unclear", "whether", ",", "in", "addition", "to", "established", "markers", "as", "troponin", "T", "(", "TnT", ")", ",", "determination", "of", "CRP", "in", "patients", "admitted", "for", "ACS", "contributes", "significantly", "to", "the", "diagnosis", "and", "prognosis", "of", "ACS", ".", "Patients", "and", "Methods", ":", "We", "investigated", "50", "patients", "with", "ACS", "(", "59.4", "SD", "13.9", "years", ")", "in", "the", "first", "hour", "after", "admission", "and", "4", "-", "24h", "later", "with", "respect", "to", "TnT", "(", "Elecsys", ",", "Roche", "Diagnostics", ")", "and", "CRP", "(", "biokit", ",", "modified", "Quantex", "CRP", "plus", ",", "analytical", "sensitivity", "0.02mg", "/", "dL", ")", ".", "Fifty", "percent", "of", "the", "patients", "were", "classified", "as", "having", "unstable", "angina", "retrospectively", ".", "All", "patients", "were", "followed", "in", "the", "6", "weeks", "post", "discharge", "regarding", "death", "and", "recurrent", "ACS", ".", "Results", ":", "The", "cumulative", "event", "rate", "at", "6", "weeks", "after", "discharge", "was", "62.5", "%", "for", "patients", "being", "CRP", "and", "TnT", "positive", "compared", "to", "35.3", "%", "in", "TnT", "positive", "and", "CRP", "negative", "patients", ".", "In", "TnT", "negative", "patients", "a", "positive", "CRP", "test", "predicted", "33.3", "%", "of", "events", "and", "28.8", "%", "of", "patients", "negative", "for", "CRP", "and", "TnT", "had", "events", "at", "42", "days", "post", "discharge", ".", "Logistic", "regression", "analysis", "regarding", "the", "primary", "endpoint", "including", "TnT", "and", "CRP", "(", "4", "-", "24h", "values", ")", ",", "age", ",", "gender", "and", "diagnosis", "resulted", "in", "independent", "prediction", "of", "ACS", "or", "death", "by", "TnT", "(", "cutoff", "0.1µg", "/", "L", ",", "p=0.048", ",", "odds", "ratio=7.5", ")", "and", "CRP", "(", "cutoff", "0.862mg", "/", "dL", ",", "p=0.026", ",", "odds", "ratio=5.3", ")", ".", "Sensitivity", "/", "specificity", "for", "AMI", "diagnosis", "were", "69.6%/75", "%", "for", "TnT", "and", "12%/72", "%", "for", "CRP", "in", "the", "first", "hour", "and", "91.3%/68.2", "%", "for", "TnT", "and", "68%/72", "%", "for", "CRP", "4", "-", "24h", "later", ".", "Conclusions", ":", "Besides", "TnT", ",", "high", "sensitivity", "CRP", "determination", "has", "no", "additional", "value", "for", "early", "AMI", "diagnosis", ".", "The", "prognosis", "of", "these", "patients", "during", "the", "first", "24", "hours", "is", "significantly", "and", "independently", "predicted", "by", "CRP", "measurements", "in", "addition", "to", "troponin", "T." ]

[ "umlsterm" ]

role is an umlsterm, pathogenesis is an umlsterm, syndromes is an umlsterm, C - reactive protein is an umlsterm, CRP is an umlsterm, acute phase protein is an umlsterm, markers is an umlsterm, troponin T is an umlsterm, TnT is an umlsterm, determination is an umlsterm, CRP is an umlsterm, patients is an umlsterm, diagnosis is an umlsterm, prognosis is an umlsterm, Patients is an umlsterm, Methods is an umlsterm, patients is an umlsterm, TnT is an umlsterm, Diagnostics is an umlsterm, CRP is an umlsterm, CRP is an umlsterm, sensitivity is an umlsterm, patients is an umlsterm, unstable angina is an umlsterm, All is an umlsterm, patients is an umlsterm, discharge is an umlsterm, death is an umlsterm, discharge is an umlsterm, patients is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, patients is an umlsterm, TnT is an umlsterm, patients is an umlsterm, CRP is an umlsterm, test is an umlsterm, patients is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, discharge is an umlsterm, Logistic regression is an umlsterm, analysis is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, values is an umlsterm, age is an umlsterm, gender is an umlsterm, diagnosis is an umlsterm, death is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, AMI is an umlsterm, diagnosis is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, CRP is an umlsterm, TnT is an umlsterm, sensitivity is an umlsterm, CRP is an umlsterm, determination is an umlsterm, value is an umlsterm, AMI is an umlsterm, diagnosis is an umlsterm, prognosis is an umlsterm, patients is an umlsterm, CRP is an umlsterm, measurements is an umlsterm, troponin is an umlsterm

ZfuerKardiologie.00890658.eng.abstr_task1

Sentence: Background : It has been suggested that inflammatory processes play a role in the pathogenesis of acute coronary syndromes ( ACS ) . C-reactive protein ( CRP ) is a classic acute phase protein . It is yet unclear whether , in addition to established markers as troponin T ( TnT ) , determination of CRP in patients admitted for ACS contributes significantly to the diagnosis and prognosis of ACS . Patients and Methods : We investigated 50 patients with ACS ( 59.4 SD 13.9 years ) in the first hour after admission and 4-24h later with respect to TnT ( Elecsys , Roche Diagnostics ) and CRP ( biokit , modified Quantex CRP plus , analytical sensitivity 0.02mg/dL). Fifty percent of the patients were classified as having unstable angina retrospectively . All patients were followed in the 6 weeks post discharge regarding death and recurrent ACS . Results : The cumulative event rate at 6 weeks after discharge was 62.5% for patients being CRP and TnT positive compared to 35.3% in TnT positive and CRP negative patients . In TnT negative patients a positive CRP test predicted 33.3% of events and 28.8% of patients negative for CRP and TnT had events at 42 days post discharge . Logistic regression analysis regarding the primary endpoint including TnT and CRP ( 4-24h values ) , age , gender and diagnosis resulted in independent prediction of ACS or death by TnT ( cutoff 0.1µg/L, p=0.048, odds ratio=7.5) and CRP ( cutoff 0.862mg/dL, p=0.026, odds ratio=5.3). Sensitivity/specificity for AMI diagnosis were 69.6%/75% for TnT and 12%/72% for CRP in the first hour and 91.3%/68.2% for TnT and 68%/72% for CRP 4-24h later . Conclusions : Besides TnT , high sensitivity CRP determination has no additional value for early AMI diagnosis . The prognosis of these patients during the first 24 hours is significantly and independently predicted by CRP measurements in addition to troponin T. Instructions: please typing these entity words according to sentence: role, pathogenesis, syndromes, C - reactive protein, CRP, acute phase protein, markers, troponin T, TnT, determination, CRP, patients, diagnosis, prognosis, Patients, Methods, patients, TnT, Diagnostics, CRP, CRP, sensitivity, patients, unstable angina, All, patients, discharge, death, discharge, patients, CRP, TnT, TnT, CRP, patients, TnT, patients, CRP, test, patients, CRP, TnT, discharge, Logistic regression, analysis, TnT, CRP, values, age, gender, diagnosis, death, TnT, CRP, AMI, diagnosis, TnT, CRP, TnT, CRP, TnT, sensitivity, CRP, determination, value, AMI, diagnosis, prognosis, patients, CRP, measurements, troponin Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Background : It has been suggested that inflammatory processes play a role in the pathogenesis of acute coronary syndromes ( ACS ) . C-reactive protein ( CRP ) is a classic acute phase protein . It is yet unclear whether , in addition to established markers as troponin T ( TnT ) , determination of CRP in patients admitted for ACS contributes significantly to the diagnosis and prognosis of ACS . Patients and Methods : We investigated 50 patients with ACS ( 59.4 SD 13.9 years ) in the first hour after admission and 4-24h later with respect to TnT ( Elecsys , Roche Diagnostics ) and CRP ( biokit , modified Quantex CRP plus , analytical sensitivity 0.02mg/dL). Fifty percent of the patients were classified as having unstable angina retrospectively . All patients were followed in the 6 weeks post discharge regarding death and recurrent ACS . Results : The cumulative event rate at 6 weeks after discharge was 62.5% for patients being CRP and TnT positive compared to 35.3% in TnT positive and CRP negative patients . In TnT negative patients a positive CRP test predicted 33.3% of events and 28.8% of patients negative for CRP and TnT had events at 42 days post discharge . Logistic regression analysis regarding the primary endpoint including TnT and CRP ( 4-24h values ) , age , gender and diagnosis resulted in independent prediction of ACS or death by TnT ( cutoff 0.1µg/L, p=0.048, odds ratio=7.5) and CRP ( cutoff 0.862mg/dL, p=0.026, odds ratio=5.3). Sensitivity/specificity for AMI diagnosis were 69.6%/75% for TnT and 12%/72% for CRP in the first hour and 91.3%/68.2% for TnT and 68%/72% for CRP 4-24h later . Conclusions : Besides TnT , high sensitivity CRP determination has no additional value for early AMI diagnosis . The prognosis of these patients during the first 24 hours is significantly and independently predicted by CRP measurements in addition to troponin T.

[ "Background", ":", "It", "has", "been", "suggested", "that", "inflammatory", "processes", "play", "a", "role", "in", "the", "pathogenesis", "of", "acute", "coronary", "syndromes", "(", "ACS", ")", ".", "C", "-", "reactive", "protein", "(", "CRP", ")", "is", "a", "classic", "acute", "phase", "protein", ".", "It", "is", "yet", "unclear", "whether", ",", "in", "addition", "to", "established", "markers", "as", "troponin", "T", "(", "TnT", ")", ",", "determination", "of", "CRP", "in", "patients", "admitted", "for", "ACS", "contributes", "significantly", "to", "the", "diagnosis", "and", "prognosis", "of", "ACS", ".", "Patients", "and", "Methods", ":", "We", "investigated", "50", "patients", "with", "ACS", "(", "59.4", "SD", "13.9", "years", ")", "in", "the", "first", "hour", "after", "admission", "and", "4", "-", "24h", "later", "with", "respect", "to", "TnT", "(", "Elecsys", ",", "Roche", "Diagnostics", ")", "and", "CRP", "(", "biokit", ",", "modified", "Quantex", "CRP", "plus", ",", "analytical", "sensitivity", "0.02mg", "/", "dL", ")", ".", "Fifty", "percent", "of", "the", "patients", "were", "classified", "as", "having", "unstable", "angina", "retrospectively", ".", "All", "patients", "were", "followed", "in", "the", "6", "weeks", "post", "discharge", "regarding", "death", "and", "recurrent", "ACS", ".", "Results", ":", "The", "cumulative", "event", "rate", "at", "6", "weeks", "after", "discharge", "was", "62.5", "%", "for", "patients", "being", "CRP", "and", "TnT", "positive", "compared", "to", "35.3", "%", "in", "TnT", "positive", "and", "CRP", "negative", "patients", ".", "In", "TnT", "negative", "patients", "a", "positive", "CRP", "test", "predicted", "33.3", "%", "of", "events", "and", "28.8", "%", "of", "patients", "negative", "for", "CRP", "and", "TnT", "had", "events", "at", "42", "days", "post", "discharge", ".", "Logistic", "regression", "analysis", "regarding", "the", "primary", "endpoint", "including", "TnT", "and", "CRP", "(", "4", "-", "24h", "values", ")", ",", "age", ",", "gender", "and", "diagnosis", "resulted", "in", "independent", "prediction", "of", "ACS", "or", "death", "by", "TnT", "(", "cutoff", "0.1µg", "/", "L", ",", "p=0.048", ",", "odds", "ratio=7.5", ")", "and", "CRP", "(", "cutoff", "0.862mg", "/", "dL", ",", "p=0.026", ",", "odds", "ratio=5.3", ")", ".", "Sensitivity", "/", "specificity", "for", "AMI", "diagnosis", "were", "69.6%/75", "%", "for", "TnT", "and", "12%/72", "%", "for", "CRP", "in", "the", "first", "hour", "and", "91.3%/68.2", "%", "for", "TnT", "and", "68%/72", "%", "for", "CRP", "4", "-", "24h", "later", ".", "Conclusions", ":", "Besides", "TnT", ",", "high", "sensitivity", "CRP", "determination", "has", "no", "additional", "value", "for", "early", "AMI", "diagnosis", ".", "The", "prognosis", "of", "these", "patients", "during", "the", "first", "24", "hours", "is", "significantly", "and", "independently", "predicted", "by", "CRP", "measurements", "in", "addition", "to", "troponin", "T." ]

[ "umlsterm" ]

role, pathogenesis, syndromes, C - reactive protein, CRP, acute phase protein, markers, troponin T, TnT, determination, CRP, patients, diagnosis, prognosis, Patients, Methods, patients, TnT, Diagnostics, CRP, CRP, sensitivity, patients, unstable angina, All, patients, discharge, death, discharge, patients, CRP, TnT, TnT, CRP, patients, TnT, patients, CRP, test, patients, CRP, TnT, discharge, Logistic regression, analysis, TnT, CRP, values, age, gender, diagnosis, death, TnT, CRP, AMI, diagnosis, TnT, CRP, TnT, CRP, TnT, sensitivity, CRP, determination, value, AMI, diagnosis, prognosis, patients, CRP, measurements, troponin

ZfuerKardiologie.00890658.eng.abstr_task2

Sentence: Background : It has been suggested that inflammatory processes play a role in the pathogenesis of acute coronary syndromes ( ACS ) . C-reactive protein ( CRP ) is a classic acute phase protein . It is yet unclear whether , in addition to established markers as troponin T ( TnT ) , determination of CRP in patients admitted for ACS contributes significantly to the diagnosis and prognosis of ACS . Patients and Methods : We investigated 50 patients with ACS ( 59.4 SD 13.9 years ) in the first hour after admission and 4-24h later with respect to TnT ( Elecsys , Roche Diagnostics ) and CRP ( biokit , modified Quantex CRP plus , analytical sensitivity 0.02mg/dL). Fifty percent of the patients were classified as having unstable angina retrospectively . All patients were followed in the 6 weeks post discharge regarding death and recurrent ACS . Results : The cumulative event rate at 6 weeks after discharge was 62.5% for patients being CRP and TnT positive compared to 35.3% in TnT positive and CRP negative patients . In TnT negative patients a positive CRP test predicted 33.3% of events and 28.8% of patients negative for CRP and TnT had events at 42 days post discharge . Logistic regression analysis regarding the primary endpoint including TnT and CRP ( 4-24h values ) , age , gender and diagnosis resulted in independent prediction of ACS or death by TnT ( cutoff 0.1µg/L, p=0.048, odds ratio=7.5) and CRP ( cutoff 0.862mg/dL, p=0.026, odds ratio=5.3). Sensitivity/specificity for AMI diagnosis were 69.6%/75% for TnT and 12%/72% for CRP in the first hour and 91.3%/68.2% for TnT and 68%/72% for CRP 4-24h later . Conclusions : Besides TnT , high sensitivity CRP determination has no additional value for early AMI diagnosis . The prognosis of these patients during the first 24 hours is significantly and independently predicted by CRP measurements in addition to troponin T. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Background : It has been suggested that inflammatory processes play a role in the pathogenesis of acute coronary syndromes ( ACS ) . C-reactive protein ( CRP ) is a classic acute phase protein . It is yet unclear whether , in addition to established markers as troponin T ( TnT ) , determination of CRP in patients admitted for ACS contributes significantly to the diagnosis and prognosis of ACS . Patients and Methods : We investigated 50 patients with ACS ( 59.4 SD 13.9 years ) in the first hour after admission and 4-24h later with respect to TnT ( Elecsys , Roche Diagnostics ) and CRP ( biokit , modified Quantex CRP plus , analytical sensitivity 0.02mg/dL). Fifty percent of the patients were classified as having unstable angina retrospectively . All patients were followed in the 6 weeks post discharge regarding death and recurrent ACS . Results : The cumulative event rate at 6 weeks after discharge was 62.5% for patients being CRP and TnT positive compared to 35.3% in TnT positive and CRP negative patients . In TnT negative patients a positive CRP test predicted 33.3% of events and 28.8% of patients negative for CRP and TnT had events at 42 days post discharge . Logistic regression analysis regarding the primary endpoint including TnT and CRP ( 4-24h values ) , age , gender and diagnosis resulted in independent prediction of ACS or death by TnT ( cutoff 0.1µg/L, p=0.048, odds ratio=7.5) and CRP ( cutoff 0.862mg/dL, p=0.026, odds ratio=5.3). Sensitivity/specificity for AMI diagnosis were 69.6%/75% for TnT and 12%/72% for CRP in the first hour and 91.3%/68.2% for TnT and 68%/72% for CRP 4-24h later . Conclusions : Besides TnT , high sensitivity CRP determination has no additional value for early AMI diagnosis . The prognosis of these patients during the first 24 hours is significantly and independently predicted by CRP measurements in addition to troponin T.

[ "Background", ":", "It", "has", "been", "suggested", "that", "inflammatory", "processes", "play", "a", "role", "in", "the", "pathogenesis", "of", "acute", "coronary", "syndromes", "(", "ACS", ")", ".", "C", "-", "reactive", "protein", "(", "CRP", ")", "is", "a", "classic", "acute", "phase", "protein", ".", "It", "is", "yet", "unclear", "whether", ",", "in", "addition", "to", "established", "markers", "as", "troponin", "T", "(", "TnT", ")", ",", "determination", "of", "CRP", "in", "patients", "admitted", "for", "ACS", "contributes", "significantly", "to", "the", "diagnosis", "and", "prognosis", "of", "ACS", ".", "Patients", "and", "Methods", ":", "We", "investigated", "50", "patients", "with", "ACS", "(", "59.4", "SD", "13.9", "years", ")", "in", "the", "first", "hour", "after", "admission", "and", "4", "-", "24h", "later", "with", "respect", "to", "TnT", "(", "Elecsys", ",", "Roche", "Diagnostics", ")", "and", "CRP", "(", "biokit", ",", "modified", "Quantex", "CRP", "plus", ",", "analytical", "sensitivity", "0.02mg", "/", "dL", ")", ".", "Fifty", "percent", "of", "the", "patients", "were", "classified", "as", "having", "unstable", "angina", "retrospectively", ".", "All", "patients", "were", "followed", "in", "the", "6", "weeks", "post", "discharge", "regarding", "death", "and", "recurrent", "ACS", ".", "Results", ":", "The", "cumulative", "event", "rate", "at", "6", "weeks", "after", "discharge", "was", "62.5", "%", "for", "patients", "being", "CRP", "and", "TnT", "positive", "compared", "to", "35.3", "%", "in", "TnT", "positive", "and", "CRP", "negative", "patients", ".", "In", "TnT", "negative", "patients", "a", "positive", "CRP", "test", "predicted", "33.3", "%", "of", "events", "and", "28.8", "%", "of", "patients", "negative", "for", "CRP", "and", "TnT", "had", "events", "at", "42", "days", "post", "discharge", ".", "Logistic", "regression", "analysis", "regarding", "the", "primary", "endpoint", "including", "TnT", "and", "CRP", "(", "4", "-", "24h", "values", ")", ",", "age", ",", "gender", "and", "diagnosis", "resulted", "in", "independent", "prediction", "of", "ACS", "or", "death", "by", "TnT", "(", "cutoff", "0.1µg", "/", "L", ",", "p=0.048", ",", "odds", "ratio=7.5", ")", "and", "CRP", "(", "cutoff", "0.862mg", "/", "dL", ",", "p=0.026", ",", "odds", "ratio=5.3", ")", ".", "Sensitivity", "/", "specificity", "for", "AMI", "diagnosis", "were", "69.6%/75", "%", "for", "TnT", "and", "12%/72", "%", "for", "CRP", "in", "the", "first", "hour", "and", "91.3%/68.2", "%", "for", "TnT", "and", "68%/72", "%", "for", "CRP", "4", "-", "24h", "later", ".", "Conclusions", ":", "Besides", "TnT", ",", "high", "sensitivity", "CRP", "determination", "has", "no", "additional", "value", "for", "early", "AMI", "diagnosis", ".", "The", "prognosis", "of", "these", "patients", "during", "the", "first", "24", "hours", "is", "significantly", "and", "independently", "predicted", "by", "CRP", "measurements", "in", "addition", "to", "troponin", "T." ]

[ "umlsterm" ]

sarcoidosis is a Diseases & Disorders, etanercept is a Chemicals & Drugs, rheumatoid arthritis is a Diseases & Disorders

1675_task0

Sentence: Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Chemicals & Drugs, Diseases & Disorders

[ "O", "O", "B-Diseases & Disorders", "O", "B-Chemicals & Drugs", "O", "O", "B-Diseases & Disorders", "I-Diseases & Disorders", "O", "O" ]

Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.

[ "Development", "of", "sarcoidosis", "in", "etanercept", "-", "treated", "rheumatoid", "arthritis", "patients", "." ]

[ "Diseases & Disorders", "", "Chemicals & Drugs" ]

sarcoidosis is a Diseases & Disorders, etanercept is a Chemicals & Drugs, rheumatoid arthritis is a Diseases & Disorders

1675_task1

Sentence: Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Instructions: please typing these entity words according to sentence: sarcoidosis, etanercept, rheumatoid arthritis Options: Chemicals & Drugs, Diseases & Disorders

[ "O", "O", "B-Diseases & Disorders", "O", "B-Chemicals & Drugs", "O", "O", "B-Diseases & Disorders", "I-Diseases & Disorders", "O", "O" ]

Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.

[ "Development", "of", "sarcoidosis", "in", "etanercept", "-", "treated", "rheumatoid", "arthritis", "patients", "." ]

[ "Diseases & Disorders", "", "Chemicals & Drugs" ]

sarcoidosis, etanercept, rheumatoid arthritis

1675_task2

Sentence: Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Diseases & Disorders", "O", "B-Chemicals & Drugs", "O", "O", "B-Diseases & Disorders", "I-Diseases & Disorders", "O", "O" ]

Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.

[ "Development", "of", "sarcoidosis", "in", "etanercept", "-", "treated", "rheumatoid", "arthritis", "patients", "." ]

[ "Diseases & Disorders", "", "Chemicals & Drugs" ]

Alejandra is a NOMBRE_SUJETO_ASISTENCIA, Irías Arias is a NOMBRE_SUJETO_ASISTENCIA, 3738763 is a ID_SUJETO_ASISTENCIA, 74 65745652 32 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 28010 is a TERRITORIO, 05/02/1965 is a FECHAS, España is a PAIS, 52 años is a EDAD_SUJETO_ASISTENCIA, 18/01/2018 is a FECHAS, Esther Campos Mollo is a NOMBRE_PERSONAL_SANITARIO, 28 28 50312 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 52 años is a EDAD_SUJETO_ASISTENCIA, Esther Campos Mollo is a NOMBRE_PERSONAL_SANITARIO, esthercm@hotmail.com is a CORREO_ELECTRONICO

229_task0

Sentence: Datos del paciente. Nombre: Alejandra. Apellidos: Irías Arias. NHC: 3738763. NASS: 74 65745652 32. Domicilio: C/ Principe de Vergara, 29, 5 A. Localidad/ Provincia: Madrid. CP: 28010. Datos asistenciales. Fecha de nacimiento: 05/02/1965. País de nacimiento: España. Edad: 52 años Sexo: M. Fecha de Ingreso: 18/01/2018. Médico: Esther Campos Mollo NºCol: 28 28 50312. Informe clínico del paciente: Mujer de 52 años que refirió disminución de agudeza visual (AV) espontánea en su ojo izquierdo (OI) ambliope. No tenía el antecedente de parto prematuro, ni historia familiar de enfermedad ocular. En la primera exploración, la mejor AV corregida fue de 1 en el ojo derecho (OD) (-1 cilindro 150o +3 esfera; longitud axial de 22,5mm) y de 0,025 en el ojo izquierdo (OI) (-0,75 cilindro 25o -13,25 esfera; longitud axial de 25,3mm). El estudio biomicroscópico del OI permitió identificar la mancha de Mittendorf localizada en el cuadrante nasal inferior de la cápsula posterior del cristalino y el extremo anterior de la AHP con contenido hemático en su interior. El ojo adelfo era normal. Los diámetros corneales horizontales midieron 12mm en ambos ojos (AO) y la tonometría de aplanación fue de 18mm Hg en AO. La oftalmoscopia indirecta del OI mostró una hemorragia intravítrea leve difusa. El trayecto de la AHP se pudo seguir desde el nervio óptico hasta la cristaloides posterior. La arteria, fijada en sus dos extremos, se desplazaba libremente con los movimientos oculares. El vítreo posterior estaba desprendido parcialmente de la retina. No se hallaron anomalías retinianas periféricas, ni signos de tracción vitreorretiniana o desprendimiento de retina. El fondo del OD era normal. La hemorragia se reabsorbió gradualmente en el transcurso de una semana. La AHP se pudo distinguir con más claridad permitiendo un mejor estudio anatómico. En la tomografía de coherencia óptica (TCO) se apreciaron las características morfológicas de la papila de Bergmeister. De esta, surgía la AHP que mostró una estructura tubular con un interior hiporreflectivo. En la ecografía en modo B se evidenció una imagen lineal hiperecogénica respecto al vítreo que se correspondía con la AHP y un desprendimiento parcial de vítreo posterior. El eco-doppler demostró el flujo sanguíneo normal de la arteria central de la retina y de las arterias ciliares posteriores aunque no se objetivó la presencia de flujo sanguíneo activo en la AHP. El hemograma y las pruebas específicas de coagulación fueron normales. El hemovítreo se reabsorbió completamente y la paciente recuperó la visión de 0,2 que presentaba antes de sobrevenir la hemorragia a causa de una ambliopía por anisometropía. No hubo recurrencia de sangrado en 6 meses de seguimiento. Responsable clínico: Dra. Esther Campos Mollo Correo electrónico: esthercm@hotmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Alejandra. Apellidos: Irías Arias. NHC: 3738763. NASS: 74 65745652 32. Domicilio: C/ Principe de Vergara, 29, 5 A. Localidad/ Provincia: Madrid. CP: 28010. Datos asistenciales. Fecha de nacimiento: 05/02/1965. País de nacimiento: España. Edad: 52 años Sexo: M. Fecha de Ingreso: 18/01/2018. Médico: Esther Campos Mollo NºCol: 28 28 50312. Informe clínico del paciente: Mujer de 52 años que refirió disminución de agudeza visual (AV) espontánea en su ojo izquierdo (OI) ambliope. No tenía el antecedente de parto prematuro, ni historia familiar de enfermedad ocular. En la primera exploración, la mejor AV corregida fue de 1 en el ojo derecho (OD) (-1 cilindro 150o +3 esfera; longitud axial de 22,5mm) y de 0,025 en el ojo izquierdo (OI) (-0,75 cilindro 25o -13,25 esfera; longitud axial de 25,3mm). El estudio biomicroscópico del OI permitió identificar la mancha de Mittendorf localizada en el cuadrante nasal inferior de la cápsula posterior del cristalino y el extremo anterior de la AHP con contenido hemático en su interior. El ojo adelfo era normal. Los diámetros corneales horizontales midieron 12mm en ambos ojos (AO) y la tonometría de aplanación fue de 18mm Hg en AO. La oftalmoscopia indirecta del OI mostró una hemorragia intravítrea leve difusa. El trayecto de la AHP se pudo seguir desde el nervio óptico hasta la cristaloides posterior. La arteria, fijada en sus dos extremos, se desplazaba libremente con los movimientos oculares. El vítreo posterior estaba desprendido parcialmente de la retina. No se hallaron anomalías retinianas periféricas, ni signos de tracción vitreorretiniana o desprendimiento de retina. El fondo del OD era normal. La hemorragia se reabsorbió gradualmente en el transcurso de una semana. La AHP se pudo distinguir con más claridad permitiendo un mejor estudio anatómico. En la tomografía de coherencia óptica (TCO) se apreciaron las características morfológicas de la papila de Bergmeister. De esta, surgía la AHP que mostró una estructura tubular con un interior hiporreflectivo. En la ecografía en modo B se evidenció una imagen lineal hiperecogénica respecto al vítreo que se correspondía con la AHP y un desprendimiento parcial de vítreo posterior. El eco-doppler demostró el flujo sanguíneo normal de la arteria central de la retina y de las arterias ciliares posteriores aunque no se objetivó la presencia de flujo sanguíneo activo en la AHP. El hemograma y las pruebas específicas de coagulación fueron normales. El hemovítreo se reabsorbió completamente y la paciente recuperó la visión de 0,2 que presentaba antes de sobrevenir la hemorragia a causa de una ambliopía por anisometropía. No hubo recurrencia de sangrado en 6 meses de seguimiento. Responsable clínico: Dra. Esther Campos Mollo Correo electrónico: esthercm@hotmail.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Alejandra", ".", "\n", "Apellidos", ":", "Irías", "Arias", ".", "\n", "NHC", ":", "3738763", ".", "\n", "NASS", ":", "74", "65745652", "32", ".", "\n", "Domicilio", ":", "C/", "Principe", "de", "Vergara", ",", "29", ",", "5", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28010", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "05/02/1965", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "52", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "18/01/2018", ".", "\n", "Médico", ":", "Esther", "Campos", "Mollo", "NºCol", ":", "28", "28", "50312", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "52", "años", "que", "refirió", "disminución", "de", "agudeza", "visual", "(", "AV", ")", "espontánea", "en", "su", "ojo", "izquierdo", "(", "OI", ")", "ambliope", ".", "No", "tenía", "el", "antecedente", "de", "parto", "prematuro", ",", "ni", "historia", "familiar", "de", "enfermedad", "ocular", ".", "\n", "En", "la", "primera", "exploración", ",", "la", "mejor", "AV", "corregida", "fue", "de", "1", "en", "el", "ojo", "derecho", "(", "OD", ")", "(", "-1", "cilindro", "150o", "+3", "esfera", ";", "longitud", "axial", "de", "22,5", "mm", ")", "y", "de", "0,025", "en", "el", "ojo", "izquierdo", "(", "OI", ")", "(", "-0,75", "cilindro", "25o", "-13,25", "esfera", ";", "longitud", "axial", "de", "25,3", "mm", ")", ".", "\n", "El", "estudio", "biomicroscópico", "del", "OI", "permitió", "identificar", "la", "mancha", "de", "Mittendorf", "localizada", "en", "el", "cuadrante", "nasal", "inferior", "de", "la", "cápsula", "posterior", "del", "cristalino", "y", "el", "extremo", "anterior", "de", "la", "AHP", "con", "contenido", "hemático", "en", "su", "interior", ".", "El", "ojo", "adelfo", "era", "normal", ".", "Los", "diámetros", "corneales", "horizontales", "midieron", "12", "mm", "en", "ambos", "ojos", "(", "AO", ")", "y", "la", "tonometría", "de", "aplanación", "fue", "de", "18", "mm", "Hg", "en", "AO", ".", "\n", "La", "oftalmoscopia", "indirecta", "del", "OI", "mostró", "una", "hemorragia", "intravítrea", "leve", "difusa", ".", "El", "trayecto", "de", "la", "AHP", "se", "pudo", "seguir", "desde", "el", "nervio", "óptico", "hasta", "la", "cristaloides", "posterior", ".", "La", "arteria", ",", "fijada", "en", "sus", "dos", "extremos", ",", "se", "desplazaba", "libremente", "con", "los", "movimientos", "oculares", ".", "El", "vítreo", "posterior", "estaba", "desprendido", "parcialmente", "de", "la", "retina", ".", "No", "se", "hallaron", "anomalías", "retinianas", "periféricas", ",", "ni", "signos", "de", "tracción", "vitreorretiniana", "o", "desprendimiento", "de", "retina", ".", "El", "fondo", "del", "OD", "era", "normal", ".", "\n", "La", "hemorragia", "se", "reabsorbió", "gradualmente", "en", "el", "transcurso", "de", "una", "semana", ".", "La", "AHP", "se", "pudo", "distinguir", "con", "más", "claridad", "permitiendo", "un", "mejor", "estudio", "anatómico", ".", "En", "la", "tomografía", "de", "coherencia", "óptica", "(", "TCO", ")", "se", "apreciaron", "las", "características", "morfológicas", "de", "la", "papila", "de", "Bergmeister", ".", "De", "esta", ",", "surgía", "la", "AHP", "que", "mostró", "una", "estructura", "tubular", "con", "un", "interior", "hiporreflectivo", ".", "\n", "En", "la", "ecografía", "en", "modo", "B", "se", "evidenció", "una", "imagen", "lineal", "hiperecogénica", "respecto", "al", "vítreo", "que", "se", "correspondía", "con", "la", "AHP", "y", "un", "desprendimiento", "parcial", "de", "vítreo", "posterior", ".", "El", "eco", "-", "doppler", "demostró", "el", "flujo", "sanguíneo", "normal", "de", "la", "arteria", "central", "de", "la", "retina", "y", "de", "las", "arterias", "ciliares", "posteriores", "aunque", "no", "se", "objetivó", "la", "presencia", "de", "flujo", "sanguíneo", "activo", "en", "la", "AHP", ".", "\n", "El", "hemograma", "y", "las", "pruebas", "específicas", "de", "coagulación", "fueron", "normales", ".", "El", "hemovítreo", "se", "reabsorbió", "completamente", "y", "la", "paciente", "recuperó", "la", "visión", "de", "0,2", "que", "presentaba", "antes", "de", "sobrevenir", "la", "hemorragia", "a", "causa", "de", "una", "ambliopía", "por", "anisometropía", ".", "No", "hubo", "recurrencia", "de", "sangrado", "en", "6", "meses", "de", "seguimiento", ".", "\n", "Responsable", "clínico", ":", "Dra", ".", "Esther", "Campos", "Mollo", "Correo", "electrónico", ":", "esthercm@hotmail.com", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Alejandra is a NOMBRE_SUJETO_ASISTENCIA, Irías Arias is a NOMBRE_SUJETO_ASISTENCIA, 3738763 is a ID_SUJETO_ASISTENCIA, 74 65745652 32 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 28010 is a TERRITORIO, 05/02/1965 is a FECHAS, España is a PAIS, 52 años is a EDAD_SUJETO_ASISTENCIA, 18/01/2018 is a FECHAS, Esther Campos Mollo is a NOMBRE_PERSONAL_SANITARIO, 28 28 50312 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 52 años is a EDAD_SUJETO_ASISTENCIA, Esther Campos Mollo is a NOMBRE_PERSONAL_SANITARIO, esthercm@hotmail.com is a CORREO_ELECTRONICO

229_task1

Sentence: Datos del paciente. Nombre: Alejandra. Apellidos: Irías Arias. NHC: 3738763. NASS: 74 65745652 32. Domicilio: C/ Principe de Vergara, 29, 5 A. Localidad/ Provincia: Madrid. CP: 28010. Datos asistenciales. Fecha de nacimiento: 05/02/1965. País de nacimiento: España. Edad: 52 años Sexo: M. Fecha de Ingreso: 18/01/2018. Médico: Esther Campos Mollo NºCol: 28 28 50312. Informe clínico del paciente: Mujer de 52 años que refirió disminución de agudeza visual (AV) espontánea en su ojo izquierdo (OI) ambliope. No tenía el antecedente de parto prematuro, ni historia familiar de enfermedad ocular. En la primera exploración, la mejor AV corregida fue de 1 en el ojo derecho (OD) (-1 cilindro 150o +3 esfera; longitud axial de 22,5mm) y de 0,025 en el ojo izquierdo (OI) (-0,75 cilindro 25o -13,25 esfera; longitud axial de 25,3mm). El estudio biomicroscópico del OI permitió identificar la mancha de Mittendorf localizada en el cuadrante nasal inferior de la cápsula posterior del cristalino y el extremo anterior de la AHP con contenido hemático en su interior. El ojo adelfo era normal. Los diámetros corneales horizontales midieron 12mm en ambos ojos (AO) y la tonometría de aplanación fue de 18mm Hg en AO. La oftalmoscopia indirecta del OI mostró una hemorragia intravítrea leve difusa. El trayecto de la AHP se pudo seguir desde el nervio óptico hasta la cristaloides posterior. La arteria, fijada en sus dos extremos, se desplazaba libremente con los movimientos oculares. El vítreo posterior estaba desprendido parcialmente de la retina. No se hallaron anomalías retinianas periféricas, ni signos de tracción vitreorretiniana o desprendimiento de retina. El fondo del OD era normal. La hemorragia se reabsorbió gradualmente en el transcurso de una semana. La AHP se pudo distinguir con más claridad permitiendo un mejor estudio anatómico. En la tomografía de coherencia óptica (TCO) se apreciaron las características morfológicas de la papila de Bergmeister. De esta, surgía la AHP que mostró una estructura tubular con un interior hiporreflectivo. En la ecografía en modo B se evidenció una imagen lineal hiperecogénica respecto al vítreo que se correspondía con la AHP y un desprendimiento parcial de vítreo posterior. El eco-doppler demostró el flujo sanguíneo normal de la arteria central de la retina y de las arterias ciliares posteriores aunque no se objetivó la presencia de flujo sanguíneo activo en la AHP. El hemograma y las pruebas específicas de coagulación fueron normales. El hemovítreo se reabsorbió completamente y la paciente recuperó la visión de 0,2 que presentaba antes de sobrevenir la hemorragia a causa de una ambliopía por anisometropía. No hubo recurrencia de sangrado en 6 meses de seguimiento. Responsable clínico: Dra. Esther Campos Mollo Correo electrónico: esthercm@hotmail.com Instructions: please typing these entity words according to sentence: Alejandra, Irías Arias, 3738763, 74 65745652 32, Madrid, 28010, 05/02/1965, España, 52 años, 18/01/2018, Esther Campos Mollo, 28 28 50312, Mujer, 52 años, Esther Campos Mollo, esthercm@hotmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Alejandra. Apellidos: Irías Arias. NHC: 3738763. NASS: 74 65745652 32. Domicilio: C/ Principe de Vergara, 29, 5 A. Localidad/ Provincia: Madrid. CP: 28010. Datos asistenciales. Fecha de nacimiento: 05/02/1965. País de nacimiento: España. Edad: 52 años Sexo: M. Fecha de Ingreso: 18/01/2018. Médico: Esther Campos Mollo NºCol: 28 28 50312. Informe clínico del paciente: Mujer de 52 años que refirió disminución de agudeza visual (AV) espontánea en su ojo izquierdo (OI) ambliope. No tenía el antecedente de parto prematuro, ni historia familiar de enfermedad ocular. En la primera exploración, la mejor AV corregida fue de 1 en el ojo derecho (OD) (-1 cilindro 150o +3 esfera; longitud axial de 22,5mm) y de 0,025 en el ojo izquierdo (OI) (-0,75 cilindro 25o -13,25 esfera; longitud axial de 25,3mm). El estudio biomicroscópico del OI permitió identificar la mancha de Mittendorf localizada en el cuadrante nasal inferior de la cápsula posterior del cristalino y el extremo anterior de la AHP con contenido hemático en su interior. El ojo adelfo era normal. Los diámetros corneales horizontales midieron 12mm en ambos ojos (AO) y la tonometría de aplanación fue de 18mm Hg en AO. La oftalmoscopia indirecta del OI mostró una hemorragia intravítrea leve difusa. El trayecto de la AHP se pudo seguir desde el nervio óptico hasta la cristaloides posterior. La arteria, fijada en sus dos extremos, se desplazaba libremente con los movimientos oculares. El vítreo posterior estaba desprendido parcialmente de la retina. No se hallaron anomalías retinianas periféricas, ni signos de tracción vitreorretiniana o desprendimiento de retina. El fondo del OD era normal. La hemorragia se reabsorbió gradualmente en el transcurso de una semana. La AHP se pudo distinguir con más claridad permitiendo un mejor estudio anatómico. En la tomografía de coherencia óptica (TCO) se apreciaron las características morfológicas de la papila de Bergmeister. De esta, surgía la AHP que mostró una estructura tubular con un interior hiporreflectivo. En la ecografía en modo B se evidenció una imagen lineal hiperecogénica respecto al vítreo que se correspondía con la AHP y un desprendimiento parcial de vítreo posterior. El eco-doppler demostró el flujo sanguíneo normal de la arteria central de la retina y de las arterias ciliares posteriores aunque no se objetivó la presencia de flujo sanguíneo activo en la AHP. El hemograma y las pruebas específicas de coagulación fueron normales. El hemovítreo se reabsorbió completamente y la paciente recuperó la visión de 0,2 que presentaba antes de sobrevenir la hemorragia a causa de una ambliopía por anisometropía. No hubo recurrencia de sangrado en 6 meses de seguimiento. Responsable clínico: Dra. Esther Campos Mollo Correo electrónico: esthercm@hotmail.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Alejandra", ".", "\n", "Apellidos", ":", "Irías", "Arias", ".", "\n", "NHC", ":", "3738763", ".", "\n", "NASS", ":", "74", "65745652", "32", ".", "\n", "Domicilio", ":", "C/", "Principe", "de", "Vergara", ",", "29", ",", "5", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28010", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "05/02/1965", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "52", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "18/01/2018", ".", "\n", "Médico", ":", "Esther", "Campos", "Mollo", "NºCol", ":", "28", "28", "50312", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "52", "años", "que", "refirió", "disminución", "de", "agudeza", "visual", "(", "AV", ")", "espontánea", "en", "su", "ojo", "izquierdo", "(", "OI", ")", "ambliope", ".", "No", "tenía", "el", "antecedente", "de", "parto", "prematuro", ",", "ni", "historia", "familiar", "de", "enfermedad", "ocular", ".", "\n", "En", "la", "primera", "exploración", ",", "la", "mejor", "AV", "corregida", "fue", "de", "1", "en", "el", "ojo", "derecho", "(", "OD", ")", "(", "-1", "cilindro", "150o", "+3", "esfera", ";", "longitud", "axial", "de", "22,5", "mm", ")", "y", "de", "0,025", "en", "el", "ojo", "izquierdo", "(", "OI", ")", "(", "-0,75", "cilindro", "25o", "-13,25", "esfera", ";", "longitud", "axial", "de", "25,3", "mm", ")", ".", "\n", "El", "estudio", "biomicroscópico", "del", "OI", "permitió", "identificar", "la", "mancha", "de", "Mittendorf", "localizada", "en", "el", "cuadrante", "nasal", "inferior", "de", "la", "cápsula", "posterior", "del", "cristalino", "y", "el", "extremo", "anterior", "de", "la", "AHP", "con", "contenido", "hemático", "en", "su", "interior", ".", "El", "ojo", "adelfo", "era", "normal", ".", "Los", "diámetros", "corneales", "horizontales", "midieron", "12", "mm", "en", "ambos", "ojos", "(", "AO", ")", "y", "la", "tonometría", "de", "aplanación", "fue", "de", "18", "mm", "Hg", "en", "AO", ".", "\n", "La", "oftalmoscopia", "indirecta", "del", "OI", "mostró", "una", "hemorragia", "intravítrea", "leve", "difusa", ".", "El", "trayecto", "de", "la", "AHP", "se", "pudo", "seguir", "desde", "el", "nervio", "óptico", "hasta", "la", "cristaloides", "posterior", ".", "La", "arteria", ",", "fijada", "en", "sus", "dos", "extremos", ",", "se", "desplazaba", "libremente", "con", "los", "movimientos", "oculares", ".", "El", "vítreo", "posterior", "estaba", "desprendido", "parcialmente", "de", "la", "retina", ".", "No", "se", "hallaron", "anomalías", "retinianas", "periféricas", ",", "ni", "signos", "de", "tracción", "vitreorretiniana", "o", "desprendimiento", "de", "retina", ".", "El", "fondo", "del", "OD", "era", "normal", ".", "\n", "La", "hemorragia", "se", "reabsorbió", "gradualmente", "en", "el", "transcurso", "de", "una", "semana", ".", "La", "AHP", "se", "pudo", "distinguir", "con", "más", "claridad", "permitiendo", "un", "mejor", "estudio", "anatómico", ".", "En", "la", "tomografía", "de", "coherencia", "óptica", "(", "TCO", ")", "se", "apreciaron", "las", "características", "morfológicas", "de", "la", "papila", "de", "Bergmeister", ".", "De", "esta", ",", "surgía", "la", "AHP", "que", "mostró", "una", "estructura", "tubular", "con", "un", "interior", "hiporreflectivo", ".", "\n", "En", "la", "ecografía", "en", "modo", "B", "se", "evidenció", "una", "imagen", "lineal", "hiperecogénica", "respecto", "al", "vítreo", "que", "se", "correspondía", "con", "la", "AHP", "y", "un", "desprendimiento", "parcial", "de", "vítreo", "posterior", ".", "El", "eco", "-", "doppler", "demostró", "el", "flujo", "sanguíneo", "normal", "de", "la", "arteria", "central", "de", "la", "retina", "y", "de", "las", "arterias", "ciliares", "posteriores", "aunque", "no", "se", "objetivó", "la", "presencia", "de", "flujo", "sanguíneo", "activo", "en", "la", "AHP", ".", "\n", "El", "hemograma", "y", "las", "pruebas", "específicas", "de", "coagulación", "fueron", "normales", ".", "El", "hemovítreo", "se", "reabsorbió", "completamente", "y", "la", "paciente", "recuperó", "la", "visión", "de", "0,2", "que", "presentaba", "antes", "de", "sobrevenir", "la", "hemorragia", "a", "causa", "de", "una", "ambliopía", "por", "anisometropía", ".", "No", "hubo", "recurrencia", "de", "sangrado", "en", "6", "meses", "de", "seguimiento", ".", "\n", "Responsable", "clínico", ":", "Dra", ".", "Esther", "Campos", "Mollo", "Correo", "electrónico", ":", "esthercm@hotmail.com", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Alejandra, Irías Arias, 3738763, 74 65745652 32, Madrid, 28010, 05/02/1965, España, 52 años, 18/01/2018, Esther Campos Mollo, 28 28 50312, Mujer, 52 años, Esther Campos Mollo, esthercm@hotmail.com

229_task2

Sentence: Datos del paciente. Nombre: Alejandra. Apellidos: Irías Arias. NHC: 3738763. NASS: 74 65745652 32. Domicilio: C/ Principe de Vergara, 29, 5 A. Localidad/ Provincia: Madrid. CP: 28010. Datos asistenciales. Fecha de nacimiento: 05/02/1965. País de nacimiento: España. Edad: 52 años Sexo: M. Fecha de Ingreso: 18/01/2018. Médico: Esther Campos Mollo NºCol: 28 28 50312. Informe clínico del paciente: Mujer de 52 años que refirió disminución de agudeza visual (AV) espontánea en su ojo izquierdo (OI) ambliope. No tenía el antecedente de parto prematuro, ni historia familiar de enfermedad ocular. En la primera exploración, la mejor AV corregida fue de 1 en el ojo derecho (OD) (-1 cilindro 150o +3 esfera; longitud axial de 22,5mm) y de 0,025 en el ojo izquierdo (OI) (-0,75 cilindro 25o -13,25 esfera; longitud axial de 25,3mm). El estudio biomicroscópico del OI permitió identificar la mancha de Mittendorf localizada en el cuadrante nasal inferior de la cápsula posterior del cristalino y el extremo anterior de la AHP con contenido hemático en su interior. El ojo adelfo era normal. Los diámetros corneales horizontales midieron 12mm en ambos ojos (AO) y la tonometría de aplanación fue de 18mm Hg en AO. La oftalmoscopia indirecta del OI mostró una hemorragia intravítrea leve difusa. El trayecto de la AHP se pudo seguir desde el nervio óptico hasta la cristaloides posterior. La arteria, fijada en sus dos extremos, se desplazaba libremente con los movimientos oculares. El vítreo posterior estaba desprendido parcialmente de la retina. No se hallaron anomalías retinianas periféricas, ni signos de tracción vitreorretiniana o desprendimiento de retina. El fondo del OD era normal. La hemorragia se reabsorbió gradualmente en el transcurso de una semana. La AHP se pudo distinguir con más claridad permitiendo un mejor estudio anatómico. En la tomografía de coherencia óptica (TCO) se apreciaron las características morfológicas de la papila de Bergmeister. De esta, surgía la AHP que mostró una estructura tubular con un interior hiporreflectivo. En la ecografía en modo B se evidenció una imagen lineal hiperecogénica respecto al vítreo que se correspondía con la AHP y un desprendimiento parcial de vítreo posterior. El eco-doppler demostró el flujo sanguíneo normal de la arteria central de la retina y de las arterias ciliares posteriores aunque no se objetivó la presencia de flujo sanguíneo activo en la AHP. El hemograma y las pruebas específicas de coagulación fueron normales. El hemovítreo se reabsorbió completamente y la paciente recuperó la visión de 0,2 que presentaba antes de sobrevenir la hemorragia a causa de una ambliopía por anisometropía. No hubo recurrencia de sangrado en 6 meses de seguimiento. Responsable clínico: Dra. Esther Campos Mollo Correo electrónico: esthercm@hotmail.com Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Alejandra. Apellidos: Irías Arias. NHC: 3738763. NASS: 74 65745652 32. Domicilio: C/ Principe de Vergara, 29, 5 A. Localidad/ Provincia: Madrid. CP: 28010. Datos asistenciales. Fecha de nacimiento: 05/02/1965. País de nacimiento: España. Edad: 52 años Sexo: M. Fecha de Ingreso: 18/01/2018. Médico: Esther Campos Mollo NºCol: 28 28 50312. Informe clínico del paciente: Mujer de 52 años que refirió disminución de agudeza visual (AV) espontánea en su ojo izquierdo (OI) ambliope. No tenía el antecedente de parto prematuro, ni historia familiar de enfermedad ocular. En la primera exploración, la mejor AV corregida fue de 1 en el ojo derecho (OD) (-1 cilindro 150o +3 esfera; longitud axial de 22,5mm) y de 0,025 en el ojo izquierdo (OI) (-0,75 cilindro 25o -13,25 esfera; longitud axial de 25,3mm). El estudio biomicroscópico del OI permitió identificar la mancha de Mittendorf localizada en el cuadrante nasal inferior de la cápsula posterior del cristalino y el extremo anterior de la AHP con contenido hemático en su interior. El ojo adelfo era normal. Los diámetros corneales horizontales midieron 12mm en ambos ojos (AO) y la tonometría de aplanación fue de 18mm Hg en AO. La oftalmoscopia indirecta del OI mostró una hemorragia intravítrea leve difusa. El trayecto de la AHP se pudo seguir desde el nervio óptico hasta la cristaloides posterior. La arteria, fijada en sus dos extremos, se desplazaba libremente con los movimientos oculares. El vítreo posterior estaba desprendido parcialmente de la retina. No se hallaron anomalías retinianas periféricas, ni signos de tracción vitreorretiniana o desprendimiento de retina. El fondo del OD era normal. La hemorragia se reabsorbió gradualmente en el transcurso de una semana. La AHP se pudo distinguir con más claridad permitiendo un mejor estudio anatómico. En la tomografía de coherencia óptica (TCO) se apreciaron las características morfológicas de la papila de Bergmeister. De esta, surgía la AHP que mostró una estructura tubular con un interior hiporreflectivo. En la ecografía en modo B se evidenció una imagen lineal hiperecogénica respecto al vítreo que se correspondía con la AHP y un desprendimiento parcial de vítreo posterior. El eco-doppler demostró el flujo sanguíneo normal de la arteria central de la retina y de las arterias ciliares posteriores aunque no se objetivó la presencia de flujo sanguíneo activo en la AHP. El hemograma y las pruebas específicas de coagulación fueron normales. El hemovítreo se reabsorbió completamente y la paciente recuperó la visión de 0,2 que presentaba antes de sobrevenir la hemorragia a causa de una ambliopía por anisometropía. No hubo recurrencia de sangrado en 6 meses de seguimiento. Responsable clínico: Dra. Esther Campos Mollo Correo electrónico: esthercm@hotmail.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Alejandra", ".", "\n", "Apellidos", ":", "Irías", "Arias", ".", "\n", "NHC", ":", "3738763", ".", "\n", "NASS", ":", "74", "65745652", "32", ".", "\n", "Domicilio", ":", "C/", "Principe", "de", "Vergara", ",", "29", ",", "5", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28010", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "05/02/1965", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "52", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "18/01/2018", ".", "\n", "Médico", ":", "Esther", "Campos", "Mollo", "NºCol", ":", "28", "28", "50312", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "52", "años", "que", "refirió", "disminución", "de", "agudeza", "visual", "(", "AV", ")", "espontánea", "en", "su", "ojo", "izquierdo", "(", "OI", ")", "ambliope", ".", "No", "tenía", "el", "antecedente", "de", "parto", "prematuro", ",", "ni", "historia", "familiar", "de", "enfermedad", "ocular", ".", "\n", "En", "la", "primera", "exploración", ",", "la", "mejor", "AV", "corregida", "fue", "de", "1", "en", "el", "ojo", "derecho", "(", "OD", ")", "(", "-1", "cilindro", "150o", "+3", "esfera", ";", "longitud", "axial", "de", "22,5", "mm", ")", "y", "de", "0,025", "en", "el", "ojo", "izquierdo", "(", "OI", ")", "(", "-0,75", "cilindro", "25o", "-13,25", "esfera", ";", "longitud", "axial", "de", "25,3", "mm", ")", ".", "\n", "El", "estudio", "biomicroscópico", "del", "OI", "permitió", "identificar", "la", "mancha", "de", "Mittendorf", "localizada", "en", "el", "cuadrante", "nasal", "inferior", "de", "la", "cápsula", "posterior", "del", "cristalino", "y", "el", "extremo", "anterior", "de", "la", "AHP", "con", "contenido", "hemático", "en", "su", "interior", ".", "El", "ojo", "adelfo", "era", "normal", ".", "Los", "diámetros", "corneales", "horizontales", "midieron", "12", "mm", "en", "ambos", "ojos", "(", "AO", ")", "y", "la", "tonometría", "de", "aplanación", "fue", "de", "18", "mm", "Hg", "en", "AO", ".", "\n", "La", "oftalmoscopia", "indirecta", "del", "OI", "mostró", "una", "hemorragia", "intravítrea", "leve", "difusa", ".", "El", "trayecto", "de", "la", "AHP", "se", "pudo", "seguir", "desde", "el", "nervio", "óptico", "hasta", "la", "cristaloides", "posterior", ".", "La", "arteria", ",", "fijada", "en", "sus", "dos", "extremos", ",", "se", "desplazaba", "libremente", "con", "los", "movimientos", "oculares", ".", "El", "vítreo", "posterior", "estaba", "desprendido", "parcialmente", "de", "la", "retina", ".", "No", "se", "hallaron", "anomalías", "retinianas", "periféricas", ",", "ni", "signos", "de", "tracción", "vitreorretiniana", "o", "desprendimiento", "de", "retina", ".", "El", "fondo", "del", "OD", "era", "normal", ".", "\n", "La", "hemorragia", "se", "reabsorbió", "gradualmente", "en", "el", "transcurso", "de", "una", "semana", ".", "La", "AHP", "se", "pudo", "distinguir", "con", "más", "claridad", "permitiendo", "un", "mejor", "estudio", "anatómico", ".", "En", "la", "tomografía", "de", "coherencia", "óptica", "(", "TCO", ")", "se", "apreciaron", "las", "características", "morfológicas", "de", "la", "papila", "de", "Bergmeister", ".", "De", "esta", ",", "surgía", "la", "AHP", "que", "mostró", "una", "estructura", "tubular", "con", "un", "interior", "hiporreflectivo", ".", "\n", "En", "la", "ecografía", "en", "modo", "B", "se", "evidenció", "una", "imagen", "lineal", "hiperecogénica", "respecto", "al", "vítreo", "que", "se", "correspondía", "con", "la", "AHP", "y", "un", "desprendimiento", "parcial", "de", "vítreo", "posterior", ".", "El", "eco", "-", "doppler", "demostró", "el", "flujo", "sanguíneo", "normal", "de", "la", "arteria", "central", "de", "la", "retina", "y", "de", "las", "arterias", "ciliares", "posteriores", "aunque", "no", "se", "objetivó", "la", "presencia", "de", "flujo", "sanguíneo", "activo", "en", "la", "AHP", ".", "\n", "El", "hemograma", "y", "las", "pruebas", "específicas", "de", "coagulación", "fueron", "normales", ".", "El", "hemovítreo", "se", "reabsorbió", "completamente", "y", "la", "paciente", "recuperó", "la", "visión", "de", "0,2", "que", "presentaba", "antes", "de", "sobrevenir", "la", "hemorragia", "a", "causa", "de", "una", "ambliopía", "por", "anisometropía", ".", "No", "hubo", "recurrencia", "de", "sangrado", "en", "6", "meses", "de", "seguimiento", ".", "\n", "Responsable", "clínico", ":", "Dra", ".", "Esther", "Campos", "Mollo", "Correo", "electrónico", ":", "esthercm@hotmail.com", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Morphological is an umlsterm, joints is an umlsterm, surgical treatment is an umlsterm, pain is an umlsterm, symptoms is an umlsterm, treatment is an umlsterm, diagnostic is an umlsterm, treatment is an umlsterm, forms is an umlsterm

ManuelleMedizin.80360072.eng.abstr_task0

Sentence: Morphological changes in the peripheral joints are an indication for the necessity of surgical treatment , particularly when said changes lead to pain and functional disturbances . However , in the absence of either one , or both , of these symptoms conservative orthopaedic treatment should be considered . Taking into consideration the actuality diagnostic factors , conservative orthopaedic treatment forms which should be considered , either singly or in combination with each other , will be described . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Morphological changes in the peripheral joints are an indication for the necessity of surgical treatment , particularly when said changes lead to pain and functional disturbances . However , in the absence of either one , or both , of these symptoms conservative orthopaedic treatment should be considered . Taking into consideration the actuality diagnostic factors , conservative orthopaedic treatment forms which should be considered , either singly or in combination with each other , will be described .

[ "Morphological", "changes", "in", "the", "peripheral", "joints", "are", "an", "indication", "for", "the", "necessity", "of", "surgical", "treatment", ",", "particularly", "when", "said", "changes", "lead", "to", "pain", "and", "functional", "disturbances", ".", "However", ",", "in", "the", "absence", "of", "either", "one", ",", "or", "both", ",", "of", "these", "symptoms", "conservative", "orthopaedic", "treatment", "should", "be", "considered", ".", "Taking", "into", "consideration", "the", "actuality", "diagnostic", "factors", ",", "conservative", "orthopaedic", "treatment", "forms", "which", "should", "be", "considered", ",", "either", "singly", "or", "in", "combination", "with", "each", "other", ",", "will", "be", "described", "." ]

[ "umlsterm" ]

Morphological is an umlsterm, joints is an umlsterm, surgical treatment is an umlsterm, pain is an umlsterm, symptoms is an umlsterm, treatment is an umlsterm, diagnostic is an umlsterm, treatment is an umlsterm, forms is an umlsterm

ManuelleMedizin.80360072.eng.abstr_task1

Sentence: Morphological changes in the peripheral joints are an indication for the necessity of surgical treatment , particularly when said changes lead to pain and functional disturbances . However , in the absence of either one , or both , of these symptoms conservative orthopaedic treatment should be considered . Taking into consideration the actuality diagnostic factors , conservative orthopaedic treatment forms which should be considered , either singly or in combination with each other , will be described . Instructions: please typing these entity words according to sentence: Morphological, joints, surgical treatment, pain, symptoms, treatment, diagnostic, treatment, forms Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Morphological changes in the peripheral joints are an indication for the necessity of surgical treatment , particularly when said changes lead to pain and functional disturbances . However , in the absence of either one , or both , of these symptoms conservative orthopaedic treatment should be considered . Taking into consideration the actuality diagnostic factors , conservative orthopaedic treatment forms which should be considered , either singly or in combination with each other , will be described .

[ "Morphological", "changes", "in", "the", "peripheral", "joints", "are", "an", "indication", "for", "the", "necessity", "of", "surgical", "treatment", ",", "particularly", "when", "said", "changes", "lead", "to", "pain", "and", "functional", "disturbances", ".", "However", ",", "in", "the", "absence", "of", "either", "one", ",", "or", "both", ",", "of", "these", "symptoms", "conservative", "orthopaedic", "treatment", "should", "be", "considered", ".", "Taking", "into", "consideration", "the", "actuality", "diagnostic", "factors", ",", "conservative", "orthopaedic", "treatment", "forms", "which", "should", "be", "considered", ",", "either", "singly", "or", "in", "combination", "with", "each", "other", ",", "will", "be", "described", "." ]

[ "umlsterm" ]

Morphological, joints, surgical treatment, pain, symptoms, treatment, diagnostic, treatment, forms

ManuelleMedizin.80360072.eng.abstr_task2

Sentence: Morphological changes in the peripheral joints are an indication for the necessity of surgical treatment , particularly when said changes lead to pain and functional disturbances . However , in the absence of either one , or both , of these symptoms conservative orthopaedic treatment should be considered . Taking into consideration the actuality diagnostic factors , conservative orthopaedic treatment forms which should be considered , either singly or in combination with each other , will be described . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Morphological changes in the peripheral joints are an indication for the necessity of surgical treatment , particularly when said changes lead to pain and functional disturbances . However , in the absence of either one , or both , of these symptoms conservative orthopaedic treatment should be considered . Taking into consideration the actuality diagnostic factors , conservative orthopaedic treatment forms which should be considered , either singly or in combination with each other , will be described .

[ "Morphological", "changes", "in", "the", "peripheral", "joints", "are", "an", "indication", "for", "the", "necessity", "of", "surgical", "treatment", ",", "particularly", "when", "said", "changes", "lead", "to", "pain", "and", "functional", "disturbances", ".", "However", ",", "in", "the", "absence", "of", "either", "one", ",", "or", "both", ",", "of", "these", "symptoms", "conservative", "orthopaedic", "treatment", "should", "be", "considered", ".", "Taking", "into", "consideration", "the", "actuality", "diagnostic", "factors", ",", "conservative", "orthopaedic", "treatment", "forms", "which", "should", "be", "considered", ",", "either", "singly", "or", "in", "combination", "with", "each", "other", ",", "will", "be", "described", "." ]

[ "umlsterm" ]

Chinese herbal medicine is a Intervention_Pharmacological, Chinese herbal medicine ( CHM ) is a Intervention_Pharmacological, wait - list control ( WLC ) is a Intervention_Control, individualized CHM decoctions is a Intervention_Pharmacological, therapeutically inert placebo decoction is a Intervention_Control, measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; is a Outcome_Pain, Endometriosis Health Profile-30 ( EHP-30 ) endometriosis - specific quality - of - life questionnaire is a Outcome_Other, Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient - centered health questionnaire is a Outcome_Physical, Liver and renal function is a Outcome_Physical, EHP-30 and MYMOP scores is a Outcome_Physical, VAS scores is a Outcome_Physical

50976_task0

Sentence: A feasibility study exploring the role of Chinese herbal medicine in the treatment of endometriosis . BACKGROUND Endometriosis is a common and disabling gynecologic condition affecting between 5 % and 15 % of women of childbearing age . Conventional medical intervention has unpleasant side-effects , and symptoms frequently return after treatment . Preliminary evidence suggests Chinese herbal medicine ( CHM ) may contribute to the treatment of endometriosis . OBJECTIVES The aims of this study were to test the feasibility of a novel methodology for investigating individualized decoctions of CHM rigorously and to gather preliminary data on the treatment effect of CHM for a larger definitive trial . DESIGN This was a 16-week prospective , double blinded , randomized controlled trial of 40 women with laparoscopically confirmed endometriosis . SETTINGS The trial was conducted at a private CHM clinic in Hove ( U.K. ) and at a National Health Service outpatient clinic in London ( U.K. ) . INTERVENTIONS Participants were initially randomized to either wait-list control ( WLC ) or treatment groups to receive either individualized CHM decoctions or a therapeutically inert placebo decoction . OUTCOME MEASURES Four 10-cm visual analogue scales ( VAS ) were used to measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; these measurements were recorded weekly . The Endometriosis Health Profile-30 ( EHP-30 ) endometriosis-specific quality-of-life questionnaire was completed at the beginning and at the end of the trial . The Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient-centered health questionnaire was completed monthly . Liver and renal function was measured at 0 , 4 , 8 , and 16 weeks . RESULTS Twenty-eight ( 28 ) women completed the trial . High dropout rates led to the suspension of the WLC . Randomization , double blinding , and allocation concealment was achieved successfully . Adjusted mean differences favored the active treatment in the EHP-30 and MYMOP scores . VAS scores favored the active treatment for relief of menstrual pain and the placebo group for reduction of daily pain . CONCLUSIONS the methodology successfully allowed individualized CHM decoctions to be tested rigorously . There are nonspecific contextual effects from CHM that require further investigation . Provisional data were generated to warrant a larger , more-definitive study . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Outcome_Physical, Outcome_Pain, Outcome_Other

[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A feasibility study exploring the role of Chinese herbal medicine in the treatment of endometriosis . BACKGROUND Endometriosis is a common and disabling gynecologic condition affecting between 5 % and 15 % of women of childbearing age . Conventional medical intervention has unpleasant side-effects , and symptoms frequently return after treatment . Preliminary evidence suggests Chinese herbal medicine ( CHM ) may contribute to the treatment of endometriosis . OBJECTIVES The aims of this study were to test the feasibility of a novel methodology for investigating individualized decoctions of CHM rigorously and to gather preliminary data on the treatment effect of CHM for a larger definitive trial . DESIGN This was a 16-week prospective , double blinded , randomized controlled trial of 40 women with laparoscopically confirmed endometriosis . SETTINGS The trial was conducted at a private CHM clinic in Hove ( U.K. ) and at a National Health Service outpatient clinic in London ( U.K. ) . INTERVENTIONS Participants were initially randomized to either wait-list control ( WLC ) or treatment groups to receive either individualized CHM decoctions or a therapeutically inert placebo decoction . OUTCOME MEASURES Four 10-cm visual analogue scales ( VAS ) were used to measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; these measurements were recorded weekly . The Endometriosis Health Profile-30 ( EHP-30 ) endometriosis-specific quality-of-life questionnaire was completed at the beginning and at the end of the trial . The Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient-centered health questionnaire was completed monthly . Liver and renal function was measured at 0 , 4 , 8 , and 16 weeks . RESULTS Twenty-eight ( 28 ) women completed the trial . High dropout rates led to the suspension of the WLC . Randomization , double blinding , and allocation concealment was achieved successfully . Adjusted mean differences favored the active treatment in the EHP-30 and MYMOP scores . VAS scores favored the active treatment for relief of menstrual pain and the placebo group for reduction of daily pain . CONCLUSIONS the methodology successfully allowed individualized CHM decoctions to be tested rigorously . There are nonspecific contextual effects from CHM that require further investigation . Provisional data were generated to warrant a larger , more-definitive study .

[ "A", "feasibility", "study", "exploring", "the", "role", "of", "Chinese", "herbal", "medicine", "in", "the", "treatment", "of", "endometriosis", ".", "BACKGROUND", "Endometriosis", "is", "a", "common", "and", "disabling", "gynecologic", "condition", "affecting", "between", "5", "%", "and", "15", "%", "of", "women", "of", "childbearing", "age", ".", "Conventional", "medical", "intervention", "has", "unpleasant", "side", "-", "effects", ",", "and", "symptoms", "frequently", "return", "after", "treatment", ".", "Preliminary", "evidence", "suggests", "Chinese", "herbal", "medicine", "(", "CHM", ")", "may", "contribute", "to", "the", "treatment", "of", "endometriosis", ".", "OBJECTIVES", "The", "aims", "of", "this", "study", "were", "to", "test", "the", "feasibility", "of", "a", "novel", "methodology", "for", "investigating", "individualized", "decoctions", "of", "CHM", "rigorously", "and", "to", "gather", "preliminary", "data", "on", "the", "treatment", "effect", "of", "CHM", "for", "a", "larger", "definitive", "trial", ".", "DESIGN", "This", "was", "a", "16-week", "prospective", ",", "double", "blinded", ",", "randomized", "controlled", "trial", "of", "40", "women", "with", "laparoscopically", "confirmed", "endometriosis", ".", "SETTINGS", "The", "trial", "was", "conducted", "at", "a", "private", "CHM", "clinic", "in", "Hove", "(", "U.K.", ")", "and", "at", "a", "National", "Health", "Service", "outpatient", "clinic", "in", "London", "(", "U.K.", ")", ".", "INTERVENTIONS", "Participants", "were", "initially", "randomized", "to", "either", "wait", "-", "list", "control", "(", "WLC", ")", "or", "treatment", "groups", "to", "receive", "either", "individualized", "CHM", "decoctions", "or", "a", "therapeutically", "inert", "placebo", "decoction", ".", "OUTCOME", "MEASURES", "Four", "10-cm", "visual", "analogue", "scales", "(", "VAS", ")", "were", "used", "to", "measure", "menstrual", "pain", ",", "daily", "pain", ",", "and", "pain", "on", "intercourse", "and", "bowel", "movement", ";", "these", "measurements", "were", "recorded", "weekly", ".", "The", "Endometriosis", "Health", "Profile-30", "(", "EHP-30", ")", "endometriosis", "-", "specific", "quality", "-", "of", "-", "life", "questionnaire", "was", "completed", "at", "the", "beginning", "and", "at", "the", "end", "of", "the", "trial", ".", "The", "Measure", "Yourself", "Medical", "Outcomes", "Profile", "(", "MYMOP", ")", "a", "patient", "-", "centered", "health", "questionnaire", "was", "completed", "monthly", ".", "Liver", "and", "renal", "function", "was", "measured", "at", "0", ",", "4", ",", "8", ",", "and", "16", "weeks", ".", "RESULTS", "Twenty", "-", "eight", "(", "28", ")", "women", "completed", "the", "trial", ".", "High", "dropout", "rates", "led", "to", "the", "suspension", "of", "the", "WLC", ".", "Randomization", ",", "double", "blinding", ",", "and", "allocation", "concealment", "was", "achieved", "successfully", ".", "Adjusted", "mean", "differences", "favored", "the", "active", "treatment", "in", "the", "EHP-30", "and", "MYMOP", "scores", ".", "VAS", "scores", "favored", "the", "active", "treatment", "for", "relief", "of", "menstrual", "pain", "and", "the", "placebo", "group", "for", "reduction", "of", "daily", "pain", ".", "CONCLUSIONS", "the", "methodology", "successfully", "allowed", "individualized", "CHM", "decoctions", "to", "be", "tested", "rigorously", ".", "There", "are", "nonspecific", "contextual", "effects", "from", "CHM", "that", "require", "further", "investigation", ".", "Provisional", "data", "were", "generated", "to", "warrant", "a", "larger", ",", "more", "-", "definitive", "study", "." ]

[ "Outcome_Other", "Outcome_Physical", "Outcome_Pain", "Intervention_Control", "Intervention_Pharmacological" ]

Chinese herbal medicine is a Intervention_Pharmacological, Chinese herbal medicine ( CHM ) is a Intervention_Pharmacological, wait - list control ( WLC ) is a Intervention_Control, individualized CHM decoctions is a Intervention_Pharmacological, therapeutically inert placebo decoction is a Intervention_Control, measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; is a Outcome_Pain, Endometriosis Health Profile-30 ( EHP-30 ) endometriosis - specific quality - of - life questionnaire is a Outcome_Other, Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient - centered health questionnaire is a Outcome_Physical, Liver and renal function is a Outcome_Physical, EHP-30 and MYMOP scores is a Outcome_Physical, VAS scores is a Outcome_Physical

50976_task1

Sentence: A feasibility study exploring the role of Chinese herbal medicine in the treatment of endometriosis . BACKGROUND Endometriosis is a common and disabling gynecologic condition affecting between 5 % and 15 % of women of childbearing age . Conventional medical intervention has unpleasant side-effects , and symptoms frequently return after treatment . Preliminary evidence suggests Chinese herbal medicine ( CHM ) may contribute to the treatment of endometriosis . OBJECTIVES The aims of this study were to test the feasibility of a novel methodology for investigating individualized decoctions of CHM rigorously and to gather preliminary data on the treatment effect of CHM for a larger definitive trial . DESIGN This was a 16-week prospective , double blinded , randomized controlled trial of 40 women with laparoscopically confirmed endometriosis . SETTINGS The trial was conducted at a private CHM clinic in Hove ( U.K. ) and at a National Health Service outpatient clinic in London ( U.K. ) . INTERVENTIONS Participants were initially randomized to either wait-list control ( WLC ) or treatment groups to receive either individualized CHM decoctions or a therapeutically inert placebo decoction . OUTCOME MEASURES Four 10-cm visual analogue scales ( VAS ) were used to measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; these measurements were recorded weekly . The Endometriosis Health Profile-30 ( EHP-30 ) endometriosis-specific quality-of-life questionnaire was completed at the beginning and at the end of the trial . The Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient-centered health questionnaire was completed monthly . Liver and renal function was measured at 0 , 4 , 8 , and 16 weeks . RESULTS Twenty-eight ( 28 ) women completed the trial . High dropout rates led to the suspension of the WLC . Randomization , double blinding , and allocation concealment was achieved successfully . Adjusted mean differences favored the active treatment in the EHP-30 and MYMOP scores . VAS scores favored the active treatment for relief of menstrual pain and the placebo group for reduction of daily pain . CONCLUSIONS the methodology successfully allowed individualized CHM decoctions to be tested rigorously . There are nonspecific contextual effects from CHM that require further investigation . Provisional data were generated to warrant a larger , more-definitive study . Instructions: please typing these entity words according to sentence: Chinese herbal medicine, Chinese herbal medicine ( CHM ), wait - list control ( WLC ), individualized CHM decoctions, therapeutically inert placebo decoction, measure menstrual pain , daily pain , and pain on intercourse and bowel movement ;, Endometriosis Health Profile-30 ( EHP-30 ) endometriosis - specific quality - of - life questionnaire, Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient - centered health questionnaire, Liver and renal function, EHP-30 and MYMOP scores, VAS scores Options: Intervention_Pharmacological, Intervention_Control, Outcome_Physical, Outcome_Pain, Outcome_Other

[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A feasibility study exploring the role of Chinese herbal medicine in the treatment of endometriosis . BACKGROUND Endometriosis is a common and disabling gynecologic condition affecting between 5 % and 15 % of women of childbearing age . Conventional medical intervention has unpleasant side-effects , and symptoms frequently return after treatment . Preliminary evidence suggests Chinese herbal medicine ( CHM ) may contribute to the treatment of endometriosis . OBJECTIVES The aims of this study were to test the feasibility of a novel methodology for investigating individualized decoctions of CHM rigorously and to gather preliminary data on the treatment effect of CHM for a larger definitive trial . DESIGN This was a 16-week prospective , double blinded , randomized controlled trial of 40 women with laparoscopically confirmed endometriosis . SETTINGS The trial was conducted at a private CHM clinic in Hove ( U.K. ) and at a National Health Service outpatient clinic in London ( U.K. ) . INTERVENTIONS Participants were initially randomized to either wait-list control ( WLC ) or treatment groups to receive either individualized CHM decoctions or a therapeutically inert placebo decoction . OUTCOME MEASURES Four 10-cm visual analogue scales ( VAS ) were used to measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; these measurements were recorded weekly . The Endometriosis Health Profile-30 ( EHP-30 ) endometriosis-specific quality-of-life questionnaire was completed at the beginning and at the end of the trial . The Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient-centered health questionnaire was completed monthly . Liver and renal function was measured at 0 , 4 , 8 , and 16 weeks . RESULTS Twenty-eight ( 28 ) women completed the trial . High dropout rates led to the suspension of the WLC . Randomization , double blinding , and allocation concealment was achieved successfully . Adjusted mean differences favored the active treatment in the EHP-30 and MYMOP scores . VAS scores favored the active treatment for relief of menstrual pain and the placebo group for reduction of daily pain . CONCLUSIONS the methodology successfully allowed individualized CHM decoctions to be tested rigorously . There are nonspecific contextual effects from CHM that require further investigation . Provisional data were generated to warrant a larger , more-definitive study .

[ "A", "feasibility", "study", "exploring", "the", "role", "of", "Chinese", "herbal", "medicine", "in", "the", "treatment", "of", "endometriosis", ".", "BACKGROUND", "Endometriosis", "is", "a", "common", "and", "disabling", "gynecologic", "condition", "affecting", "between", "5", "%", "and", "15", "%", "of", "women", "of", "childbearing", "age", ".", "Conventional", "medical", "intervention", "has", "unpleasant", "side", "-", "effects", ",", "and", "symptoms", "frequently", "return", "after", "treatment", ".", "Preliminary", "evidence", "suggests", "Chinese", "herbal", "medicine", "(", "CHM", ")", "may", "contribute", "to", "the", "treatment", "of", "endometriosis", ".", "OBJECTIVES", "The", "aims", "of", "this", "study", "were", "to", "test", "the", "feasibility", "of", "a", "novel", "methodology", "for", "investigating", "individualized", "decoctions", "of", "CHM", "rigorously", "and", "to", "gather", "preliminary", "data", "on", "the", "treatment", "effect", "of", "CHM", "for", "a", "larger", "definitive", "trial", ".", "DESIGN", "This", "was", "a", "16-week", "prospective", ",", "double", "blinded", ",", "randomized", "controlled", "trial", "of", "40", "women", "with", "laparoscopically", "confirmed", "endometriosis", ".", "SETTINGS", "The", "trial", "was", "conducted", "at", "a", "private", "CHM", "clinic", "in", "Hove", "(", "U.K.", ")", "and", "at", "a", "National", "Health", "Service", "outpatient", "clinic", "in", "London", "(", "U.K.", ")", ".", "INTERVENTIONS", "Participants", "were", "initially", "randomized", "to", "either", "wait", "-", "list", "control", "(", "WLC", ")", "or", "treatment", "groups", "to", "receive", "either", "individualized", "CHM", "decoctions", "or", "a", "therapeutically", "inert", "placebo", "decoction", ".", "OUTCOME", "MEASURES", "Four", "10-cm", "visual", "analogue", "scales", "(", "VAS", ")", "were", "used", "to", "measure", "menstrual", "pain", ",", "daily", "pain", ",", "and", "pain", "on", "intercourse", "and", "bowel", "movement", ";", "these", "measurements", "were", "recorded", "weekly", ".", "The", "Endometriosis", "Health", "Profile-30", "(", "EHP-30", ")", "endometriosis", "-", "specific", "quality", "-", "of", "-", "life", "questionnaire", "was", "completed", "at", "the", "beginning", "and", "at", "the", "end", "of", "the", "trial", ".", "The", "Measure", "Yourself", "Medical", "Outcomes", "Profile", "(", "MYMOP", ")", "a", "patient", "-", "centered", "health", "questionnaire", "was", "completed", "monthly", ".", "Liver", "and", "renal", "function", "was", "measured", "at", "0", ",", "4", ",", "8", ",", "and", "16", "weeks", ".", "RESULTS", "Twenty", "-", "eight", "(", "28", ")", "women", "completed", "the", "trial", ".", "High", "dropout", "rates", "led", "to", "the", "suspension", "of", "the", "WLC", ".", "Randomization", ",", "double", "blinding", ",", "and", "allocation", "concealment", "was", "achieved", "successfully", ".", "Adjusted", "mean", "differences", "favored", "the", "active", "treatment", "in", "the", "EHP-30", "and", "MYMOP", "scores", ".", "VAS", "scores", "favored", "the", "active", "treatment", "for", "relief", "of", "menstrual", "pain", "and", "the", "placebo", "group", "for", "reduction", "of", "daily", "pain", ".", "CONCLUSIONS", "the", "methodology", "successfully", "allowed", "individualized", "CHM", "decoctions", "to", "be", "tested", "rigorously", ".", "There", "are", "nonspecific", "contextual", "effects", "from", "CHM", "that", "require", "further", "investigation", ".", "Provisional", "data", "were", "generated", "to", "warrant", "a", "larger", ",", "more", "-", "definitive", "study", "." ]

[ "Outcome_Other", "Outcome_Physical", "Outcome_Pain", "Intervention_Control", "Intervention_Pharmacological" ]

Chinese herbal medicine, Chinese herbal medicine ( CHM ), wait - list control ( WLC ), individualized CHM decoctions, therapeutically inert placebo decoction, measure menstrual pain , daily pain , and pain on intercourse and bowel movement ;, Endometriosis Health Profile-30 ( EHP-30 ) endometriosis - specific quality - of - life questionnaire, Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient - centered health questionnaire, Liver and renal function, EHP-30 and MYMOP scores, VAS scores

50976_task2

Sentence: A feasibility study exploring the role of Chinese herbal medicine in the treatment of endometriosis . BACKGROUND Endometriosis is a common and disabling gynecologic condition affecting between 5 % and 15 % of women of childbearing age . Conventional medical intervention has unpleasant side-effects , and symptoms frequently return after treatment . Preliminary evidence suggests Chinese herbal medicine ( CHM ) may contribute to the treatment of endometriosis . OBJECTIVES The aims of this study were to test the feasibility of a novel methodology for investigating individualized decoctions of CHM rigorously and to gather preliminary data on the treatment effect of CHM for a larger definitive trial . DESIGN This was a 16-week prospective , double blinded , randomized controlled trial of 40 women with laparoscopically confirmed endometriosis . SETTINGS The trial was conducted at a private CHM clinic in Hove ( U.K. ) and at a National Health Service outpatient clinic in London ( U.K. ) . INTERVENTIONS Participants were initially randomized to either wait-list control ( WLC ) or treatment groups to receive either individualized CHM decoctions or a therapeutically inert placebo decoction . OUTCOME MEASURES Four 10-cm visual analogue scales ( VAS ) were used to measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; these measurements were recorded weekly . The Endometriosis Health Profile-30 ( EHP-30 ) endometriosis-specific quality-of-life questionnaire was completed at the beginning and at the end of the trial . The Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient-centered health questionnaire was completed monthly . Liver and renal function was measured at 0 , 4 , 8 , and 16 weeks . RESULTS Twenty-eight ( 28 ) women completed the trial . High dropout rates led to the suspension of the WLC . Randomization , double blinding , and allocation concealment was achieved successfully . Adjusted mean differences favored the active treatment in the EHP-30 and MYMOP scores . VAS scores favored the active treatment for relief of menstrual pain and the placebo group for reduction of daily pain . CONCLUSIONS the methodology successfully allowed individualized CHM decoctions to be tested rigorously . There are nonspecific contextual effects from CHM that require further investigation . Provisional data were generated to warrant a larger , more-definitive study . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A feasibility study exploring the role of Chinese herbal medicine in the treatment of endometriosis . BACKGROUND Endometriosis is a common and disabling gynecologic condition affecting between 5 % and 15 % of women of childbearing age . Conventional medical intervention has unpleasant side-effects , and symptoms frequently return after treatment . Preliminary evidence suggests Chinese herbal medicine ( CHM ) may contribute to the treatment of endometriosis . OBJECTIVES The aims of this study were to test the feasibility of a novel methodology for investigating individualized decoctions of CHM rigorously and to gather preliminary data on the treatment effect of CHM for a larger definitive trial . DESIGN This was a 16-week prospective , double blinded , randomized controlled trial of 40 women with laparoscopically confirmed endometriosis . SETTINGS The trial was conducted at a private CHM clinic in Hove ( U.K. ) and at a National Health Service outpatient clinic in London ( U.K. ) . INTERVENTIONS Participants were initially randomized to either wait-list control ( WLC ) or treatment groups to receive either individualized CHM decoctions or a therapeutically inert placebo decoction . OUTCOME MEASURES Four 10-cm visual analogue scales ( VAS ) were used to measure menstrual pain , daily pain , and pain on intercourse and bowel movement ; these measurements were recorded weekly . The Endometriosis Health Profile-30 ( EHP-30 ) endometriosis-specific quality-of-life questionnaire was completed at the beginning and at the end of the trial . The Measure Yourself Medical Outcomes Profile ( MYMOP ) a patient-centered health questionnaire was completed monthly . Liver and renal function was measured at 0 , 4 , 8 , and 16 weeks . RESULTS Twenty-eight ( 28 ) women completed the trial . High dropout rates led to the suspension of the WLC . Randomization , double blinding , and allocation concealment was achieved successfully . Adjusted mean differences favored the active treatment in the EHP-30 and MYMOP scores . VAS scores favored the active treatment for relief of menstrual pain and the placebo group for reduction of daily pain . CONCLUSIONS the methodology successfully allowed individualized CHM decoctions to be tested rigorously . There are nonspecific contextual effects from CHM that require further investigation . Provisional data were generated to warrant a larger , more-definitive study .

[ "A", "feasibility", "study", "exploring", "the", "role", "of", "Chinese", "herbal", "medicine", "in", "the", "treatment", "of", "endometriosis", ".", "BACKGROUND", "Endometriosis", "is", "a", "common", "and", "disabling", "gynecologic", "condition", "affecting", "between", "5", "%", "and", "15", "%", "of", "women", "of", "childbearing", "age", ".", "Conventional", "medical", "intervention", "has", "unpleasant", "side", "-", "effects", ",", "and", "symptoms", "frequently", "return", "after", "treatment", ".", "Preliminary", "evidence", "suggests", "Chinese", "herbal", "medicine", "(", "CHM", ")", "may", "contribute", "to", "the", "treatment", "of", "endometriosis", ".", "OBJECTIVES", "The", "aims", "of", "this", "study", "were", "to", "test", "the", "feasibility", "of", "a", "novel", "methodology", "for", "investigating", "individualized", "decoctions", "of", "CHM", "rigorously", "and", "to", "gather", "preliminary", "data", "on", "the", "treatment", "effect", "of", "CHM", "for", "a", "larger", "definitive", "trial", ".", "DESIGN", "This", "was", "a", "16-week", "prospective", ",", "double", "blinded", ",", "randomized", "controlled", "trial", "of", "40", "women", "with", "laparoscopically", "confirmed", "endometriosis", ".", "SETTINGS", "The", "trial", "was", "conducted", "at", "a", "private", "CHM", "clinic", "in", "Hove", "(", "U.K.", ")", "and", "at", "a", "National", "Health", "Service", "outpatient", "clinic", "in", "London", "(", "U.K.", ")", ".", "INTERVENTIONS", "Participants", "were", "initially", "randomized", "to", "either", "wait", "-", "list", "control", "(", "WLC", ")", "or", "treatment", "groups", "to", "receive", "either", "individualized", "CHM", "decoctions", "or", "a", "therapeutically", "inert", "placebo", "decoction", ".", "OUTCOME", "MEASURES", "Four", "10-cm", "visual", "analogue", "scales", "(", "VAS", ")", "were", "used", "to", "measure", "menstrual", "pain", ",", "daily", "pain", ",", "and", "pain", "on", "intercourse", "and", "bowel", "movement", ";", "these", "measurements", "were", "recorded", "weekly", ".", "The", "Endometriosis", "Health", "Profile-30", "(", "EHP-30", ")", "endometriosis", "-", "specific", "quality", "-", "of", "-", "life", "questionnaire", "was", "completed", "at", "the", "beginning", "and", "at", "the", "end", "of", "the", "trial", ".", "The", "Measure", "Yourself", "Medical", "Outcomes", "Profile", "(", "MYMOP", ")", "a", "patient", "-", "centered", "health", "questionnaire", "was", "completed", "monthly", ".", "Liver", "and", "renal", "function", "was", "measured", "at", "0", ",", "4", ",", "8", ",", "and", "16", "weeks", ".", "RESULTS", "Twenty", "-", "eight", "(", "28", ")", "women", "completed", "the", "trial", ".", "High", "dropout", "rates", "led", "to", "the", "suspension", "of", "the", "WLC", ".", "Randomization", ",", "double", "blinding", ",", "and", "allocation", "concealment", "was", "achieved", "successfully", ".", "Adjusted", "mean", "differences", "favored", "the", "active", "treatment", "in", "the", "EHP-30", "and", "MYMOP", "scores", ".", "VAS", "scores", "favored", "the", "active", "treatment", "for", "relief", "of", "menstrual", "pain", "and", "the", "placebo", "group", "for", "reduction", "of", "daily", "pain", ".", "CONCLUSIONS", "the", "methodology", "successfully", "allowed", "individualized", "CHM", "decoctions", "to", "be", "tested", "rigorously", ".", "There", "are", "nonspecific", "contextual", "effects", "from", "CHM", "that", "require", "further", "investigation", ".", "Provisional", "data", "were", "generated", "to", "warrant", "a", "larger", ",", "more", "-", "definitive", "study", "." ]

[ "Outcome_Other", "Outcome_Physical", "Outcome_Pain", "Intervention_Control", "Intervention_Pharmacological" ]

reflex is an umlsterm, causes is an umlsterm, arrhythmias is an umlsterm, complication is an umlsterm, surgical is an umlsterm, rectus muscle is an umlsterm, lidocaine is an umlsterm, muscle is an umlsterm, incidence is an umlsterm, reflex is an umlsterm

DerOpthalmologe.70940354.eng.abstr_task0

Sentence: Introduction : The oculocardiac reflex causes severe bradycardic arrhythmias and is a frequent complication during surgical manipulation at the medial rectus muscle . The purpose of this study was to evaluate the influence of lidocaine administered topically on the muscle on the incidence of the oculocardiac reflex . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Introduction : The oculocardiac reflex causes severe bradycardic arrhythmias and is a frequent complication during surgical manipulation at the medial rectus muscle . The purpose of this study was to evaluate the influence of lidocaine administered topically on the muscle on the incidence of the oculocardiac reflex .

[ "Introduction", ":", "The", "oculocardiac", "reflex", "causes", "severe", "bradycardic", "arrhythmias", "and", "is", "a", "frequent", "complication", "during", "surgical", "manipulation", "at", "the", "medial", "rectus", "muscle", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "influence", "of", "lidocaine", "administered", "topically", "on", "the", "muscle", "on", "the", "incidence", "of", "the", "oculocardiac", "reflex", "." ]

[ "umlsterm" ]

reflex is an umlsterm, causes is an umlsterm, arrhythmias is an umlsterm, complication is an umlsterm, surgical is an umlsterm, rectus muscle is an umlsterm, lidocaine is an umlsterm, muscle is an umlsterm, incidence is an umlsterm, reflex is an umlsterm

DerOpthalmologe.70940354.eng.abstr_task1

Sentence: Introduction : The oculocardiac reflex causes severe bradycardic arrhythmias and is a frequent complication during surgical manipulation at the medial rectus muscle . The purpose of this study was to evaluate the influence of lidocaine administered topically on the muscle on the incidence of the oculocardiac reflex . Instructions: please typing these entity words according to sentence: reflex, causes, arrhythmias, complication, surgical, rectus muscle, lidocaine, muscle, incidence, reflex Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Introduction : The oculocardiac reflex causes severe bradycardic arrhythmias and is a frequent complication during surgical manipulation at the medial rectus muscle . The purpose of this study was to evaluate the influence of lidocaine administered topically on the muscle on the incidence of the oculocardiac reflex .

[ "Introduction", ":", "The", "oculocardiac", "reflex", "causes", "severe", "bradycardic", "arrhythmias", "and", "is", "a", "frequent", "complication", "during", "surgical", "manipulation", "at", "the", "medial", "rectus", "muscle", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "influence", "of", "lidocaine", "administered", "topically", "on", "the", "muscle", "on", "the", "incidence", "of", "the", "oculocardiac", "reflex", "." ]

[ "umlsterm" ]

reflex, causes, arrhythmias, complication, surgical, rectus muscle, lidocaine, muscle, incidence, reflex

DerOpthalmologe.70940354.eng.abstr_task2

Sentence: Introduction : The oculocardiac reflex causes severe bradycardic arrhythmias and is a frequent complication during surgical manipulation at the medial rectus muscle . The purpose of this study was to evaluate the influence of lidocaine administered topically on the muscle on the incidence of the oculocardiac reflex . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Introduction : The oculocardiac reflex causes severe bradycardic arrhythmias and is a frequent complication during surgical manipulation at the medial rectus muscle . The purpose of this study was to evaluate the influence of lidocaine administered topically on the muscle on the incidence of the oculocardiac reflex .

[ "Introduction", ":", "The", "oculocardiac", "reflex", "causes", "severe", "bradycardic", "arrhythmias", "and", "is", "a", "frequent", "complication", "during", "surgical", "manipulation", "at", "the", "medial", "rectus", "muscle", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "influence", "of", "lidocaine", "administered", "topically", "on", "the", "muscle", "on", "the", "incidence", "of", "the", "oculocardiac", "reflex", "." ]

[ "umlsterm" ]

detrusor overactivity is an outcome, bladder capacity is an outcome

1634_task0

Sentence: Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased bladder capacity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O" ]

Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased bladder capacity .

[ "Overall", ",", "13", "patients", "(", "46.4", "%", ")", "had", "detrusor", "overactivity", "and", "14", "(", "50", "%", ")", "had", "decreased", "bladder", "capacity", "." ]

[ "outcome" ]

detrusor overactivity is an outcome, bladder capacity is an outcome

1634_task1

Sentence: Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased bladder capacity . Instructions: please typing these entity words according to sentence: detrusor overactivity, bladder capacity Options: outcome

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O" ]

Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased bladder capacity .

[ "Overall", ",", "13", "patients", "(", "46.4", "%", ")", "had", "detrusor", "overactivity", "and", "14", "(", "50", "%", ")", "had", "decreased", "bladder", "capacity", "." ]

[ "outcome" ]

detrusor overactivity, bladder capacity

1634_task2

Sentence: Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased bladder capacity . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O" ]

Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased bladder capacity .

[ "Overall", ",", "13", "patients", "(", "46.4", "%", ")", "had", "detrusor", "overactivity", "and", "14", "(", "50", "%", ")", "had", "decreased", "bladder", "capacity", "." ]

[ "outcome" ]

calcium bioavailability is an outcome

376_task0

Sentence: In accordance , calcium bioavailability in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , BD % = 38.2 +/- 3.6 ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome

[ "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In accordance , calcium bioavailability in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , BD % = 38.2 +/- 3.6 ) .

[ "In", "accordance", ",", "calcium", "bioavailability", "in", "adolescents", "did", "not", "vary", "between", "the", "diets", "(", "%", "WD", "=", "40.4", "+", "/-", "5.1", ",", "BD", "%", "=", "38.2", "+", "/-", "3.6", ")", "." ]

[ "outcome" ]

calcium bioavailability is an outcome

376_task1

Sentence: In accordance , calcium bioavailability in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , BD % = 38.2 +/- 3.6 ) . Instructions: please typing these entity words according to sentence: calcium bioavailability Options: outcome

[ "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In accordance , calcium bioavailability in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , BD % = 38.2 +/- 3.6 ) .

[ "In", "accordance", ",", "calcium", "bioavailability", "in", "adolescents", "did", "not", "vary", "between", "the", "diets", "(", "%", "WD", "=", "40.4", "+", "/-", "5.1", ",", "BD", "%", "=", "38.2", "+", "/-", "3.6", ")", "." ]

[ "outcome" ]

calcium bioavailability

376_task2

Sentence: In accordance , calcium bioavailability in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , BD % = 38.2 +/- 3.6 ) . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In accordance , calcium bioavailability in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , BD % = 38.2 +/- 3.6 ) .

[ "In", "accordance", ",", "calcium", "bioavailability", "in", "adolescents", "did", "not", "vary", "between", "the", "diets", "(", "%", "WD", "=", "40.4", "+", "/-", "5.1", ",", "BD", "%", "=", "38.2", "+", "/-", "3.6", ")", "." ]

[ "outcome" ]

Prognose is an umlsterm, krankenhausepidemiologische is an umlsterm, Interventionsstudien is an umlsterm

ZfuerKardiologie.90880014.ger.abstr_task0

Sentence: Einleitung : Daten zur Prognose der Herzinsuffizienz stuetzen sich bislang auf bevoelkerungsepidemiologische und retrospektive krankenhausepidemiologische Untersuchungen sowie klinische Interventionsstudien . Alle diese Quellen sind nur eingeschraenkt auf den klinischen Alltag uebertragbar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Einleitung : Daten zur Prognose der Herzinsuffizienz stuetzen sich bislang auf bevoelkerungsepidemiologische und retrospektive krankenhausepidemiologische Untersuchungen sowie klinische Interventionsstudien . Alle diese Quellen sind nur eingeschraenkt auf den klinischen Alltag uebertragbar .

[ "Einleitung", ":", "Daten", "zur", "Prognose", "der", "Herzinsuffizienz", "stuetzen", "sich", "bislang", "auf", "bevoelkerungsepidemiologische", "und", "retrospektive", "krankenhausepidemiologische", "Untersuchungen", "sowie", "klinische", "Interventionsstudien", ".", "Alle", "diese", "Quellen", "sind", "nur", "eingeschraenkt", "auf", "den", "klinischen", "Alltag", "uebertragbar", "." ]

[ "umlsterm" ]

Prognose is an umlsterm, krankenhausepidemiologische is an umlsterm, Interventionsstudien is an umlsterm

ZfuerKardiologie.90880014.ger.abstr_task1

Sentence: Einleitung : Daten zur Prognose der Herzinsuffizienz stuetzen sich bislang auf bevoelkerungsepidemiologische und retrospektive krankenhausepidemiologische Untersuchungen sowie klinische Interventionsstudien . Alle diese Quellen sind nur eingeschraenkt auf den klinischen Alltag uebertragbar . Instructions: please typing these entity words according to sentence: Prognose, krankenhausepidemiologische, Interventionsstudien Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Einleitung : Daten zur Prognose der Herzinsuffizienz stuetzen sich bislang auf bevoelkerungsepidemiologische und retrospektive krankenhausepidemiologische Untersuchungen sowie klinische Interventionsstudien . Alle diese Quellen sind nur eingeschraenkt auf den klinischen Alltag uebertragbar .

[ "Einleitung", ":", "Daten", "zur", "Prognose", "der", "Herzinsuffizienz", "stuetzen", "sich", "bislang", "auf", "bevoelkerungsepidemiologische", "und", "retrospektive", "krankenhausepidemiologische", "Untersuchungen", "sowie", "klinische", "Interventionsstudien", ".", "Alle", "diese", "Quellen", "sind", "nur", "eingeschraenkt", "auf", "den", "klinischen", "Alltag", "uebertragbar", "." ]

[ "umlsterm" ]

Prognose, krankenhausepidemiologische, Interventionsstudien

ZfuerKardiologie.90880014.ger.abstr_task2

Sentence: Einleitung : Daten zur Prognose der Herzinsuffizienz stuetzen sich bislang auf bevoelkerungsepidemiologische und retrospektive krankenhausepidemiologische Untersuchungen sowie klinische Interventionsstudien . Alle diese Quellen sind nur eingeschraenkt auf den klinischen Alltag uebertragbar . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Einleitung : Daten zur Prognose der Herzinsuffizienz stuetzen sich bislang auf bevoelkerungsepidemiologische und retrospektive krankenhausepidemiologische Untersuchungen sowie klinische Interventionsstudien . Alle diese Quellen sind nur eingeschraenkt auf den klinischen Alltag uebertragbar .

[ "Einleitung", ":", "Daten", "zur", "Prognose", "der", "Herzinsuffizienz", "stuetzen", "sich", "bislang", "auf", "bevoelkerungsepidemiologische", "und", "retrospektive", "krankenhausepidemiologische", "Untersuchungen", "sowie", "klinische", "Interventionsstudien", ".", "Alle", "diese", "Quellen", "sind", "nur", "eingeschraenkt", "auf", "den", "klinischen", "Alltag", "uebertragbar", "." ]

[ "umlsterm" ]

Clonidine clearance is a Outcome_Physical, newborns is a Participant_Age, neonatal abstinence syndrome is a Participant_Condition, pharmacokinetic ( PK ) profile is a Outcome_Physical, oral clonidine is a Intervention_Pharmacological, Plasma clonidine concentration data is a Outcome_Other, 36 is a Participant_Sample-size, 1 to 25 days is a Participant_Age, PK model of clonidine is a Outcome_Other, plasma concentrations of clonidine is a Outcome_Other, body weight and PNA is a Outcome_Physical, apparent clearance is a Outcome_Other

45736_task0

Sentence: Clonidine clearance matures rapidly during the early postnatal period : a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome . The population pharmacokinetic ( PK ) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome , and significant covariates affecting its PK parameters were identified . Plasma clonidine concentration data were obtained from a clinical trial in which 36 newborns , aged 1 to 25 days ( postnatal age , PNA ) and weighing 2.1 to 3.9 kg , were enrolled to take multiple oral doses of clonidine . The population PK model of clonidine was developed by NONMEM , and significant covariates were identified , followed by nonparametric bootstraps ( 2000 replicates ) and simulation experiments . A 1-compartment open linear PK model was chosen to describe plasma concentrations of clonidine , and body weight and PNA were significant covariates for apparent clearance ( CL/F ) as follows : CL/F ( L/h ) = 15.2 × [ body weight ( kg ) /70 ] ( 0.75 ) × [ PNA ( day ) ( 0.441 ) / ( 4.06 ( 0.441 ) + PNA ( day ) ( 0.441 ) ) ] . Furthermore , CL/F of clonidine increased rapidly with PNA during the first month of life after body weight was adjusted . Any optimal dosage regimen for clonidine in term neonates should be based on infant 's age and body weight , and 1.5 µg/kg every 4 hours is proposed starting the second week of life based on the simulation results . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Clonidine clearance matures rapidly during the early postnatal period : a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome . The population pharmacokinetic ( PK ) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome , and significant covariates affecting its PK parameters were identified . Plasma clonidine concentration data were obtained from a clinical trial in which 36 newborns , aged 1 to 25 days ( postnatal age , PNA ) and weighing 2.1 to 3.9 kg , were enrolled to take multiple oral doses of clonidine . The population PK model of clonidine was developed by NONMEM , and significant covariates were identified , followed by nonparametric bootstraps ( 2000 replicates ) and simulation experiments . A 1-compartment open linear PK model was chosen to describe plasma concentrations of clonidine , and body weight and PNA were significant covariates for apparent clearance ( CL/F ) as follows : CL/F ( L/h ) = 15.2 × [ body weight ( kg ) /70 ] ( 0.75 ) × [ PNA ( day ) ( 0.441 ) / ( 4.06 ( 0.441 ) + PNA ( day ) ( 0.441 ) ) ] . Furthermore , CL/F of clonidine increased rapidly with PNA during the first month of life after body weight was adjusted . Any optimal dosage regimen for clonidine in term neonates should be based on infant 's age and body weight , and 1.5 µg/kg every 4 hours is proposed starting the second week of life based on the simulation results .

[ "Clonidine", "clearance", "matures", "rapidly", "during", "the", "early", "postnatal", "period", ":", "a", "population", "pharmacokinetic", "analysis", "in", "newborns", "with", "neonatal", "abstinence", "syndrome", ".", "The", "population", "pharmacokinetic", "(", "PK", ")", "profile", "of", "oral", "clonidine", "was", "characterized", "in", "newborns", "with", "neonatal", "abstinence", "syndrome", ",", "and", "significant", "covariates", "affecting", "its", "PK", "parameters", "were", "identified", ".", "Plasma", "clonidine", "concentration", "data", "were", "obtained", "from", "a", "clinical", "trial", "in", "which", "36", "newborns", ",", "aged", "1", "to", "25", "days", "(", "postnatal", "age", ",", "PNA", ")", "and", "weighing", "2.1", "to", "3.9", "kg", ",", "were", "enrolled", "to", "take", "multiple", "oral", "doses", "of", "clonidine", ".", "The", "population", "PK", "model", "of", "clonidine", "was", "developed", "by", "NONMEM", ",", "and", "significant", "covariates", "were", "identified", ",", "followed", "by", "nonparametric", "bootstraps", "(", "2000", "replicates", ")", "and", "simulation", "experiments", ".", "A", "1-compartment", "open", "linear", "PK", "model", "was", "chosen", "to", "describe", "plasma", "concentrations", "of", "clonidine", ",", "and", "body", "weight", "and", "PNA", "were", "significant", "covariates", "for", "apparent", "clearance", "(", "CL", "/", "F", ")", "as", "follows", ":", "CL", "/", "F", "(", "L", "/", "h", ")", "=", "15.2", "×", "[", "body", "weight", "(", "kg", ")", "/70", "]", "(", "0.75", ")", "×", "[", "PNA", "(", "day", ")", "(", "0.441", ")", "/", "(", "4.06", "(", "0.441", ")", "+", "PNA", "(", "day", ")", "(", "0.441", ")", ")", "]", ".", "Furthermore", ",", "CL", "/", "F", "of", "clonidine", "increased", "rapidly", "with", "PNA", "during", "the", "first", "month", "of", "life", "after", "body", "weight", "was", "adjusted", ".", "Any", "optimal", "dosage", "regimen", "for", "clonidine", "in", "term", "neonates", "should", "be", "based", "on", "infant", "'", "s", "age", "and", "body", "weight", ",", "and", "1.5", "µg", "/", "kg", "every", "4", "hours", "is", "proposed", "starting", "the", "second", "week", "of", "life", "based", "on", "the", "simulation", "results", "." ]

[ "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Age", "Participant_Sample-size" ]

Clonidine clearance is a Outcome_Physical, newborns is a Participant_Age, neonatal abstinence syndrome is a Participant_Condition, pharmacokinetic ( PK ) profile is a Outcome_Physical, oral clonidine is a Intervention_Pharmacological, Plasma clonidine concentration data is a Outcome_Other, 36 is a Participant_Sample-size, 1 to 25 days is a Participant_Age, PK model of clonidine is a Outcome_Other, plasma concentrations of clonidine is a Outcome_Other, body weight and PNA is a Outcome_Physical, apparent clearance is a Outcome_Other

45736_task1

Sentence: Clonidine clearance matures rapidly during the early postnatal period : a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome . The population pharmacokinetic ( PK ) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome , and significant covariates affecting its PK parameters were identified . Plasma clonidine concentration data were obtained from a clinical trial in which 36 newborns , aged 1 to 25 days ( postnatal age , PNA ) and weighing 2.1 to 3.9 kg , were enrolled to take multiple oral doses of clonidine . The population PK model of clonidine was developed by NONMEM , and significant covariates were identified , followed by nonparametric bootstraps ( 2000 replicates ) and simulation experiments . A 1-compartment open linear PK model was chosen to describe plasma concentrations of clonidine , and body weight and PNA were significant covariates for apparent clearance ( CL/F ) as follows : CL/F ( L/h ) = 15.2 × [ body weight ( kg ) /70 ] ( 0.75 ) × [ PNA ( day ) ( 0.441 ) / ( 4.06 ( 0.441 ) + PNA ( day ) ( 0.441 ) ) ] . Furthermore , CL/F of clonidine increased rapidly with PNA during the first month of life after body weight was adjusted . Any optimal dosage regimen for clonidine in term neonates should be based on infant 's age and body weight , and 1.5 µg/kg every 4 hours is proposed starting the second week of life based on the simulation results . Instructions: please typing these entity words according to sentence: Clonidine clearance, newborns, neonatal abstinence syndrome, pharmacokinetic ( PK ) profile, oral clonidine, Plasma clonidine concentration data, 36, 1 to 25 days, PK model of clonidine, plasma concentrations of clonidine, body weight and PNA, apparent clearance Options: Intervention_Pharmacological, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Clonidine clearance matures rapidly during the early postnatal period : a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome . The population pharmacokinetic ( PK ) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome , and significant covariates affecting its PK parameters were identified . Plasma clonidine concentration data were obtained from a clinical trial in which 36 newborns , aged 1 to 25 days ( postnatal age , PNA ) and weighing 2.1 to 3.9 kg , were enrolled to take multiple oral doses of clonidine . The population PK model of clonidine was developed by NONMEM , and significant covariates were identified , followed by nonparametric bootstraps ( 2000 replicates ) and simulation experiments . A 1-compartment open linear PK model was chosen to describe plasma concentrations of clonidine , and body weight and PNA were significant covariates for apparent clearance ( CL/F ) as follows : CL/F ( L/h ) = 15.2 × [ body weight ( kg ) /70 ] ( 0.75 ) × [ PNA ( day ) ( 0.441 ) / ( 4.06 ( 0.441 ) + PNA ( day ) ( 0.441 ) ) ] . Furthermore , CL/F of clonidine increased rapidly with PNA during the first month of life after body weight was adjusted . Any optimal dosage regimen for clonidine in term neonates should be based on infant 's age and body weight , and 1.5 µg/kg every 4 hours is proposed starting the second week of life based on the simulation results .

[ "Clonidine", "clearance", "matures", "rapidly", "during", "the", "early", "postnatal", "period", ":", "a", "population", "pharmacokinetic", "analysis", "in", "newborns", "with", "neonatal", "abstinence", "syndrome", ".", "The", "population", "pharmacokinetic", "(", "PK", ")", "profile", "of", "oral", "clonidine", "was", "characterized", "in", "newborns", "with", "neonatal", "abstinence", "syndrome", ",", "and", "significant", "covariates", "affecting", "its", "PK", "parameters", "were", "identified", ".", "Plasma", "clonidine", "concentration", "data", "were", "obtained", "from", "a", "clinical", "trial", "in", "which", "36", "newborns", ",", "aged", "1", "to", "25", "days", "(", "postnatal", "age", ",", "PNA", ")", "and", "weighing", "2.1", "to", "3.9", "kg", ",", "were", "enrolled", "to", "take", "multiple", "oral", "doses", "of", "clonidine", ".", "The", "population", "PK", "model", "of", "clonidine", "was", "developed", "by", "NONMEM", ",", "and", "significant", "covariates", "were", "identified", ",", "followed", "by", "nonparametric", "bootstraps", "(", "2000", "replicates", ")", "and", "simulation", "experiments", ".", "A", "1-compartment", "open", "linear", "PK", "model", "was", "chosen", "to", "describe", "plasma", "concentrations", "of", "clonidine", ",", "and", "body", "weight", "and", "PNA", "were", "significant", "covariates", "for", "apparent", "clearance", "(", "CL", "/", "F", ")", "as", "follows", ":", "CL", "/", "F", "(", "L", "/", "h", ")", "=", "15.2", "×", "[", "body", "weight", "(", "kg", ")", "/70", "]", "(", "0.75", ")", "×", "[", "PNA", "(", "day", ")", "(", "0.441", ")", "/", "(", "4.06", "(", "0.441", ")", "+", "PNA", "(", "day", ")", "(", "0.441", ")", ")", "]", ".", "Furthermore", ",", "CL", "/", "F", "of", "clonidine", "increased", "rapidly", "with", "PNA", "during", "the", "first", "month", "of", "life", "after", "body", "weight", "was", "adjusted", ".", "Any", "optimal", "dosage", "regimen", "for", "clonidine", "in", "term", "neonates", "should", "be", "based", "on", "infant", "'", "s", "age", "and", "body", "weight", ",", "and", "1.5", "µg", "/", "kg", "every", "4", "hours", "is", "proposed", "starting", "the", "second", "week", "of", "life", "based", "on", "the", "simulation", "results", "." ]

[ "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Age", "Participant_Sample-size" ]

Clonidine clearance, newborns, neonatal abstinence syndrome, pharmacokinetic ( PK ) profile, oral clonidine, Plasma clonidine concentration data, 36, 1 to 25 days, PK model of clonidine, plasma concentrations of clonidine, body weight and PNA, apparent clearance

45736_task2

Sentence: Clonidine clearance matures rapidly during the early postnatal period : a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome . The population pharmacokinetic ( PK ) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome , and significant covariates affecting its PK parameters were identified . Plasma clonidine concentration data were obtained from a clinical trial in which 36 newborns , aged 1 to 25 days ( postnatal age , PNA ) and weighing 2.1 to 3.9 kg , were enrolled to take multiple oral doses of clonidine . The population PK model of clonidine was developed by NONMEM , and significant covariates were identified , followed by nonparametric bootstraps ( 2000 replicates ) and simulation experiments . A 1-compartment open linear PK model was chosen to describe plasma concentrations of clonidine , and body weight and PNA were significant covariates for apparent clearance ( CL/F ) as follows : CL/F ( L/h ) = 15.2 × [ body weight ( kg ) /70 ] ( 0.75 ) × [ PNA ( day ) ( 0.441 ) / ( 4.06 ( 0.441 ) + PNA ( day ) ( 0.441 ) ) ] . Furthermore , CL/F of clonidine increased rapidly with PNA during the first month of life after body weight was adjusted . Any optimal dosage regimen for clonidine in term neonates should be based on infant 's age and body weight , and 1.5 µg/kg every 4 hours is proposed starting the second week of life based on the simulation results . Instructions: please extract entity words from the input sentence

[ "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Clonidine clearance matures rapidly during the early postnatal period : a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome . The population pharmacokinetic ( PK ) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome , and significant covariates affecting its PK parameters were identified . Plasma clonidine concentration data were obtained from a clinical trial in which 36 newborns , aged 1 to 25 days ( postnatal age , PNA ) and weighing 2.1 to 3.9 kg , were enrolled to take multiple oral doses of clonidine . The population PK model of clonidine was developed by NONMEM , and significant covariates were identified , followed by nonparametric bootstraps ( 2000 replicates ) and simulation experiments . A 1-compartment open linear PK model was chosen to describe plasma concentrations of clonidine , and body weight and PNA were significant covariates for apparent clearance ( CL/F ) as follows : CL/F ( L/h ) = 15.2 × [ body weight ( kg ) /70 ] ( 0.75 ) × [ PNA ( day ) ( 0.441 ) / ( 4.06 ( 0.441 ) + PNA ( day ) ( 0.441 ) ) ] . Furthermore , CL/F of clonidine increased rapidly with PNA during the first month of life after body weight was adjusted . Any optimal dosage regimen for clonidine in term neonates should be based on infant 's age and body weight , and 1.5 µg/kg every 4 hours is proposed starting the second week of life based on the simulation results .

[ "Clonidine", "clearance", "matures", "rapidly", "during", "the", "early", "postnatal", "period", ":", "a", "population", "pharmacokinetic", "analysis", "in", "newborns", "with", "neonatal", "abstinence", "syndrome", ".", "The", "population", "pharmacokinetic", "(", "PK", ")", "profile", "of", "oral", "clonidine", "was", "characterized", "in", "newborns", "with", "neonatal", "abstinence", "syndrome", ",", "and", "significant", "covariates", "affecting", "its", "PK", "parameters", "were", "identified", ".", "Plasma", "clonidine", "concentration", "data", "were", "obtained", "from", "a", "clinical", "trial", "in", "which", "36", "newborns", ",", "aged", "1", "to", "25", "days", "(", "postnatal", "age", ",", "PNA", ")", "and", "weighing", "2.1", "to", "3.9", "kg", ",", "were", "enrolled", "to", "take", "multiple", "oral", "doses", "of", "clonidine", ".", "The", "population", "PK", "model", "of", "clonidine", "was", "developed", "by", "NONMEM", ",", "and", "significant", "covariates", "were", "identified", ",", "followed", "by", "nonparametric", "bootstraps", "(", "2000", "replicates", ")", "and", "simulation", "experiments", ".", "A", "1-compartment", "open", "linear", "PK", "model", "was", "chosen", "to", "describe", "plasma", "concentrations", "of", "clonidine", ",", "and", "body", "weight", "and", "PNA", "were", "significant", "covariates", "for", "apparent", "clearance", "(", "CL", "/", "F", ")", "as", "follows", ":", "CL", "/", "F", "(", "L", "/", "h", ")", "=", "15.2", "×", "[", "body", "weight", "(", "kg", ")", "/70", "]", "(", "0.75", ")", "×", "[", "PNA", "(", "day", ")", "(", "0.441", ")", "/", "(", "4.06", "(", "0.441", ")", "+", "PNA", "(", "day", ")", "(", "0.441", ")", ")", "]", ".", "Furthermore", ",", "CL", "/", "F", "of", "clonidine", "increased", "rapidly", "with", "PNA", "during", "the", "first", "month", "of", "life", "after", "body", "weight", "was", "adjusted", ".", "Any", "optimal", "dosage", "regimen", "for", "clonidine", "in", "term", "neonates", "should", "be", "based", "on", "infant", "'", "s", "age", "and", "body", "weight", ",", "and", "1.5", "µg", "/", "kg", "every", "4", "hours", "is", "proposed", "starting", "the", "second", "week", "of", "life", "based", "on", "the", "simulation", "results", "." ]

[ "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Age", "Participant_Sample-size" ]

patients is an umlsterm, sport activities is an umlsterm, total knee replacement is an umlsterm, recommendations is an umlsterm

DerOrthopaede.00290739.eng.abstr_task0

Sentence: Many patients would like to resume some sport activities after total knee replacement ; however , most recommendations are based on subjective opinion rather than scientific evidence . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Many patients would like to resume some sport activities after total knee replacement ; however , most recommendations are based on subjective opinion rather than scientific evidence .

[ "Many", "patients", "would", "like", "to", "resume", "some", "sport", "activities", "after", "total", "knee", "replacement", ";", "however", ",", "most", "recommendations", "are", "based", "on", "subjective", "opinion", "rather", "than", "scientific", "evidence", "." ]

[ "umlsterm" ]

patients is an umlsterm, sport activities is an umlsterm, total knee replacement is an umlsterm, recommendations is an umlsterm

DerOrthopaede.00290739.eng.abstr_task1

Sentence: Many patients would like to resume some sport activities after total knee replacement ; however , most recommendations are based on subjective opinion rather than scientific evidence . Instructions: please typing these entity words according to sentence: patients, sport activities, total knee replacement, recommendations Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Many patients would like to resume some sport activities after total knee replacement ; however , most recommendations are based on subjective opinion rather than scientific evidence .

[ "Many", "patients", "would", "like", "to", "resume", "some", "sport", "activities", "after", "total", "knee", "replacement", ";", "however", ",", "most", "recommendations", "are", "based", "on", "subjective", "opinion", "rather", "than", "scientific", "evidence", "." ]

[ "umlsterm" ]

patients, sport activities, total knee replacement, recommendations

DerOrthopaede.00290739.eng.abstr_task2

Sentence: Many patients would like to resume some sport activities after total knee replacement ; however , most recommendations are based on subjective opinion rather than scientific evidence . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Many patients would like to resume some sport activities after total knee replacement ; however , most recommendations are based on subjective opinion rather than scientific evidence .

[ "Many", "patients", "would", "like", "to", "resume", "some", "sport", "activities", "after", "total", "knee", "replacement", ";", "however", ",", "most", "recommendations", "are", "based", "on", "subjective", "opinion", "rather", "than", "scientific", "evidence", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Morbiditaet is an umlsterm, Patientenkollektiv is an umlsterm

DerChirurg.90701475.ger.abstr_task0

Sentence: Zusammenfassung . Proktologische Erkrankungen werden bei HIV-Infizierten ueberaus haeufig beobachtet . Dennoch herrscht Unsicherheit , wie diese Patienten behandelt werden sollen . Im Rahmen einer retrospektiven Untersuchung von 29 HIV-Infizierten , die sich einem operativen Eingriff der Anorectalregion unterziehen mussten , konnte gezeigt werden , dass Fortgeschritten-HIV-Infizierte eine hoehere postoperative Letalitaet und Morbiditaet haben . Daraus ergibt sich , dass die Indikation zu einem anorectalen Eingriff bei diesem Patientenkollektiv anders zu stellen ist als bei HIV-Negativen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Proktologische Erkrankungen werden bei HIV-Infizierten ueberaus haeufig beobachtet . Dennoch herrscht Unsicherheit , wie diese Patienten behandelt werden sollen . Im Rahmen einer retrospektiven Untersuchung von 29 HIV-Infizierten , die sich einem operativen Eingriff der Anorectalregion unterziehen mussten , konnte gezeigt werden , dass Fortgeschritten-HIV-Infizierte eine hoehere postoperative Letalitaet und Morbiditaet haben . Daraus ergibt sich , dass die Indikation zu einem anorectalen Eingriff bei diesem Patientenkollektiv anders zu stellen ist als bei HIV-Negativen .

[ "Zusammenfassung", ".", "Proktologische", "Erkrankungen", "werden", "bei", "HIV", "-", "Infizierten", "ueberaus", "haeufig", "beobachtet", ".", "Dennoch", "herrscht", "Unsicherheit", ",", "wie", "diese", "Patienten", "behandelt", "werden", "sollen", ".", "Im", "Rahmen", "einer", "retrospektiven", "Untersuchung", "von", "29", "HIV", "-", "Infizierten", ",", "die", "sich", "einem", "operativen", "Eingriff", "der", "Anorectalregion", "unterziehen", "mussten", ",", "konnte", "gezeigt", "werden", ",", "dass", "Fortgeschritten", "-", "HIV", "-", "Infizierte", "eine", "hoehere", "postoperative", "Letalitaet", "und", "Morbiditaet", "haben", ".", "Daraus", "ergibt", "sich", ",", "dass", "die", "Indikation", "zu", "einem", "anorectalen", "Eingriff", "bei", "diesem", "Patientenkollektiv", "anders", "zu", "stellen", "ist", "als", "bei", "HIV", "-", "Negativen", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Morbiditaet is an umlsterm, Patientenkollektiv is an umlsterm

DerChirurg.90701475.ger.abstr_task1

Sentence: Zusammenfassung . Proktologische Erkrankungen werden bei HIV-Infizierten ueberaus haeufig beobachtet . Dennoch herrscht Unsicherheit , wie diese Patienten behandelt werden sollen . Im Rahmen einer retrospektiven Untersuchung von 29 HIV-Infizierten , die sich einem operativen Eingriff der Anorectalregion unterziehen mussten , konnte gezeigt werden , dass Fortgeschritten-HIV-Infizierte eine hoehere postoperative Letalitaet und Morbiditaet haben . Daraus ergibt sich , dass die Indikation zu einem anorectalen Eingriff bei diesem Patientenkollektiv anders zu stellen ist als bei HIV-Negativen . Instructions: please typing these entity words according to sentence: Patienten, Morbiditaet, Patientenkollektiv Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Proktologische Erkrankungen werden bei HIV-Infizierten ueberaus haeufig beobachtet . Dennoch herrscht Unsicherheit , wie diese Patienten behandelt werden sollen . Im Rahmen einer retrospektiven Untersuchung von 29 HIV-Infizierten , die sich einem operativen Eingriff der Anorectalregion unterziehen mussten , konnte gezeigt werden , dass Fortgeschritten-HIV-Infizierte eine hoehere postoperative Letalitaet und Morbiditaet haben . Daraus ergibt sich , dass die Indikation zu einem anorectalen Eingriff bei diesem Patientenkollektiv anders zu stellen ist als bei HIV-Negativen .

[ "Zusammenfassung", ".", "Proktologische", "Erkrankungen", "werden", "bei", "HIV", "-", "Infizierten", "ueberaus", "haeufig", "beobachtet", ".", "Dennoch", "herrscht", "Unsicherheit", ",", "wie", "diese", "Patienten", "behandelt", "werden", "sollen", ".", "Im", "Rahmen", "einer", "retrospektiven", "Untersuchung", "von", "29", "HIV", "-", "Infizierten", ",", "die", "sich", "einem", "operativen", "Eingriff", "der", "Anorectalregion", "unterziehen", "mussten", ",", "konnte", "gezeigt", "werden", ",", "dass", "Fortgeschritten", "-", "HIV", "-", "Infizierte", "eine", "hoehere", "postoperative", "Letalitaet", "und", "Morbiditaet", "haben", ".", "Daraus", "ergibt", "sich", ",", "dass", "die", "Indikation", "zu", "einem", "anorectalen", "Eingriff", "bei", "diesem", "Patientenkollektiv", "anders", "zu", "stellen", "ist", "als", "bei", "HIV", "-", "Negativen", "." ]

[ "umlsterm" ]

Patienten, Morbiditaet, Patientenkollektiv

DerChirurg.90701475.ger.abstr_task2

Sentence: Zusammenfassung . Proktologische Erkrankungen werden bei HIV-Infizierten ueberaus haeufig beobachtet . Dennoch herrscht Unsicherheit , wie diese Patienten behandelt werden sollen . Im Rahmen einer retrospektiven Untersuchung von 29 HIV-Infizierten , die sich einem operativen Eingriff der Anorectalregion unterziehen mussten , konnte gezeigt werden , dass Fortgeschritten-HIV-Infizierte eine hoehere postoperative Letalitaet und Morbiditaet haben . Daraus ergibt sich , dass die Indikation zu einem anorectalen Eingriff bei diesem Patientenkollektiv anders zu stellen ist als bei HIV-Negativen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Proktologische Erkrankungen werden bei HIV-Infizierten ueberaus haeufig beobachtet . Dennoch herrscht Unsicherheit , wie diese Patienten behandelt werden sollen . Im Rahmen einer retrospektiven Untersuchung von 29 HIV-Infizierten , die sich einem operativen Eingriff der Anorectalregion unterziehen mussten , konnte gezeigt werden , dass Fortgeschritten-HIV-Infizierte eine hoehere postoperative Letalitaet und Morbiditaet haben . Daraus ergibt sich , dass die Indikation zu einem anorectalen Eingriff bei diesem Patientenkollektiv anders zu stellen ist als bei HIV-Negativen .

[ "Zusammenfassung", ".", "Proktologische", "Erkrankungen", "werden", "bei", "HIV", "-", "Infizierten", "ueberaus", "haeufig", "beobachtet", ".", "Dennoch", "herrscht", "Unsicherheit", ",", "wie", "diese", "Patienten", "behandelt", "werden", "sollen", ".", "Im", "Rahmen", "einer", "retrospektiven", "Untersuchung", "von", "29", "HIV", "-", "Infizierten", ",", "die", "sich", "einem", "operativen", "Eingriff", "der", "Anorectalregion", "unterziehen", "mussten", ",", "konnte", "gezeigt", "werden", ",", "dass", "Fortgeschritten", "-", "HIV", "-", "Infizierte", "eine", "hoehere", "postoperative", "Letalitaet", "und", "Morbiditaet", "haben", ".", "Daraus", "ergibt", "sich", ",", "dass", "die", "Indikation", "zu", "einem", "anorectalen", "Eingriff", "bei", "diesem", "Patientenkollektiv", "anders", "zu", "stellen", "ist", "als", "bei", "HIV", "-", "Negativen", "." ]

[ "umlsterm" ]

T cell - specific negative regulation is an other_name, human cytokine IL-4 is a protein_molecule

85804_task0

Sentence: T cell-specific negative regulation of transcription of the human cytokine IL-4. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_molecule, other_name

[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]

T cell-specific negative regulation of transcription of the human cytokine IL-4.

[ "T", "cell", "-", "specific", "negative", "regulation", "of", "transcription", "of", "the", "human", "cytokine", "IL-4", "." ]

[ "DNA_domain_or_region", "other_name", "protein_family_or_group", "polynucleotide", "protein_molecule", "cell_type" ]

T cell - specific negative regulation is an other_name, human cytokine IL-4 is a protein_molecule

85804_task1

Sentence: T cell-specific negative regulation of transcription of the human cytokine IL-4. Instructions: please typing these entity words according to sentence: T cell - specific negative regulation, human cytokine IL-4 Options: protein_molecule, other_name

[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]

T cell-specific negative regulation of transcription of the human cytokine IL-4.

[ "T", "cell", "-", "specific", "negative", "regulation", "of", "transcription", "of", "the", "human", "cytokine", "IL-4", "." ]

[ "DNA_domain_or_region", "other_name", "protein_family_or_group", "polynucleotide", "protein_molecule", "cell_type" ]

T cell - specific negative regulation, human cytokine IL-4

85804_task2

Sentence: T cell-specific negative regulation of transcription of the human cytokine IL-4. Instructions: please extract entity words from the input sentence

[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]

T cell-specific negative regulation of transcription of the human cytokine IL-4.

[ "T", "cell", "-", "specific", "negative", "regulation", "of", "transcription", "of", "the", "human", "cytokine", "IL-4", "." ]

[ "DNA_domain_or_region", "other_name", "protein_family_or_group", "polynucleotide", "protein_molecule", "cell_type" ]

Metastasis is an umlsterm, tumor is an umlsterm, cells is an umlsterm, stages is an umlsterm, adhesion is an umlsterm, extracellular matrix is an umlsterm, locomotion is an umlsterm, tumor is an umlsterm, cells is an umlsterm, cells is an umlsterm, endothelium is an umlsterm, metastases is an umlsterm, growth is an umlsterm, metastases is an umlsterm, tumor is an umlsterm, cells is an umlsterm, growth factors is an umlsterm, anti - proteolytic is an umlsterm, anti - angiogenic is an umlsterm, therapeutic is an umlsterm, control is an umlsterm, metastatic is an umlsterm, growth is an umlsterm, goal is an umlsterm, drugs is an umlsterm, clinical research is an umlsterm

DerChirurg.80691315.eng.abstr_task0

Sentence: Metastasis formation is a multistep process that requires tumor cells to progress through many different stages . One of the first steps is a disturbance of the epithelial integrity through a decrease in intercellular homotypic adhesion . Proteolysis of the extracellular matrix , as well as increased locomotion , leads to intravasation and dissemination of the tumor cells . In the target organs metastasizing cells adhere to the endothelium , extravasate and form metastases . Finally , neoangiogenesis is required for the initiation as well as the growth of the metastases , providing the tumor cells with both nutritive agents and growth factors . This leads to the conclusion that anti-proteolytic and anti-angiogenic substances could provide effective therapeutic approaches for the control of metastatic growth . Whether or not this goal can be accomplished by synthetic or endogenous drugs must still be demonstrated by basic and definitive clinical research . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Metastasis formation is a multistep process that requires tumor cells to progress through many different stages . One of the first steps is a disturbance of the epithelial integrity through a decrease in intercellular homotypic adhesion . Proteolysis of the extracellular matrix , as well as increased locomotion , leads to intravasation and dissemination of the tumor cells . In the target organs metastasizing cells adhere to the endothelium , extravasate and form metastases . Finally , neoangiogenesis is required for the initiation as well as the growth of the metastases , providing the tumor cells with both nutritive agents and growth factors . This leads to the conclusion that anti-proteolytic and anti-angiogenic substances could provide effective therapeutic approaches for the control of metastatic growth . Whether or not this goal can be accomplished by synthetic or endogenous drugs must still be demonstrated by basic and definitive clinical research .

[ "Metastasis", "formation", "is", "a", "multistep", "process", "that", "requires", "tumor", "cells", "to", "progress", "through", "many", "different", "stages", ".", "One", "of", "the", "first", "steps", "is", "a", "disturbance", "of", "the", "epithelial", "integrity", "through", "a", "decrease", "in", "intercellular", "homotypic", "adhesion", ".", "Proteolysis", "of", "the", "extracellular", "matrix", ",", "as", "well", "as", "increased", "locomotion", ",", "leads", "to", "intravasation", "and", "dissemination", "of", "the", "tumor", "cells", ".", "In", "the", "target", "organs", "metastasizing", "cells", "adhere", "to", "the", "endothelium", ",", "extravasate", "and", "form", "metastases", ".", "Finally", ",", "neoangiogenesis", "is", "required", "for", "the", "initiation", "as", "well", "as", "the", "growth", "of", "the", "metastases", ",", "providing", "the", "tumor", "cells", "with", "both", "nutritive", "agents", "and", "growth", "factors", ".", "This", "leads", "to", "the", "conclusion", "that", "anti", "-", "proteolytic", "and", "anti", "-", "angiogenic", "substances", "could", "provide", "effective", "therapeutic", "approaches", "for", "the", "control", "of", "metastatic", "growth", ".", "Whether", "or", "not", "this", "goal", "can", "be", "accomplished", "by", "synthetic", "or", "endogenous", "drugs", "must", "still", "be", "demonstrated", "by", "basic", "and", "definitive", "clinical", "research", "." ]

[ "umlsterm" ]

Metastasis is an umlsterm, tumor is an umlsterm, cells is an umlsterm, stages is an umlsterm, adhesion is an umlsterm, extracellular matrix is an umlsterm, locomotion is an umlsterm, tumor is an umlsterm, cells is an umlsterm, cells is an umlsterm, endothelium is an umlsterm, metastases is an umlsterm, growth is an umlsterm, metastases is an umlsterm, tumor is an umlsterm, cells is an umlsterm, growth factors is an umlsterm, anti - proteolytic is an umlsterm, anti - angiogenic is an umlsterm, therapeutic is an umlsterm, control is an umlsterm, metastatic is an umlsterm, growth is an umlsterm, goal is an umlsterm, drugs is an umlsterm, clinical research is an umlsterm

DerChirurg.80691315.eng.abstr_task1

Sentence: Metastasis formation is a multistep process that requires tumor cells to progress through many different stages . One of the first steps is a disturbance of the epithelial integrity through a decrease in intercellular homotypic adhesion . Proteolysis of the extracellular matrix , as well as increased locomotion , leads to intravasation and dissemination of the tumor cells . In the target organs metastasizing cells adhere to the endothelium , extravasate and form metastases . Finally , neoangiogenesis is required for the initiation as well as the growth of the metastases , providing the tumor cells with both nutritive agents and growth factors . This leads to the conclusion that anti-proteolytic and anti-angiogenic substances could provide effective therapeutic approaches for the control of metastatic growth . Whether or not this goal can be accomplished by synthetic or endogenous drugs must still be demonstrated by basic and definitive clinical research . Instructions: please typing these entity words according to sentence: Metastasis, tumor, cells, stages, adhesion, extracellular matrix, locomotion, tumor, cells, cells, endothelium, metastases, growth, metastases, tumor, cells, growth factors, anti - proteolytic, anti - angiogenic, therapeutic, control, metastatic, growth, goal, drugs, clinical research Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Metastasis formation is a multistep process that requires tumor cells to progress through many different stages . One of the first steps is a disturbance of the epithelial integrity through a decrease in intercellular homotypic adhesion . Proteolysis of the extracellular matrix , as well as increased locomotion , leads to intravasation and dissemination of the tumor cells . In the target organs metastasizing cells adhere to the endothelium , extravasate and form metastases . Finally , neoangiogenesis is required for the initiation as well as the growth of the metastases , providing the tumor cells with both nutritive agents and growth factors . This leads to the conclusion that anti-proteolytic and anti-angiogenic substances could provide effective therapeutic approaches for the control of metastatic growth . Whether or not this goal can be accomplished by synthetic or endogenous drugs must still be demonstrated by basic and definitive clinical research .

[ "Metastasis", "formation", "is", "a", "multistep", "process", "that", "requires", "tumor", "cells", "to", "progress", "through", "many", "different", "stages", ".", "One", "of", "the", "first", "steps", "is", "a", "disturbance", "of", "the", "epithelial", "integrity", "through", "a", "decrease", "in", "intercellular", "homotypic", "adhesion", ".", "Proteolysis", "of", "the", "extracellular", "matrix", ",", "as", "well", "as", "increased", "locomotion", ",", "leads", "to", "intravasation", "and", "dissemination", "of", "the", "tumor", "cells", ".", "In", "the", "target", "organs", "metastasizing", "cells", "adhere", "to", "the", "endothelium", ",", "extravasate", "and", "form", "metastases", ".", "Finally", ",", "neoangiogenesis", "is", "required", "for", "the", "initiation", "as", "well", "as", "the", "growth", "of", "the", "metastases", ",", "providing", "the", "tumor", "cells", "with", "both", "nutritive", "agents", "and", "growth", "factors", ".", "This", "leads", "to", "the", "conclusion", "that", "anti", "-", "proteolytic", "and", "anti", "-", "angiogenic", "substances", "could", "provide", "effective", "therapeutic", "approaches", "for", "the", "control", "of", "metastatic", "growth", ".", "Whether", "or", "not", "this", "goal", "can", "be", "accomplished", "by", "synthetic", "or", "endogenous", "drugs", "must", "still", "be", "demonstrated", "by", "basic", "and", "definitive", "clinical", "research", "." ]

[ "umlsterm" ]

Metastasis, tumor, cells, stages, adhesion, extracellular matrix, locomotion, tumor, cells, cells, endothelium, metastases, growth, metastases, tumor, cells, growth factors, anti - proteolytic, anti - angiogenic, therapeutic, control, metastatic, growth, goal, drugs, clinical research

DerChirurg.80691315.eng.abstr_task2

Sentence: Metastasis formation is a multistep process that requires tumor cells to progress through many different stages . One of the first steps is a disturbance of the epithelial integrity through a decrease in intercellular homotypic adhesion . Proteolysis of the extracellular matrix , as well as increased locomotion , leads to intravasation and dissemination of the tumor cells . In the target organs metastasizing cells adhere to the endothelium , extravasate and form metastases . Finally , neoangiogenesis is required for the initiation as well as the growth of the metastases , providing the tumor cells with both nutritive agents and growth factors . This leads to the conclusion that anti-proteolytic and anti-angiogenic substances could provide effective therapeutic approaches for the control of metastatic growth . Whether or not this goal can be accomplished by synthetic or endogenous drugs must still be demonstrated by basic and definitive clinical research . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Metastasis formation is a multistep process that requires tumor cells to progress through many different stages . One of the first steps is a disturbance of the epithelial integrity through a decrease in intercellular homotypic adhesion . Proteolysis of the extracellular matrix , as well as increased locomotion , leads to intravasation and dissemination of the tumor cells . In the target organs metastasizing cells adhere to the endothelium , extravasate and form metastases . Finally , neoangiogenesis is required for the initiation as well as the growth of the metastases , providing the tumor cells with both nutritive agents and growth factors . This leads to the conclusion that anti-proteolytic and anti-angiogenic substances could provide effective therapeutic approaches for the control of metastatic growth . Whether or not this goal can be accomplished by synthetic or endogenous drugs must still be demonstrated by basic and definitive clinical research .

[ "Metastasis", "formation", "is", "a", "multistep", "process", "that", "requires", "tumor", "cells", "to", "progress", "through", "many", "different", "stages", ".", "One", "of", "the", "first", "steps", "is", "a", "disturbance", "of", "the", "epithelial", "integrity", "through", "a", "decrease", "in", "intercellular", "homotypic", "adhesion", ".", "Proteolysis", "of", "the", "extracellular", "matrix", ",", "as", "well", "as", "increased", "locomotion", ",", "leads", "to", "intravasation", "and", "dissemination", "of", "the", "tumor", "cells", ".", "In", "the", "target", "organs", "metastasizing", "cells", "adhere", "to", "the", "endothelium", ",", "extravasate", "and", "form", "metastases", ".", "Finally", ",", "neoangiogenesis", "is", "required", "for", "the", "initiation", "as", "well", "as", "the", "growth", "of", "the", "metastases", ",", "providing", "the", "tumor", "cells", "with", "both", "nutritive", "agents", "and", "growth", "factors", ".", "This", "leads", "to", "the", "conclusion", "that", "anti", "-", "proteolytic", "and", "anti", "-", "angiogenic", "substances", "could", "provide", "effective", "therapeutic", "approaches", "for", "the", "control", "of", "metastatic", "growth", ".", "Whether", "or", "not", "this", "goal", "can", "be", "accomplished", "by", "synthetic", "or", "endogenous", "drugs", "must", "still", "be", "demonstrated", "by", "basic", "and", "definitive", "clinical", "research", "." ]

[ "umlsterm" ]

coenzyme A is an umlsterm, reductase is an umlsterm, inhibitors is an umlsterm, role is an umlsterm, heart is an umlsterm, adverse effect is an umlsterm, myopathies is an umlsterm, interactions is an umlsterm, drugs is an umlsterm, patients is an umlsterm, myoglobinuria is an umlsterm, rhabdomyolysis is an umlsterm, operations is an umlsterm, aortic valve is an umlsterm, defect is an umlsterm, coronary artery bypass is an umlsterm, grafting is an umlsterm, coronary heart disease is an umlsterm, patients is an umlsterm, HMG - CoA reductase inhibitors is an umlsterm, operation is an umlsterm, diuresis is an umlsterm, concentrations is an umlsterm, kinase is an umlsterm, myoglobin is an umlsterm

ZfuerHerzThoraxGefaesschirurgie.80120201.eng.abstr_task0

Sentence: Hydroxymethylglutaryl coenzyme A reductase inhibitors play an important role in the propyhlaxis of coronary heart desease . A possible adverse effect is the induction of myopathies , which are described predominantly as interactions with other drugs . Two patients suffered myoglobinuria caused by rhabdomyolysis after cardiosurgical operations . In one case , a mechanical aortic valve prothesis was implanted for a combined valvular defect ; in a second case , a coronary artery bypass grafting was performed for coronary heart disease . Both patients had taken HMG-CoA reductase inhibitors before the operation . Under forced diuresis , the elevated serum concentrations of creatin kinase and myoglobin decreased continuously . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

Hydroxymethylglutaryl coenzyme A reductase inhibitors play an important role in the propyhlaxis of coronary heart desease . A possible adverse effect is the induction of myopathies , which are described predominantly as interactions with other drugs . Two patients suffered myoglobinuria caused by rhabdomyolysis after cardiosurgical operations . In one case , a mechanical aortic valve prothesis was implanted for a combined valvular defect ; in a second case , a coronary artery bypass grafting was performed for coronary heart disease . Both patients had taken HMG-CoA reductase inhibitors before the operation . Under forced diuresis , the elevated serum concentrations of creatin kinase and myoglobin decreased continuously .

[ "Hydroxymethylglutaryl", "coenzyme", "A", "reductase", "inhibitors", "play", "an", "important", "role", "in", "the", "propyhlaxis", "of", "coronary", "heart", "desease", ".", "A", "possible", "adverse", "effect", "is", "the", "induction", "of", "myopathies", ",", "which", "are", "described", "predominantly", "as", "interactions", "with", "other", "drugs", ".", "Two", "patients", "suffered", "myoglobinuria", "caused", "by", "rhabdomyolysis", "after", "cardiosurgical", "operations", ".", "In", "one", "case", ",", "a", "mechanical", "aortic", "valve", "prothesis", "was", "implanted", "for", "a", "combined", "valvular", "defect", ";", "in", "a", "second", "case", ",", "a", "coronary", "artery", "bypass", "grafting", "was", "performed", "for", "coronary", "heart", "disease", ".", "Both", "patients", "had", "taken", "HMG", "-", "CoA", "reductase", "inhibitors", "before", "the", "operation", ".", "Under", "forced", "diuresis", ",", "the", "elevated", "serum", "concentrations", "of", "creatin", "kinase", "and", "myoglobin", "decreased", "continuously", "." ]

[ "umlsterm" ]

coenzyme A is an umlsterm, reductase is an umlsterm, inhibitors is an umlsterm, role is an umlsterm, heart is an umlsterm, adverse effect is an umlsterm, myopathies is an umlsterm, interactions is an umlsterm, drugs is an umlsterm, patients is an umlsterm, myoglobinuria is an umlsterm, rhabdomyolysis is an umlsterm, operations is an umlsterm, aortic valve is an umlsterm, defect is an umlsterm, coronary artery bypass is an umlsterm, grafting is an umlsterm, coronary heart disease is an umlsterm, patients is an umlsterm, HMG - CoA reductase inhibitors is an umlsterm, operation is an umlsterm, diuresis is an umlsterm, concentrations is an umlsterm, kinase is an umlsterm, myoglobin is an umlsterm

ZfuerHerzThoraxGefaesschirurgie.80120201.eng.abstr_task1

Sentence: Hydroxymethylglutaryl coenzyme A reductase inhibitors play an important role in the propyhlaxis of coronary heart desease . A possible adverse effect is the induction of myopathies , which are described predominantly as interactions with other drugs . Two patients suffered myoglobinuria caused by rhabdomyolysis after cardiosurgical operations . In one case , a mechanical aortic valve prothesis was implanted for a combined valvular defect ; in a second case , a coronary artery bypass grafting was performed for coronary heart disease . Both patients had taken HMG-CoA reductase inhibitors before the operation . Under forced diuresis , the elevated serum concentrations of creatin kinase and myoglobin decreased continuously . Instructions: please typing these entity words according to sentence: coenzyme A, reductase, inhibitors, role, heart, adverse effect, myopathies, interactions, drugs, patients, myoglobinuria, rhabdomyolysis, operations, aortic valve, defect, coronary artery bypass, grafting, coronary heart disease, patients, HMG - CoA reductase inhibitors, operation, diuresis, concentrations, kinase, myoglobin Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

Hydroxymethylglutaryl coenzyme A reductase inhibitors play an important role in the propyhlaxis of coronary heart desease . A possible adverse effect is the induction of myopathies , which are described predominantly as interactions with other drugs . Two patients suffered myoglobinuria caused by rhabdomyolysis after cardiosurgical operations . In one case , a mechanical aortic valve prothesis was implanted for a combined valvular defect ; in a second case , a coronary artery bypass grafting was performed for coronary heart disease . Both patients had taken HMG-CoA reductase inhibitors before the operation . Under forced diuresis , the elevated serum concentrations of creatin kinase and myoglobin decreased continuously .

[ "Hydroxymethylglutaryl", "coenzyme", "A", "reductase", "inhibitors", "play", "an", "important", "role", "in", "the", "propyhlaxis", "of", "coronary", "heart", "desease", ".", "A", "possible", "adverse", "effect", "is", "the", "induction", "of", "myopathies", ",", "which", "are", "described", "predominantly", "as", "interactions", "with", "other", "drugs", ".", "Two", "patients", "suffered", "myoglobinuria", "caused", "by", "rhabdomyolysis", "after", "cardiosurgical", "operations", ".", "In", "one", "case", ",", "a", "mechanical", "aortic", "valve", "prothesis", "was", "implanted", "for", "a", "combined", "valvular", "defect", ";", "in", "a", "second", "case", ",", "a", "coronary", "artery", "bypass", "grafting", "was", "performed", "for", "coronary", "heart", "disease", ".", "Both", "patients", "had", "taken", "HMG", "-", "CoA", "reductase", "inhibitors", "before", "the", "operation", ".", "Under", "forced", "diuresis", ",", "the", "elevated", "serum", "concentrations", "of", "creatin", "kinase", "and", "myoglobin", "decreased", "continuously", "." ]

[ "umlsterm" ]

coenzyme A, reductase, inhibitors, role, heart, adverse effect, myopathies, interactions, drugs, patients, myoglobinuria, rhabdomyolysis, operations, aortic valve, defect, coronary artery bypass, grafting, coronary heart disease, patients, HMG - CoA reductase inhibitors, operation, diuresis, concentrations, kinase, myoglobin

ZfuerHerzThoraxGefaesschirurgie.80120201.eng.abstr_task2

Sentence: Hydroxymethylglutaryl coenzyme A reductase inhibitors play an important role in the propyhlaxis of coronary heart desease . A possible adverse effect is the induction of myopathies , which are described predominantly as interactions with other drugs . Two patients suffered myoglobinuria caused by rhabdomyolysis after cardiosurgical operations . In one case , a mechanical aortic valve prothesis was implanted for a combined valvular defect ; in a second case , a coronary artery bypass grafting was performed for coronary heart disease . Both patients had taken HMG-CoA reductase inhibitors before the operation . Under forced diuresis , the elevated serum concentrations of creatin kinase and myoglobin decreased continuously . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

Hydroxymethylglutaryl coenzyme A reductase inhibitors play an important role in the propyhlaxis of coronary heart desease . A possible adverse effect is the induction of myopathies , which are described predominantly as interactions with other drugs . Two patients suffered myoglobinuria caused by rhabdomyolysis after cardiosurgical operations . In one case , a mechanical aortic valve prothesis was implanted for a combined valvular defect ; in a second case , a coronary artery bypass grafting was performed for coronary heart disease . Both patients had taken HMG-CoA reductase inhibitors before the operation . Under forced diuresis , the elevated serum concentrations of creatin kinase and myoglobin decreased continuously .

[ "Hydroxymethylglutaryl", "coenzyme", "A", "reductase", "inhibitors", "play", "an", "important", "role", "in", "the", "propyhlaxis", "of", "coronary", "heart", "desease", ".", "A", "possible", "adverse", "effect", "is", "the", "induction", "of", "myopathies", ",", "which", "are", "described", "predominantly", "as", "interactions", "with", "other", "drugs", ".", "Two", "patients", "suffered", "myoglobinuria", "caused", "by", "rhabdomyolysis", "after", "cardiosurgical", "operations", ".", "In", "one", "case", ",", "a", "mechanical", "aortic", "valve", "prothesis", "was", "implanted", "for", "a", "combined", "valvular", "defect", ";", "in", "a", "second", "case", ",", "a", "coronary", "artery", "bypass", "grafting", "was", "performed", "for", "coronary", "heart", "disease", ".", "Both", "patients", "had", "taken", "HMG", "-", "CoA", "reductase", "inhibitors", "before", "the", "operation", ".", "Under", "forced", "diuresis", ",", "the", "elevated", "serum", "concentrations", "of", "creatin", "kinase", "and", "myoglobin", "decreased", "continuously", "." ]

[ "umlsterm" ]

E2F1 is a Gene_or_gene_product, p53 is a Gene_or_gene_product, hepatitis B viral X protein is a Gene_or_gene_product, Hbx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, hepatitis B virus X protein is a Gene_or_gene_product, HBx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, chloramphenicol acetyl transferase is a Gene_or_gene_product, CAT is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, thymidine kinase is a Gene_or_gene_product, tk is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, GAL4 is a Gene_or_gene_product, pRb is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product

94_task0

Sentence: E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. The functional effect of the interaction of E2F1 and hepatitis B virus X protein (HBx) on the promoter of human p53 gene was studied using chloramphenicol acetyl transferase (CAT) assay. E2F1 activated the p53 promoter through E2F1 binding site. As previously reported, HBx repressed the p53 promoter through E-box. When E2F1 was cotransfected with HBx, E2F1 overcame the repressive effect of HBx on the p53 promoter through the E2F1 site. However, in the thymidine kinase (tk) heterologous promoter system with the E2F1 binding sites, cotransfection of E2F1 and HBx showed a strong synergistic activation. An in vitro interaction assay showed that E2F1 and HBx physically bind with each other. Analyses of the interaction domain with the GAL4 fusion protein showed that the pRb-binding domain of E2F1 was necessary for the functional interaction of these two proteins. Taken together, these results imply the functional inhibitory action of E2F1 on the HBV life cycle and HBV-mediated hepatocellular carcinogenesis (HCC). Therefore, the normal or enhanced function of E2F1 gene would be important in controlling the HBx function in HCC. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene_or_gene_product

[ "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O" ]

E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. The functional effect of the interaction of E2F1 and hepatitis B virus X protein (HBx) on the promoter of human p53 gene was studied using chloramphenicol acetyl transferase (CAT) assay. E2F1 activated the p53 promoter through E2F1 binding site. As previously reported, HBx repressed the p53 promoter through E-box. When E2F1 was cotransfected with HBx, E2F1 overcame the repressive effect of HBx on the p53 promoter through the E2F1 site. However, in the thymidine kinase (tk) heterologous promoter system with the E2F1 binding sites, cotransfection of E2F1 and HBx showed a strong synergistic activation. An in vitro interaction assay showed that E2F1 and HBx physically bind with each other. Analyses of the interaction domain with the GAL4 fusion protein showed that the pRb-binding domain of E2F1 was necessary for the functional interaction of these two proteins. Taken together, these results imply the functional inhibitory action of E2F1 on the HBV life cycle and HBV-mediated hepatocellular carcinogenesis (HCC). Therefore, the normal or enhanced function of E2F1 gene would be important in controlling the HBx function in HCC.

[ "E2F1", "activates", "the", "human", "p53", "promoter", "and", "overcomes", "the", "repressive", "effect", "of", "hepatitis", "B", "viral", "X", "protein", "(", "Hbx", ")", "on", "the", "p53", "promoter", ".", "\n", "The", "functional", "effect", "of", "the", "interaction", "of", "E2F1", "and", "hepatitis", "B", "virus", "X", "protein", "(", "HBx", ")", "on", "the", "promoter", "of", "human", "p53", "gene", "was", "studied", "using", "chloramphenicol", "acetyl", "transferase", "(", "CAT", ")", "assay", ".", "E2F1", "activated", "the", "p53", "promoter", "through", "E2F1", "binding", "site", ".", "As", "previously", "reported", ",", "HBx", "repressed", "the", "p53", "promoter", "through", "E", "-", "box", ".", "When", "E2F1", "was", "cotransfected", "with", "HBx", ",", "E2F1", "overcame", "the", "repressive", "effect", "of", "HBx", "on", "the", "p53", "promoter", "through", "the", "E2F1", "site", ".", "However", ",", "in", "the", "thymidine", "kinase", "(", "tk", ")", "heterologous", "promoter", "system", "with", "the", "E2F1", "binding", "sites", ",", "cotransfection", "of", "E2F1", "and", "HBx", "showed", "a", "strong", "synergistic", "activation", ".", "An", "in", "vitro", "interaction", "assay", "showed", "that", "E2F1", "and", "HBx", "physically", "bind", "with", "each", "other", ".", "Analyses", "of", "the", "interaction", "domain", "with", "the", "GAL4", "fusion", "protein", "showed", "that", "the", "pRb", "-", "binding", "domain", "of", "E2F1", "was", "necessary", "for", "the", "functional", "interaction", "of", "these", "two", "proteins", ".", "Taken", "together", ",", "these", "results", "imply", "the", "functional", "inhibitory", "action", "of", "E2F1", "on", "the", "HBV", "life", "cycle", "and", "HBV", "-", "mediated", "hepatocellular", "carcinogenesis", "(", "HCC", ")", ".", "Therefore", ",", "the", "normal", "or", "enhanced", "function", "of", "E2F1", "gene", "would", "be", "important", "in", "controlling", "the", "HBx", "function", "in", "HCC", ".", "\n" ]

[ "Gene_or_gene_product" ]

E2F1 is a Gene_or_gene_product, p53 is a Gene_or_gene_product, hepatitis B viral X protein is a Gene_or_gene_product, Hbx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, hepatitis B virus X protein is a Gene_or_gene_product, HBx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, chloramphenicol acetyl transferase is a Gene_or_gene_product, CAT is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, p53 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, thymidine kinase is a Gene_or_gene_product, tk is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product, GAL4 is a Gene_or_gene_product, pRb is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, HBx is a Gene_or_gene_product

94_task1

Sentence: E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. The functional effect of the interaction of E2F1 and hepatitis B virus X protein (HBx) on the promoter of human p53 gene was studied using chloramphenicol acetyl transferase (CAT) assay. E2F1 activated the p53 promoter through E2F1 binding site. As previously reported, HBx repressed the p53 promoter through E-box. When E2F1 was cotransfected with HBx, E2F1 overcame the repressive effect of HBx on the p53 promoter through the E2F1 site. However, in the thymidine kinase (tk) heterologous promoter system with the E2F1 binding sites, cotransfection of E2F1 and HBx showed a strong synergistic activation. An in vitro interaction assay showed that E2F1 and HBx physically bind with each other. Analyses of the interaction domain with the GAL4 fusion protein showed that the pRb-binding domain of E2F1 was necessary for the functional interaction of these two proteins. Taken together, these results imply the functional inhibitory action of E2F1 on the HBV life cycle and HBV-mediated hepatocellular carcinogenesis (HCC). Therefore, the normal or enhanced function of E2F1 gene would be important in controlling the HBx function in HCC. Instructions: please typing these entity words according to sentence: E2F1, p53, hepatitis B viral X protein, Hbx, p53, E2F1, hepatitis B virus X protein, HBx, p53, chloramphenicol acetyl transferase, CAT, E2F1, p53, E2F1, HBx, p53, E2F1, HBx, E2F1, HBx, p53, E2F1, thymidine kinase, tk, E2F1, E2F1, HBx, E2F1, HBx, GAL4, pRb, E2F1, E2F1, E2F1, HBx Options: Gene_or_gene_product

[ "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O" ]

E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. The functional effect of the interaction of E2F1 and hepatitis B virus X protein (HBx) on the promoter of human p53 gene was studied using chloramphenicol acetyl transferase (CAT) assay. E2F1 activated the p53 promoter through E2F1 binding site. As previously reported, HBx repressed the p53 promoter through E-box. When E2F1 was cotransfected with HBx, E2F1 overcame the repressive effect of HBx on the p53 promoter through the E2F1 site. However, in the thymidine kinase (tk) heterologous promoter system with the E2F1 binding sites, cotransfection of E2F1 and HBx showed a strong synergistic activation. An in vitro interaction assay showed that E2F1 and HBx physically bind with each other. Analyses of the interaction domain with the GAL4 fusion protein showed that the pRb-binding domain of E2F1 was necessary for the functional interaction of these two proteins. Taken together, these results imply the functional inhibitory action of E2F1 on the HBV life cycle and HBV-mediated hepatocellular carcinogenesis (HCC). Therefore, the normal or enhanced function of E2F1 gene would be important in controlling the HBx function in HCC.

[ "E2F1", "activates", "the", "human", "p53", "promoter", "and", "overcomes", "the", "repressive", "effect", "of", "hepatitis", "B", "viral", "X", "protein", "(", "Hbx", ")", "on", "the", "p53", "promoter", ".", "\n", "The", "functional", "effect", "of", "the", "interaction", "of", "E2F1", "and", "hepatitis", "B", "virus", "X", "protein", "(", "HBx", ")", "on", "the", "promoter", "of", "human", "p53", "gene", "was", "studied", "using", "chloramphenicol", "acetyl", "transferase", "(", "CAT", ")", "assay", ".", "E2F1", "activated", "the", "p53", "promoter", "through", "E2F1", "binding", "site", ".", "As", "previously", "reported", ",", "HBx", "repressed", "the", "p53", "promoter", "through", "E", "-", "box", ".", "When", "E2F1", "was", "cotransfected", "with", "HBx", ",", "E2F1", "overcame", "the", "repressive", "effect", "of", "HBx", "on", "the", "p53", "promoter", "through", "the", "E2F1", "site", ".", "However", ",", "in", "the", "thymidine", "kinase", "(", "tk", ")", "heterologous", "promoter", "system", "with", "the", "E2F1", "binding", "sites", ",", "cotransfection", "of", "E2F1", "and", "HBx", "showed", "a", "strong", "synergistic", "activation", ".", "An", "in", "vitro", "interaction", "assay", "showed", "that", "E2F1", "and", "HBx", "physically", "bind", "with", "each", "other", ".", "Analyses", "of", "the", "interaction", "domain", "with", "the", "GAL4", "fusion", "protein", "showed", "that", "the", "pRb", "-", "binding", "domain", "of", "E2F1", "was", "necessary", "for", "the", "functional", "interaction", "of", "these", "two", "proteins", ".", "Taken", "together", ",", "these", "results", "imply", "the", "functional", "inhibitory", "action", "of", "E2F1", "on", "the", "HBV", "life", "cycle", "and", "HBV", "-", "mediated", "hepatocellular", "carcinogenesis", "(", "HCC", ")", ".", "Therefore", ",", "the", "normal", "or", "enhanced", "function", "of", "E2F1", "gene", "would", "be", "important", "in", "controlling", "the", "HBx", "function", "in", "HCC", ".", "\n" ]

[ "Gene_or_gene_product" ]

E2F1, p53, hepatitis B viral X protein, Hbx, p53, E2F1, hepatitis B virus X protein, HBx, p53, chloramphenicol acetyl transferase, CAT, E2F1, p53, E2F1, HBx, p53, E2F1, HBx, E2F1, HBx, p53, E2F1, thymidine kinase, tk, E2F1, E2F1, HBx, E2F1, HBx, GAL4, pRb, E2F1, E2F1, E2F1, HBx

94_task2

Sentence: E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. The functional effect of the interaction of E2F1 and hepatitis B virus X protein (HBx) on the promoter of human p53 gene was studied using chloramphenicol acetyl transferase (CAT) assay. E2F1 activated the p53 promoter through E2F1 binding site. As previously reported, HBx repressed the p53 promoter through E-box. When E2F1 was cotransfected with HBx, E2F1 overcame the repressive effect of HBx on the p53 promoter through the E2F1 site. However, in the thymidine kinase (tk) heterologous promoter system with the E2F1 binding sites, cotransfection of E2F1 and HBx showed a strong synergistic activation. An in vitro interaction assay showed that E2F1 and HBx physically bind with each other. Analyses of the interaction domain with the GAL4 fusion protein showed that the pRb-binding domain of E2F1 was necessary for the functional interaction of these two proteins. Taken together, these results imply the functional inhibitory action of E2F1 on the HBV life cycle and HBV-mediated hepatocellular carcinogenesis (HCC). Therefore, the normal or enhanced function of E2F1 gene would be important in controlling the HBx function in HCC. Instructions: please extract entity words from the input sentence

[ "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O" ]

E2F1 activates the human p53 promoter and overcomes the repressive effect of hepatitis B viral X protein (Hbx) on the p53 promoter. The functional effect of the interaction of E2F1 and hepatitis B virus X protein (HBx) on the promoter of human p53 gene was studied using chloramphenicol acetyl transferase (CAT) assay. E2F1 activated the p53 promoter through E2F1 binding site. As previously reported, HBx repressed the p53 promoter through E-box. When E2F1 was cotransfected with HBx, E2F1 overcame the repressive effect of HBx on the p53 promoter through the E2F1 site. However, in the thymidine kinase (tk) heterologous promoter system with the E2F1 binding sites, cotransfection of E2F1 and HBx showed a strong synergistic activation. An in vitro interaction assay showed that E2F1 and HBx physically bind with each other. Analyses of the interaction domain with the GAL4 fusion protein showed that the pRb-binding domain of E2F1 was necessary for the functional interaction of these two proteins. Taken together, these results imply the functional inhibitory action of E2F1 on the HBV life cycle and HBV-mediated hepatocellular carcinogenesis (HCC). Therefore, the normal or enhanced function of E2F1 gene would be important in controlling the HBx function in HCC.

[ "E2F1", "activates", "the", "human", "p53", "promoter", "and", "overcomes", "the", "repressive", "effect", "of", "hepatitis", "B", "viral", "X", "protein", "(", "Hbx", ")", "on", "the", "p53", "promoter", ".", "\n", "The", "functional", "effect", "of", "the", "interaction", "of", "E2F1", "and", "hepatitis", "B", "virus", "X", "protein", "(", "HBx", ")", "on", "the", "promoter", "of", "human", "p53", "gene", "was", "studied", "using", "chloramphenicol", "acetyl", "transferase", "(", "CAT", ")", "assay", ".", "E2F1", "activated", "the", "p53", "promoter", "through", "E2F1", "binding", "site", ".", "As", "previously", "reported", ",", "HBx", "repressed", "the", "p53", "promoter", "through", "E", "-", "box", ".", "When", "E2F1", "was", "cotransfected", "with", "HBx", ",", "E2F1", "overcame", "the", "repressive", "effect", "of", "HBx", "on", "the", "p53", "promoter", "through", "the", "E2F1", "site", ".", "However", ",", "in", "the", "thymidine", "kinase", "(", "tk", ")", "heterologous", "promoter", "system", "with", "the", "E2F1", "binding", "sites", ",", "cotransfection", "of", "E2F1", "and", "HBx", "showed", "a", "strong", "synergistic", "activation", ".", "An", "in", "vitro", "interaction", "assay", "showed", "that", "E2F1", "and", "HBx", "physically", "bind", "with", "each", "other", ".", "Analyses", "of", "the", "interaction", "domain", "with", "the", "GAL4", "fusion", "protein", "showed", "that", "the", "pRb", "-", "binding", "domain", "of", "E2F1", "was", "necessary", "for", "the", "functional", "interaction", "of", "these", "two", "proteins", ".", "Taken", "together", ",", "these", "results", "imply", "the", "functional", "inhibitory", "action", "of", "E2F1", "on", "the", "HBV", "life", "cycle", "and", "HBV", "-", "mediated", "hepatocellular", "carcinogenesis", "(", "HCC", ")", ".", "Therefore", ",", "the", "normal", "or", "enhanced", "function", "of", "E2F1", "gene", "would", "be", "important", "in", "controlling", "the", "HBx", "function", "in", "HCC", ".", "\n" ]

[ "Gene_or_gene_product" ]

cuffs -- is a Outcome_Physical, efficacy is a Outcome_Other, cuff pressure release valve is a Intervention_Other, performance is a Outcome_Other, ( is a Intervention_Physical, CPRV is a Intervention_Other, paediatric cuffed tracheal tubes is a Participant_Condition, with is a Intervention_Other, and without is a Intervention_Physical, 50 is a Participant_Sample-size, children is a Participant_Age, general anaesthesia with tracheal intubation and standardized anaesthesia technique is a Participant_Condition, reliable cuff pressure release is a Outcome_Physical

23067_task0

Sentence: Nitrous oxide diffusion into tracheal tube cuffs -- efficacy of a new prototype cuff pressure release valve . BACKGROUND The aim of this study was to evaluate the performance of a new cuff pressure release valve ( CPRV ) , in which the release pressure can be adjusted from 10 to 25 cmH2O , particularly intended to control pressure in paediatric cuffed tracheal tubes and to avoid cuff hyperinflation caused by N2O diffusion . METHODS In vitro : the PRV was set to 10 , 15 , 20 or 25 cmH2O release pressure and connected to a cuffed tube placed into a box flushed with 66 % N2O in O2 . The cuff pressure was monitored with and without CPRV for 60 min . Experiments were performed four times using two different CPRVs . In vivo : with Institutional Review Board approval , CPRV was studied in 50 children undergoing general anaesthesia with tracheal intubation and standardized anaesthesia technique ( including 66 % N2O in O2 ) and ventilator settings . Patients were randomized into two groups ( with and without CPRV ) . The cuff pressure baseline was 20 cmH2O and CPRV was set to 25 cmH2O . If the cuff pressure exceeded 25 cmH2O , it was manually released to 20 cmH2O . The numbers of deflations in both groups were noted and compared by Mann-Whitney U-test ( P < 0.05 ) . RESULTS In vitro : the cuff pressure exceeded 50 cmH2O after 60 min without CPRV , but did not exceed the settings with CPRV . In vivo : there was no need to manually deflate the cuff in the CPRV group but , in every patient in the control group , three ( two to seven ) deflating manoeuvres were required within the first hour of anaesthesia ( P < 0.0001 ) . CONCLUSION The CPRV allows reliable cuff pressure release at various pressure levels and reliably prevents cuff pressure increases caused by N2O . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition, Intervention_Other, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other

[ "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nitrous oxide diffusion into tracheal tube cuffs -- efficacy of a new prototype cuff pressure release valve . BACKGROUND The aim of this study was to evaluate the performance of a new cuff pressure release valve ( CPRV ) , in which the release pressure can be adjusted from 10 to 25 cmH2O , particularly intended to control pressure in paediatric cuffed tracheal tubes and to avoid cuff hyperinflation caused by N2O diffusion . METHODS In vitro : the PRV was set to 10 , 15 , 20 or 25 cmH2O release pressure and connected to a cuffed tube placed into a box flushed with 66 % N2O in O2 . The cuff pressure was monitored with and without CPRV for 60 min . Experiments were performed four times using two different CPRVs . In vivo : with Institutional Review Board approval , CPRV was studied in 50 children undergoing general anaesthesia with tracheal intubation and standardized anaesthesia technique ( including 66 % N2O in O2 ) and ventilator settings . Patients were randomized into two groups ( with and without CPRV ) . The cuff pressure baseline was 20 cmH2O and CPRV was set to 25 cmH2O . If the cuff pressure exceeded 25 cmH2O , it was manually released to 20 cmH2O . The numbers of deflations in both groups were noted and compared by Mann-Whitney U-test ( P < 0.05 ) . RESULTS In vitro : the cuff pressure exceeded 50 cmH2O after 60 min without CPRV , but did not exceed the settings with CPRV . In vivo : there was no need to manually deflate the cuff in the CPRV group but , in every patient in the control group , three ( two to seven ) deflating manoeuvres were required within the first hour of anaesthesia ( P < 0.0001 ) . CONCLUSION The CPRV allows reliable cuff pressure release at various pressure levels and reliably prevents cuff pressure increases caused by N2O .

[ "Nitrous", "oxide", "diffusion", "into", "tracheal", "tube", "cuffs", "--", "efficacy", "of", "a", "new", "prototype", "cuff", "pressure", "release", "valve", ".", "BACKGROUND", "The", "aim", "of", "this", "study", "was", "to", "evaluate", "the", "performance", "of", "a", "new", "cuff", "pressure", "release", "valve", "(", "CPRV", ")", ",", "in", "which", "the", "release", "pressure", "can", "be", "adjusted", "from", "10", "to", "25", "cmH2O", ",", "particularly", "intended", "to", "control", "pressure", "in", "paediatric", "cuffed", "tracheal", "tubes", "and", "to", "avoid", "cuff", "hyperinflation", "caused", "by", "N2O", "diffusion", ".", "METHODS", "In", "vitro", ":", "the", "PRV", "was", "set", "to", "10", ",", "15", ",", "20", "or", "25", "cmH2O", "release", "pressure", "and", "connected", "to", "a", "cuffed", "tube", "placed", "into", "a", "box", "flushed", "with", "66", "%", "N2O", "in", "O2", ".", "The", "cuff", "pressure", "was", "monitored", "with", "and", "without", "CPRV", "for", "60", "min", ".", "Experiments", "were", "performed", "four", "times", "using", "two", "different", "CPRVs", ".", "In", "vivo", ":", "with", "Institutional", "Review", "Board", "approval", ",", "CPRV", "was", "studied", "in", "50", "children", "undergoing", "general", "anaesthesia", "with", "tracheal", "intubation", "and", "standardized", "anaesthesia", "technique", "(", "including", "66", "%", "N2O", "in", "O2", ")", "and", "ventilator", "settings", ".", "Patients", "were", "randomized", "into", "two", "groups", "(", "with", "and", "without", "CPRV", ")", ".", "The", "cuff", "pressure", "baseline", "was", "20", "cmH2O", "and", "CPRV", "was", "set", "to", "25", "cmH2O", ".", "If", "the", "cuff", "pressure", "exceeded", "25", "cmH2O", ",", "it", "was", "manually", "released", "to", "20", "cmH2O", ".", "The", "numbers", "of", "deflations", "in", "both", "groups", "were", "noted", "and", "compared", "by", "Mann", "-", "Whitney", "U", "-", "test", "(", "P", "<", "0.05", ")", ".", "RESULTS", "In", "vitro", ":", "the", "cuff", "pressure", "exceeded", "50", "cmH2O", "after", "60", "min", "without", "CPRV", ",", "but", "did", "not", "exceed", "the", "settings", "with", "CPRV", ".", "In", "vivo", ":", "there", "was", "no", "need", "to", "manually", "deflate", "the", "cuff", "in", "the", "CPRV", "group", "but", ",", "in", "every", "patient", "in", "the", "control", "group", ",", "three", "(", "two", "to", "seven", ")", "deflating", "manoeuvres", "were", "required", "within", "the", "first", "hour", "of", "anaesthesia", "(", "P", "<", "0.0001", ")", ".", "CONCLUSION", "The", "CPRV", "allows", "reliable", "cuff", "pressure", "release", "at", "various", "pressure", "levels", "and", "reliably", "prevents", "cuff", "pressure", "increases", "caused", "by", "N2O", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Other", "Intervention_Physical", "Outcome_Other", "Participant_Age", "Participant_Sample-size" ]

cuffs -- is a Outcome_Physical, efficacy is a Outcome_Other, cuff pressure release valve is a Intervention_Other, performance is a Outcome_Other, ( is a Intervention_Physical, CPRV is a Intervention_Other, paediatric cuffed tracheal tubes is a Participant_Condition, with is a Intervention_Other, and without is a Intervention_Physical, 50 is a Participant_Sample-size, children is a Participant_Age, general anaesthesia with tracheal intubation and standardized anaesthesia technique is a Participant_Condition, reliable cuff pressure release is a Outcome_Physical

23067_task1

Sentence: Nitrous oxide diffusion into tracheal tube cuffs -- efficacy of a new prototype cuff pressure release valve . BACKGROUND The aim of this study was to evaluate the performance of a new cuff pressure release valve ( CPRV ) , in which the release pressure can be adjusted from 10 to 25 cmH2O , particularly intended to control pressure in paediatric cuffed tracheal tubes and to avoid cuff hyperinflation caused by N2O diffusion . METHODS In vitro : the PRV was set to 10 , 15 , 20 or 25 cmH2O release pressure and connected to a cuffed tube placed into a box flushed with 66 % N2O in O2 . The cuff pressure was monitored with and without CPRV for 60 min . Experiments were performed four times using two different CPRVs . In vivo : with Institutional Review Board approval , CPRV was studied in 50 children undergoing general anaesthesia with tracheal intubation and standardized anaesthesia technique ( including 66 % N2O in O2 ) and ventilator settings . Patients were randomized into two groups ( with and without CPRV ) . The cuff pressure baseline was 20 cmH2O and CPRV was set to 25 cmH2O . If the cuff pressure exceeded 25 cmH2O , it was manually released to 20 cmH2O . The numbers of deflations in both groups were noted and compared by Mann-Whitney U-test ( P < 0.05 ) . RESULTS In vitro : the cuff pressure exceeded 50 cmH2O after 60 min without CPRV , but did not exceed the settings with CPRV . In vivo : there was no need to manually deflate the cuff in the CPRV group but , in every patient in the control group , three ( two to seven ) deflating manoeuvres were required within the first hour of anaesthesia ( P < 0.0001 ) . CONCLUSION The CPRV allows reliable cuff pressure release at various pressure levels and reliably prevents cuff pressure increases caused by N2O . Instructions: please typing these entity words according to sentence: cuffs --, efficacy, cuff pressure release valve, performance, (, CPRV, paediatric cuffed tracheal tubes, with, and without, 50, children, general anaesthesia with tracheal intubation and standardized anaesthesia technique, reliable cuff pressure release Options: Intervention_Physical, Participant_Condition, Intervention_Other, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other

[ "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nitrous oxide diffusion into tracheal tube cuffs -- efficacy of a new prototype cuff pressure release valve . BACKGROUND The aim of this study was to evaluate the performance of a new cuff pressure release valve ( CPRV ) , in which the release pressure can be adjusted from 10 to 25 cmH2O , particularly intended to control pressure in paediatric cuffed tracheal tubes and to avoid cuff hyperinflation caused by N2O diffusion . METHODS In vitro : the PRV was set to 10 , 15 , 20 or 25 cmH2O release pressure and connected to a cuffed tube placed into a box flushed with 66 % N2O in O2 . The cuff pressure was monitored with and without CPRV for 60 min . Experiments were performed four times using two different CPRVs . In vivo : with Institutional Review Board approval , CPRV was studied in 50 children undergoing general anaesthesia with tracheal intubation and standardized anaesthesia technique ( including 66 % N2O in O2 ) and ventilator settings . Patients were randomized into two groups ( with and without CPRV ) . The cuff pressure baseline was 20 cmH2O and CPRV was set to 25 cmH2O . If the cuff pressure exceeded 25 cmH2O , it was manually released to 20 cmH2O . The numbers of deflations in both groups were noted and compared by Mann-Whitney U-test ( P < 0.05 ) . RESULTS In vitro : the cuff pressure exceeded 50 cmH2O after 60 min without CPRV , but did not exceed the settings with CPRV . In vivo : there was no need to manually deflate the cuff in the CPRV group but , in every patient in the control group , three ( two to seven ) deflating manoeuvres were required within the first hour of anaesthesia ( P < 0.0001 ) . CONCLUSION The CPRV allows reliable cuff pressure release at various pressure levels and reliably prevents cuff pressure increases caused by N2O .

[ "Nitrous", "oxide", "diffusion", "into", "tracheal", "tube", "cuffs", "--", "efficacy", "of", "a", "new", "prototype", "cuff", "pressure", "release", "valve", ".", "BACKGROUND", "The", "aim", "of", "this", "study", "was", "to", "evaluate", "the", "performance", "of", "a", "new", "cuff", "pressure", "release", "valve", "(", "CPRV", ")", ",", "in", "which", "the", "release", "pressure", "can", "be", "adjusted", "from", "10", "to", "25", "cmH2O", ",", "particularly", "intended", "to", "control", "pressure", "in", "paediatric", "cuffed", "tracheal", "tubes", "and", "to", "avoid", "cuff", "hyperinflation", "caused", "by", "N2O", "diffusion", ".", "METHODS", "In", "vitro", ":", "the", "PRV", "was", "set", "to", "10", ",", "15", ",", "20", "or", "25", "cmH2O", "release", "pressure", "and", "connected", "to", "a", "cuffed", "tube", "placed", "into", "a", "box", "flushed", "with", "66", "%", "N2O", "in", "O2", ".", "The", "cuff", "pressure", "was", "monitored", "with", "and", "without", "CPRV", "for", "60", "min", ".", "Experiments", "were", "performed", "four", "times", "using", "two", "different", "CPRVs", ".", "In", "vivo", ":", "with", "Institutional", "Review", "Board", "approval", ",", "CPRV", "was", "studied", "in", "50", "children", "undergoing", "general", "anaesthesia", "with", "tracheal", "intubation", "and", "standardized", "anaesthesia", "technique", "(", "including", "66", "%", "N2O", "in", "O2", ")", "and", "ventilator", "settings", ".", "Patients", "were", "randomized", "into", "two", "groups", "(", "with", "and", "without", "CPRV", ")", ".", "The", "cuff", "pressure", "baseline", "was", "20", "cmH2O", "and", "CPRV", "was", "set", "to", "25", "cmH2O", ".", "If", "the", "cuff", "pressure", "exceeded", "25", "cmH2O", ",", "it", "was", "manually", "released", "to", "20", "cmH2O", ".", "The", "numbers", "of", "deflations", "in", "both", "groups", "were", "noted", "and", "compared", "by", "Mann", "-", "Whitney", "U", "-", "test", "(", "P", "<", "0.05", ")", ".", "RESULTS", "In", "vitro", ":", "the", "cuff", "pressure", "exceeded", "50", "cmH2O", "after", "60", "min", "without", "CPRV", ",", "but", "did", "not", "exceed", "the", "settings", "with", "CPRV", ".", "In", "vivo", ":", "there", "was", "no", "need", "to", "manually", "deflate", "the", "cuff", "in", "the", "CPRV", "group", "but", ",", "in", "every", "patient", "in", "the", "control", "group", ",", "three", "(", "two", "to", "seven", ")", "deflating", "manoeuvres", "were", "required", "within", "the", "first", "hour", "of", "anaesthesia", "(", "P", "<", "0.0001", ")", ".", "CONCLUSION", "The", "CPRV", "allows", "reliable", "cuff", "pressure", "release", "at", "various", "pressure", "levels", "and", "reliably", "prevents", "cuff", "pressure", "increases", "caused", "by", "N2O", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Other", "Intervention_Physical", "Outcome_Other", "Participant_Age", "Participant_Sample-size" ]

cuffs --, efficacy, cuff pressure release valve, performance, (, CPRV, paediatric cuffed tracheal tubes, with, and without, 50, children, general anaesthesia with tracheal intubation and standardized anaesthesia technique, reliable cuff pressure release

23067_task2

Sentence: Nitrous oxide diffusion into tracheal tube cuffs -- efficacy of a new prototype cuff pressure release valve . BACKGROUND The aim of this study was to evaluate the performance of a new cuff pressure release valve ( CPRV ) , in which the release pressure can be adjusted from 10 to 25 cmH2O , particularly intended to control pressure in paediatric cuffed tracheal tubes and to avoid cuff hyperinflation caused by N2O diffusion . METHODS In vitro : the PRV was set to 10 , 15 , 20 or 25 cmH2O release pressure and connected to a cuffed tube placed into a box flushed with 66 % N2O in O2 . The cuff pressure was monitored with and without CPRV for 60 min . Experiments were performed four times using two different CPRVs . In vivo : with Institutional Review Board approval , CPRV was studied in 50 children undergoing general anaesthesia with tracheal intubation and standardized anaesthesia technique ( including 66 % N2O in O2 ) and ventilator settings . Patients were randomized into two groups ( with and without CPRV ) . The cuff pressure baseline was 20 cmH2O and CPRV was set to 25 cmH2O . If the cuff pressure exceeded 25 cmH2O , it was manually released to 20 cmH2O . The numbers of deflations in both groups were noted and compared by Mann-Whitney U-test ( P < 0.05 ) . RESULTS In vitro : the cuff pressure exceeded 50 cmH2O after 60 min without CPRV , but did not exceed the settings with CPRV . In vivo : there was no need to manually deflate the cuff in the CPRV group but , in every patient in the control group , three ( two to seven ) deflating manoeuvres were required within the first hour of anaesthesia ( P < 0.0001 ) . CONCLUSION The CPRV allows reliable cuff pressure release at various pressure levels and reliably prevents cuff pressure increases caused by N2O . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nitrous oxide diffusion into tracheal tube cuffs -- efficacy of a new prototype cuff pressure release valve . BACKGROUND The aim of this study was to evaluate the performance of a new cuff pressure release valve ( CPRV ) , in which the release pressure can be adjusted from 10 to 25 cmH2O , particularly intended to control pressure in paediatric cuffed tracheal tubes and to avoid cuff hyperinflation caused by N2O diffusion . METHODS In vitro : the PRV was set to 10 , 15 , 20 or 25 cmH2O release pressure and connected to a cuffed tube placed into a box flushed with 66 % N2O in O2 . The cuff pressure was monitored with and without CPRV for 60 min . Experiments were performed four times using two different CPRVs . In vivo : with Institutional Review Board approval , CPRV was studied in 50 children undergoing general anaesthesia with tracheal intubation and standardized anaesthesia technique ( including 66 % N2O in O2 ) and ventilator settings . Patients were randomized into two groups ( with and without CPRV ) . The cuff pressure baseline was 20 cmH2O and CPRV was set to 25 cmH2O . If the cuff pressure exceeded 25 cmH2O , it was manually released to 20 cmH2O . The numbers of deflations in both groups were noted and compared by Mann-Whitney U-test ( P < 0.05 ) . RESULTS In vitro : the cuff pressure exceeded 50 cmH2O after 60 min without CPRV , but did not exceed the settings with CPRV . In vivo : there was no need to manually deflate the cuff in the CPRV group but , in every patient in the control group , three ( two to seven ) deflating manoeuvres were required within the first hour of anaesthesia ( P < 0.0001 ) . CONCLUSION The CPRV allows reliable cuff pressure release at various pressure levels and reliably prevents cuff pressure increases caused by N2O .

[ "Nitrous", "oxide", "diffusion", "into", "tracheal", "tube", "cuffs", "--", "efficacy", "of", "a", "new", "prototype", "cuff", "pressure", "release", "valve", ".", "BACKGROUND", "The", "aim", "of", "this", "study", "was", "to", "evaluate", "the", "performance", "of", "a", "new", "cuff", "pressure", "release", "valve", "(", "CPRV", ")", ",", "in", "which", "the", "release", "pressure", "can", "be", "adjusted", "from", "10", "to", "25", "cmH2O", ",", "particularly", "intended", "to", "control", "pressure", "in", "paediatric", "cuffed", "tracheal", "tubes", "and", "to", "avoid", "cuff", "hyperinflation", "caused", "by", "N2O", "diffusion", ".", "METHODS", "In", "vitro", ":", "the", "PRV", "was", "set", "to", "10", ",", "15", ",", "20", "or", "25", "cmH2O", "release", "pressure", "and", "connected", "to", "a", "cuffed", "tube", "placed", "into", "a", "box", "flushed", "with", "66", "%", "N2O", "in", "O2", ".", "The", "cuff", "pressure", "was", "monitored", "with", "and", "without", "CPRV", "for", "60", "min", ".", "Experiments", "were", "performed", "four", "times", "using", "two", "different", "CPRVs", ".", "In", "vivo", ":", "with", "Institutional", "Review", "Board", "approval", ",", "CPRV", "was", "studied", "in", "50", "children", "undergoing", "general", "anaesthesia", "with", "tracheal", "intubation", "and", "standardized", "anaesthesia", "technique", "(", "including", "66", "%", "N2O", "in", "O2", ")", "and", "ventilator", "settings", ".", "Patients", "were", "randomized", "into", "two", "groups", "(", "with", "and", "without", "CPRV", ")", ".", "The", "cuff", "pressure", "baseline", "was", "20", "cmH2O", "and", "CPRV", "was", "set", "to", "25", "cmH2O", ".", "If", "the", "cuff", "pressure", "exceeded", "25", "cmH2O", ",", "it", "was", "manually", "released", "to", "20", "cmH2O", ".", "The", "numbers", "of", "deflations", "in", "both", "groups", "were", "noted", "and", "compared", "by", "Mann", "-", "Whitney", "U", "-", "test", "(", "P", "<", "0.05", ")", ".", "RESULTS", "In", "vitro", ":", "the", "cuff", "pressure", "exceeded", "50", "cmH2O", "after", "60", "min", "without", "CPRV", ",", "but", "did", "not", "exceed", "the", "settings", "with", "CPRV", ".", "In", "vivo", ":", "there", "was", "no", "need", "to", "manually", "deflate", "the", "cuff", "in", "the", "CPRV", "group", "but", ",", "in", "every", "patient", "in", "the", "control", "group", ",", "three", "(", "two", "to", "seven", ")", "deflating", "manoeuvres", "were", "required", "within", "the", "first", "hour", "of", "anaesthesia", "(", "P", "<", "0.0001", ")", ".", "CONCLUSION", "The", "CPRV", "allows", "reliable", "cuff", "pressure", "release", "at", "various", "pressure", "levels", "and", "reliably", "prevents", "cuff", "pressure", "increases", "caused", "by", "N2O", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Other", "Intervention_Physical", "Outcome_Other", "Participant_Age", "Participant_Sample-size" ]

ulceration is an umlsterm, skin is an umlsterm, patients is an umlsterm, rheumatoid arthritis is an umlsterm, disease is an umlsterm, mortality is an umlsterm, pathogenesis is an umlsterm, ulceration is an umlsterm, causes is an umlsterm, development is an umlsterm, immune complex is an umlsterm, vasculitis is an umlsterm, treatment is an umlsterm, drugs is an umlsterm, side effects is an umlsterm, treatment is an umlsterm, venous insufficiency is an umlsterm, ulceration is an umlsterm, autoimmune disease is an umlsterm, immunosuppressive drugs is an umlsterm, plasmapheresis is an umlsterm, Adjuvant is an umlsterm, treatment is an umlsterm, pain is an umlsterm, analgesics is an umlsterm, blood is an umlsterm, perfusion is an umlsterm, drugs is an umlsterm, therapy is an umlsterm, ulcers is an umlsterm, inflammatory reaction is an umlsterm, surgical is an umlsterm, patients is an umlsterm, muscle is an umlsterm, flaps is an umlsterm, skin grafts is an umlsterm, ulceration is an umlsterm, rheumatoid arthritis is an umlsterm, treatment is an umlsterm, rheumatoid arthritis is an umlsterm, immunotherapy is an umlsterm, monoclonal antibodies is an umlsterm

DerHautarzt.50460406.eng.abstr_task0

Sentence: The appearance of severe ulceration of the skin in patients with rheumatoid arthritis is often associated with a tendency to progression of the underlying disease , involvement of internal organs and increased mortality . In the pathogenesis of such ulceration there are multiple causes for their development , persistence and tendency to poor healing . They include localized or generalized immune complex vasculitis , treatment with anti-inflammatory drugs and their side effects following the treatment , arterial and venous insufficiency , and mechanical factors . The management of severe ulceration requires stabilization of the underlying autoimmune disease , e.g. with high doses of glucocorticosteroids or other immunosuppressive drugs or plasmapheresis . Adjuvant treatment of pain with analgesics , improvement of blood perfusion and anti-inflammatory drugs should accompany the topical therapy of ulcers . After suppression of the local inflammatory reaction surgical intervention becomes necessary in most of the patients , and vascularized muscle flaps should be used in preference to meshgrafts or split skin grafts for extensive ulceration in rheumatoid arthritis . A hopeful perspective in the treatment of severe rheumatoid arthritis might be opened up with immunotherapy using monoclonal antibodies . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]

The appearance of severe ulceration of the skin in patients with rheumatoid arthritis is often associated with a tendency to progression of the underlying disease , involvement of internal organs and increased mortality . In the pathogenesis of such ulceration there are multiple causes for their development , persistence and tendency to poor healing . They include localized or generalized immune complex vasculitis , treatment with anti-inflammatory drugs and their side effects following the treatment , arterial and venous insufficiency , and mechanical factors . The management of severe ulceration requires stabilization of the underlying autoimmune disease , e.g. with high doses of glucocorticosteroids or other immunosuppressive drugs or plasmapheresis . Adjuvant treatment of pain with analgesics , improvement of blood perfusion and anti-inflammatory drugs should accompany the topical therapy of ulcers . After suppression of the local inflammatory reaction surgical intervention becomes necessary in most of the patients , and vascularized muscle flaps should be used in preference to meshgrafts or split skin grafts for extensive ulceration in rheumatoid arthritis . A hopeful perspective in the treatment of severe rheumatoid arthritis might be opened up with immunotherapy using monoclonal antibodies .

[ "The", "appearance", "of", "severe", "ulceration", "of", "the", "skin", "in", "patients", "with", "rheumatoid", "arthritis", "is", "often", "associated", "with", "a", "tendency", "to", "progression", "of", "the", "underlying", "disease", ",", "involvement", "of", "internal", "organs", "and", "increased", "mortality", ".", "In", "the", "pathogenesis", "of", "such", "ulceration", "there", "are", "multiple", "causes", "for", "their", "development", ",", "persistence", "and", "tendency", "to", "poor", "healing", ".", "They", "include", "localized", "or", "generalized", "immune", "complex", "vasculitis", ",", "treatment", "with", "anti", "-", "inflammatory", "drugs", "and", "their", "side", "effects", "following", "the", "treatment", ",", "arterial", "and", "venous", "insufficiency", ",", "and", "mechanical", "factors", ".", "The", "management", "of", "severe", "ulceration", "requires", "stabilization", "of", "the", "underlying", "autoimmune", "disease", ",", "e.g", ".", "with", "high", "doses", "of", "glucocorticosteroids", "or", "other", "immunosuppressive", "drugs", "or", "plasmapheresis", ".", "Adjuvant", "treatment", "of", "pain", "with", "analgesics", ",", "improvement", "of", "blood", "perfusion", "and", "anti", "-", "inflammatory", "drugs", "should", "accompany", "the", "topical", "therapy", "of", "ulcers", ".", "After", "suppression", "of", "the", "local", "inflammatory", "reaction", "surgical", "intervention", "becomes", "necessary", "in", "most", "of", "the", "patients", ",", "and", "vascularized", "muscle", "flaps", "should", "be", "used", "in", "preference", "to", "meshgrafts", "or", "split", "skin", "grafts", "for", "extensive", "ulceration", "in", "rheumatoid", "arthritis", ".", "A", "hopeful", "perspective", "in", "the", "treatment", "of", "severe", "rheumatoid", "arthritis", "might", "be", "opened", "up", "with", "immunotherapy", "using", "monoclonal", "antibodies", "." ]

[ "umlsterm" ]

ulceration is an umlsterm, skin is an umlsterm, patients is an umlsterm, rheumatoid arthritis is an umlsterm, disease is an umlsterm, mortality is an umlsterm, pathogenesis is an umlsterm, ulceration is an umlsterm, causes is an umlsterm, development is an umlsterm, immune complex is an umlsterm, vasculitis is an umlsterm, treatment is an umlsterm, drugs is an umlsterm, side effects is an umlsterm, treatment is an umlsterm, venous insufficiency is an umlsterm, ulceration is an umlsterm, autoimmune disease is an umlsterm, immunosuppressive drugs is an umlsterm, plasmapheresis is an umlsterm, Adjuvant is an umlsterm, treatment is an umlsterm, pain is an umlsterm, analgesics is an umlsterm, blood is an umlsterm, perfusion is an umlsterm, drugs is an umlsterm, therapy is an umlsterm, ulcers is an umlsterm, inflammatory reaction is an umlsterm, surgical is an umlsterm, patients is an umlsterm, muscle is an umlsterm, flaps is an umlsterm, skin grafts is an umlsterm, ulceration is an umlsterm, rheumatoid arthritis is an umlsterm, treatment is an umlsterm, rheumatoid arthritis is an umlsterm, immunotherapy is an umlsterm, monoclonal antibodies is an umlsterm

DerHautarzt.50460406.eng.abstr_task1

Sentence: The appearance of severe ulceration of the skin in patients with rheumatoid arthritis is often associated with a tendency to progression of the underlying disease , involvement of internal organs and increased mortality . In the pathogenesis of such ulceration there are multiple causes for their development , persistence and tendency to poor healing . They include localized or generalized immune complex vasculitis , treatment with anti-inflammatory drugs and their side effects following the treatment , arterial and venous insufficiency , and mechanical factors . The management of severe ulceration requires stabilization of the underlying autoimmune disease , e.g. with high doses of glucocorticosteroids or other immunosuppressive drugs or plasmapheresis . Adjuvant treatment of pain with analgesics , improvement of blood perfusion and anti-inflammatory drugs should accompany the topical therapy of ulcers . After suppression of the local inflammatory reaction surgical intervention becomes necessary in most of the patients , and vascularized muscle flaps should be used in preference to meshgrafts or split skin grafts for extensive ulceration in rheumatoid arthritis . A hopeful perspective in the treatment of severe rheumatoid arthritis might be opened up with immunotherapy using monoclonal antibodies . Instructions: please typing these entity words according to sentence: ulceration, skin, patients, rheumatoid arthritis, disease, mortality, pathogenesis, ulceration, causes, development, immune complex, vasculitis, treatment, drugs, side effects, treatment, venous insufficiency, ulceration, autoimmune disease, immunosuppressive drugs, plasmapheresis, Adjuvant, treatment, pain, analgesics, blood, perfusion, drugs, therapy, ulcers, inflammatory reaction, surgical, patients, muscle, flaps, skin grafts, ulceration, rheumatoid arthritis, treatment, rheumatoid arthritis, immunotherapy, monoclonal antibodies Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]

The appearance of severe ulceration of the skin in patients with rheumatoid arthritis is often associated with a tendency to progression of the underlying disease , involvement of internal organs and increased mortality . In the pathogenesis of such ulceration there are multiple causes for their development , persistence and tendency to poor healing . They include localized or generalized immune complex vasculitis , treatment with anti-inflammatory drugs and their side effects following the treatment , arterial and venous insufficiency , and mechanical factors . The management of severe ulceration requires stabilization of the underlying autoimmune disease , e.g. with high doses of glucocorticosteroids or other immunosuppressive drugs or plasmapheresis . Adjuvant treatment of pain with analgesics , improvement of blood perfusion and anti-inflammatory drugs should accompany the topical therapy of ulcers . After suppression of the local inflammatory reaction surgical intervention becomes necessary in most of the patients , and vascularized muscle flaps should be used in preference to meshgrafts or split skin grafts for extensive ulceration in rheumatoid arthritis . A hopeful perspective in the treatment of severe rheumatoid arthritis might be opened up with immunotherapy using monoclonal antibodies .

[ "The", "appearance", "of", "severe", "ulceration", "of", "the", "skin", "in", "patients", "with", "rheumatoid", "arthritis", "is", "often", "associated", "with", "a", "tendency", "to", "progression", "of", "the", "underlying", "disease", ",", "involvement", "of", "internal", "organs", "and", "increased", "mortality", ".", "In", "the", "pathogenesis", "of", "such", "ulceration", "there", "are", "multiple", "causes", "for", "their", "development", ",", "persistence", "and", "tendency", "to", "poor", "healing", ".", "They", "include", "localized", "or", "generalized", "immune", "complex", "vasculitis", ",", "treatment", "with", "anti", "-", "inflammatory", "drugs", "and", "their", "side", "effects", "following", "the", "treatment", ",", "arterial", "and", "venous", "insufficiency", ",", "and", "mechanical", "factors", ".", "The", "management", "of", "severe", "ulceration", "requires", "stabilization", "of", "the", "underlying", "autoimmune", "disease", ",", "e.g", ".", "with", "high", "doses", "of", "glucocorticosteroids", "or", "other", "immunosuppressive", "drugs", "or", "plasmapheresis", ".", "Adjuvant", "treatment", "of", "pain", "with", "analgesics", ",", "improvement", "of", "blood", "perfusion", "and", "anti", "-", "inflammatory", "drugs", "should", "accompany", "the", "topical", "therapy", "of", "ulcers", ".", "After", "suppression", "of", "the", "local", "inflammatory", "reaction", "surgical", "intervention", "becomes", "necessary", "in", "most", "of", "the", "patients", ",", "and", "vascularized", "muscle", "flaps", "should", "be", "used", "in", "preference", "to", "meshgrafts", "or", "split", "skin", "grafts", "for", "extensive", "ulceration", "in", "rheumatoid", "arthritis", ".", "A", "hopeful", "perspective", "in", "the", "treatment", "of", "severe", "rheumatoid", "arthritis", "might", "be", "opened", "up", "with", "immunotherapy", "using", "monoclonal", "antibodies", "." ]

[ "umlsterm" ]